

-1-

T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AGAINST FOLR1 AND CD3

Sequence Listing

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 9, 2015, is named 32186_SL.txt and is 445,570 bytes in size.

5

Field of the Invention

The present invention generally relates to bispecific antigen binding molecules for activating T cells, in particular to bispecific antibodies targeting CD3 and Folate Receptor 1 (FolR1). In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention
10 further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Background

The selective destruction of an individual cell or a specific cell type is often desirable in a variety
15 of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy tumor cells, while leaving healthy cells and tissues intact and undamaged.

An attractive way of achieving this is by inducing an immune response against the tumor, to make immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) attack and destroy tumor cells. CTLs constitute the most potent effector cells of the immune
20 system, however they cannot be activated by the effector mechanism mediated by the Fc domain of conventional therapeutic antibodies.

In this regard, bispecific antibodies designed to bind with one "arm" to a surface antigen on target cells, and with the second "arm" to an activating, invariant component of the T cell receptor (TCR) complex, have become of interest in recent years. The simultaneous binding of
25 such an antibody to both of its targets will force a temporary interaction between target cell and T cell, causing activation of any cytotoxic T cell and subsequent lysis of the target cell. Hence,

-2-

the immune response is re-directed to the target cells and is independent of peptide antigen presentation by the target cell or the specificity of the T cell as would be relevant for normal MHC-restricted activation of CTLs. In this context it is crucial that CTLs are only activated when a target cell is presenting the bispecific antibody to them, i.e. the immunological synapse is mimicked. Particularly desirable are bispecific antibodies that do not require lymphocyte preconditioning or co-stimulation in order to elicit efficient lysis of target cells.

FOLR1 is expressed on epithelial tumor cells of various origins, e.g., ovarian cancer, lung cancer, breast cancer, renal cancer, colorectal cancer, endometrial cancer. Several approaches to target FOLR1 with therapeutic antibodies, such as farletuzumab, antibody drug conjugates, or adoptive T cell therapy for imaging of tumors have been described (Kandalaf et al., J Transl Med. 2012 Aug 3;10:157. doi: 10.1186/1479-5876-10-157; van Dam et al., Nat Med. 2011 Sep 18;17(10):1315-9. doi: 10.1038/nm.2472; Clifton et al., Hum Vaccin. 2011 Feb;7(2):183-90. Epub 2011 Feb 1; Kelemen et al., Int J Cancer. 2006 Jul 15;119(2):243-50; Vaitilingam et al., J Nucl Med. 2012 Jul;53(7); Teng et al., 2012 Aug;9(8):901-8. doi: 10.1517/17425247.2012.694863. Epub 2012 Jun 5. Some attempts have been made to target folate receptor-positive tumors with constructs that target the folate receptor and CD3 (Kranz et al., Proc Natl Acad Sci U S A. Sep 26, 1995; 92(20): 9057–9061; Roy et al., Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31; Huiting Cui et al Biol Chem. Aug 17, 2012; 287(34): 28206–28214; Lamers et al., Int. J. Cancer. 60(4):450 (1995); Thompson et al., MAbs. 2009 Jul-Aug;1(4):348-56. Epub 2009 Jul 19; Mezzanzanica et al., Int. J. Cancer, 41, 609–615 (1988). However, the approaches taken so far have many disadvantages. The molecules used thus far could not be readily and reliably produced as they require chemical cross linking. Similarly, hybrid molecules cannot be produced at large scale as human proteins and require the use of rat, murine or other proteins that are highly immunogenic when administered to humans and, thus, of limited therapeutic value. Further, many of the existing molecules retained FcγR binding. Thus, there remains a need for novel, improved bispecific antibodies for targeted T cell mediated immunotherapy. The present invention provides bispecific antigen binding molecules designed for targeted T cell activation, particularly, bispecific antigen binding molecules suitable as effective and safe therapeutics that can be readily produced and dosed.

Summary of the Invention

In one aspect, the invention provides a T cell activating bispecific antigen binding molecule comprising

-3-

- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3, and which comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34; and
- (ii) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1).

In one embodiment, the T cell activating bispecific antigen binding molecule comprises a first antigen binding moiety that comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31. In one embodiment, the T cell activating bispecific antigen binding molecule additionally comprises (iii) a third antigen binding moiety capable of specific binding to FolR1. In one embodiment, the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one embodiment, the third antigen binding moiety is identical to the second antigen binding moiety.

In one embodiment of the T cell activating bispecific antigen binding molecule of the above embodiments, at least one of the second and third antigen binding moiety is a Fab molecule. In one embodiment, the T cell activating bispecific antigen binding molecule of the above embodiments, additionally comprises an Fc domain composed of a first and a second subunit capable of stable association. In some embodiments, the first antigen binding moiety and the second antigen binding moiety are each connected at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In some embodiments, a third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, optionally via a peptide linker.

In one embodiment of the T cell activating bispecific antigen binding molecule of the above embodiments, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34. In one embodiment, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises a variable heavy chain comprising an amino

-4-

- acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31. In one embodiment, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 65. In one embodiment, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 55 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 64.
- 10 In another embodiment, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 50 and at least one light chain CDR selected from the group of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54. In one embodiment, the antigen binding moiety capable of specific binding to FolR1 comprises (a) a complementarity determining region heavy chain 1 (CDR-H1) amino acid sequences of SEQ ID NO: 8; (b) a CDR-H2 amino acid sequence of SEQ ID NO: 9; (c) a CDR-H3 amino acid sequence of SEQ ID NO: 50; (d) a complementarity determining region light chain 1 (CDR-L1) amino acid sequence of SEQ ID NO: 52; (e) a CDR-L2 amino acid sequence of SEQ ID NO: 53, and (f) a CDR-L3 amino acid sequence of SEQ ID NO: 54. In one embodiment, the antigen binding moiety capable of specific binding to FolR1 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 49 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 51.
- 15 In another embodiment, the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 275 and SEQ ID NO: 315 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34. In one embodiment, the antigen binding moiety capable of specific binding to FolR1 comprises (a) a complementarity determining region heavy chain 1 (CDR-H1) amino acid sequences of SEQ ID NO: 16; (b) a CDR-H2 amino acid sequence of SEQ ID NO: 275; (c) a CDR-H3 amino acid sequence of SEQ ID NO: 315; (d) a complementarity determining region light chain 1 (CDR-L1) amino acid sequence of SEQ ID NO: 32; (e) a CDR-L2 amino acid sequence of SEQ ID NO: 33, and (f) a CDR-L3 amino acid sequence of SEQ ID NO: 34. In one embodiment, the antigen binding moiety capable of specific
- 25
- 30

-5-

binding to FolR1 comprises a variable heavy chain domain (VH) comprising an amino acid sequence of SEQ ID NO: 274 and a variable light chain domain (VL) comprising an amino acid sequence of SEQ ID NO: 31.

In one embodiment, the T cell activating bispecific antigen binding molecule of the above
5 embodiments binds to a human FolR1. In one embodiment, the T cell activating bispecific
antigen binding molecule of the above embodiments binds to a human FolR1 and a cynomolgus
monkey FolR1. In one embodiment, the T cell activating bispecific antigen binding molecule of
the above embodiments binds to a human FolR1, a cynomolgus monkey FolR1 and a murine
FolR1. In one embodiment, the T cell activating bispecific antigen binding molecule of the
10 above embodiments binds to a human FolR1, a cynomolgus monkey FolR1 and not a murine
FolR1.

In one embodiment of the T cell activating bispecific antigen binding molecule of any of the
above embodiments, the first antigen binding moiety is a crossover Fab molecule wherein either
the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged.
15 In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above
embodiments comprises not more than one antigen binding moiety capable of specific binding to
CD3. In one embodiment of the T cell activating bispecific antigen binding molecule, the first
and the second antigen binding moiety and the Fc domain are part of an immunoglobulin
molecule. In one embodiment, the Fc domain is an IgG class immunoglobulin, specifically an
20 IgG₁ or IgG₄, Fc domain. In one embodiment, the Fc domain is a human Fc domain.

In one embodiment of the T cell activating bispecific antigen binding molecule of any of the
above embodiments, the Fc domain comprises a modification promoting the association of the
first and the second subunit of the Fc domain. In one embodiment, in the CH3 domain of the
first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue
25 having a larger side chain volume, thereby generating a protuberance within the CH3 domain of
the first subunit which is positionable in a cavity within the CH3 domain of the second subunit,
and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced
with an amino acid residue having a smaller side chain volume, thereby generating a cavity
within the CH3 domain of the second subunit within which the protuberance within the CH3
30 domain of the first subunit is positionable. In one embodiment, the Fc domain comprises at least
one amino acid substitution that reduces binding to an Fc receptor and/or effector function, as
compared to a native IgG₁ Fc domain. In one embodiment, each subunit of the Fc domain
comprises three amino acid substitutions that reduce binding to an activating Fc receptor and/or

-6-

effector function wherein said amino acid substitutions are L234A, L235A and P329G (Kabat numbering). In one embodiment, the Fc receptor is an Fc γ receptor. In one embodiment, the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

In one embodiment of the T cell activating bispecific antigen binding molecule of any of the
5 above embodiments, the T cell activating bispecific antigen binding molecule induces proliferation of a human CD3 positive T cell in vitro. In one embodiment, the T cell activating bispecific antigen binding molecule induces human peripheral blood mononuclear cell mediated killing of a FolR1-expressing human tumor cell in vitro. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of a FolR1-
10 expressing human tumor cell in vitro. In one embodiment, the T cell is a CD8 positive T cell. In one embodiment, the FolR1-expressing human tumor cell is a HeLa, Skov-3, HT-29, or HRCepiC cell. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing human tumor cell in vitro with an EC50 of between about 36 pM and about 39573 pM after 24 hours. In one embodiment, the T cell
15 activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 36 pM after 24 hours. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 178.4 pM after 24 hours. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated
20 killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 134.5 pM or greater after 48 hours.

In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments induces upregulation of cell surface expression of at least one of CD25 and CD69 on the T cell as measured by flow cytometry. In one embodiment, the T cell is a CD4 positive T
25 cell or a CD8 positive T cell. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments binds human FolR1 with an apparent K_D of about 5.36 pM to about 4 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 4 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds murine FolR1 with
30 an apparent K_D of about 1.5 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM.

In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments is specific for FolR1 and does not bind to FolR2 or FolR3. In one embodiment,

-7-

the T cell activating bispecific antigen binding molecule of any of the above embodiments has an affinity (monovalent binding) of 1 μ M or greater. In one embodiment, the affinity is around 1.4 μ M for human FolR1. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments has an avidity (bivalent binding) of about 1-100nM or lower. In one embodiment, the avidity is about 10 nM or less. In one embodiment, the avidity is 10 nM.

In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments binds to FolR1 expressed on a human tumor cell. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments binds to a conformational epitope on human FolR1. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments does not bind to human Folate Receptor 2 (FolR2) or to human Folate Receptor 3 (FolR3). In one embodiment of the T cell activating bispecific antigen binding molecule of any of the above embodiments, the antigen binding moiety binds to a FolR1 polypeptide comprising the amino acids 25 to 234 of human FolR1 (SEQ ID NO:227). In one embodiment of the T cell activating bispecific antigen binding molecule of any of the above embodiments, the FolR1 antigen binding moiety binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:227, 230 and 231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence of SEQ ID NOs:228 and 229.

In another aspect, the invention provides for a bispecific antibody comprising a) a first antigen-binding site that competes for binding to human FolR1 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 49 and a variable light chain domain of SEQ ID NO: 51; and b) a second antigen-binding site that competes for binding to human CD3 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31, wherein binding competition is measured using a surface plasmon resonance assay.

In another aspect, the invention provides for a bispecific antibody comprising a) a first antigen-binding site that competes for binding to human FolR1 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 274 and a variable light chain domain of SEQ ID NO: 31; and b) a second antigen-binding site that competes for binding to human CD3 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31, wherein binding competition is measured using a surface plasmon resonance assay.

-8-

In another aspect, the invention provides for a T cell activating bispecific antigen binding molecule comprising a first antigen binding moiety capable of specific binding to CD3, and a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1), wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human

5 FolR1 as a first reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 49 and a variable light chain domain of SEQ ID NO: 51; and wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human CD3 as a second reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31.

10 In another aspect, the invention provides for a T cell activating bispecific antigen binding molecule comprising a first antigen binding moiety capable of specific binding to CD3, and a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1), wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human FolR1 as a first reference antibody comprising a variable heavy chain domain (VH) of SEQ ID
15 NO: 274 and a variable light chain domain (VL) of SEQ ID NO: 31; and wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human CD3 as a second reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain (VL) of SEQ ID NO: 31.

In another aspect, the invention relates to an antibody or an antigen-binding fragment thereof that
20 competes for binding to human FolR1 with an antibody that comprises a variable heavy chain domain (VH) of SEQ ID NO: 274 and a variable light chain domain of SEQ ID NO: 31, wherein binding competition is measured using a surface plasmon resonance assay.

In one aspect, the invention provides for a T cell activating bispecific antigen binding molecule, wherein the antigen binding molecule comprises a first, second, third, fourth and fifth
25 polypeptide chain that form a first, a second and a third antigen binding moiety, wherein the first antigen binding moiety is capable of binding CD3 and the second and the third antigen binding moiety each are capable of binding Folate Receptor 1 (FolR1), wherein a) the first and the second polypeptide chain comprise, in amino (N)-terminal to carboxyl (C)-terminal direction, VLD1 and CLD1; b) the third polypeptide chain comprises, in N-terminal to C-terminal
30 direction, VLD2 and CH1D2; c) the fourth polypeptide chain comprises, in N-terminal to C-terminal direction, VHD1, CH1D1, CH2D1 and CH3D1; d) the fifth polypeptide chain comprises VHD1, CH1D1, VHD2, CLD2, CH2D2 and CH3D2; wherein VLD1 is a first light chain variable domain, VLD2 is a second light chain variable domain, CLD1 is a first light chain

-9-

constant domain, CLD2 is a second light chain constant domain, VHD1 is a first heavy chain variable domain, VHD2 is a second heavy chain variable domain, CH1D1 is a first heavy chain constant domain 1, CH1D2 is a second heavy chain constant domain 1, CH2D1 is a first heavy chain constant domain 2, CH2D2 is a second heavy chain constant domain 2, CH3D1 is a first heavy chain constant domain 3, and CH3D2 is a second heavy chain constant domain 3.

In one embodiment of the T cell activating bispecific antigen binding molecule, (i) the third polypeptide chain and VHD2 and CLD2 of the fifth polypeptide chain form the first antigen binding moiety capable of binding CD3; (ii) the first polypeptide chain and VHD1 and CH1D1 of the fourth polypeptide chain form the second binding moiety capable of binding to FolR1; and (iii) the second polypeptide chain and VHD1 and CH1D1 of the fifth polypeptide chain form the third binding moiety capable of binding to FolR1. In one embodiment, CH2D1, CH3D1, CH2D2 and CH3D2 form an Fc domain of an IgG class immunoglobulin. In one embodiment, the Fc domain is a human Fc domain. In one embodiment, the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain. In one embodiment, CH3D2 comprises an amino acid residue having a larger side chain volume, which is positionable in a cavity within CH3D1. In one embodiment, the Fc domain comprises at least one amino acid substitution that reduces binding to an Fc receptor and/or effector function, as compared to a native IgG₁ Fc domain. In one embodiment, each subunit of the Fc domain comprises three amino acid substitutions that reduce at least one of binding to an activating Fc receptor and effector function wherein said amino acid substitutions are L234A, L235A and P329G according to Kabat numbering. In one embodiment, the Fc receptor is an Fcγ receptor. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces proliferation of a human CD3 positive T cell in vitro. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces human peripheral blood mononuclear cell mediated killing of a FolR1-expressing human tumor cell in vitro. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of a FolR1-expressing human tumor cell in vitro. In one such embodiment, the FolR1-expressing human tumor cell is a HeLa, Skov-3, HT-29, or HRCEpiC cell. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC₅₀ of between about 36 pM and about 39573 pM after 24 hours. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC₅₀ of about 36 pM after 24 hours.

-10-

In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 178.4 pM after 24 hours. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 134.5 pM or greater after 48 hours. In one of the above embodiments, the T cell activating bispecific antigen binding molecule induces upregulation of cell surface expression of at least one of CD25 and CD69 on the T cell as measured by flow cytometry. In one such embodiments, the T cell is a CD4 positive T cell or a CD8 positive T cell. In one of the above embodiments, wherein the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 5.36 pM to about 4 nM. In one of the above embodiments, the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 4 nM. In one of the above embodiments, the T cell activating bispecific antigen binding molecule binds murine FolR1 with an apparent K_D of about 1.5 nM. In one of the above embodiments, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM. In one of the above embodiments, the T cell activating bispecific antigen binding molecule binds to FolR1 expressed on a human tumor cell. In one of the above embodiments, the T cell activating bispecific antigen binding molecule binds to a conformational epitope on human FolR1. In one of the above embodiments, the T cell activating bispecific antigen binding molecule does not bind to human Folate Receptor 2 (FolR2) or to human Folate Receptor 3 (FolR3). In one of the above embodiments, the antigen binding moiety binds to a FolR1 polypeptide comprising the amino acids 25 to 234 of human FolR1 (SEQ ID NO:227). In one of the above embodiments, the FolR1 antigen binding moiety binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:227, 230 and 231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence of SEQ ID NOs:228 and 229. In one of the above embodiments, the T cell activating bispecific antigen binding molecule is a humanized or a chimeric molecule. In one of the above embodiments, VHD2 and CH1D1 are linked through a peptide linker. In one of the above embodiments of the T cell activating bispecific antigen binding molecule, the first and second polypeptide chain comprise the amino acid sequence of SEQ ID NO:230. In one of the above embodiments of the T cell activating bispecific antigen binding molecule, the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:86. In one of the above embodiments of the T cell activating bispecific antigen binding molecule, the fourth polypeptide

chain comprises the amino acid sequence of SEQ ID NO:309. In one of the above embodiments of the T cell activating bispecific antigen binding molecule, the fifth polypeptide chain comprises the amino acid sequence of SEQ ID NO:308. In one of the above embodiments of the T cell activating bispecific antigen binding molecule, the first and second polypeptide chain
5 comprise the amino acid sequence of SEQ ID NO:230; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:86; the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:309; and the fifth polypeptide chain comprise the amino acid sequence of SEQ ID NO:308.

In one aspect, the invention provides for a T cell activating bispecific antigen binding molecule
10 comprising the amino acid sequence of SEQ ID NO:308. In one embodiment, the T cell activating bispecific antigen binding molecule of the above embodiment further comprises the amino acid sequence of SEQ ID NO:230 and of SEQ ID NO:86.

In one aspect, the invention provides for an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:308. In one aspect, the invention provides for an isolated polypeptide
15 comprising the amino acid sequence of SEQ ID NO:309.

In one aspect, the invention provides for a T cell activating bispecific antigen binding molecule comprising the amino acid sequence of SEQ ID NO:276. In one embodiment, the T cell activating bispecific antigen binding molecule of the above embodiment further comprises the amino acid sequence of SEQ ID NO:277 and of SEQ ID NO:35.

20 In one aspect, the invention provides for an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:277. In one aspect, the invention provides for an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:276.

In one aspect, the invention provides for an isolated polynucleotide encoding the T cell activating bispecific antigen binding molecule of any one of the embodiments disclosed herein.

25 In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:169. In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:246. In one embodiment, the invention provides for an isolated polynucleotide encoding
30 a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:247. In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:97. In one embodiment, the invention provides for an isolated

-12-

polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:198.

In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID

5 NO:287. In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:288. In one embodiment, the invention provides for an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:289.

10 In one aspect, the invention provides for an isolated polypeptide encoded by the polynucleotide of the above embodiment. In another aspect, the invention provides for a vector, particularly an expression vector, comprising the polynucleotide encoding the T cell activating bispecific antigen binding molecule of any one of the embodiments disclosed herein. In another aspect, the invention provides for a host cell comprising a polynucleotide or a vector of any of the
15 embodiments disclosed herein.

In one aspect, the invention provides for a method of producing the T cell activating bispecific antigen binding molecule capable of specific binding to CD3 and a target cell antigen, comprising the steps of a) culturing the host cell of the above embodiments under conditions suitable for the expression of the T cell activating bispecific antigen binding molecule and b)
20 recovering the T cell activating bispecific antigen binding molecule.

In one aspect, the invention provides for T cell activating bispecific antigen binding molecule produced by the method of the above embodiment.

In one aspect, the invention provides for a pharmaceutical composition comprising the T cell activating bispecific antigen binding molecule of any one of the above embodiments and a
25 pharmaceutically acceptable carrier. In one aspect, the invention provides for the T cell activating bispecific antigen binding molecule of any one of the above embodiments or the pharmaceutical composition of any of the above embodiments for use as a medicament.

In one aspect, the invention provides for the T cell activating bispecific antigen binding molecule of any one of the above embodiments or the pharmaceutical composition of any one of the above
30 embodiments for use in the treatment of a disease in an individual in need thereof. In some embodiments, the disease is cancer. In one aspect, the invention provides for a use of the T cell activating bispecific antigen binding molecule of any one of the above embodiments for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

-13-

In one aspect, the invention provides for a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of the above embodiments in a pharmaceutically acceptable form. In some embodiments, said disease is a cancer.

In one aspect, the invention provides for a method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of the above embodiments in the presence of a T cell.

In one aspect, the invention provides for the invention as described hereinbefore.

Brief Description of the Drawings

Figures 1A-I illustrate exemplary configurations of the T cell activating bispecific antigen binding molecules (TCBs) of the invention. All constructs except the kappa-lambda format in (Fig. 1I) have P329G LALA mutations and comprise knob-into-hole Fc fragments with knob-into-hole modifications. (Fig. 1A) Illustration of the “FolR1 TCB 2+1 inverted (common light chain)”. The FolR1 binder is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain comprising the knob modification. These constructs are not crossed and have three times the same VLCL light chain. (Fig. 1B) Illustration of the “FolR1 TCB 1+1 head-to-tail (common light chain)”. These constructs are not crossed and have two times the same VLCL light chain. (Fig. 1C) Illustration of the “FolR1 TCB 1+1 classical (common light chain)”. These constructs are not crossed and have two times the same VLCL light chain. (Fig. 1D) Illustration of the “FolR1 TCB 2+1 classical (common light chain)”. The CD3 binder is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain comprising the knob modification. These constructs are not crossed and have three times the same VLCL light chain. (Fig. 1E) Illustration of the “FolR1 TCB 2+1 crossfab classical”. These constructs comprise a Ck-VH chain for the CD3 binder instead of the conventional CH1-VH chain. The CD3 binder is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain comprising the knob modification. (Fig. 1F) Illustration of the “FolR1 TCB 2+1 crossfab inverted”. These constructs comprise a Ck-VH chain for the CD3 binder instead of the conventional CH1-VH chain. The FolR1 binder is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain comprising the knob modification. (Fig. 1G) Illustration of the “FolR1 TCB 1+1 crossfab head-

-14-

to-tail". These constructs comprise a Ck-VH chain for the CD3 binder instead of the conventional CH1-VH chain. (Fig. 1H) Illustration of the "FolR1 TCB 1+1 crossfab classical". These constructs comprise a Ck-VH chain for the CD3 binder instead of the conventional CH1-VH chain. Figure 1I illustrates the CD3/FolR1 kappa-lambda antibody format. These constructs
5 comprise a crossed common light chain VLCH1 and one crossed VHCL chain specific for CD3 and one crossed VHCL chain specific for FolR1.

Figures 2A-C depict graphs summarizing Binding of FolR1 IgG binders to HeLa cells. Binding of newly generated FolR1 binders to FolR1 expressed on HeLa cells were determined by flow cytometry. Bound antibodies were detected with a fluorescently labeled anti-human secondary
10 antibody.

Figures 3A-B depict graphs summarizing specificity of FolR1 binders for FolR1. Binding of FolR1 IgGs to HEK cells transiently transfected with either FolR1 or FolR2 was analyzed by flow cytometry to identify clones which bind specifically to FolR1 and not to FolR2. The antibodies were detected with a fluorescently labeled anti-human secondary antibody.

15 **Figures 4A-B** depict graphs summarizing cross-reactivity of FolR1 binders to cyFolR1. Cross-reactivity of the FolR1 antibodies to cyno FolR1 was addressed on HEK cells transiently transfected with cyFolR1 by flow cytometry. The antibodies were detected with a fluorescently labeled anti-human secondary antibody.

Figure 5 depicts a graph illustrating internalization of FolR1 TCBs after binding. Internalization
20 of the four FolR1 TCBs after binding to FolR1 was tested on HeLa cells. Remaining FolR1 TCBs on the surface were detected with a fluorescently labeled anti-human secondary antibody after indicated time points of incubation at 37°C. Percentage of internalization was calculated.

Figures 6A-E depict graphs summarizing binding of FolR1 IgGs to cells with different FolR1 expression levels. Binding of 9D11, 16D5 and Mov19 IgG to tumor cells with different FolR1
25 expression levels was analyzed by flow cytometry. DP47 IgG was included as isotype control and MKN-45 were included as FolR1 negative cell line. The antibodies were detected with a fluorescently labeled anti-human secondary antibody.

Figures 7A-L depict graphs summarizing T cell mediated killing of HT-29 and SKOV3 cells. FolR1 TCBs were used to test T cell mediated killing of HT-29 and SKOV3 tumor cells and
30 upregulation of activation marker on T cells upon killing. (Figs. 7A-D) T cell mediated killing of

-15-

HT-29 and SKOV3 cells in the presence of 9D11 FolR1 TCB and 16D5 FolR1 TCB was measured by LDH release after 24 h and 48 h. DP47 TCB was included as negative control. After 48 h incubation upregulation of the activation marker CD25 and CD69 on CD8 T cells and CD4 T cells upon killing of SKOV3 (Figs. 7E-H) or HT-29 (Fig. 7I-L) tumor cells was assessed
 5 by flow cytometry.

Figure 8 depicts a graph showing absence of anti-FolR1 binding to erythrocytes. Erythrocytes were gated as CD235a positive population and binding of 9D11 IgG, 16D5 IgG, Mov19 IgG and DP47 IgG to this population was determined by flow cytometry. The antibodies were detected with a fluorescently labeled anti-human secondary antibody.

10 **Figures 9A-D** depict graphs summarizing activation marker upregulation in whole blood. CD25 and CD69 activation marker upregulation of CD4 T cells and CD8 T cells 24 h after addition of 9D11 FolR1 TCB, 16D5 FolR1 TCB, Mov19 FolR1 TCB and DP47 TCB was analyzed by flow cytometry.

Figure 10 Binding of 9D11 TCB a-glyco variants to HeLa cells. Binding of 9D11 FolR1 TCB a-glyco variants to HeLa cells was compared to binding of the original 9D11 TCB on HeLa cells.
 15 The antibodies were detected with a fluorescently labeled anti-human secondary antibody and binding was determined by flow cytometry.

Figures 11A-F depict graphs summarizing T cell mediated killing with 9D11 FolR1 TCB a-glyco variants of tumor cells. 9D11 FolR1 TCB a-glyco variants were used to test T cell mediated killing of (Fig. 11A-D) SKOV3, MKN-45 (as FolR1 negative control) and (Fig. 11E-F) HT-29 tumor cells in comparison to killing with the original 9D11 FolR1 TCB. As read-out
 20 LDH release after 24 h and 48 h was used.

Figures 12A-X depict graphs summarizing T cell mediated killing of primary epithelial cells. Primary epithelial cells with very low levels of FolR1 were used to test T cell mediated killing
 25 with 16D5 FolR1 TCB and 9D11 FolR1 TCB, DP47 TCB was included as a negative control and HT29 cells were included as positive control. (Figs. 12A-H) LDH release of human retinal pigment (HRP), human renal cortical (HRC), human bronchial (HB) and of HT29 cells was determined after 24 h and 48 h. CD25 and CD69 activation marker upregulation on CD4 T cells and CD8 T cells upon killing of (Figs. 12I-L) HRP, (Figs. 12M-P) HRC, (Figs. 12Q-T) HB and
 30 (Figs. 12 U-X) HT29 was determined after 48 h by flow cytometry.

-16-

Figures 13A-C show a comparison of different TCB formats with 16D5. Four different TCB formats containing the FolR1 binder 16D5 were compared in Fig. 13A binding to HeLa cells, in Fig. 14 B T cell mediated killing of SKOV3 cells after 24 h and 48 h and in Fig. 14C CD25 and CD69 activation marker upregulation on CD4 T cells and CD8 T cells 48 h after killing.

- 5 **Figures 14A-C** depict a comparison of different TCB formats with 9D11. Three different TCB formats containing the FolR1 binder 9D11 were compared in A) binding to HeLa cells, in B) T cell mediated killing of SKOV3 cells after 24 h and 48 h and in C) CD25 and CD69 activation marker upregulation on CD4 T cells and CD8 T cells 48 h after killing.

Figure 15 depicts a PK-profile of FOLR1 TCB in NOG mice for three different doses.

- 10 **Figure 16** illustrates an experimental protocol for efficacy study with FOLR1 TCB.

Figures 17A-B depict tumor growth curves. (Fig. 17A) Mean values and SEM of tumor volumes in the different treatment groups. (Fig. 17B) Tumor growth of single mice in all treatment groups. TGI (tumor growth inhibition) give the percentage of the Mean tumor volume compared to vehicle group.

- 15 **Figure 18** shows tumor weights at study termination.

Figures 19A-B show FACS analysis of tumor infiltrating T-cells at study day 32. (Fig. 19A) Tumor single cells suspensions were stained with anti-human CD3/CD4/CD8 and analyzed by flow cytometry. (Fig. 19B) Mean values and SEM of T-cell counts per mg tumor tissue in different treatment groups.

- 20 **Figures 20A-B** show FACS analysis for T-cell activation / degranulation and cytokine secretion at study day 32. CD4+ (Fig. 20A) and CD8+ (Fig. 20B) tumor infiltrating T-cells were stained for cytokines, activation and degranulation markers. Displayed are the mean values and SEM of T-cell counts per mg tumor tissue in different treatment groups.

- 25 **Figures 21A-B** show percent tumor lysis. SKOV3 cells were incubated with PBMCs in the presence of either kappa lambda FoLR1 TCB or DP47 TCB. After 24 h (Fig. 21A) and 48 h (Fig. 21B) killing of tumor cells was determined by measuring LDH release.

Figures 22A-D show CD25 and CD69 upregulation on CD4 T cells. SKOV3 cells were incubated with PBMCs in the presence of either kappa lambda FoLR1 TCB or DP47 TCB. After

-17-

48 h CD25 and CD69 upregulation on CD4 T cells (Fig. 22A-B) and CD8 T cells (Fig. 22C-D) was measured by flow cytometry.

Figures 23A-B show percent tumor lysis. T-cell killing of SKov-3 cells (medium FolR1) induced by 36F2 TCB, Mov19 TCB and 21A5 TCB after 24h (Fig. 23A) and 48 h (Fig. 23B) of incubation (E:T = 10:1, effectors human PBMCs).

Figures 24A-C show T-cell killing induced by 36F2 TCB, 16D5 TCB, 16D5 TCB classical, 16D5 TCB 1+1 and 16D5 TCB HT of Hela (high FolR1) (Fig. 24A), Skov-3 (medium FolR1) (Fig. 24B) and HT-29 (low FolR1) (Fig. 24C) human tumor cells (E:T = 10:1, effectors human PBMCs, incubation time 24 h). DP47 TCB was included as non-binding control.

Figures 25A-C show upregulation of CD25 and CD69 on human CD8+ (Fig. 25A, B) and CD4+ (Fig. 25C), T cells after T cell-mediated killing of Hela cells (high FolR1) (Fig. 25A), SKov-3 cells (medium FolR1) (Fig. 25B) and HT-29 cells (low FolR1) (Fig. 25C) (E:T = 10:1, 48 h incubation) induced by 36F2 TCB, 16D5 TCB and DP47 TCB (non-binding control).

Figures 26A-F show T-cell killing induced by 36F2 TCB, 16D5 TCB and DP47 TCB of human Renal Cortical Epithelial Cells (Fig. 26A, B), human Retinal Pigment Epithelial Cells (Fig. 26C, D) and HT-29 cells (Fig. 26E, F) cells after 24h (Fig. 26A, C, E) and 48 h (Fig. 26B, D, F) of incubation (E:T = 10:1, effectors human PBMCs).

Figure 27 depicts a table summarizing quantification of FolR1 binding sites on various normal and cancer cells lines.

Figures 28A-B show binding of 16D5 TCB and its corresponding CD3 deamidation variants 16D5 TCB N100A and 16D5 TCB S100aA and 9D11 TCB and its demidation variants 9D11 TCB N100A and 9D11 TCB S100aA to human CD3 expressed on Jurkat cells.

Figures 29A-B show T-cell killing of SKov-3 (medium FolR1) human tumor cells induced by 16D5 TCB and its corresponding CD3 deamidation variants 16D5 TCB N100A and 16D5 TCB S100aA (Fig. 29A) and 9D11 TCB and its demidation variants 9D11 TCB N100A and 9D11 TCB S100aA (Fig. 29B) (E:T = 10:1, effectors human PBMCs, incubation time 24 h). DP47 TCB was included as non-binding control.

-18-

Figure 30A-B show T-cell killing of HT-29 (low FolR1) human tumor cells induced by 16D5 TCB and its corresponding CD3 deamidation variants 16D5 TCB N100A and 16D5 TCB S100aA (Fig. 30A) and 9D11 TCB and its demidation variants 9D11 TCB N100A and 9D11 TCB S100aA (Fig. 30B) (E:T = 10:1, effectors human PBMCs, incubation time 24 h). DP47
5 TCB was included as non-binding control.

Figures 31A-C show mean fluorescence intensity and tumor cell lysis.

Figures 32A-E shows binding of 36F2 TCB, 16D5 TCB and 16D5 HC/LC variants to human
10 FolR1 expressed on Hela cells.

Figure 33 shows binding of 36F2 TCB, 16D5 TCB and the two 16D5 affinity reduced variants 16D5 W96Y/D52E TCB and 16D5 G49S/S93A TCB to human FolR1 on Hela cells.

Figures 34A-E show binding of 36F2 TCB, 16D5 TCB and 16D5 HC/LC variants to human
15 FolR1 expressed on HT-29 cells.

Figures 35A-D show binding of intermediate FolR1 binders (6E10 TCB, 14B1 TCB and 9C7 TCB), 16D5 TCB and 36F2 TCB to HEK293T cells expressing either human or mouse FolR1 or
20 FolR2.

Figure 36A-F show T-cell killing of Hela (high FolR1 expression), SKov-3 (medium FolR1 expression) and HT-29 (low FolR1 expression) human tumor cells induced by intermediate FolR1 binders (6E10 TCB, 14B1 TCB and 9C7 TCB), 16D5 TCB and 36F2 TCB after 24 h (A-
25 C) and 48 h (D-F) of incubation. Human PBMCs were used as effector cells (E:T = 10:1).

Figure 37A-F shows T-cell killing of Hela (high FolR1 expression), SKov-3 (medium FolR1 expression) and HT-29 (low FolR1 expression) human tumor cells induced by affinity reduced 16D5 variants (16D5-G49S/S93A TCB, 16D5-G49S/K53A TCB, 16D5 W96Y TCB, 16D5
30 W96Y/D52E TCB), 16D5 TCB and 36F2 TCB after 24 h (Fig.38A-C) and 48 h (Fig.38D-F) of incubation. Human PBMCs were used as effector cells (E:T = 10:1).

Figure 38A-F show T-cell killing of primary human cells from retinal pigment epithelium and renal cortical epithelium induced by affinity reduced 16D5 variants (16D5-G49S/S93A TCB,

-19-

16D5 W96Y/D52E TCB), 16D5 TCB, 36F2 TCB and the intermediate FolR1 binder 14B1 TCB was assessed after 24 h (Fig.39A-C) and 48 h (Fig.39D-F) of incubation (E:T = 10:1, effectors human PBMCs). HT-29 cells (low FolR1 expression) were included as control cell line and DP47 TCB served as non-binding control.

5

Figures 39A-B show single dose PK of FOLR1 TCB constructs in female NOG mice.

Figures 40A-G show in vivo efficacy of FOLR1 TCB constructs (16D5, 16D5 G49S/S93A and 16D5 W96Y/D52E) after human PBMC transfer in Hela-bearing NOG mice.

10

Figure 41 shows that Farletuzumab (dark green, second from the top) and Mov19 (grey, top) are able to bind on huFolR1 that is captured on 16D5, demonstrating that the 16D5 series binders recognize an epitope distinct from that recognized by either Farletuzumab or Mov19.

15

Detailed Description of the Invention

Definitions

Terms are used herein as generally used in the art, unless otherwise defined in the following.

As used herein, the term "antigen binding molecule" refers in its broadest sense to a molecule that specifically binds an antigenic determinant. Examples of antigen binding molecules are immunoglobulins and derivatives, e.g. fragments, thereof.

The term "bispecific" means that the antigen binding molecule is able to specifically bind to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises at least two antigen binding sites, each of which is specific for a different antigenic determinant. In certain embodiments the bispecific antigen binding molecule is capable of simultaneously binding two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.

The term "valent" as used herein denotes the presence of a specified number of antigen binding sites in an antigen binding molecule. As such, the term "monovalent binding to an antigen" denotes the presence of one (and not more than one) antigen binding site specific for the antigen in the antigen binding molecule.

An "antigen binding site" refers to the site, i.e. one or more amino acid residues, of an antigen binding molecule which provides interaction with the antigen. For example, the antigen binding site of an antibody comprises amino acid residues from the complementarity determining regions

-20-

(CDRs). A native immunoglobulin molecule typically has two antigen binding sites, a Fab molecule typically has a single antigen binding site.

As used herein, the term "antigen binding moiety" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, an antigen binding moiety is able to direct the entity to which it is attached (e.g. a second antigen binding moiety) to a target site, for example to a specific type of tumor cell or tumor stroma bearing the antigenic determinant. In another embodiment an antigen binding moiety is able to activate signaling through its target antigen, for example a T cell receptor complex antigen. Antigen binding moieties include antibodies and fragments thereof as further defined herein. Particular antigen binding moieties include an antigen binding domain of an antibody, comprising an antibody heavy chain variable region and an antibody light chain variable region. In certain embodiments, the antigen binding moieties may comprise antibody constant regions as further defined herein and known in the art. Useful heavy chain constant regions include any of the five isotypes: α , δ , ϵ , γ , or μ . Useful light chain constant regions include any of the two isotypes: κ and λ .

As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope," and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM). The proteins referred to as antigens herein, e.g., FolR1 and CD3, can be any native form the proteins from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g. mice and rats), unless otherwise indicated. In a particular embodiment the antigen is a human protein. Where reference is made to a specific protein herein, the term encompasses the "full-length", unprocessed protein as well as any form of the protein that results from processing in the cell. The term also encompasses naturally occurring variants of the protein, e.g. splice variants or allelic variants. Exemplary human proteins useful as antigens include, but are not limited to: FolR1 (Folate receptor alpha (FRA); Folate binding protein (FBP); human FolR1 UniProt no.: P15328; murine FolR1 UniProt no.: P35846; cynomolgus FolR1 UniProt no.: G7PR14) and CD3, particularly the epsilon subunit of CD3 (see UniProt no. P07766 (version 130), NCBI RefSeq no. NP_000724.1, SEQ ID NO:150 for the human sequence; or UniProt no. Q95LI5 (version 49), NCBI GenBank no. BAB71849.1, for the cynomolgus [*Macaca fascicularis*] sequence). The T

-21-

cell activating bispecific antigen binding molecule of the invention binds to an epitope of CD3 or a target cell antigen that is conserved among the CD3 or target antigen from different species. In certain embodiments the T cell activating bispecific antigen binding molecule of the invention binds to CD3 and FolR1, but does not bind to FolR2 (Folate receptor beta; FRB; human FolR2 UniProt no.: P14207) or FolR3 (Folate receptor gamma; human FolR3 UniProt no.: P41439).

By "specific binding" is meant that the binding is selective for the antigen and can be discriminated from unwanted or non-specific interactions. The ability of an antigen binding moiety to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance (SPR) technique (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of an antigen binding moiety to an unrelated protein is less than about 10% of the binding of the antigen binding moiety to the antigen as measured, e.g., by SPR. In certain embodiments, an antigen binding moiety that binds to the antigen, or an antigen binding molecule comprising that antigen binding moiety, has a dissociation constant (K_D) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M).

"Affinity" refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., an antigen binding moiety and an antigen, or a receptor and its ligand). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_D), which is the ratio of dissociation and association rate constants (k_{off} and k_{on} , respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by well-established methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).

"Reduced binding", for example reduced binding to an Fc receptor, refers to a decrease in affinity for the respective interaction, as measured for example by SPR. For clarity the term includes also reduction of the affinity to zero (or below the detection limit of the analytic method), i.e. complete abolishment of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the respective interaction.

-22-

“T cell activation” as used herein refers to one or more cellular response of a T lymphocyte, particularly a cytotoxic T lymphocyte, selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. The T cell activating bispecific antigen binding molecules of the invention are capable
5 of inducing T cell activation. Suitable assays to measure T cell activation are known in the art described herein.

A “target cell antigen” as used herein refers to an antigenic determinant presented on the surface of a target cell, for example a cell in a tumor such as a cancer cell or a cell of the tumor stroma. In particular “target cell antigen” refers to Folate Receptor 1.

10 As used herein, the terms “first” and “second” with respect to antigen binding moieties etc., are used for convenience of distinguishing when there is more than one of each type of moiety. Use of these terms is not intended to confer a specific order or orientation of the T cell activating bispecific antigen binding molecule unless explicitly so stated.

A “Fab molecule” refers to a protein consisting of the VH and CH1 domain of the heavy chain
15 (the “Fab heavy chain”) and the VL and CL domain of the light chain (the “Fab light chain”) of an immunoglobulin.

The term “Fab molecules having identical VLCL light chains” as used therein refers to binders that share one light chain but still have separate specificities, e.g., can bind CD3 or FolR1. In some embodiments the T- cell activating bispecific molecules comprise at least two Fab
20 molecules having identical VLCL light chains. The corresponding heavy chains are remodeled and confer specific binding to the T cell activating bispecific antigen CD3 and the target cell antigen FolR1, respectively.

By “fused” is meant that the components (e.g. a Fab molecule and an Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.

25 As used herein, the term “single-chain” refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In certain embodiments, one of the antigen binding moieties is a single-chain Fab molecule, i.e. a Fab molecule wherein the Fab light chain and the Fab heavy chain are connected by a peptide linker to form a single peptide chain. In a particular such embodiment, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab
30 heavy chain in the single-chain Fab molecule.

By a “crossover” Fab molecule (also termed “Crossfab”) is meant a Fab molecule wherein either the variable regions or the constant regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable

-23-

- region and the heavy chain constant region, and a peptide chain composed of the heavy chain variable region and the light chain constant region. For clarity, in a crossover Fab molecule wherein the variable regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant region is referred to herein as the “heavy chain” of the crossover Fab molecule. Conversely, in a crossover Fab molecule wherein the constant regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain variable region is referred to herein as the “heavy chain” of the crossover Fab molecule. An antibody that comprises one or more CrossFabs is referred to herein as “CrossMab.”
- 10 In contrast thereto, by a “conventional” Fab molecule is meant a Fab molecule in its natural format, i.e. comprising a heavy chain composed of the heavy chain variable and constant regions (VH-CH1), and a light chain composed of the light chain variable and constant regions (VL-CL). The term “immunoglobulin molecule” refers to a protein having the structure of a naturally occurring antibody. For example, immunoglobulins of the IgG class are heterotetrameric
- 15 glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a
- 20 light chain variable domain, followed by a constant light (CL) domain, also called a light chain constant region. The heavy chain of an immunoglobulin may be assigned to one of five types, called α (IgA), δ (IgD), ϵ (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes, e.g. γ_1 (IgG₁), γ_2 (IgG₂), γ_3 (IgG₃), γ_4 (IgG₄), α_1 (IgA₁) and α_2 (IgA₂). The light chain of an immunoglobulin may be assigned to one of two types, called kappa (κ) and lambda (λ), based
- 25 on the amino acid sequence of its constant domain. An immunoglobulin essentially consists of two Fab molecules and an Fc domain, linked via the immunoglobulin hinge region.
- The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, and antibody fragments so long as they exhibit the desired antigen-binding activity.
- 30 An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂, diabodies, linear antibodies, single-chain antibody molecules (e.g. scFv), and single-domain antibodies. For

-24-

a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see e.g. Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046. Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see e.g. U.S. Patent No. 6,248,516 B1). Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.

The term "antigen binding domain" refers to the part of an antibody that comprises the area which specifically binds to and is complementary to part or all of an antigen. An antigen binding domain may be provided by, for example, one or more antibody variable domains (also called antibody variable regions). Particularly, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

The term "hypervariable region" or "HVR", as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops"). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the complementarity determining regions

-25-

(CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. Hypervariable regions (HVRs) are also referred to as "complementarity determining regions" (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table A as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

TABLE A. CDR Definitions¹

CDR	Kabat	Chothia	AbM ²
V _H CDR1	31-35	26-32	26-35
V _H CDR2	50-65	52-58	50-58
V _H CDR3	95-102	95-102	95-102
V _L CDR1	24-34	26-32	24-34
V _L CDR2	50-56	50-52	50-56
V _L CDR3	89-97	91-96	89-97

¹Numbering of all CDR definitions in Table A is according to the numbering conventions set forth by Kabat et al. (see below).

²"AbM" with a lowercase "b" as used in Table A refers to the CDRs as defined by Oxford Molecular's "AbM" antibody modeling software.

Kabat et al. also defined a numbering system for variable region sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of "Kabat numbering" to any variable region sequence, without reliance on any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system set forth by Kabat et al., U.S. Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.

The polypeptide sequences of the sequence listing are not numbered according to the Kabat numbering system. However, it is well within the ordinary skill of one in the art to convert the numbering of the sequences of the Sequence Listing to Kabat numbering.

"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

The "class" of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

The term "Fc domain" or "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an IgG heavy chain might vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. A "subunit" of an Fc domain as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e. a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association. For example, a subunit of an IgG Fc domain comprises an IgG CH2 and an IgG CH3 constant domain.

A "modification promoting the association of the first and the second subunit of the Fc domain" is a manipulation of the peptide backbone or the post-translational modifications of an Fc domain subunit that reduces or prevents the association of a polypeptide comprising the Fc domain subunit with an identical polypeptide to form a homodimer. A modification promoting association as used herein particularly includes separate modifications made to each of the two Fc domain subunits desired to associate (i.e. the first and the second subunit of the Fc domain), wherein the modifications are complementary to each other so as to promote association of the

-27-

two Fc domain subunits. For example, a modification promoting association may alter the structure or charge of one or both of the Fc domain subunits so as to make their association sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between a polypeptide comprising the first Fc domain subunit and a polypeptide comprising the second
5 Fc domain subunit, which might be non-identical in the sense that further components fused to each of the subunits (e.g. antigen binding moieties) are not the same. In some embodiments the modification promoting association comprises an amino acid mutation in the Fc domain, specifically an amino acid substitution. In a particular embodiment, the modification promoting association comprises a separate amino acid mutation, specifically an amino acid substitution, in
10 each of the two subunits of the Fc domain.

The term “effector functions” refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular
15 phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation.

As used herein, the terms “engineer, engineered, engineering”, are considered to include any manipulation of the peptide backbone or the post-translational modifications of a naturally
20 occurring or recombinant polypeptide or fragment thereof. Engineering includes modifications of the amino acid sequence, of the glycosylation pattern, or of the side chain group of individual amino acids, as well as combinations of these approaches.

The term “amino acid mutation” as used herein is meant to encompass amino acid substitutions, deletions, insertions, and modifications. Any combination of substitution, deletion, insertion, and
25 modification can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., reduced binding to an Fc receptor, or increased association with another peptide. Amino acid sequence deletions and insertions include amino- and/or carboxy-terminal deletions and insertions of amino acids. Particular amino acid mutations are amino acid substitutions. For the purpose of altering e.g. the binding characteristics of an Fc
30 region, non-conservative amino acid substitutions, i.e. replacing one amino acid with another amino acid having different structural and/or chemical properties, are particularly preferred. Amino acid substitutions include replacement by non-naturally occurring amino acids or by naturally occurring amino acid derivatives of the twenty standard amino acids (e.g. 4-

-28-

hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis and the like. It is contemplated that methods of altering the side chain group of an amino acid by methods other than genetic engineering, such as chemical modification, may also be useful. Various designations may be used herein to indicate the same amino acid mutation. For example, a substitution from proline at position 329 of the Fc domain to glycine can be indicated as 329G, G329, G₃₂₉, P329G, or Pro329Gly.

As used herein, term "polypeptide" refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any chain of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "protein," "amino acid chain," or any other term used to refer to a chain of two or more amino acids, are included within the definition of "polypeptide," and the term "polypeptide" may be used instead of, or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. A polypeptide may be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including by chemical synthesis. A polypeptide of the invention may be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides may have a defined three-dimensional structure, although they do not necessarily have such structure. Polypeptides with a defined three-dimensional structure are referred to as folded, and polypeptides which do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and are referred to as unfolded.

By an "isolated" polypeptide or a variant, or derivative thereof is intended a polypeptide that is not in its natural milieu. No particular level of purification is required. For example, an isolated polypeptide can be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the purpose of the invention, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.

-29-

“Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not
5 considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to
10 achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered
15 under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons,
20 the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

25 where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless
30 specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

-30-

The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, e.g. messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA). A polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g. an amide bond, such as found in peptide nucleic acids (PNA). The term "nucleic acid molecule" refers to
5 any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a polynucleotide.

By "isolated" nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the
10 purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is
15 different from its natural chromosomal location. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding
20 site, or a transcription terminator.

By a nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the
25 reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the 5' or 3'
30 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%

-31-

identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).

The term "expression cassette" refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the invention comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.

The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery. In one embodiment, the expression vector of the invention comprises an expression cassette that comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.

The terms "host cell", "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, e.g. mammalian cultured cells, such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a

-32-

few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.

An "activating Fc receptor" is an Fc receptor that following engagement by an Fc domain of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector
5 functions. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism leading to the lysis of antibody-coated target cells by immune effector cells. The target cells are cells to which antibodies or derivatives thereof comprising an Fc region specifically bind, generally via the
10 protein part that is N-terminal to the Fc region. As used herein, the term "reduced ADCC" is defined as either a reduction in the number of target cells that are lysed in a given time, at a given concentration of antibody in the medium surrounding the target cells, by the mechanism of ADCC defined above, and/or an increase in the concentration of antibody in the medium surrounding the target cells, required to achieve the lysis of a given number of target cells in a
15 given time, by the mechanism of ADCC. The reduction in ADCC is relative to the ADCC mediated by the same antibody produced by the same type of host cells, using the same standard production, purification, formulation and storage methods (which are known to those skilled in the art), but that has not been engineered. For example the reduction in ADCC mediated by an antibody comprising in its Fc domain an amino acid substitution that reduces ADCC, is relative
20 to the ADCC mediated by the same antibody without this amino acid substitution in the Fc domain. Suitable assays to measure ADCC are well known in the art (see e.g. PCT publication no. WO 2006/082515 or PCT publication no. WO 2012/130831).

An "effective amount" of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.

25 A "therapeutically effective amount" of an agent, e.g. a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.

An "individual" or "subject" is a mammal. Mammals include, but are not limited to,
30 domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and non-human primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the individual or subject is a human.

The term "pharmaceutical composition" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

- 5 A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of a disease in the
10 individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved
15 prognosis. In some embodiments, T cell activating bispecific antigen binding molecules of the invention are used to delay development of a disease or to slow the progression of a disease.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule
20 that induces a biological activity of a native polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, including engineered antibody fragments, fragments or amino acid sequence variants of native polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a polypeptide may comprise contacting a polypeptide with
25 a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the polypeptide.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of
30 such therapeutic products.

All references, publication, patents and patent applications disclosed herein are hereby incorporated by reference in their entirety.

Detailed Description of the Embodiments

The T cell activating bispecific antigen binding molecule of the invention is bispecific, i.e. it comprises at least two antigen binding moieties capable of specific binding to two distinct antigenic determinants, i.e. to CD3 and to FolR1. According to the invention, the antigen binding moieties are Fab molecules (i.e. antigen binding domains composed of a heavy and a light chain, each comprising a variable and a constant region). In one embodiment said Fab molecules are human. In another embodiment said Fab molecules are humanized. In yet another embodiment said Fab molecules comprise human heavy and light chain constant regions.

The T cell activating bispecific antigen binding molecule of the invention is capable of simultaneous binding to the target cell antigen FolR1 and CD3. In one embodiment, the T cell activating bispecific antigen binding molecule is capable of crosslinking a T cell and a FolR1 expressing target cell by simultaneous binding to the target cell antigen FolR1 and CD3. In an even more particular embodiment, such simultaneous binding results in lysis of the FolR1 expressing target cell, particularly a FolR1 expressing tumor cell. In one embodiment, such simultaneous binding results in activation of the T cell. In other embodiments, such simultaneous binding results in a cellular response of a T lymphocyte, particularly a cytotoxic T lymphocyte, selected from the group of: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. In one embodiment, binding of the T cell activating bispecific antigen binding molecule to CD3 without simultaneous binding to the target cell antigen FolR1 does not result in T cell activation.

In one embodiment, the T cell activating bispecific antigen binding molecule is capable of re-directing cytotoxic activity of a T cell to a FolR1 expressing target cell. In a particular embodiment, said re-direction is independent of MHC-mediated peptide antigen presentation by the target cell and and/or specificity of the T cell.

Particularly, a T cell according to some of the embodiments of the invention is a cytotoxic T cell. In some embodiments the T cell is a CD4⁺ or a CD8⁺ T cell, particularly a CD8⁺ T cell.

The T cell activating bispecific antigen binding molecule of the invention comprises at least one antigen binding moiety capable of binding to CD3 (also referred to herein as an “CD3 antigen binding moiety” or “first antigen binding moiety”). In a particular embodiment, the T cell activating bispecific antigen binding molecule comprises not more than one antigen binding moiety capable of specific binding to CD3. In one embodiment the T cell activating bispecific antigen binding molecule provides monovalent binding to CD3. In a particular embodiment CD3 is human CD3 or cynomolgus CD3, most particularly human CD3. In a particular embodiment

-35-

the CD3 antigen binding moiety is cross-reactive for (i.e. specifically binds to) human and cynomolgus CD3. In some embodiments, the first antigen binding moiety is capable of specific binding to the epsilon subunit of CD3 (see UniProt no. P07766 (version 130), NCBI RefSeq no. NP_000724.1, SEQ ID NO:150 for the human sequence; UniProt no. Q95LI5 (version 49), NCBI GenBank no. BAB71849.1, for the cynomolgus [*Macaca fascicularis*] sequence).

In some embodiments, the CD3 antigen binding moiety comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.

10 In one embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34.

In one embodiment the CD3 antigen binding moiety comprises a variable heavy chain
15 comprising an amino acid sequence of: SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of: SEQ ID NO: 31.

In one embodiment the CD3 antigen binding moiety comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or
20 100% identical to SEQ ID NO: 31.

The T cell activating bispecific antigen binding molecule of the invention comprises at least one antigen binding moiety capable of binding to the target cell antigen FolR1 (also referred to herein as an "FolR1 binding moiety" or "second" or "third" antigen binding moiety). In one embodiment, the antigen binding moiety capable of binding to the target cell antigen FolR1 does
25 not bind to FolR2 or FolR3. In a particular embodiment the FolR1 antigen binding moiety is cross-reactive for (i.e. specifically binds to) human and cynomolgus FolR1. In certain embodiments, the T cell activating bispecific antigen binding molecule comprises two antigen binding moieties capable of binding to the target cell antigen FolR1. In a particular such embodiment, each of these antigen binding moieties specifically binds to the same antigenic
30 determinant. In an even more particular embodiment, all of these antigen binding moieties are identical. In one embodiment the T cell activating bispecific antigen binding molecule comprises not more than two antigen binding moieties capable of binding to FolR1.

-36-

The FolR1 binding moiety is generally a Fab molecule that specifically binds to FolR1 and is able to direct the T cell activating bispecific antigen binding molecule to which it is connected to a target site, for example to a specific type of tumor cell that expresses FolR1.

In one aspect the present invention provides a T cell activating bispecific antigen binding molecule comprising

- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3, and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34; and
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1).

In one embodiment the first antigen binding moiety which is a Fab molecule capable of specific binding to CD3 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

In one embodiment the T cell activating bispecific antigen binding molecule additionally comprises

- (iii) a third antigen binding moiety which is a Fab molecule capable of specific binding to FolR1.

In one such embodiment the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one such embodiment the third antigen binding moiety is identical to the second antigen binding moiety.

In one embodiment the T cell activating bispecific antigen binding molecule of any of the above embodiments additionally comprises an Fc domain composed of a first and a second subunit capable of stable association.

In one embodiment the first antigen binding moiety and the second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.

-37-

In one embodiment the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, optionally via a peptide linker.

In a further particular embodiment, not more than one antigen binding moiety capable of specific binding to CD3 is present in the T cell activating bispecific antigen binding molecule (i.e. the T cell activating bispecific antigen binding molecule provides monovalent binding to CD3).

T cell activating bispecific antigen binding molecule with a common light chain

The inventors of the present invention generated a bispecific antibody wherein the binding moieties share a common light chain that retains the specificity and efficacy of the parent monospecific antibody for CD3 and can bind a second antigen (e.g., FolR1) using the same light chain. The generation of a bispecific molecule with a common light chain that retains the binding properties of the parent antibody is not straight-forward as the common CDRs of the hybrid light chain have to effectuate the binding specificity for both targets. In one aspect the present invention provides a T cell activating bispecific antigen binding molecule comprising a first and a second antigen binding moiety, one of which is a Fab molecule capable of specific binding to CD3 and the other one of which is a Fab molecule capable of specific binding to FolR1, wherein the first and the second Fab molecule have identical VLCL light chains. In one embodiment said identical light chain (VLCL) comprises the light chain CDRs of SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34. In one embodiment said identical light chain (VLCL) comprises SEQ ID NO. 35.

In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3, and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.

- In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and
- 5 the light chain CDR3 of SEQ ID NO:34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 16, the heavy chain CDR2 of SEQ ID NO: 17, the heavy chain CDR3 of SEQ ID NO:18, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34.
- 10 In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising
- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- 15 (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- 20 In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising
- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3, and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and
- 25 at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 16, SEQ ID NO:
- 30 275 and SEQ ID NO: 315 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.

-39-

In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

- 5 (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3, and which comprises the heavy chain complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39, and the light chain CDR amino acid sequences of SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34;
- 10 (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) and which comprises the heavy chain complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 16, SEQ ID NO: 275 and SEQ ID NO: 315, and the light chain CDR amino acid sequences of SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34.

In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

- 15 (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31;
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 274 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

- 25 (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

-40-

In a further embodiment, the antigen binding moiety that is specific for FolR1 comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:15 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 31 or variants thereof that retain
5 functionality.

In one embodiment the T cell activating bispecific antigen binding molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:15, and a polypeptide sequence that is at least about 95%, 96%, 97%,
10 98%, 99% or 100% identical to SEQ ID NO: 31.

In one embodiment the T cell activating bispecific antigen binding molecule additionally comprises

(iii) a third antigen binding moiety (which is a Fab molecule) capable of specific
15 binding to FolR1.

In one such embodiment the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one such embodiment the third antigen binding moiety is identical to
20 the second antigen binding moiety.

Hence in one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

(i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3,
25 and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;
(ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to
30 Folate Receptor 1 (FolR1) and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.

-41-

- (iii) a third antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) and which comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.

In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO: 39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO: 34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 16, the heavy chain CDR2 of SEQ ID NO: 17, the heavy chain CDR3 of SEQ ID NO: 18, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO: 34.

In one embodiment the present invention provides a T cell activating bispecific antigen binding molecule comprising

- (i) a first antigen binding moiety which is a Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- (iii) a third antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

Thus, in one embodiment, the invention relates to bispecific molecules wherein at least two binding moieties have identical light chains and corresponding remodeled heavy chains that confer the specific binding to the T cell activating antigen CD3 and the target cell antigen FolR1, respectively. The use of this so-called 'common light chain' principle, i.e. combining two binders that share one light chain but still have separate specificities, prevents light chain

-42-

mispairing. Thus, there are less side products during production, facilitating the homogenous preparation of T cell activating bispecific antigen binding molecules.

5 The components of the T cell activating bispecific antigen binding molecule can be fused to each other in a variety of configurations. Exemplary configurations are depicted in Figures 1A-I and are further described below.

In some embodiments, said T cell activating bispecific antigen binding molecule further comprises an Fc domain composed of a first and a second subunit capable of stable association. Below exemplary embodiments of T cell activating bispecific antigen binding molecule
10 comprising an Fc domain are described.

T cell activating bispecific antigen binding molecule with a crossover Fab fragment

The inventors of the present invention generated a second bispecific antibody format wherein one of the binding moieties is a crossover Fab fragment. In one aspect of the invention a
15 monovalent bispecific antibody is provided, wherein one of the Fab fragments of an IgG molecule is replaced by a crossover Fab fragment. Crossover Fab fragments are Fab fragments wherein either the variable regions or the constant regions of the heavy and light chain are exchanged. Bispecific antibody formats comprising crossover Fab fragments have been described, for example, in WO2009080252, WO2009080253, WO2009080251, WO2009080254,
20 WO2010/136172, WO2010/145792 and WO2013/026831. In a particular embodiment, the first antigen binding moiety is a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged. Such modification prevent mispairing of heavy and light chains from different Fab molecules, thereby improving the yield and purity of the T cell activating bispecific antigen binding molecule of the invention in
25 recombinant production. In a particular crossover Fab molecule useful for the T cell activating bispecific antigen binding molecule of the invention, the variable regions of the Fab light chain and the Fab heavy chain are exchanged. In another crossover Fab molecule useful for the T cell activating bispecific antigen binding molecule of the invention, the constant regions of the Fab light chain and the Fab heavy chain are exchanged.

30 In one embodiment the T cell activating bispecific antigen binding molecule comprises

(i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3, comprising at least one heavy chain complementarity determining region (CDR)

-43-

selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;

- (ii) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 65.

In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO: 39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO: 34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 56, the heavy chain CDR3 of SEQ ID NO: 57, the light chain CDR1 of SEQ ID NO: 59, the light chain CDR2 of SEQ ID NO: 60, and the light chain CDR3 of SEQ ID NO: 65.

15

In one embodiment, the second antigen binding moiety is a conventional Fab molecule.

In one embodiment the T cell activating bispecific antigen binding molecule comprises

- (i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 55 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 64.

25

In one embodiment, the second antigen binding moiety is a conventional Fab molecule.

In a further embodiment, the antigen binding moiety that is specific for FolR1 comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 55 and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 64 or variants thereof that retain functionality.

30

-44-

In one embodiment the T cell activating bispecific antigen binding molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 31, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:55, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 64.

In one embodiment the T cell activating bispecific antigen binding molecule additionally comprises

10 (iii) a third antigen binding moiety capable of specific binding to FolR1.

In one embodiment, the third antigen binding moiety is a conventional Fab molecule. In one embodiment, the third antigen binding moiety is a crossover Fab molecule.

15 In one such embodiment the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one such embodiment the third antigen binding moiety is identical to the second antigen binding moiety.

20 In one embodiment the T cell activating bispecific antigen binding molecule comprises

(i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3, comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;

(ii) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 65.

30 (iii) a third antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from

-45-

the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 65.

In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 56, the heavy chain CDR3 of SEQ ID NO:57, the light chain CDR1 of SEQ ID NO: 59, the light chain CDR2 of SEQ ID NO: 60, and the light chain CDR3 of SEQ ID NO:65.

10

In one embodiment, the second antigen binding moiety and the third antigen binding moiety are both a conventional Fab molecule.

In one embodiment the T cell activating bispecific antigen binding molecule comprises

15 (i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.

(ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid

20 sequence of SEQ ID NO: 55 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 64.

(iii) a third antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 55 and a variable light chain comprising an amino acid sequence of SEQ ID NO:

25 64.

In one embodiment, the second antigen binding moiety and the third antigen binding moiety are both a conventional Fab molecule.

In one embodiment the T cell activating bispecific antigen binding molecule comprises

(i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding

30 to CD3, comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and

-46-

at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;

- (ii) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 50 and at least one light chain CDR selected from the group of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54.

In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO: 39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO: 34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO: 50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO: 54.

- 15 In one embodiment, the second antigen binding moiety is a conventional Fab molecule. In one embodiment, the second antigen binding moiety is a crossover Fab molecule.

In one embodiment the T cell activating bispecific antigen binding molecule comprises

- (i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 49 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 51.

In one embodiment, the second antigen binding moiety is a conventional Fab molecule. In one embodiment, the second antigen binding moiety is a crossover Fab molecule.

- In a further embodiment, the antigen binding moiety that is specific for FolR1 comprises a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 49 and a light chain variable region sequence that is at least about 95%,

-47-

96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 51 or variants thereof that retain functionality.

In one embodiment the T cell activating bispecific antigen binding molecule comprises a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 31, a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 49, and a polypeptide sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 51.

10 In one embodiment the T cell activating bispecific antigen binding molecule additionally comprises

(iii) a third antigen binding moiety capable of specific binding to FolR1.

In one embodiment, the third antigen binding moiety is a conventional Fab molecule. In one embodiment, the second antigen binding moiety is a crossover Fab molecule.

In one such embodiment the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one such embodiment the third antigen binding moiety is identical to the second antigen binding moiety.

In one embodiment the T cell activating bispecific antigen binding molecule comprises

(i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3, comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;

(ii) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 49 and at least one light chain CDR selected from the group of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54.

-48-

(iii) a third antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 50 and at least one light chain CDR selected from the group of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54.

- 5 In one such embodiment the CD3 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and the FolR1 antigen binding moiety comprises the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain
10 CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54.

In one embodiment, the second antigen binding moiety and the third antigen binding moiety are both a conventional Fab molecule.

15

In one embodiment the T cell activating bispecific antigen binding molecule comprises

- (i) a first antigen binding moiety which is a crossover Fab molecule capable of specific binding to CD3 comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
- 20 (ii) a second antigen binding moiety which is a Fab molecule capable of specific binding to Folate Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 49 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 51.
- (iii) a third antigen binding moiety which is a Fab molecule capable of specific binding to Folate
25 Receptor 1 (FolR1) comprising a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 49 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 51.

In one embodiment, the second antigen binding moiety and the third antigen binding moiety are both a conventional Fab molecule.

- 30 Thus, in one embodiment, the invention relates to bispecific molecules wherein two binding moieties confer specific binding to FolR1 and one binding moiety confers specificity to the T cell activating antigen CD3. One of the heavy chains is modified to ensure proper pairing of the

-49-

heavy and light chains, thus eliminating the need for a common light chain approach. The presence of two FolR1 binding sites enables appropriate engagement with the target antigen FolR1 and the activation of T cells.

The components of the T cell activating bispecific antigen binding molecule can be fused to each other in a variety of configurations. Exemplary configurations are depicted in Figures 1A-I and are further described below.

In some embodiments, said T cell activating bispecific antigen binding molecule further comprises an Fc domain composed of a first and a second subunit capable of stable association. Below exemplary embodiments of T cell activating bispecific antigen binding molecule comprising an Fc domain are described.

T cell activating bispecific antigen binding molecule formats

As depicted above and in Figures 1A-I, in one embodiment the T cell activating bispecific antigen binding molecules comprise at least two Fab fragments having identical light chains (VLCL) and having different heavy chains (VHCL) which confer the specificities to two different antigens, i.e. one Fab fragment is capable of specific binding to a T cell activating antigen CD3 and the other Fab fragment is capable of specific binding to the target cell antigen FolR1.

In another embodiment the T cell activating bispecific antigen binding molecule comprises at least two antigen binding moieties (Fab molecules), one of which is a crossover Fab molecule and one of which is a conventional Fab molecule. In one such embodiment the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule and the second antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule.

These components of the T cell activating bispecific antigen binding molecule can be fused to each other in a variety of configurations. Exemplary configurations are depicted in Figures 1A-I.

In some embodiments, the first and second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain. In a specific such embodiment, the T cell activating bispecific antigen binding molecule essentially consists of a first and a second antigen binding moiety, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, wherein the first and second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain. In one such embodiment the first

-50-

and second antigen binding moiety both are Fab fragments and have identical light chains (VLCL). In another such embodiment the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule and the second antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule.

- 5 In one embodiment, the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety. In a specific such embodiment, the T cell activating bispecific antigen binding molecule essentially consists of a first and a second
10 antigen binding moiety, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, wherein the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety, and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain. In one such embodiment
15 the first and second antigen binding moiety both are Fab fragments and have identical light chains (VLCL). In another such embodiment the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule and the second antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule. Optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may
20 additionally be fused to each other.

- In other embodiments, the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In a particular such embodiment, the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety. In a specific
25 such embodiment, the T cell activating bispecific antigen binding molecule essentially consists of a first and a second antigen binding moiety, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, wherein the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of
30 the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain. In one such embodiment the first and second antigen binding moiety both are Fab fragments and have identical light chains (VLCL). In another such embodiment the first antigen binding moiety

-51-

capable of specific binding to CD3 is a crossover Fab molecule and the second antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule. Optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may additionally be fused to each other.

5

The antigen binding moieties may be fused to the Fc domain or to each other directly or through a peptide linker, comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and are described herein. Suitable, non-immunogenic peptide linkers include, for example, $(G_4S)_n$ (SEQ ID NO: 300), $(SG_4)_n$ (SEQ ID NO: 301), $(G_4S)_n$ (SEQ ID NO: 300) or $G_4(SG_4)_n$ (SEQ ID NO: 302) peptide linkers. “n” is generally a number between 1 and 10, typically between 2 and 4. A particularly suitable peptide linker for fusing the Fab light chains of the first and the second antigen binding moiety to each other is $(G_4S)_2$ (SEQ ID NO: 303). An exemplary peptide linker suitable for connecting the Fab heavy chains of the first and the second antigen binding moiety is EPKSC(D)- $(G_4S)_2$ (SEQ ID NOS 304 and 305).
15 Additionally, linkers may comprise (a portion of) an immunoglobulin hinge region. Particularly where an antigen binding moiety is fused to the N-terminus of an Fc domain subunit, it may be fused via an immunoglobulin hinge region or a portion thereof, with or without an additional peptide linker.

20 It has been found by the inventors of the present invention that T cell activating bispecific antigen binding molecule comprising two binding moieties specific for the target cell antigen FolR have superior characteristics compared to T cell activating bispecific antigen binding molecule comprising only one binding moiety specific for the target cell antigen FolR.

25 Accordingly, in certain embodiments, the T cell activating bispecific antigen binding molecule of the invention further comprises a third antigen binding moiety which is a Fab molecule capable of specific binding to FolR. In one such embodiment the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences. In one such
30 embodiment the third antigen binding moiety is identical to the second antigen binding moiety (i.e. they comprise the same amino acid sequences).

-52-

In one embodiment, the first and second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety. In a specific such embodiment, the T cell activating bispecific antigen binding molecule essentially consists of a first, a second and a third antigen binding moiety, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, wherein the first and second antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety. In one such embodiment the first, second and third antigen binding moiety are conventional Fab fragments and have identical light chains (VLCL). In another such embodiment the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule and the second and third antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule. Optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the third antigen binding moiety may additionally be fused to each other.

Accordingly, in certain embodiments, the T cell activating bispecific antigen binding molecule of the invention comprises five polypeptide chains that form a first, a second and a third antigen binding moiety wherein the first antigen binding moiety is capable of binding CD3 and the second and the third antigen binding moiety each are capable of binding Folate Receptor 1 (FolR1). The first and the second polypeptide chain comprise, in amino (N)-terminal to carboxyl (C)-terminal direction, a first light chain variable domain (VLD1) and a first light chain constant domain (CLD1). The third polypeptide chain comprises, in N-terminal to C-terminal direction, second light chain variable domain (VLD2) and a second heavy chain constant domain 1 (CH1D2). The fourth polypeptide chain comprises, in N-terminal to C-terminal direction, a first heavy chain variable domain (VHD1), a first heavy chain constant domain 1 (CH1D1), a first heavy chain constant domain 2 (CH2D1) and a first heavy chain constant domain 3 (CH3D1). The fifth polypeptide chain comprises VHD1, CH1D1, a second heavy chain variable domain (VHD2), a second light chain constant domain (CLD2), a second heavy chain constant domain 2 (CH2D2) and a second heavy chain constant domain 3 (CH3D2). The third polypeptide chain and VHD2 and CLD2 of the fifth polypeptide chain form the first antigen binding moiety capable of binding CD3. The second polypeptide chain and VHD1 and CH1D1 of the fifth polypeptide chain form the third binding moiety capable of binding to FolR1. The first

-53-

polypeptide chain and VHD1 and CH1D1 of the fourth polypeptide chain form the second binding moiety capable of binding to FolR1.

- In another embodiment, the second and the third antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety. In a specific such embodiment, the T cell activating bispecific antigen binding molecule essentially consists of a first, a second and a third antigen binding moiety, an Fc domain composed of a first and a second subunit, and optionally one or more peptide linkers, wherein the second and third antigen binding moiety are each fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the third antigen binding moiety. In one such embodiment the first, second and third antigen binding moiety are conventional Fab fragments and have identical light chains (VLCL). In another such embodiment the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule and the second and third antigen binding moiety capable of specific binding to FolR is a conventional Fab molecule. Optionally, the Fab light chain of the first antigen binding moiety and the Fab light chain of the second antigen binding moiety may additionally be fused to each other.
- The antigen binding moieties may be fused to the Fc domain directly or through a peptide linker. In a particular embodiment the antigen binding moieties are each fused to the Fc domain through an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is a human IgG₁ hinge region.
- In one embodiment the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule. In a particular embodiment the immunoglobulin molecule is an IgG class immunoglobulin. In an even more particular embodiment the immunoglobulin is an IgG₁ subclass immunoglobulin. In another embodiment the immunoglobulin is an IgG₄ subclass immunoglobulin. In a further particular embodiment the immunoglobulin is a human immunoglobulin. In other embodiments the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin.

-54-

In a particular embodiment said T cell activating bispecific antigen binding molecule the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule, and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, wherein the first,
5 second and third antigen binding moiety are conventional Fab fragments and have identical light chains (VLCL) , wherein the first antigen binding moiety capable of specific binding to CD3 comprises at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34;
10 and the second and the third antigen binding moiety capable of specific binding to FolR1 comprise at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34.

15 In a particular embodiment said T cell activating bispecific antigen binding molecule the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule, and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, wherein the first, second and third antigen binding moiety are conventional Fab fragments and have identical light
20 chains (VLCL), wherein the first antigen binding moiety capable of specific binding to CD3 comprises a variable heavy chain comprising a sequence of SEQ ID NO: 36, a variable light chain comprising a sequence of SEQ ID NO: 31; and the second and the third antigen binding moiety capable of specific binding to FolR1 comprise a variable heavy chain comprising a sequence of SEQ ID NO: 15, a variable light chain comprising a sequence of SEQ ID NO: 31.

25

In a particular embodiment said T cell activating bispecific antigen binding molecule the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule, and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety and the first antigen
30 binding moiety capable of specific binding to CD3 is a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged, comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one

-55-

light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34; and the second and the third antigen binding moiety capable of specific binding to FolR1 comprise at least one heavy chain complementarity determining region (CDR) selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60 and SEQ ID NO: 65.

In a particular embodiment said T cell activating bispecific antigen binding molecule the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule, and the third antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety and the first antigen binding moiety capable of specific binding to CD3 is a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged, wherein the first antigen binding moiety capable of specific binding to CD3 comprises a variable heavy chain comprising a sequence of SEQ ID NO: 36, a variable light chain comprising a sequence of SEQ ID NO: 31; and the second and the third antigen binding moiety capable of specific binding to FolR1 comprise a variable heavy chain comprising a sequence of SEQ ID NO: 55, a variable light chain comprising a sequence of SEQ ID NO: 65.

In one embodiment the T cell activating bispecific antigen binding molecule is monovalent for each antigen. In a particular embodiment the T cell activating bispecific antigen binding molecule can bind to human CD3 and human folate receptor alpha (FolR1) and was made without employing a hetero-dimerization approach, such as, e.g., knob-into-hole technology. For example, the molecule can be produced by employing a common light chain library and CrossMab technology. In a particular embodiment, The variable region of the CD3 binder is fused to the CH1 domain of a standard human IgG1 antibody to form the VLVH crossed molecule (fused to Fc) which is common for both specificities. To generate the crossed counterparts (VHCL), a CD3 specific variable heavy chain domain is fused to a constant human λ light chain whereas a variable heavy chain domain specific for human FolR1 (e.g., isolated from a common light chain library) is fused to a constant human κ light chain. The resulting desired molecule with correctly paired chains comprises both kappa and lambda light chains or fragments thereof. Consequently, this desired bispecific molecule species can be purified from mispaired or homodimeric species with sequential purification steps selecting for kappa and lambda light chain, in either sequence. In one particular embodiment, purification of the desired

-56-

bispecific antibody employs subsequent purification steps with KappaSelect and LambdaFabSelect columns (GE Healthcare) to remove undesired homodimeric antibodies.

Fc domain

5 The Fc domain of the T cell activating bispecific antigen binding molecule consists of a pair of polypeptide chains comprising heavy chain domains of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain are capable of stable association with each other. In one embodiment the T cell
10 activating bispecific antigen binding molecule of the invention comprises not more than one Fc domain.

In one embodiment according to the invention the Fc domain of the T cell activating bispecific antigen binding molecule is an IgG Fc domain. In a particular embodiment the Fc domain is an IgG₁ Fc domain. In another embodiment the Fc domain is an IgG₄ Fc domain. In a more specific
15 embodiment, the Fc domain is an IgG₄ Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), particularly the amino acid substitution S228P. This amino acid substitution reduces in vivo Fab arm exchange of IgG₄ antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In a further particular embodiment the Fc domain is human. An exemplary sequence of a human IgG₁ Fc region is given in SEQ ID
20 NO:245.

Fc domain modifications promoting heterodimerization

T cell activating bispecific antigen binding molecules according to the invention comprise different antigen binding moieties, fused to one or the other of the two subunits of the Fc domain,
25 thus the two subunits of the Fc domain are typically comprised in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization leads to several possible combinations of the two polypeptides. To improve the yield and purity of T cell activating bispecific antigen binding molecules in recombinant production, it will thus be advantageous to introduce in the Fc domain of the T cell activating bispecific antigen binding
30 molecule a modification promoting the association of the desired polypeptides.

Accordingly, in particular embodiments the Fc domain of the T cell activating bispecific antigen binding molecule according to the invention comprises a modification promoting the association of the first and the second subunit of the Fc domain. The site of most extensive protein-protein

-57-

interaction between the two subunits of a human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one embodiment said modification is in the CH3 domain of the Fc domain.

In a specific embodiment said modification is a so-called “knob-into-hole” modification, comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole”

5 modification in the other one of the two subunits of the Fc domain.

The knob-into-hole technology is described e.g. in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the

10 protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones

15 (e.g. alanine or threonine).

Accordingly, in a particular embodiment, in the CH3 domain of the first subunit of the Fc domain of the T cell activating bispecific antigen binding molecule an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within

20 the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.

The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides,

25 e.g. by site-specific mutagenesis, or by peptide synthesis.

In a specific embodiment, in the CH3 domain of the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V). In one embodiment, in the second subunit of the Fc domain additionally the

30 threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A).

In yet a further embodiment, in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc

-58-

domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C). Introduction of these two cysteine residues results in formation of a disulfide bridge between the two subunits of the Fc domain, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

- 5 In a particular embodiment the antigen binding moiety capable of binding to CD3 is fused (optionally via the antigen binding moiety capable of binding to FolR1 on a target cell antigen) to the first subunit of the Fc domain (comprising the “knob” modification). Without wishing to be bound by theory, fusion of the antigen binding moiety capable of binding to CD3 to the knob-containing subunit of the Fc domain will (further) minimize the generation of antigen binding
10 molecules comprising two antigen binding moieties capable of binding to CD3 (steric clash of two knob-containing polypeptides).

- In an alternative embodiment a modification promoting association of the first and the second subunit of the Fc domain comprises a modification mediating electrostatic steering effects, e.g. as described in PCT publication WO 2009/089004. Generally, this method involves replacement
15 of one or more amino acid residues at the interface of the two Fc domain subunits by charged amino acid residues so that homodimer formation becomes electrostatically unfavorable but heterodimerization electrostatically favorable.

Fc domain modifications abolishing Fc receptor binding and/or effector function

- The Fc domain confers to the T cell activating bispecific antigen binding molecule favorable
20 pharmacokinetic properties, including a long serum half-life which contributes to good accumulation in the target tissue and a favorable tissue-blood distribution ratio. At the same time it may, however, lead to undesirable targeting of the T cell activating bispecific antigen binding molecule to cells expressing Fc receptors rather than to the preferred antigen-bearing cells. Moreover, the co-activation of Fc receptor signaling pathways may lead to cytokine release
25 which, in combination with the T cell activating properties and the long half-life of the antigen binding molecule, results in excessive activation of cytokine receptors and severe side effects upon systemic administration. Activation of (Fc receptor-bearing) immune cells other than T cells may even reduce efficacy of the T cell activating bispecific antigen binding molecule due to the potential destruction of T cells e.g. by NK cells.

- 30 Accordingly, in particular embodiments the Fc domain of the T cell activating bispecific antigen binding molecules according to the invention exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG₁ Fc domain. In one such embodiment the Fc domain (or the T cell activating bispecific antigen binding molecule

-59-

comprising said Fc domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10% and most preferably less than 5% of the binding affinity to an Fc receptor, as compared to a native IgG₁ Fc domain (or a T cell activating bispecific antigen binding molecule comprising a native IgG₁ Fc domain), and/or less than 50%, preferably less than 20%, more preferably less than 10% and most preferably less than 5% of the effector function, as compared to a native IgG₁ Fc domain domain (or a T cell activating bispecific antigen binding molecule comprising a native IgG₁ Fc domain). In one embodiment, the Fc domain domain (or the T cell activating bispecific antigen binding molecule comprising said Fc domain) does not substantially bind to an Fc receptor and/or induce effector function. In a particular embodiment the Fc receptor is an Fc γ receptor. In one embodiment the Fc receptor is a human Fc receptor. In one embodiment the Fc receptor is an activating Fc receptor. In a specific embodiment the Fc receptor is an activating human Fc γ receptor, more specifically human Fc γ RIIIa, Fc γ RI or Fc γ RIIa, most specifically human Fc γ RIIIa. In one embodiment the effector function is one or more selected from the group of CDC, ADCC, ADCP, and cytokine secretion. In a particular embodiment the effector function is ADCC. In one embodiment the Fc domain domain exhibits substantially similar binding affinity to neonatal Fc receptor (FcRn), as compared to a native IgG₁ Fc domain domain. Substantially similar binding to FcRn is achieved when the Fc domain (or the T cell activating bispecific antigen binding molecule comprising said Fc domain) exhibits greater than about 70%, particularly greater than about 80%, more particularly greater than about 90% of the binding affinity of a native IgG₁ Fc domain (or the T cell activating bispecific antigen binding molecule comprising a native IgG₁ Fc domain) to FcRn.

In certain embodiments the Fc domain is engineered to have reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a non-engineered Fc domain. In particular embodiments, the Fc domain of the T cell activating bispecific antigen binding molecule comprises one or more amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function. Typically, the same one or more amino acid mutation is present in each of the two subunits of the Fc domain. In one embodiment the amino acid mutation reduces the binding affinity of the Fc domain to an Fc receptor. In one embodiment the amino acid mutation reduces the binding affinity of the Fc domain to an Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In embodiments where there is more than one amino acid mutation that reduces the binding affinity of the Fc domain to the Fc receptor, the combination of these amino acid mutations may reduce the binding affinity of the Fc domain to an Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one

-60-

embodiment the T cell activating bispecific antigen binding molecule comprising an engineered Fc domain exhibits less than 20%, particularly less than 10%, more particularly less than 5% of the binding affinity to an Fc receptor as compared to a T cell activating bispecific antigen binding molecule comprising a non-engineered Fc domain. In a particular embodiment the Fc receptor is an Fc γ receptor. In some embodiments the Fc receptor is a human Fc receptor. In some embodiments the Fc receptor is an activating Fc receptor. In a specific embodiment the Fc receptor is an activating human Fc γ receptor, more specifically human Fc γ RIIIa, Fc γ RI or Fc γ RIIa, most specifically human Fc γ RIIIa. Preferably, binding to each of these receptors is reduced. In some embodiments binding affinity to a complement component, specifically binding affinity to C1q, is also reduced. In one embodiment binding affinity to neonatal Fc receptor (FcRn) is not reduced. Substantially similar binding to FcRn, i.e. preservation of the binding affinity of the Fc domain to said receptor, is achieved when the Fc domain (or the T cell activating bispecific antigen binding molecule comprising said Fc domain) exhibits greater than about 70% of the binding affinity of a non-engineered form of the Fc domain (or the T cell activating bispecific antigen binding molecule comprising said non-engineered form of the Fc domain) to FcRn. The Fc domain, or T cell activating bispecific antigen binding molecules of the invention comprising said Fc domain, may exhibit greater than about 80% and even greater than about 90% of such affinity. In certain embodiments the Fc domain of the T cell activating bispecific antigen binding molecule is engineered to have reduced effector function, as compared to a non-engineered Fc domain. The reduced effector function can include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling inducing apoptosis, reduced crosslinking of target-bound antibodies, reduced dendritic cell maturation, or reduced T cell priming. In one embodiment the reduced effector function is one or more selected from the group of reduced CDC, reduced ADCC, reduced ADCP, and reduced cytokine secretion. In a particular embodiment the reduced effector function is reduced ADCC. In one embodiment the reduced ADCC is less than 20% of the ADCC induced by a non-engineered Fc domain (or a T cell activating bispecific antigen binding molecule comprising a non-engineered Fc domain).

-61-

In one embodiment the amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function is an amino acid substitution. In one embodiment the Fc domain comprises an amino acid substitution at a position selected from the group of E233, L234, L235, N297, P331 and P329. In a more specific embodiment the Fc domain comprises an amino acid substitution at a position selected from the group of L234, L235 and P329. In some embodiments the Fc domain comprises the amino acid substitutions L234A and L235A. In one such embodiment, the Fc domain is an IgG₁ Fc domain, particularly a human IgG₁ Fc domain. In one embodiment the Fc domain comprises an amino acid substitution at position P329. In a more specific embodiment the amino acid substitution is P329A or P329G, particularly P329G. In one embodiment the Fc domain comprises an amino acid substitution at position P329 and a further amino acid substitution at a position selected from E233, L234, L235, N297 and P331. In a more specific embodiment the further amino acid substitution is E233P, L234A, L235A, L235E, N297A, N297D or P331S. In particular embodiments the Fc domain comprises amino acid substitutions at positions P329, L234 and L235. In more particular embodiments the Fc domain comprises the amino acid mutations L234A, L235A and P329G ("P329G LALA"). In one such embodiment, the Fc domain is an IgG₁ Fc domain, particularly a human IgG₁ Fc domain. The "P329G LALA" combination of amino acid substitutions almost completely abolishes Fcγ receptor binding of a human IgG₁ Fc domain, as described in PCT publication no. WO 2012/130831, incorporated herein by reference in its entirety. WO 2012/130831 also describes methods of preparing such mutant Fc domains and methods for determining its properties such as Fc receptor binding or effector functions.

IgG₄ antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions as compared to IgG₁ antibodies. Hence, in some embodiments the Fc domain of the T cell activating bispecific antigen binding molecules of the invention is an IgG₄ Fc domain, particularly a human IgG₄ Fc domain. In one embodiment the IgG₄ Fc domain comprises amino acid substitutions at position S228, specifically the amino acid substitution S228P. To further reduce its binding affinity to an Fc receptor and/or its effector function, in one embodiment the IgG₄ Fc domain comprises an amino acid substitution at position L235, specifically the amino acid substitution L235E. In another embodiment, the IgG₄ Fc domain comprises an amino acid substitution at position P329, specifically the amino acid substitution P329G. In a particular embodiment, the IgG₄ Fc domain comprises amino acid substitutions at positions S228, L235 and P329, specifically amino acid substitutions S228P, L235E and P329G. Such IgG₄ Fc domain

-62-

mutants and their Fc γ receptor binding properties are described in PCT publication no. WO 2012/130831, incorporated herein by reference in its entirety.

In a particular embodiment the Fc domain exhibiting reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG₁ Fc domain, is a human IgG₁ Fc domain comprising the amino acid substitutions L234A, L235A and optionally P329G, or a
5 human IgG₄ Fc domain comprising the amino acid substitutions S228P, L235E and optionally P329G.

In certain embodiments N-glycosylation of the Fc domain has been eliminated. In one such embodiment the Fc domain comprises an amino acid mutation at position N297, particularly an
10 amino acid substitution replacing asparagine by alanine (N297A) or aspartic acid (N297D).

In addition to the Fc domains described hereinabove and in PCT publication no. WO 2012/130831, Fc domains with reduced Fc receptor binding and/or effector function also include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two
15 or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).

Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, and the
20 like. The correct nucleotide changes can be verified for example by sequencing.

Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon Resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare), and Fc receptors such as may be obtained by recombinant expression. A suitable such binding assay is described herein. Alternatively, binding affinity of Fc domains or cell activating
25 bispecific antigen binding molecules comprising an Fc domain for Fc receptors may be evaluated using cell lines known to express particular Fc receptors, such as human NK cells expressing Fc γ IIIa receptor.

Effector function of an Fc domain, or a T cell activating bispecific antigen binding molecule comprising an Fc domain, can be measured by methods known in the art. A suitable assay for
30 measuring ADCC is described herein. Other examples of *in vitro* assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987).

-63-

Alternatively, non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g. in a animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

In some embodiments, binding of the Fc domain to a complement component, specifically to C1q, is reduced. Accordingly, in some embodiments wherein the Fc domain is engineered to have reduced effector function, said reduced effector function includes reduced CDC. C1q binding assays may be carried out to determine whether the T cell activating bispecific antigen binding molecule is able to bind C1q and hence has CDC activity. See e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

Biological properties and functional characteristics of

T cell activating bispecific antigen binding molecules

One of skill in the art can appreciate the advantageous efficiency of a molecule that selectively distinguishes between cancerous and non-cancerous, healthy cells. One way to accomplish this goal is by appropriate target selection. Markers expressed exclusively on tumor cells can be employed to selectively target effector molecules or cells to tumor cells while sparing normal cells that do not express such marker. However, in some instances, so called tumor cell markers are also expressed in normal tissue, albeit at lower levels. This expression in normal tissue raises the possibility of toxicity. Thus, there was a need in the art for molecules that can more selectively target tumor cells. The invention described herein provides for T cell activating bispecific antigen binding molecules that selectively target FolR1-positive tumor cells and not normal, non-cancerous cells that express FolR1 at low levels or not at all. In one embodiment, the T cell activating bispecific antigen binding molecule comprises at least two, preferably two, FolR1 binding moieties of relatively low affinity that confer an avidity effect which allows for differentiation between high and low FolR1 expressing cells. Because tumor cells express FolR1 at high or intermediate levels, this embodiment of the invention selectively binds to, and/or induces killing of, tumor cells and not normal, non-cancerous cells that express FolR1 at low

-64-

levels or not at all. In one embodiment, the T cell activating bispecific antigen binding molecule is in the 2+1 inverted format. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of FolR1-positive tumor cells and not non-tumor cells and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54.

In one specific embodiment, the T cell activating bispecific antigen binding molecule does not induce killing of a normal cells having less than about 1000 copies of FolR1 its surface.

In addition to the above advantageous characteristics, one embodiment of the invention does not require chemical cross linking or a hybrid approach to be produced. Accordingly, in one embodiment, the invention provides for T cell activating bispecific antigen binding molecule capable of production in CHO cells. In one embodiment, the T cell activating bispecific antigen binding molecule comprises humanized and human polypeptides. In one embodiment, the T cell activating bispecific antigen binding molecule does not cause FcγR crosslinking. In one such embodiment, the T cell activating bispecific antigen binding molecule is capable of production in CHO cells and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54.

As noted above, some embodiments contemplated herein include T cell activating bispecific antigen binding molecules having two binding moieties that confer specific binding to FolR1 and one binding moiety that confers specificity to the T cell activating antigen CD3, wherein each individual FolR1 binding moiety engages the antigen with low affinity. Because the molecule comprises two antigen binding moieties that confer binding to FolR1, the overall avidity of the molecule, nevertheless, provides effective binding to FolR1-expressing target cells and activation of T cells to induce T cell effector function. Considering that while FolR1 is

-65-

expressed at various level on tumor cells, it is also expressed at very low levels (e.g., less than about 1000 copies on the cell surface) in certain normal cells, one of skill in the art can readily recognize the advantageous efficiency of such a molecule for use as a therapeutic agent. Such molecule selectively targets tumor cells over normal cells. Such molecule, thus, can be administered to an individual in need thereof with significantly less concern about toxicity resulting from FolR1 positive normal cells compared to molecules that bind to FolR1 with high affinity to induce effector function. In a preferred embodiment, the T cell activating bispecific antigen binding molecules have a monovalent binding affinity to huFolR1 in the micromolar range and an avidity to huFolR1 in the nanomolar range.

10

In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 10 nM to about 40 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 10 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 10 nM and about 30 nM, respectively. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of about 1400 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of about 1400 nM and to cynomolgus FolR1 with a monovalent binding K_D of about 5600 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 10 nM and with a monovalent binding K_D of about 1400 nM.

In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 5.36 pM to about 4 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 4 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds murine FolR1 with an apparent K_D of about 1.5 nM. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM. In a specific embodiment, the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 4 nM, binds murine FolR1 with an apparent K_D of about 1.5 nM, and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38,

25
30

-66-

the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54. In one embodiment, the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54.

As described above, the T cell activating bispecific antigen binding molecules contemplated herein can induce T cell effector function, e.g., cell surface marker expression, cytokine production, T cell mediated killing. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing target cell, such as a human tumor cell, in vitro. In one embodiment, the T cell is a CD8 positive T cell. Examples of FolR1-expressing human tumor cells include but are not limited to Hela, Skov-3, HT-29, and HRCEpiC cells. Other FolR1 positive human cancer cells that can be used for in vitro testing are readily available to the skilled artisan. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing human tumor cell in vitro with an EC50 of between about 36 pM and about 39573 pM after 24 hours. Specifically contemplated are T cell activating bispecific antigen binding molecules that induce T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 36 pM after 24 hours. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 178.4 pM after 24 hours. In one embodiment, the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 134.5 pM or greater after 48 hours. The EC50 can be measure by methods known in the art, for example by methods disclosed herein by the examples.

-67-

In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments induces upregulation of cell surface expression of at least one of CD25 and CD69 on the T cell as measured by flow cytometry. In one embodiment, the T cell is a CD4 positive T cell or a CD8 positive T cell.

- 5 In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments binds to FolR1 expressed on a human tumor cell. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments binds to a conformational epitope on human FolR1. In one embodiment, the T cell activating bispecific antigen binding molecule of any of the above embodiments does not bind to human Folate
- 10 Receptor 2 (FolR2) or to human Folate Receptor 3 (FolR3). In one embodiment of the T cell activating bispecific antigen binding molecule of any of the above embodiments, the antigen binding moiety binds to a FolR1 polypeptide comprising the amino acids 25 to 234 of human FolR1 (SEQ ID NO:227). In one embodiment of the T cell activating bispecific antigen binding molecule of any of the above embodiments, the FolR1 antigen binding moiety binds to a FolR1
- 15 polypeptide comprising the amino acid sequence of SEQ ID NO:227, to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:230 and to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence of SEQ ID NOs:228 or 229. In one specific embodiment, the T cell activating bispecific antigen binding molecule
- 20 comprises a FolR1 antigen binding moiety that binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:227, 230 and 231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence of SEQ ID NOs:228 or 229, and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of
- 25 SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 8, the heavy chain CDR2 of SEQ ID NO: 9, the heavy chain CDR3 of SEQ ID NO:50, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 53, and the light chain CDR3 of SEQ ID NO:54.
- 30 In one embodiment of the T cell activating bispecific antigen binding molecule of any of the above embodiments, the FolR1 antigen binding moiety binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:227 and to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:231, and wherein the FolR1 antigen binding moiety does not bind

-68-

to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:228, 229 or 230. In one specific embodiment, the T cell activating bispecific antigen binding molecule comprises a FolR1 antigen binding moiety that binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:227 and to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NO:231, and wherein the FolR1 antigen binding moiety does not bind to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:228, 229 or 230, and comprises a CD3 antigen binding moiety that comprises the heavy chain CDR1 of SEQ ID NO: 37, the heavy chain CDR2 of SEQ ID NO: 38, the heavy chain CDR3 of SEQ ID NO:39, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34 and two FolR1 antigen binding moieties that each comprise the heavy chain CDR1 of SEQ ID NO: 16, the heavy chain CDR2 of SEQ ID NO: 275, the heavy chain CDR3 of SEQ ID NO:315, the light chain CDR1 of SEQ ID NO: 32, the light chain CDR2 of SEQ ID NO: 33, and the light chain CDR3 of SEQ ID NO:34.

With respect to the FolR1, the T cell activating bispecific antigen binding molecules contemplated herein can have agonist, antagonist or neutral effect. Examples of agonist effect include induction or enhancement of signaling through the FolR1 upon engagement by the FolR1 binding moiety with the FolR1 receptor on the target cell. Examples of antagonist activity include abrogation or reduction of signaling through the FolR1 upon engagement by the FolR1 binding moiety with the FolR1 receptor on the target cell. This can, for example, occur by blocking or reducing the interaction between folate with FolR1. Sequence variants of the embodiments disclosed herein having lower affinity while retaining the above described biological properties are specifically contemplated.

25

Immunoconjugates

The invention also pertains to immunoconjugates comprising a T cell activating bispecific antigen binding molecule conjugated to a cytotoxic agent such as a chemotherapeutic agent, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

30

Polynucleotides

The invention further provides isolated polynucleotides encoding a T cell activating bispecific antigen binding molecule as described herein or a fragment thereof.

Polynucleotides of the invention include those that are at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequences set forth in SEQ ID NOs:151-226 including functional fragments or variants thereof.

- The polynucleotides encoding T cell activating bispecific antigen binding molecules of the invention may be expressed as a single polynucleotide that encodes the entire T cell activating bispecific antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-expressed. Polypeptides encoded by polynucleotides that are co-expressed may associate through, e.g., disulfide bonds or other means to form a functional T cell activating bispecific antigen binding molecule. For example, the light chain portion of an antigen binding moiety may be encoded by a separate polynucleotide from the portion of the T cell activating bispecific antigen binding molecule comprising the heavy chain portion of the antigen binding moiety, an Fc domain subunit and optionally (part of) another antigen binding moiety. When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the antigen binding moiety. In another example, the portion of the T cell activating bispecific antigen binding molecule comprising one of the two Fc domain subunits and optionally (part of) one or more antigen binding moieties could be encoded by a separate polynucleotide from the portion of the T cell activating bispecific antigen binding molecule comprising the the other of the two Fc domain subunits and optionally (part of) an antigen binding moiety. When co-expressed, the Fc domain subunits will associate to form the Fc domain.
- In some embodiments, the isolated polynucleotide encodes the entire T cell activating bispecific antigen binding molecule according to the invention as described herein. In other embodiments, the isolated polynucleotide encodes a polypeptides comprised in the T cell activating bispecific antigen binding molecule according to the invention as described herein.

- In another embodiment, the present invention is directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment thereof, wherein the polynucleotide comprises a sequence that encodes a variable region sequence as shown in SEQ ID NOs 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182 and 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223.
- In another embodiment, the present invention is directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule or fragment thereof, wherein the polynucleotide comprises a sequence that encodes a polypeptide sequence as shown in SEQ ID NOs:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,

-70-

28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 1, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 5 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244. In another embodiment, the invention is further directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment thereof, wherein the polynucleotide comprises a sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, or 99% identical to a nucleotide sequence shown in SEQ ID NOs 97, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 12, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 246, 247. In another embodiment, the 15 invention is directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment thereof, wherein the polynucleotide comprises a nucleic acid sequence shown in SEQ ID NOs 97, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 20 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 12, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 246, 247. In another embodiment, the invention is directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment thereof, wherein the polynucleotide comprises a sequence that encodes a variable region sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 25 identical to an amino acid sequence in SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 11, 13, 15, 19, 21, 12, 25, 27, 29, 31, 36, 41, 45, 49, 51, 55, 58, 62, 64, 66, 68, 70, 72, 74, 76, 78, 82, 113, 114, 115, 116, 117, 118, 119, 12, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135. In another embodiment, the invention is directed to an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule or fragment thereof, wherein the polynucleotide 30 comprises a sequence that encodes a polypeptide comprising one or more sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence in SEQ ID NOs: 8, 9, 50, 37, 38, and 39. The invention encompasses an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment

-71-

thereof, wherein the polynucleotide comprises a sequence that encodes the variable region sequence of SEQ ID NOs 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182 and 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223
5 with conservative amino acid substitutions. The invention also encompasses an isolated polynucleotide encoding a T cell activating bispecific antigen binding molecule of the invention or fragment thereof, wherein the polynucleotide comprises a sequence that encodes the polypeptide sequence of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
10 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 1, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 and 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243,
15 244 with conservative amino acid substitutions.

In certain embodiments the polynucleotide or nucleic acid is DNA. In other embodiments, a polynucleotide of the present invention is RNA, for example, in the form of messenger RNA (mRNA). RNA of the present invention may be single stranded or double stranded.

20 **Recombinant Methods**

T cell activating bispecific antigen binding molecules of the invention may be obtained, for example, by solid-state peptide synthesis (e.g. Merrifield solid phase synthesis) or recombinant production. For recombinant production one or more polynucleotide encoding the T cell activating bispecific antigen binding molecule (fragment), e.g., as described above, is isolated
25 and inserted into one or more vectors for further cloning and/or expression in a host cell. Such polynucleotide may be readily isolated and sequenced using conventional procedures. In one embodiment a vector, preferably an expression vector, comprising one or more of the polynucleotides of the invention is provided. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of a T cell
30 activating bispecific antigen binding molecule (fragment) along with appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, N.Y. (1989); and Ausubel et al., CURRENT

-72-

PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y (1989). The expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which the polynucleotide encoding the T cell activating bispecific antigen binding molecule (fragment) (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements. As used herein, a "coding region" is a portion of nucleic acid which consists of codons translated into amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5' and 3' untranslated regions, and the like, are not part of a coding region. Two or more coding regions can be present in a single polynucleotide construct, e.g. on a single vector, or in separate polynucleotide constructs, e.g. on separate (different) vectors. Furthermore, any vector may contain a single coding region, or may comprise two or more coding regions, e.g. a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage. In addition, a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the T cell activating bispecific antigen binding molecule (fragment) of the invention, or variant or derivative thereof. Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, e.g. a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated" if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription.

-73-

Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions, which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g. the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g. the early promoter), and retroviruses (such as, e.g. Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit α -globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as inducible promoters (e.g. promoters inducible tetracyclins). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence). The expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).

Polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention. For example, if secretion of the T cell activating bispecific antigen binding molecule is desired, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding a T cell activating bispecific antigen binding molecule of the invention or a fragment thereof. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or "mature" form of the polypeptide. In certain embodiments, the native signal peptide, e.g. an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it. Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, may be used. For example, the wild-type leader sequence may be

-74-

substituted with the leader sequence of human tissue plasminogen activator (TPA) or mouse β -glucuronidase.

DNA encoding a short protein sequence that could be used to facilitate later purification (e.g. a histidine tag) or assist in labeling the T cell activating bispecific antigen binding molecule may
5 be included within or at the ends of the T cell activating bispecific antigen binding molecule (fragment) encoding polynucleotide.

In a further embodiment, a host cell comprising one or more polynucleotides of the invention is provided. In certain embodiments a host cell comprising one or more vectors of the invention is provided. The polynucleotides and vectors may incorporate any of the features, singly or in
10 combination, described herein in relation to polynucleotides and vectors, respectively. In one such embodiment a host cell comprises (e.g. has been transformed or transfected with) a vector comprising a polynucleotide that encodes (part of) a T cell activating bispecific antigen binding molecule of the invention. As used herein, the term "host cell" refers to any kind of cellular system which can be engineered to generate the T cell activating bispecific antigen binding
15 molecules of the invention or fragments thereof. Host cells suitable for replicating and for supporting expression of T cell activating bispecific antigen binding molecules are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of the T cell activating bispecific antigen binding
20 molecule for clinical applications. Suitable host cells include prokaryotic microorganisms, such as *E. coli*, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such
25 as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized", resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. See Gerngross, *Nat Biotech* 22, 1409-1414 (2004), and Li et al., *Nat Biotech* 24, 210-215 (2006). Suitable host cells for the expression of (glycosylated) polypeptides are also derived from
30 multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells. Plant cell cultures can also be utilized as hosts. See e.g. US Patent Nos. 5,959,177, 6,040,498,

-75-

6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7);

5 human embryonic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep

10 G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr⁻ CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see,

15 e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese

20 Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., Y0, NS0, Sp20 cell).

Standard technologies are known in the art to express foreign genes in these systems. Cells expressing a polypeptide comprising either the heavy or the light chain of an antigen binding domain such as an antibody, may be engineered so as to also express the other of the antibody

25 chains such that the expressed product is an antibody that has both a heavy and a light chain.

In one embodiment, a method of producing a T cell activating bispecific antigen binding molecule according to the invention is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding the T cell activating bispecific antigen binding molecule, as provided herein, under conditions suitable for expression of the T cell activating

30 bispecific antigen binding molecule, and recovering the T cell activating bispecific antigen binding molecule from the host cell (or host cell culture medium).

The components of the T cell activating bispecific antigen binding molecule are genetically fused to each other. T cell activating bispecific antigen binding molecule can be designed such

-76-

that its components are fused directly to each other or indirectly through a linker sequence. The composition and length of the linker may be determined in accordance with methods well known in the art and may be tested for efficacy. Examples of linker sequences between different components of T cell activating bispecific antigen binding molecules are found in the sequences
5 provided herein. Additional sequences may also be included to incorporate a cleavage site to separate the individual components of the fusion if desired, for example an endopeptidase recognition sequence.

In certain embodiments the one or more antigen binding moieties of the T cell activating bispecific antigen binding molecules comprise at least an antibody variable region capable of
10 binding an antigenic determinant. Variable regions can form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof. Methods to produce polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g. Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced
15 recombinantly (e.g. as described in U.S. patent No. 4,186,567) or can be obtained, for example, by screening combinatorial libraries comprising variable heavy chains and variable light chains (see e.g. U.S. Patent. No. 5,969,108, McCafferty).

Any animal species of antibody, antibody fragment, antigen binding domain or variable region can be used in the T cell activating bispecific antigen binding molecules of the invention. Non-
20 limiting antibodies, antibody fragments, antigen binding domains or variable regions useful in the present invention can be of murine, primate, or human origin. If the T cell activating bispecific antigen binding molecule is intended for human use, a chimeric form of antibody may be used wherein the constant regions of the antibody are from a human. A humanized or fully human form of the antibody can also be prepared in accordance with methods well known in the
25 art (see e. g. U.S. Patent No. 5,565,332 to Winter). Humanization may be achieved by various methods including, but not limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g. recipient antibody) framework and constant regions with or without retention of critical framework residues (e.g. those that are important for retaining good antigen binding affinity or antibody functions), (b) grafting only the non-human specificity-determining regions
30 (SDRs or a-CDRs; the residues critical for the antibody-antigen interaction) onto human framework and constant regions, or (c) transplanting the entire non-human variable domains, but "cloaking" them with a human-like section by replacement of surface residues. Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, Front

-77-

Biosci 13, 1619-1633 (2008), and are further described, e.g., in Riechmann et al., *Nature* 332, 323-329 (1988); Queen et al., *Proc Natl Acad Sci USA* 86, 10029-10033 (1989); US Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., *Nature* 321, 522-525 (1986); Morrison et al., *Proc Natl Acad Sci* 81, 6851-6855 (1984); Morrison and Oi, *Adv Immunol* 44, 65-92 (1988); Verhoeven et al., *Science* 239, 1534-1536 (1988); Padlan, *Molec Immun* 31(3), 169-217 (1994); Kashmiri et al., *Methods* 36, 25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, *Mol Immunol* 28, 489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., *Methods* 36, 43-60 (2005) (describing "FR shuffling"); and Osbourn et al., *Methods* 36, 61-68 (2005) and Klimka et al., *Br J Cancer* 83, 252-260 (2000) (describing the "guided selection" approach to FR shuffling). Human antibodies and human variable regions can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, *Curr Opin Pharmacol* 5, 368-74 (2001) and Lonberg, *Curr Opin Immunol* 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies made by the hybridoma method (see e.g. *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Human antibodies and human variable regions may also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see e.g. Lonberg, *Nat Biotech* 23, 1117-1125 (2005)). Human antibodies and human variable regions may also be generated by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see e.g., Hoogenboom et al. in *Methods in Molecular Biology* 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); and McCafferty et al., *Nature* 348, 552-554; Clackson et al., *Nature* 352, 624-628 (1991)). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.

In certain embodiments, the antigen binding moieties useful in the present invention are engineered to have enhanced binding affinity according to, for example, the methods disclosed in U.S. Pat. Appl. Publ. No. 2004/0132066, the entire contents of which are hereby incorporated by reference. The ability of the T cell activating bispecific antigen binding molecule of the invention to bind to a specific antigenic determinant can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance technique (analyzed on a BIACORE T100 system) (Liljeblad, et al., *Glyco J* 17, 323-329 (2000)), and traditional binding assays (Heeley, *Endocr Res* 28, 217-229 (2002)). Competition assays may be used to identify an antibody, antibody fragment, antigen

-78-

binding domain or variable domain that competes with a reference antibody for binding to a particular antigen, e.g. an antibody that competes with the V9 antibody for binding to CD3. In certain embodiments, such a competing antibody binds to the same epitope (e.g. a linear or a conformational epitope) that is bound by the reference antibody. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in *Methods in Molecular Biology* vol. 66 (Humana Press, Totowa, NJ). In an exemplary competition assay, immobilized antigen (e.g. CD3) is incubated in a solution comprising a first labeled antibody that binds to the antigen (e.g. V9 antibody, described in US 6,054,297) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to the antigen. The second antibody may be present in a hybridoma supernatant. As a control, immobilized antigen is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to the antigen, excess unbound antibody is removed, and the amount of label associated with immobilized antigen is measured. If the amount of label associated with immobilized antigen is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to the antigen. See Harlow and Lane (1988) *Antibodies: A Laboratory Manual* ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

T cell activating bispecific antigen binding molecules prepared as described herein may be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be apparent to those having skill in the art. For affinity chromatography purification an antibody, ligand, receptor or antigen can be used to which the T cell activating bispecific antigen binding molecule binds. For example, for affinity chromatography purification of T cell activating bispecific antigen binding molecules of the invention, a matrix with protein A or protein G may be used. Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate a T cell activating bispecific antigen binding molecule essentially as described in the Examples. The purity of the T cell activating bispecific antigen binding molecule can be determined by any of a variety of well known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like. For example, the heavy chain fusion proteins expressed as described in the Examples were shown to be intact and properly

-79-

assembled as demonstrated by reducing SDS-PAGE (see e.g. Figure 2). Three bands were resolved at approximately Mr 25,000, Mr 50,000 and Mr 75,000, corresponding to the predicted molecular weights of the T cell activating bispecific antigen binding molecule light chain, heavy chain and heavy chain/light chain fusion protein.

5

Assays

T cell activating bispecific antigen binding molecules provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

10

Affinity assays

The affinity of the T cell activating bispecific antigen binding molecule for an Fc receptor or a target antigen can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a BIAcore instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. Alternatively, binding of T cell activating bispecific antigen binding molecules for different receptors or target antigens may be evaluated using cell lines expressing the particular receptor or target antigen, for example by flow cytometry (FACS). A specific illustrative and exemplary embodiment for measuring binding affinity is described in the following and in the Examples below.

20

According to one embodiment, K_D is measured by surface plasmon resonance using a BIACORE® T100 machine (GE Healthcare) at 25 °C.

To analyze the interaction between the Fc-portion and Fc receptors, His-tagged recombinant Fc-receptor is captured by an anti-Penta His antibody ("Penta His" disclosed as SEQ ID NO: 306) (Qiagen) immobilized on CM5 chips and the bispecific constructs are used as analytes. Briefly, carboxymethylated dextran biosensor chips (CM5, GE Healthcare) are activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Anti Penta-His antibody ("Penta-His" disclosed as SEQ ID NO: 306) is diluted with 10 mM sodium acetate, pH 5.0, to 40 µg/ml before injection at a flow rate of 5 µl/min to achieve approximately 6500 response units (RU) of coupled protein. Following the injection of the ligand, 1 M ethanolamine is injected to block unreacted groups. Subsequently the Fc-receptor is captured for 60 s at 4 or 10 nM. For kinetic measurements, four-fold serial dilutions of the bispecific construct (range between 500 nM and 4000 nM) are injected

30

-80-

in HBS-EP (GE Healthcare, 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05 % Surfactant P20, pH 7.4) at 25 °C at a flow rate of 30 µl/min for 120 s.

- To determine the affinity to the target antigen, bispecific constructs are captured by an anti human Fab specific antibody (GE Healthcare) that is immobilized on an activated CM5-sensor
- 5 chip surface as described for the anti Penta-His antibody ("Penta-His" disclosed as SEQ ID NO: 306). The final amount of coupled protein is is approximately 12000 RU. The bispecific constructs are captured for 90 s at 300 nM. The target antigens are passed through the flow cells for 180 s at a concentration range from 250 to 1000 nM with a flowrate of 30 µl/min. The dissociation is monitored for 180 s.
- 10 Bulk refractive index differences are corrected for by subtracting the response obtained on reference flow cell. The steady state response was used to derive the dissociation constant K_D by non-linear curve fitting of the Langmuir binding isotherm. Association rates (k_{on}) and dissociation rates (k_{off}) are calculated using a simple one-to-one Langmuir binding model (BIAcore® T100 Evaluation Software version 1.1.1) by simultaneously fitting the association
- 15 and dissociation sensorgrams. The equilibrium dissociation constant (K_D) is calculated as the ratio k_{off}/k_{on} . See, e.g., Chen et al., J Mol Biol 293, 865-881 (1999).

Activity assays

- Biological activity of the T cell activating bispecific antigen binding molecules of the invention
- 20 can be measured by various assays as described in the Examples. Biological activities may for example include the induction of proliferation of T cells, the induction of signaling in T cells, the induction of expression of activation markers in T cells, the induction of cytokine secretion by T cells, the induction of lysis of target cells such as tumor cells, and the induction of tumor regression and/or the improvement of survival.

25

Compositions, Formulations, and Routes of Administration

- In a further aspect, the invention provides pharmaceutical compositions comprising any of the T cell activating bispecific antigen binding molecules provided herein, e.g., for use in any of the below therapeutic methods. In one embodiment, a pharmaceutical composition comprises any of
- 30 the T cell activating bispecific antigen binding molecules provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical composition comprises any of the T cell activating bispecific antigen binding molecules provided herein and at least one additional therapeutic agent, e.g., as described below.

-81-

Further provided is a method of producing a T cell activating bispecific antigen binding molecule of the invention in a form suitable for administration in vivo, the method comprising (a) obtaining a T cell activating bispecific antigen binding molecule according to the invention, and (b) formulating the T cell activating bispecific antigen binding molecule with at least one pharmaceutically acceptable carrier, whereby a preparation of T cell activating bispecific antigen binding molecule is formulated for administration in vivo.

Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more T cell activating bispecific antigen binding molecule dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one T cell activating bispecific antigen binding molecule and optionally an additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards or corresponding authorities in other countries. Preferred compositions are lyophilized formulations or aqueous solutions. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.

The composition may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. T cell activating bispecific antigen binding molecules of the present invention (and any additional therapeutic agent) can be administered intravenously,

-82-

intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrasplenically, intrarenally, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, 5 intraumbilically, intraocularly, orally, topically, locally, by inhalation (e.g. aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g. liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, 10 incorporated herein by reference). Parenteral administration, in particular intravenous injection, is most commonly used for administering polypeptide molecules such as the T cell activating bispecific antigen binding molecules of the invention.

Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or 15 intraperitoneal injection. For injection, the T cell activating bispecific antigen binding molecules of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the T cell activating bispecific antigen binding molecules may be in 20 powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Sterile injectable solutions are prepared by incorporating the T cell activating bispecific antigen binding molecules of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Generally, dispersions are prepared by 25 incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first 30 rendered isotonic prior to injection with sufficient saline or glucose. The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin

contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein. Suitable pharmaceutically acceptable carriers include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; 5 benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; 10 monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium 15 carboxymethyl cellulose, sorbitol, dextran, or the like. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as 20 ethyl esters or triglycerides, or liposomes.

Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- 25 particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules. In particular 30 embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.

-84-

In addition to the compositions described previously, the T cell activating bispecific antigen binding molecules may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the T cell activating bispecific antigen binding molecules may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Pharmaceutical compositions comprising the T cell activating bispecific antigen binding molecules of the invention may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

The T cell activating bispecific antigen binding molecules may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

Therapeutic Methods and Compositions

Any of the T cell activating bispecific antigen binding molecules provided herein may be used in therapeutic methods. T cell activating bispecific antigen binding molecules of the invention can be used as immunotherapeutic agents, for example in the treatment of cancers.

For use in therapeutic methods, T cell activating bispecific antigen binding molecules of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the

-85-

cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

In one aspect, T cell activating bispecific antigen binding molecules of the invention for use as a medicament are provided. In further aspects, T cell activating bispecific antigen binding
5 molecules of the invention for use in treating a disease are provided. In certain embodiments, T cell activating bispecific antigen binding molecules of the invention for use in a method of treatment are provided. In one embodiment, the invention provides a T cell activating bispecific antigen binding molecule as described herein for use in the treatment of a disease in an individual in need thereof. In certain embodiments, the invention provides a T cell activating
10 bispecific antigen binding molecule for use in a method of treating an individual having a disease comprising administering to the individual a therapeutically effective amount of the T cell activating bispecific antigen binding molecule. In certain embodiments the disease to be treated is a proliferative disorder. In a particular embodiment the disease is cancer. In certain embodiments the method further comprises administering to the individual a therapeutically
15 effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer. In further embodiments, the invention provides a T cell activating bispecific antigen binding molecule as described herein for use in inducing lysis of a target cell, particularly a tumor cell. In certain embodiments, the invention provides a T cell activating bispecific antigen binding molecule for use in a method of inducing lysis of a target cell,
20 particularly a tumor cell, in an individual comprising administering to the individual an effective amount of the T cell activating bispecific antigen binding molecule to induce lysis of a target cell. An "individual" according to any of the above embodiments is a mammal, preferably a human.

In a further aspect, the invention provides for the use of a T cell activating bispecific antigen
25 binding molecule of the invention in the manufacture or preparation of a medicament. In one embodiment the medicament is for the treatment of a disease in an individual in need thereof. In a further embodiment, the medicament is for use in a method of treating a disease comprising administering to an individual having the disease a therapeutically effective amount of the medicament. In certain embodiments the disease to be treated is a proliferative disorder. In a
30 particular embodiment the disease is cancer. In one embodiment, the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer. In a further embodiment, the medicament is for inducing lysis of a target cell, particularly a tumor cell. In

still a further embodiment, the medicament is for use in a method of inducing lysis of a target cell, particularly a tumor cell, in an individual comprising administering to the individual an effective amount of the medicament to induce lysis of a target cell. An "individual" according to any of the above embodiments may be a mammal, preferably a human.

- 5 In a further aspect, the invention provides a method for treating a disease. In one embodiment, the method comprises administering to an individual having such disease a therapeutically effective amount of a T cell activating bispecific antigen binding molecule of the invention. In one embodiment a composition is administered to said individual, comprising the T cell activating bispecific antigen binding molecule of the invention in a pharmaceutically acceptable
- 10 form. In certain embodiments the disease to be treated is a proliferative disorder. In a particular embodiment the disease is cancer. In certain embodiments the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g., an anti-cancer agent if the disease to be treated is cancer. An "individual" according to any of the above embodiments may be a mammal, preferably a human.
- 15 In a further aspect, the invention provides a method for inducing lysis of a target cell, particularly a tumor cell. In one embodiment the method comprises contacting a target cell with a T cell activating bispecific antigen binding molecule of the invention in the presence of a T cell, particularly a cytotoxic T cell. In a further aspect, a method for inducing lysis of a target cell, particularly a tumor cell, in an individual is provided. In one such embodiment, the method
- 20 comprises administering to the individual an effective amount of a T cell activating bispecific antigen binding molecule to induce lysis of a target cell. In one embodiment, an "individual" is a human.

In certain embodiments the disease to be treated is a proliferative disorder, particularly cancer. Non-limiting examples of cancers include bladder cancer, brain cancer, head and neck cancer,

25 pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer. Other cell proliferation disorders that can be treated using a T cell activating bispecific antigen binding molecule of the present invention include, but are not limited to

30 neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Also included are pre-cancerous conditions or lesions and

-87-

cancer metastases. In certain embodiments the cancer is chosen from the group consisting of renal cell cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. A skilled artisan readily recognizes that in many cases the T cell activating bispecific antigen binding molecule may not provide a cure but may only provide partial benefit.

- 5 In some embodiments, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some embodiments, an amount of T cell activating bispecific antigen binding molecule that provides a physiological change is considered an "effective amount" or a "therapeutically effective amount". The subject, patient, or individual in need of treatment is typically a mammal, more specifically a human.
- 10 In some embodiments, an effective amount of a T cell activating bispecific antigen binding molecule of the invention is administered to a cell. In other embodiments, a therapeutically effective amount of a T cell activating bispecific antigen binding molecule of the invention is administered to an individual for the treatment of disease.

- For the prevention or treatment of disease, the appropriate dosage of a T cell activating bispecific antigen binding molecule of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the body weight of the patient, the type of T cell activating bispecific antigen binding molecule, the severity and course of the disease, whether the T cell activating bispecific antigen binding molecule is administered for preventive or therapeutic purposes, previous or
- 15 concurrent therapeutic interventions, the patient's clinical history and response to the T cell activating bispecific antigen binding molecule, and the discretion of the attending physician. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Various dosing schedules including but not limited to single or multiple administrations over various
- 20 time-points, bolus administration, and pulse infusion are contemplated herein.

- The T cell activating bispecific antigen binding molecule is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 $\mu\text{g/kg}$ to 15 mg/kg (e.g. 0.1 mg/kg – 10 mg/kg) of T cell activating bispecific antigen binding molecule can be an initial candidate dosage for administration to the patient, whether,
- 25 for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 $\mu\text{g/kg}$ to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease

-88-

symptoms occurs. One exemplary dosage of the T cell activating bispecific antigen binding molecule would be in the range from about 0.005 mg/kg to about 10 mg/kg. In other non-limiting examples, a dose may also comprise from about 1 microgram/kg body weight, about 5 microgram/kg body weight, about 10 microgram/kg body weight, about 50 microgram/kg body weight, about 100 microgram/kg body weight, about 200 microgram/kg body weight, about 350 microgram/kg body weight, about 500 microgram/kg body weight, about 1 milligram/kg body weight, about 5 milligram/kg body weight, about 10 milligram/kg body weight, about 50 milligram/kg body weight, about 100 milligram/kg body weight, about 200 milligram/kg body weight, about 350 milligram/kg body weight, about 500 milligram/kg body weight, to about 1000 mg/kg body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg body weight to about 100 mg/kg body weight, about 5 microgram/kg body weight to about 500 milligram/kg body weight, etc., can be administered, based on the numbers described above. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the T cell activating bispecific antigen binding molecule). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

The T cell activating bispecific antigen binding molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the T cell activating bispecific antigen binding molecules of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can be estimated initially from *in vitro* assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from *in vivo* data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

Dosage amount and interval may be adjusted individually to provide plasma levels of the T cell activating bispecific antigen binding molecules which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 50 mg/kg/day, typically from about 0.5 to 1 mg/kg/day. Therapeutically effective plasma levels may
5 be achieved by administering multiple doses each day. Levels in plasma may be measured, for example, by HPLC.

In cases of local administration or selective uptake, the effective local concentration of the T cell activating bispecific antigen binding molecules may not be related to plasma concentration. One having skill in the art will be able to optimize therapeutically effective local dosages without
10 undue experimentation.

A therapeutically effective dose of the T cell activating bispecific antigen binding molecules described herein will generally provide therapeutic benefit without causing substantial toxicity. Toxicity and therapeutic efficacy of a T cell activating bispecific antigen binding molecule can be determined by standard pharmaceutical procedures in cell culture or experimental animals.
15 Cell culture assays and animal studies can be used to determine the LD₅₀ (the dose lethal to 50% of a population) and the ED₅₀ (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD₅₀/ED₅₀. T cell activating bispecific antigen binding molecules that exhibit large therapeutic indices are preferred. In one embodiment, the T cell activating bispecific antigen
20 binding molecule according to the present invention exhibits a high therapeutic index. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages suitable for use in humans. The dosage lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon a variety of factors, e.g., the dosage form employed, the route of
25 administration utilized, the condition of the subject, and the like. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in its entirety).

The attending physician for patients treated with T cell activating bispecific antigen binding
30 molecules of the invention would know how and when to terminate, interrupt, or adjust administration due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the

-90-

disorder of interest will vary with the severity of the condition to be treated, with the route of administration, and the like. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient.

5

Other Agents and Treatments

The T cell activating bispecific antigen binding molecules of the invention may be administered in combination with one or more other agents in therapy. For instance, a T cell activating bispecific antigen binding molecule of the invention may be co-administered with at least one
10 additional therapeutic agent. The term "therapeutic agent" encompasses any agent administered to treat a symptom or disease in an individual in need of such treatment. Such additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. In certain embodiments, an additional therapeutic agent is an immunomodulatory agent, a cytostatic
15 agent, an inhibitor of cell adhesion, a cytotoxic agent, an activator of cell apoptosis, or an agent that increases the sensitivity of cells to apoptotic inducers. In a particular embodiment, the additional therapeutic agent is an anti-cancer agent, for example a microtubule disruptor, an antimetabolite, a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormonal therapy, a kinase inhibitor, a receptor antagonist, an activator of tumor cell apoptosis, or an
20 antiangiogenic agent.

Such other agents are suitably present in combination in amounts that are effective for the purpose intended. The effective amount of such other agents depends on the amount of T cell activating bispecific antigen binding molecule used, the type of disorder or treatment, and other factors discussed above. The T cell activating bispecific antigen binding molecules are generally
25 used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate
30 administration, in which case, administration of the T cell activating bispecific antigen binding molecule of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant. T cell activating bispecific antigen binding molecules of the invention can also be used in combination with radiation therapy.

In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.

15 The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a T cell

20 activating bispecific antigen binding molecule of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a T cell activating bispecific antigen binding molecule of the invention; and (b) a second container with a composition contained therein, wherein the

25 composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection

30 (BWHI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Examples

-92-

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

General methods

5 Recombinant DNA Techniques

Standard methods were used to manipulate DNA as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. The molecular biological reagents were used according to the manufacturers' instructions. General information regarding the nucleotide sequences of human immunoglobulins
10 light and heavy chains is given in: Kabat, E.A. et al., (1991) Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication No. 91-3242.

15 DNA Sequencing

DNA sequences were determined by standard double strand sequencing at Synergene (Schlieren).

Gene Synthesis

20 Desired gene segments where required were either generated by PCR using appropriate templates or were synthesized by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis. In cases where no exact gene sequence was available, oligonucleotide primers were designed based on sequences from closest homologues and the genes were isolated by RT-PCR from RNA originating from the appropriate
25 tissue. The gene segments flanked by singular restriction endonuclease cleavage sites were cloned into standard cloning / sequencing vectors. The plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of the subcloned gene fragments was confirmed by DNA sequencing. Gene segments were designed with suitable restriction sites to allow sub-cloning into the respective expression
30 vectors. All constructs were designed with a 5'-end DNA sequence coding for a leader peptide which targets proteins for secretion in eukaryotic cells.

Isolation of primary human pan T cells from PBMCs

-93-

Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation from enriched lymphocyte preparations (buffy coats) obtained from local blood banks or from fresh blood from healthy human donors. Briefly, blood was diluted with sterile PBS and carefully layered over a Histopaque gradient (Sigma, H8889). After centrifugation for 5 30 minutes at 450 x g at room temperature (brake switched off), part of the plasma above the PBMC containing interphase was discarded. The PBMCs were transferred into new 50 ml Falcon tubes and tubes were filled up with PBS to a total volume of 50 ml. The mixture was centrifuged at room temperature for 10 minutes at 400 x g (brake switched on). The supernatant was discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps at 4°C 10 for 10 minutes at 350 x g). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium, containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37°C, 5% CO₂ in the incubator until assay start.

T cell enrichment from PBMCs was performed using the Pan T Cell Isolation Kit II (Miltenyi Biotec #130-091-156), according to the manufacturer's instructions. Briefly, the cell pellets were 15 diluted in 40 µl cold buffer per 10 million cells (PBS with 0.5% BSA, 2 mM EDTA, sterile filtered) and incubated with 10 µl Biotin-Antibody Cocktail per 10 million cells for 10 min at 4°C. 30 µl cold buffer and 20 µl Anti-Biotin magnetic beads per 10 million cells were added, and the mixture incubated for another 15 min at 4°C. Cells were washed by adding 10-20x the current volume and a subsequent centrifugation step at 300 x g for 10 min. Up to 100 million 20 cells were resuspended in 500 µl buffer. Magnetic separation of unlabeled human pan T cells was performed using LS columns (Miltenyi Biotec #130-042-401) according to the manufacturer's instructions. The resulting T cell population was counted automatically (ViCell) and stored in AIM-V medium at 37°C, 5% CO₂ in the incubator until assay start (not longer than 24 h).

25

Isolation of primary human naive T cells from PBMCs

Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation from enriched lymphocyte preparations (buffy coats) obtained from local blood banks or from fresh blood from healthy human donors. T-cell enrichment from PBMCs was performed using 30 the Naive CD8⁺ T cell isolation Kit from Miltenyi Biotec (#130-093-244), according to the manufacturer's instructions, but skipping the last isolation step of CD8⁺ T cells (also see description for the isolation of primary human pan T cells).

-94-

Isolation of murine pan T cells from splenocytes

Spleens were isolated from C57BL/6 mice, transferred into a GentleMACS C-tube (Miltenyi Biotec #130-093-237) containing MACS buffer (PBS + 0.5% BSA + 2 mM EDTA) and dissociated with the GentleMACS Dissociator to obtain single-cell suspensions according to the manufacturer's instructions. The cell suspension was passed through a pre-separation filter to remove remaining undissociated tissue particles. After centrifugation at 400 x g for 4 min at 4°C, ACK Lysis Buffer was added to lyse red blood cells (incubation for 5 min at room temperature). The remaining cells were washed with MACS buffer twice, counted and used for the isolation of murine pan T cells. The negative (magnetic) selection was performed using the Pan T Cell Isolation Kit from Miltenyi Biotec (#130-090-861), following the manufacturer's instructions. The resulting T cell population was automatically counted (ViCell) and immediately used for further assays.

Isolation of primary cynomolgus PBMCs from heparinized blood

Peripheral blood mononuclear cells (PBMCs) were prepared by density centrifugation from fresh blood from healthy cynomolgus donors, as follows: Heparinized blood was diluted 1:3 with sterile PBS, and Lymphoprep medium (Axon Lab #1114545) was diluted to 90% with sterile PBS. Two volumes of the diluted blood were layered over one volume of the diluted density gradient and the PBMC fraction was separated by centrifugation for 30 min at 520 x g, without brake, at room temperature. The PBMC band was transferred into a fresh 50 ml Falcon tube and washed with sterile PBS by centrifugation for 10 min at 400 x g at 4°C. One low-speed centrifugation was performed to remove the platelets (15 min at 150 x g, 4°C), and the resulting PBMC population was automatically counted (ViCell) and immediately used for further assays.

25

Example 1**Purification of biotinylated Folate receptor-Fc fusions**

To generate new antibodies against human FolR1 the following antigens and screening tools were generated as monovalent Fc fusion proteins (the extracellular domain of the antigen linked to the hinge region of Fc-knob which is co-expressed with an Fc-hole molecule). The antigen genes were synthesized (Geneart, Regensburg, Germany) based on sequences obtained from GenBank or SwissProt and inserted into expression vectors to generate fusion proteins with Fc-knob with a C-terminal Avi-tag for in vivo or in vitro biotinylation. In vivo biotinylation was

30

-95-

achieved by co-expression of the bacterial birA gene encoding a bacterial biotin ligase during production. Expression of all genes was under control of a chimeric MPSV promoter on a plasmid containing an oriP element for stable maintenance of the plasmids in EBNA containing cell lines.

- 5 For preparation of the biotinylated monomeric antigen/Fc fusion molecules, exponentially growing suspension HEK293 EBNA cells were co-transfected with three vectors encoding the two components of fusion protein (knob and hole chains) as well as BirA, an enzyme necessary for the biotinylation reaction. The corresponding vectors were used at a 9.5 : 9.5 : 1 ratio ("antigen ECD- Fc knob-avi tag" : "Fc hole" : "BirA").
- 10 For protein production in 500 ml shake flasks, 400 million HEK293 EBNA cells were seeded 24 hours before transfection. For transfection cells were centrifuged for 5 minutes at 210 g, and supernatant was replaced by pre-warmed CD CHO medium. Expression vectors were resuspended in 20 mL of CD CHO medium containing 200 µg of vector DNA. After addition of 540 µL of polyethylenimine (PEI), the solution was mixed for 15 seconds and incubated for 10
- 15 minutes at room temperature. Afterwards, cells were mixed with the DNA/PEI solution, transferred to a 500 mL shake flask and incubated for 3 hours at 37°C in an incubator with a 5% CO₂ atmosphere. After the incubation, 160 mL of F17 medium was added and cells were cultured for 24 hours. One day after transfection, 1 mM valproic acid and 7% Feed 1 (Lonza) were added to the culture. The production medium was also supplemented with 100 µM biotin.
- 20 After 7 days of culturing, the cell supernatant was collected by spinning down cells for 15 min at 210 g. The solution was sterile filtered (0.22 µm filter), supplemented with sodium azide to a final concentration of 0.01 % (w/v), and kept at 4°C.

- Secreted proteins were purified from cell culture supernatants by affinity chromatography using Protein A, followed by size exclusion chromatography. For affinity chromatography, the
- 25 supernatant was loaded on a HiTrap ProteinA HP column (CV = 5 mL, GE Healthcare) equilibrated with 40 mL 20 mM sodium phosphate, 20 mM sodium citrate pH 7.5. Unbound protein was removed by washing with at least 10 column volumes of 20 mM sodium phosphate, 20 mM sodium citrate pH 7.5. The bound protein was eluted using a linear pH-gradient created over 20 column volumes of 20 mM sodium citrate, 100 mM sodium chloride, 100 mM glycine, pH 3.0 . The column was then washed with 10 column volumes of 20 mM sodium citrate, 100
- 30 mM sodium chloride, 100 mM glycine, pH 3.0.

-96-

pH of collected fractions was adjusted by adding 1/10 (v/v) of 0.5 M sodium phosphate, pH 8.0. The protein was concentrated and filtered prior to loading on a HiLoad Superdex 200 column (GE Healthcare) equilibrated with 20 mM histidine, 140 mM sodium chloride, pH 6.0.

- The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the FolR1-Fc-fusion was analyzed by SDS capillary electrophoresis in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). The aggregate content of samples was analyzed using a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C.

Purified antigen-Fc-fusion proteins were analyzed by surface plasmon resonance assays using commercially available antibodies to confirm correct and natural conformation of the antigens (data not shown).

- Table 1:** Antigens produced for isolation, selection and counter selection of human FolR1 antibodies

Antigen	ECD (aa)	Accession number	Sequence	Seq ID No
human FolR1	25 - 234	P15328	RIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWR KNACCSTNTSQEAHKDVSYLRFNWNHCGEMAPACKR HFIQDTCLYECSPNLGPWIIQQVDQSWRKERVNLNPLC KEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVG AACQPFHFYFPTPTVLCNEIWTSHYKVSNSYRSGSGRC IQMWFDPAQGNPNNEEVARFYAAAM	227
human FolR2	17 - 230	P14207	TMCSAQDRDILLNVCMNAKHHKTKPGPEDKLHDQCSP WKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPAC KRHF IQDTCLYECSPNLGPWIIQQVNSWRKERFLDVP LCKEDCQRWWEDCHTSHYKVSNSYRSGSGRCI AGALCRTFESYFPTPAALCEGLWSHSYKVSNSYRSGSG RCIQMWFDPAQGNPNNEEVARFYAAAMHVN	228
human FolR3	24 - 243	P41439	SARARTDLLNVCMNAKHHKTPSPPEDELYGQCSPWKK NACCTASTSQELHKDTSRLYNFNWDHCGKMEPTCKRH FIQDSCLYECSPNLGPWIIQQVNSWRKERILNPLCK EDCERWWEDCRTSYTCKSNWHKGWNWTSGINECPAGA LCSTFESYFPTPAALCEGLWSHSYKVSNSYRSGSGRCI QMWFDPAQGNPNNEEVAKFYAAAMNAGAPSRGIIDS	229
murine FolR1	25 - 232	P35846	TRARTELLNVCMNAKHHKEKPGPEDNLHDQCSPWKTN SCCSTNTSQEAHKDISYLRFNWNHCGTMTSECKRHF IQDTCLYECSPNLGPWIIQQVDQSWRKERILDVPLCKE DCQQWWEDCQSSFTCKSNWHKGWNWSSGHNECPVGAS CHPFTFYFPTSAALCEEIWSHSYKLSNSYRSGSGRCIQ MWFDPAQGNPNNEEVARFYAEAMS	230
cynomolgus FolR1	25 - 234	G7PR14	EAQTRTARARTELLNVCMNAKHHKEKPGPEDKLHEQC RPWKKNACCSTNTSQEAHKDVSYLRFNWNHCGEMAP ACKRHFIQDTCLYECSPNLGPWIIQQVDQSWRKERVNL VPLCKEDCERWWEDCRTSYCKSNWHKGWNWTSGFNKC	231

-97-

			PVGAACQPFHFYFPTPTVLCNEIWTSYKVSNSRGS GRCIQMWFDPAQGNPNEEVARFYAAAMS	
--	--	--	---	--

Table 2: Summary of the yield and final monomer content of the FolR- Fc- fusions.

Antigen	Monomer [%] (SEC)	Yield
huFolR1	100	30 mg/L
cyFolR1	100	32 mg/L
muFolR1	100	31 mg/L
huFolR2	100	16 mg/L
huFolR3	95	38 mg/L

5

Example 2**Generation of common light chain with CD3ε specificity**

The T cell activating bispecific molecules described herein comprise at least one CD3 binding moiety. This moiety can be generated by immunizing laboratory animals, screening phage library or using known anti-CD3 antibodies. The common light chain with CD3ε specificity was

10 generated by humanizing the light chain of a murine parental anti-CD3ε antibody (CH2527). For humanization of an antibody of non-human origin, the CDR residues from the non-human antibody (donor) have to be transplanted onto the framework of a human (acceptor) antibody. Generally, acceptor framework sequences are selected by aligning the sequence of the donor to a collection of potential acceptor sequences and choosing one that has either reasonable homology

15 to the donor, or shows similar amino acids at some positions critical for structure and activity. In the present case, the search for the antibody acceptor framework was performed by aligning the mouse VL-domain sequence of the parental antibody to a collection of human germline sequences and choosing the human sequence that showed high sequence identity. Surprisingly, a good match in terms of framework sequence homology was found in a rather infrequent human

20 light chain belonging to the V-domain family 7 of the lambda type, more precisely, hVL_7_46 (IMGT nomenclature, GenBank Acc No. Z73674). This infrequent human light chain was subsequently chosen as acceptor framework for humanization of the light chain of CH2527. The three complementarity determining regions (CDRs) of the mouse light chain variable domain were grafted onto this acceptor framework. Since the framework 4 region is not part of the

25 variable region of the germline V-gene, the alignment for this region (J-element) was done individually. Hence the IGLJ3-02 sequence was chosen for humanization of this light chain.

-98-

Thirteen humanized variants were generated (CH2527-VL7_46-1 to VL7_46-10, VL7_46-12 to VL7_46-14). These differ in framework residues (and combinations thereof) that were back-mutated to the murine V-domain sequence or in CDR-residues (Kabat definition) that could be kept identical to the human germline sequence. The following framework residues outside the CDRs were back-mutated to the murine residues in the final humanized VL-domain variant VL7_46-13 (murine residues listed): V36, E38, F44, G46, G49, and G57, respectively. The human J-element IGLJ3-02 was 100% identical to the J-element of the murine parental antibody.

Example 3

SPR assessment of humanized variants with CD3ε specificity

Humanized VL variants were assessed as chimera in a 2+1 classical format (Figure 1D), i.e. humanized light chain V-domains were paired with murine heavy chain V-domains. SPR assessment was carried out on a ProteOn XPR36 instrument (Bio-Rad). More precisely, the variants were captured directly from the culture supernatant on an anti-Fab derivatized GLM sensorchip (Goat Anti-Human IgG, F(ab')₂ Fragment Specific, Jackson ImmunoResearch) in vertical orientation. The following analytes were subsequently injected horizontally as single concentrations to assess binding to human and cynomolgus CD3ε: 3μM hu CD3ε(-1-26)-Fc(knob)-avi (ID807) and 2.5μM cy CD3ε(-1-26)-Fc(knob)-Avi-Fc(hole) (ID873), respectively. Binding responses were qualitatively compared to binding of the murine control construct and graded + (comparable binding observed), +/- (reduced binding observed) and - (no binding observed). The capture antibody was regenerated after each cycle of ligand capture and analyte binding and the murine construct was re-injected at the end of the study to confirm the activity of the capture surface. The results are summarized in Table 3.

-99-

humanized VL variant	binding to CD3ε
murine_CH2527-VL	+
CH2527-VL7_46-1	-
CH2527-VL7_46-2	-
CH2527-VL7_46-3	-
CH2527-VL7_46-4	-
CH2527-VL7_46-5	-
CH2527-VL7_46-6	-
CH2527-VL7_46-7	-
CH2527-VL7_46-8	-
CH2527-VL7_46-9	-
CH2527-VL7_46-10	-
CH2527-VL7_46-12	+/-
CH2527-VL7_46-13	+
CH2527-VL7_46-14	-

Table 3 Qualitative binding assessment based on SPR for the humanized light chain variants combined with the murine heavy chain of CH2527. Only the humanized light chain variant that was finally chosen, CH2527-VL7_46-13, highlighted in bold letters, exhibited comparable binding to human and cynomolgus CD3ε.

Example 4

Properties of humanized common light chain with CD3ε specificity

- 10 The light chain V-domain variant that was chosen for the humanized lead molecule is VL7_46-13. The degree of humanness, i.e. the sequence homology of the humanized V-domain to the human germline V-domain sequence was determined. For VL7_46-13, the overall sequence identity with the closest human germline homolog is 65% before humanization and 80% afterwards. Omitting the CDR regions, the sequence identity is 92% to the closest human
- 15 germline homolog. As can be seen from Table 3, VL7_46-13 is the only humanized VL variant out of a panel of 13 variants that showed comparable binding to the parental murine antibody and also retained its cross-reactivity to cynomolgus CD3ε. This result indicates that it was not trivial to humanize the murine VL-domain without losing binding affinity to CD3ε which required several back-mutations to murine framework residues (in particular G46) while
- 20 retaining G24 in CDR1. In addition, this result shows that the VL-domain plays a crucial role in target recognition. Importantly, the humanized VL-domain VL7_46-13 based on an infrequent human germline belonging to the V-domain family 7 of the lambda type and retaining affinity

-100-

and specificity for CD3 ϵ , is also suitable to be used as a common light chain in phage-displayed antibody libraries of the Fab-format and enables successful selection for novel specificities which greatly facilitates the generation and production of bispecific molecules binding to CD3 ϵ and e.g. a tumor target and sharing the same 'common' light chain.

5

Example 5

Generation of a phage displayed antibody library using a human germ-line Common Light Chain derived from HVK1-39

Several approaches to generate bispecific antibodies that resemble full length human IgG utilize modifications in the Fc region that induce heterodimerization of two distinct heavy chains. Such
10 examples include knobs-into-holes (Merchant et al., Nat Biotechnol. 1998 Jul;16(7):677-81) SEED (Davis et al., Protein Eng Des Sel. 2010 Apr;23(4):195-202) and electrostatic steering technologies (Gunasekaran et al., J Biol Chem. 2010 Jun 18;285(25):19637-46). Although these approaches enable effective heterodimerization of two distinct heavy chains, appropriate pairing of cognate light and heavy chains remains a problem. Usage of a common light chain (LC) can
15 solve this issue (Merchant, et al. Nat Biotech 16, 677–681 (1998)).

Here, we describe the generation of an antibody library for the display on a M13 phage. Essentially, we designed a multi framework library for the heavy chain with one constant (or "common") light chain. This library is designed for generating multispecific antibodies without the need to use sophisticated technologies to avoid light chain mispairing.

20 By using a common light chain the production of these molecules can be facilitated as no mispairing occurs any longer and the isolation of a highly pure bispecific antibody is facilitated. As compared to other formats the use of Fab fragments as building blocks as opposed to e.g. the use of scFv fragments results in higher thermal stability and the lack of scFv aggregation and intermolecular scFv formation.

25

Library generation

In the following the generation of an antibody library for the display on M13 phage is described. Essentially, we designed a multi framework library for the heavy chain with one constant (or "common") light chain.

30 We used these heavy chains in the library (GenBank Accession Numbers in brackets):

IGHV1-46*01 (X92343) (SEQ ID NO:104) ,

IGHV1-69*06 (L22583), (SEQ ID NO:105)

IGHV3-15*01 (X92216), (SEQ ID NO:106)

-101-

IGHV3-23*01 (M99660), (SEQ ID NO:107)

IGHV4-59*01 (AB019438), (SEQ ID NO:108)

IGHV5-51*01 (M99686), (SEQ ID NO:109)

All heavy chains use the IGHJ2 as J-element, except the IGHV1-69*06 which uses IGHJ6 sequence. The design of the randomization included the CDR-H1, CDR-H2, and CDR-H3. For CDR-H1 and CDR-H2 a “soft” randomization strategy was chosen, and the randomization oligonucleotides were such that the codon for the amino acid of the germ-line sequence was present at 50%. All other amino acids, except cysteine, were summing up for the remaining 50%. In CDR-H3, where no germ-line amino acid is present due to the presence of the genetic D-element, oligonucleotides were designed that allow for the usage of randomized inserts between the V-element and the J-element of 4 to 9 amino acids in length. Those oligonucleotides contained in their randomized part e.g. The three amino acids G/Y/S are present to 15% each, those amino acids A/D/T/R/P/L/V/N/W/F/I/E are present to 4,6% each.

Exemplary methods for generation of antibody libraries are described in Hoogenboom et al., Nucleic Acids Res. 1991, 19, 4133–413; Lee et., al J. Mol. Biol. (2004) 340, 1073–1093.

The light chain is derived from the human sequence hVK1-39, and is used in an unmodified and non-randomized fashion. This will ensure that the same light chain can be used for other projects without additional modifications.

20 Exemplary Library selection:

Selections with all affinity maturation libraries are carried out in solution according to the following procedure using a monomeric and biotinylated extracellular domain of a target antigen X.

1. 10^{12} phagemid particles of each library are bound to 100nM biotinylated soluble antigen for 0.5 h in a total volume of 1ml.
2. Biotinylated antigen is captured and specifically bound phage particles are isolated by addition of $\sim 5 \times 10^7$ streptavidin-coated magnetic beads for 10 min.
3. Beads are washed using 5-10x 1ml PBS/Tween20 and 5-10x 1ml PBS.
4. Elution of phage particles is done by addition of 1ml 100mM TEA (triethylamine) for 10 min and neutralization by addition of 500ul 1M Tris/HCl pH 7.4 and
5. Re-infection of exponentially growing E. coli TG1 bacteria, infection with helper phage VCSM13 and subsequent PEG/NaCl precipitation of phagemid particles is applied in subsequent selection rounds. Selections are carried out over 3-5 rounds using either constant or decreasing (from 10^{-7} M to 2×10^{-9} M) antigen concentrations. In round 2, capture of antigen/phage complexes is performed using neutravidin plates instead of

-102-

streptavidin beads. All binding reactions are supplemented either with 100 nM bovine serum albumin, or with non-fat milk powder in order to compete for unwanted clones arising from mere sticky binding of the antibodies to the plastic support.

Selections are being carried out over three or four rounds using decreasing antigen concentrations of the antigen starting from 100nM and going down to 5nM in the final selection round. Specific binders are defined as signals ca. $5 \times$ higher than background and are identified by ELISA. Specific binders are identified by ELISA as follows: 100 μ l of 10nM biotinylated antigen per well are coated on neutravidin plates. Fab-containing bacterial supernatants are added and binding Fabs are detected via their Flag-tags by using an anti-Flag/HRP secondary antibody. ELISA-positive clones are bacterially expressed as soluble Fab fragments in 96-well format and supernatants are subjected to a kinetic screening experiment by SPR-analysis using ProteOn XPR36 (BioRad). Clones expressing Fabs with the highest affinity constants are identified and the corresponding phagemids are sequenced. For further characterization, the Fab sequences are amplified via PCR from the phagemid and cloned via appropriate restriction sites into human IgG1 expression vectors for mammalian production.

Generation of a phage displayed antibody library using a humanized CD3 ϵ specific Common Light Chain

Here, the generation of an antibody library for the display on M13 phage is described. Essentially, we designed a multi framework library for the heavy chain with one constant (or “common”) light chain. This library was designed for the generation of Fc-containing, but Fc γ R binding inactive T cell bispecific antibodies of IgG1 P329G LALA or IgG4 SPLE PG isotype in which one or two Fab recognize a tumor surface antigen expressed on a tumor cell whereas the remaining Fab arm of the antibody recognizes CD3 ϵ on a T cell.

Library generation

In the following the generation of an antibody library for the display on M13 phage is described. Essentially, we designed a multi framework library for the heavy chain with one constant (or “common”) light chain. This library is designed solely for the generation of Fc-containing, but Fc γ R binding inactive T cell bispecific antibodies of IgG1 P329G LALA or IgG4 SPLE PG isotype.

Diversity was introduced via randomization oligonucleotides only in the CDR3 of the different heavy chains. Methods for generation of antibody libraries are well known in the art and are described in (Hoogenboom et al., Nucleic Acids Res. 1991, 19, 4133–413; or in: Lee et., al J. Mol. Biol. (2004) 340, 1073–1093).

-103-

We used these heavy chains in the library:

IGHV1-46*01 (X92343), (SEQ ID NO:104)

IGHV1-69*06 (L22583), (SEQ ID NO:105)

IGHV3-15*01 (X92216), (SEQ ID NO:106)

5 IGHV3-23*01 (M99660), (SEQ ID NO:107)

IGHV4-59*01 (AB019438), (SEQ ID NO:108)

IGHV5-51*01 (M99686), (SEQ ID NO:109)

We used the light chain derived from the humanized human and Cynomolgus CD3 ϵ specific antibody CH2527 in the library: (VL7_46-13; SEQ ID NO:112). This light chain was not

10 randomized and used without any further modifications in order to ensure compatibility with different bispecific binders.

All heavy chains use the IGHJ2 as J-element, except the IGHV1-69*06 which uses IGHJ6 sequence. The design of the randomization focused on the CDR-H3 only, and PCR oligonucleotides were designed that allow for the usage of randomized inserts between the V-

15 element and the J-element of 4 to 9 amino acids in length.

Example 6

Selection of antibody fragments from common light chain libraries (comprising light chain with CD3 ϵ specificity) to FolR1

20

The antibodies 16A3, 15A1, 18D3, 19E5, 19A4, 15H7, 15B6, 16D5, 15E12, 21D1, 16F12, 21A5, 21G8, 19H3, 20G6, and 20H7 comprising the common light chain VL7_46-13 with CD3 ϵ specificity were obtained by phage display selections against different species (human, cynomolgus and murine) of FolR1. Clones 16A3, 15A1, 18D3, 19E5, 19A4, 15H7, 15B6, 21D1, 25 16F12, 19H3, 20G6, and 20H7 were selected from a sub-library in which the common light chain was paired with a heavy chain repertoire based on the human germline VH1_46. In this sub-library, CDR3 of VH1_46 has been randomized based on 6 different CDR3 lengths. Clones 16D5, 15E12, 21A5, and 21G8 were selected from a sub-library in which the common light chain was paired with a heavy chain repertoire based on the human germline VH3_15. In this 30 sub-library, CDR3 of VH3_15 has been randomized based on 6 different CDR3 lengths. In order to obtain species cross-reactive (or murine FolR1-reactive) antibodies, the different species of FolR1 were alternated (or kept constant) in different ways over 3 rounds of biopanning: 16A3 and 15A1 (human – cynomolgus – human FolR1); 18D3 (cynomolgus – human – murine FolR1); 19E5 and 19A4 (3 rounds against murine FolR1); 15H7, 15B6, 16D5, 15E12, 21D1, 16F12,

-104-

21A5, 21G8 (human – cynomolgus – human FolR1); 19H3, 20G6, and 20H7 (3 rounds against murine FolR1).

Human, murine and cynomolgus FolR1 as antigens for the phage display selections as well as ELISA- and SPR-based screenings were transiently expressed as N-terminal monomeric Fc-
5 fusion in HEK EBNA cells and *in vivo* site-specifically biotinylated via co-expression of BirA biotin ligase at the avi-tag recognition sequence located at the C-terminus of the Fc portion carrying the receptor chain (Fc knob chain). In order to assess the specificity to FolR1, two related receptors, human FolR2 and FolR3 were generated in the same way.

Selection rounds (biopanning) were performed in solution according to the following pattern:

- 10 1. Pre-clearing of $\sim 10^{12}$ phagemid particles on maxisorp plates coated with 10 ug/ml of an unrelated human IgG to deplete the libraries of antibodies recognizing the Fc-portion of the antigen.
2. Incubating the non-Fc-binding phagemid particles with 100nM biotinylated human, cynomolgus, or murine FolR1 for 0.5h in the presence of 100nM unrelated non-biotinylated Fc
15 knob-into-hole construct for further depletion of Fc-binders in a total volume of 1ml.
3. Capturing the biotinylated FolR1 and attached specifically binding phage by transfer to 4 wells of a neutravidin pre-coated microtiter plate for 10 min (in rounds 1 & 3).
4. Washing the respective wells using 5x PBS/Tween20 and 5x PBS.
5. Eluting the phage particles by addition of 250 ul 100 mM TEA (triethylamine) per well for 10
20 min and neutralization by addition of 500 ul 1 M Tris/HCl pH 7.4 to the pooled eluates from 4 wells.
6. Post-clearing of neutralized eluates by incubation on neutravidin pre-coated microtiter plate with 100 nM biotin-captured FolR2 or FolR3 for final removal of Fc- and unspecific binders.
7. Re-infection of log-phase *E. coli* TG1 cells with the supernatant of eluted phage particles,
25 infection with helperphage VCSM13, incubation on a shaker at 30 °C over night and subsequent PEG/NaCl precipitation of phagemid particles to be used in the next selection round.

-105-

Selections were carried out over 3 rounds using constant antigen concentrations of 100nM. In round 2, in order to avoid enrichment of binders to neutravidin, capture of antigen : phage complexes was performed by addition of 5.4×10^7 streptavidin-coated magnetic beads. Specific binders were identified by ELISA as follows: 100ul of 25 nM biotinylated human, cynomolgus, or murine FolR1 and 10 ug/ml of human IgG were coated on neutravidin plates and maxisorp plates, respectively. Fab-containing bacterial supernatants were added and binding Fabs were detected via their Flag-tags using an anti-Flag/HRP secondary antibody. Clones exhibiting signals on human FolR1 and being negative on human IgG were short-listed for further analyses and were also tested in a similar fashion against the remaining two species of FolR1. They were bacterially expressed in a 0.5 liter culture volume, affinity purified and further characterized by SPR-analysis using BioRad's ProteOn XPR36 biosensor.

Affinities (K_D) of selected clones were measured by surface plasmon resonance (SPR) using a ProteOn XPR36 instrument (Biorad) at 25 °C with biotinylated human, cynomolgus, and murine FolR1 as well as human FolR2 and FolR3 (negative controls) immobilized on NLC chips by neutravidin capture. Immobilization of antigens (ligand): Recombinant antigens were diluted with PBST (10 mM phosphate, 150 mM sodium chloride pH 7.4, 0.005% Tween 20) to 10 µg/ml, then injected at 30 µl/minute in vertical orientation. Injection of analytes: For 'one-shot kinetics' measurements, injection direction was changed to horizontal orientation, two-fold dilution series of purified Fab (varying concentration ranges) were injected simultaneously along separate channels 1-5, with association times of 200 s, and dissociation times of 600 s. Buffer (PBST) was injected along the sixth channel to provide an "in-line" blank for referencing. Association rate constants (k_{on}) and dissociation rate constants (k_{off}) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K_D) was calculated as the ratio k_{off}/k_{on} . Table 4 lists the equilibrium dissociation constants (K_D) of the selected clones specific for FolR1.

Table 4: Equilibrium dissociation constants (K_D) for anti-FolR1 antibodies (Fab-format) selected by phage display from common light chain sub-libraries comprising VL7_46-13, a humanized light chain specific for CD3ε. K_D in nM.

-106-

Clone	huFolR1 [nM]	cyFolR1 [nM]	muFolR1 [nM]	huFolR2 [nM]	huFolR3 [nM]
16A3	21.7	18	very weak	no binding	no binding
15A1	30.9	17.3	very weak	no binding	no binding
18D3	93.6	40.2	very weak	no binding	no binding
19E5	522	276	19.4	no binding	no binding
19A4	2050	4250	43.1	no binding	no binding
15H7	13.4	72.5	no binding	no binding	no binding
15B6	19.1	13.9	no binding	no binding	no binding
16D5	39.5	114	no binding	no binding	no binding
15E12	55.7	137	no binding	no binding	no binding
21D1	62.6	32.1	no binding	no binding	no binding
16F12	68	90.9	no binding	no binding	no binding
21A5	68.8	131	no binding	no binding	no binding
21G8	130	261	no binding	no binding	no binding
19H3	no binding	no binding	89.7	no binding	no binding
20G6	no binding	no binding	78.5	no binding	no binding

Example 7

Selection of antibody fragments from generic multi-framework libraries to FolR1

5

The antibodies 11F8, 36F2, 9D11, 5D9, 6B6, and 14E4 were obtained by phage display selections based on generic multi-framework sub-libraries against different species (human, cynomolgus and murine) of FolR1. In these multi-framework sub-libraries, different VL-domains with randomized CDR3 (3 different lengths) are paired with different VH-domains with randomized CDR3 (6 different lengths). The selected clones are of the following VL/VH pairings: 11F8 (Vk_{1_5}/VH_{1_69}), 36F2 (Vk_{3_20}/VH_{1_46}), 9D11 (Vk_{2D_28}/VH_{1_46}), 5D9 (Vk_{3_20}/VH_{1_46}), 6B6 (Vk_{3_20}/VH_{1_46}), and 14E4 (Vk_{3_20}/VH_{3_23}). In order to obtain species cross-reactive (or murine FolR1-reactive) antibodies, the different species of FolR1 were alternated (or kept constant) in different ways over 3 or 4 rounds of biopanning:

11F8 (cynomolgus – murine – human FolR1); 36F2 (human – murine – cynomolgus – murine FolR1); 9D11 (cynomolgus – human – cynomolgus FolR1); 5D9 (human – cynomolgus – human FolR1); 6B6 (human – cynomolgus – human FolR1) and 14E4 (3 rounds against murine FolR1).

Human, murine and cynomolgus FolR1 as antigens for the phage display selections as well as ELISA- and SPR-based screenings were transiently expressed as N-terminal monomeric Fc-fusion in HEK EBNA cells and *in vivo* site-specifically biotinylated via co-expression of BirA biotin ligase at the avi-tag recognition sequence located at the C-terminus of the Fc portion carrying the receptor chain (Fc knob chain). In order to assess the specificity to FolR1, two related receptors, human FolR2 and FolR3 were generated in the same way.

-107-

Selection rounds (biopanning) were performed in solution according to the following pattern:

1. Pre-clearing of $\sim 10^{12}$ phagemid particles on maxisorp plates coated with 10 ug/ml of an unrelated human IgG to deplete the libraries of antibodies recognizing the Fc-portion of the antigen.
- 5 2. Incubating the non-Fc-binding phagemid particles with 100nM biotinylated human, cynomolgus, or murine FolR1 for 0.5h in the presence of 100nM unrelated non-biotinylated Fc knob-into-hole construct for further depletion of Fc-binders in a total volume of 1ml.
3. Capturing the biotinylated FolR1 and attached specifically binding phage by transfer to 4 wells of a neutravidin pre-coated microtiter plate for 10 min (in rounds 1 & 3).
- 10 4. Washing the respective wells using 5x PBS/Tween20 and 5x PBS.
5. Eluting the phage particles by addition of 250 ul 100 mM TEA (triethylamine) per well for 10 min and neutralization by addition of 500 ul 1 M Tris/HCl pH 7.4 to the pooled eluates from 4 wells.
6. Post-clearing of neutralized eluates by incubation on neutravidin pre-coated microtiter plate
15 with 100 nM biotin-captured FolR2 or FolR3 for final removal of Fc- and unspecific binders.
7. Re-infection of log-phase *E. coli* TG1 cells with the supernatant of eluted phage particles, infection with helperphage VCSM13, incubation on a shaker at 30 °C over night and subsequent PEG/NaCl precipitation of phagemid particles to be used in the next selection round.

Selections were carried out over 3 rounds using constant antigen concentrations of 100nM. In
20 round 2 and 4, in order to avoid enrichment of binders to neutravidin, capture of antigen : phage complexes was performed by addition of 5.4×10^7 streptavidin-coated magnetic beads. Specific binders were identified by ELISA as follows: 100ul of 25 nM biotinylated human, cynomolgus, or murine FolR1 and 10 ug/ml of human IgG were coated on neutravidin plates and maxisorp plates, respectively. Fab-containing bacterial supernatants were added and binding Fabs were
25 detected via their Flag-tags using an anti-Flag/HRP secondary antibody. Clones exhibiting signals on human FolR1 and being negative on human IgG were short-listed for further analyses and were also tested in a similar fashion against the remaining two species of FolR1. They were bacterially expressed in a 0.5 liter culture volume, affinity purified and further characterized by SPR-analysis using BioRad's ProteOn XPR36 biosensor.

-108-

Affinities (K_D) of selected clones were measured by surface plasmon resonance (SPR) using a ProteOn XPR36 instrument (Biorad) at 25 °C with biotinylated human, cynomolgus, and murine FolR1 as well as human FolR2 and FolR3 (negative controls) immobilized on NLC chips by neutravidin capture. Immobilization of antigens (ligand): Recombinant antigens were diluted with PBST (10 mM phosphate, 150 mM sodium chloride pH 7.4, 0.005% Tween 20) to 10 µg/ml, then injected at 30 µl/minute in vertical orientation. Injection of analytes: For ‘one-shot kinetics’ measurements, injection direction was changed to horizontal orientation, two-fold dilution series of purified Fab (varying concentration ranges) were injected simultaneously along separate channels 1-5, with association times of 150 or 200 s, and dissociation times of 200 or 600 s, respectively. Buffer (PBST) was injected along the sixth channel to provide an “in-line” blank for referencing. Association rate constants (k_{on}) and dissociation rate constants (k_{off}) were calculated using a simple one-to-one Langmuir binding model in ProteOn Manager v3.1 software by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K_D) was calculated as the ratio k_{off}/k_{on} . Table 5 lists the equilibrium dissociation constants (K_D) of the selected clones specific for FolR1.

Table 5: Equilibrium dissociation constants (K_D) for anti-FolR1 antibodies (Fab-format) selected by phage display from generic multi-framework sub-libraries. K_D in nM.

Clone	K_D (nM)				
	huFolR1	cyFolR1	muFolR1	huFolR2	huFolR3
11F8	632	794	1200	no binding	no binding
36F2	1810	1640	737	no binding	no binding
9D11	8.64	5.29	no binding	no binding	no binding
5D9	8.6	5.9	no binding	no binding	no binding
6B6	14.5	9.4	no binding	no binding	no binding
14E4	no binding	no binding	6.09	no binding	no binding

Example 8

20 Production and purification of novel FolR1 binders in IgG and T-cell bispecific formats

To identify FolR1 binders which are able to induce T-cell dependent killing of selected target cells the antibodies isolated from a common light chain- or Fab-library were converted into the corresponding human IgG1 format. In brief, the variable heavy and variable light chains of unique FolR1 binders from phage display were amplified by standard PCR reactions using the Fab clones as the template. The PCR products were purified and inserted (either by restriction endonuclease and ligase based cloning, or by ‘recombineering’ using the InFusion kit from Invitrogen) into suitable expression vectors in which they are fused to the appropriate human constant heavy or human constant light chain. The expression cassettes in these vectors consist

-109-

of a chimeric MPSV promoter and a synthetic polyadenylation site. In addition, the plasmids contain the oriP region from the Epstein Barr virus for the stable maintenance of the plasmids in HEK293 cells harboring the EBV nuclear antigen (EBNA). After PEI mediated transfection the antibodies were transiently produced in HEK293 EBNA cells and purified by standard ProteinA
5 affinity chromatography followed by size exclusion chromatography as described:

Transient transfection and production

All (bispecific) antibodies (if not obtained from a commercial source) used herein were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293 EBNA cells are cultivated in suspension serum
10 free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells are seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells are centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 200 µg DNA. After addition of 540 µl PEI solution is
15 vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium is added and cell are cultivated for 24 hours. One day after transfection 1 mM valporic acid and 7 % Feed 1 is added. After 7 days cultivation supernatant is collected for purification by
20 centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C. After production the supernatants were harvested and the antibody containing supernatants were filtered through 0.22 µm sterile filters and stored at 4 °C until purification.

Antibody purification

All molecules were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to HiTrap PA FF (GE Healthcare, column volume (cv) = 5 ml) equilibrated with 8 column volumes (cv)
30 *buffer A* (20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5). After washing with 10 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (20 mM sodium citrate pH 3, 100 mM NaCl, 100 mM glycine) over 12 cv. Fractions containing the protein of interest were pooled and the pH of the solution was gently adjusted to pH 6.0 (using 0.5 M Na₂HPO₄ pH 8.0).

-110-

Samples were concentrated to 2 ml using ultra-concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius) and subsequently applied to a HiLoad™ 16/60 Superdex™ 200 preparative grade (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl, 0.01% Tween-20. The aggregate content of eluted fractions was analyzed by analytical size exclusion chromatography.

- 5 Therefore, 30 µl of each fraction was applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. Fractions containing less than 2 % oligomers were pooled and concentrated to final concentration of 1 - 1.5 mg/ml using ultra concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius). The protein
- 10 concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were frozen in liquid N₂ and stored at -80 °C.
- 15 Based on *in vitro* characterization results selected binders were converted into a T-cell bispecific format. In these molecules the FolR1:CD3 binding moieties are arranged in a 2:1 order with the FolR1 Fabs being located at the N-terminus. For clones isolated from the standard Fab library the CD3 binding part was generated as a CrossFab (CH1Cκ crossing) while for the clones from the common light chain library no crossing was necessary. These bispecific molecules were
- 20 produced and purified analogously to the IgGs.

Table 6: Yield and monomer content of novel FolR1 binders in IgG and TCB format, respectively.

#	Clone	Library	IgG		TCB	
			Yield [mg/L]	Monomer [%]	Yield [mg/L]	Monomer [%]
1	11F8	Fab	8.03	96.26	--	--
2	14E4	Fab	8.90	98.12	--	--
3	15B6	CLC	7.72	100.00	--	--

-111-

4	15E12	CLC	6.19	100.00	--	--
5	15H7	CLC	8.94	100.00	--	--
6	16A3	CLC	0.60	n.d.	--	--
7	16D5	CLC	36.50	96.96	4.36	97.19
8	16F12	CLC	5.73	97.17	--	--
9	18D3	CLC	0.90	n.d.	--	--
10	19A4	CLC	38.32	100.00	37.50	100.00
11	19E5	CLC	46.09	100.00	--	--
12	19H3	CLC	7.64	100.00	--	--
13	20G6	CLC	24.00	100.00	--	--
14	20H7	CLC	45.39	100.00	--	--
15	21A5	CLC	1.38	98.56	47.31	95.08
16	21D1	CLC	5.47	100.00	--	--
17	21G8	CLC	6.14	97.28	9.27	100.00
18	36F2	Fab	11.22	100.00	18.00	100.00
19	5D9	Fab	20.50	100.00	0.93	97.32
20	6B6	Fab	3.83	100.00	4.17	91.53
21	9D11	Fab	14.61	100.00	2.63	100.00

CLC: Common light chain

Example 9**2+1 and 1+1 T-cell bispecific formats**

- 5 Four different T-cell bispecific formats were prepared for one common light chain binder (16D5) and three formats for one binder from the Fab library (9D11) to compare their killing properties in vitro.

The standard format is the 2+1 inverted format as already described (FolR1:CD3 binding moieties arranged in a 2:1 order with the FolR1 Fabs located at the N-terminus). In the 2+1
10 classical format the FolR1:CD3 binding moieties are arranged in a 2:1 order with the CD3 Fab being located at the N-terminus. Two monovalent formats were also prepared. The 1+1 head-to-tail has the FolR1:CD3 binding moieties arranged in a 1:1 order on the same arm of the molecule with the FolR1 Fab located at the N-terminus. In the 1+1 classical format the FolR1:CD3 binding moieties are present once, each on one arm of the molecule. For the 9D11 clone isolated
15 from the standard Fab library the CD3 binding part was generated as a CrossFab (CH1Ck

-112-

crossing) while for the 16D5 from the common light chain library no crossing was necessary. These bispecific molecules were produced and purified analogously to the standard inverted T-cell bispecific format.

Table 7: Summary of the yield and final monomer content of the different T-cell bispecific formats.

Construct	Monomer [%] (SEC)	Yield
16D5 FolR1 TCB 2+1 (inverted)	96%	5.4 mg/L
16D5 FolR1 TCB 2+1 (classical)	90%	4.6 mg/L
16D5 FolR1 TCB 1+1 (head-to-tail)	100 %	5.4 mg/L
16D5 FolR1 TCB 1+1 (classical)	100%	0.7 mg/L
9D11 FolR1 TCB 2+1 (inverted)	100%	2.6 mg/L
9D11 FolR1 TCB 1+1 (head-to-tail)	100%	6.1 mg/L
9D11 FolR1 TCB 1+1 (classical)	96%	1.3 mg/L
Mov19 FolR1 TCB 2+1 (inverted)	98%	3 mg/L
Mov19 FolR1 TCB 1+1 (head-to-tail)	100%	5.2 mg/L

Example 10

Biochemical characterization of FolR1 binders by surface plasmon resonance

10 Binding of FolR1 binders as IgG or in the T-cell bispecific format to different recombinant folate receptors (human FolR1, 2 and 3, murine FolR1 and cynomolgus FolR1; all as Fc fusions) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

15 *Single injections*

First the anti-FolR1 IgGs were analyzed by single injections (Table 1) to characterize their crossreactivity (to human, murine and cyno FolR1) and specificity (to human FolR1, human FolR2, human FolR3). Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) or human Folate Receptor 2 and 3 (FolR2-Fc, FolR3-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 300-400 RU. The IgGs were injected for 60 seconds at a concentration of 500 nM. IgGs binding to huFolR2 and huFolR3 were

-113-

rejected for lack of specificity. Most of the binders are only crossreactive between human and cyno FolR1, additional crossreactivity to murine FolR1 went most of the time hand in hand with loss of specificity.

Table 8: Crossreactivity and specificity of 25 new folate receptor 1 binders (as IgGs) as well as of two control IgGs (Mov19 and Farletuzumab). + means binding, - means no binding, +/- means weak binding.

Clone name	Binding to huFolR1	Binding to cyFolR1	Binding to muFolR1	Binding to huFolR2	Binding to huFolR3
Mov19	+	+	-	-	-
Farletuzumab	+	+	-	-	-
16A3	+	+	+/-	-	-
18D3	+	+	-	-	-
19E5	+	+	+	+	+
19A4	-	-	+	+	+
15H7	+	+	+	-	-
15B6	+	+	-	-	-
16D5	+	+	-	-	-
15E12	+	+	+/-	+	+
21D1	+	+	+/-	-	-
16F12	+	+	-	-	-
21A5	+	+	-	-	+/-
21G8	+	+	-	+	+
19H3	-	-	+	-	-
20G6	-	-	+	-	-
20H7	-	-	+	-	-
9D11	+	+	-	-	-
5D9	+	+	-	+	+
6B6	+	+	-	+	+
11F8	+	+	+	+	+
36F2	+	+	+	-	-
14E4	-	-	+	-	-

Avidity to Folate Receptor 1

- 10 The avidity of the interaction between the anti-FolR1 IgGs or T cell bispecifics and the recombinant folate receptors was determined as described below (Table 9).

Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 300-400 RU. The

- 15 anti-FolR1 IgGs or T cell bispecifics were passed at a concentration range from 2.1 to 500 nM

-114-

with a flow of 30 μ L/minutes through the flow cells over 180 seconds. The dissociation was monitored for 600 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated IL2 receptor Fc fusion. For the analysis of the interaction of 19H3 IgG and murine folate receptor 1, folate (Sigma F7876) was added in the HBS-EP running buffer at a concentration of 2.3 μ M. The binding curves resulting from the bivalent binding of the IgGs or T cell bispecifics were approximated to a 1:1 Langmuir binding and fitted with that model (which is not correct, but gives an idea of the avidity). The apparent avidity constants for the interactions were derived from the rate constants of the fitting using the Bia Evaluation software (GE Healthcare).

Table 9: Bivalent binding (avidity with apparent KD) of selected FolR1 binders as IgGs or as T-cell bispecifics (TCB) on human and cyno FolR1.

Analyte	Ligand	ka (1/Ms)	kd (1/s)	Apparent KD (M)
16D5 TCB	huFolR1	8.31E+04	3.53E-04	4.24E-09
	cyFolR1	1.07E+05	3.70E-04	3.45E-09
9D11 TCB	huFolR1	1.83E+05	9.83E-05	5.36E-10
	cyFolR1	2.90E+05	6.80E-05	2.35E-10
21A5 TCB	huFolR1	2.43E+05	2.64E-04	1.09E-09
	cyFolR1	2.96E+05	2.76E-04	9.32E-10
36F2 IgG	huFolR1	2.62E+06	1.51E-02	5.74E-9
	cyFolR1	3.02E+06	1.60E-02	5.31E-9
	muFolR1	3.7E+05	6.03E-04	1.63E-9
Mov19 IgG	huFolR1	8.61E+05	1.21E-04	1.4E-10
	cyFolR1	1.29E+06	1.39E-04	1.08E-10
Farletuzumab	huFolR1	1.23E+06	9E-04	7.3E-10
	cyFolR1	1.33E+06	8.68E-04	6.5E-10
19H3 IgG	muFolR1	7.1E+05	1.1E-03	1.55E-09

1. Affinity to Folate Receptor 1

The affinity of the interaction between the anti-FolR1 IgGs or the T cell bispecifics and the recombinant folate receptors was determined as described below (Table 10).

For affinity measurement, direct coupling of around 6000-7000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 IgGs or T cell bispecifics were captured at 20 nM with a flow rate of 10 μ L/min for 20 or 40 sec, the reference flow cell was left without capture. Dilution series (6.17 to 500 nM or 12.35 to 3000 nM) of human or cyno Folate Receptor 1 Fc fusion were passed on all flow cells at 30 μ L/min for 120 or

-115-

240 sec to record the association phase. The dissociation phase was monitored for 240 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 2.1 or pH 1.5. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

Table 10: Monovalent binding (affinity) of selected FolR1 binders as IgGs or as T-cell bispecifics (TCB) on human and cyno FolR1.

Ligand	Analyte	ka (1/Ms)	kd (1/s)	KD (M)
16D5 TCB	huFolR1	1.53E+04	6.88E-04	4.49E-08
	cyFolR1	1.32E+04	1.59E-03	1.21E-07
9D11 TCB	huFolR1	3.69E+04	3.00E-04	8.13E-09
	cyFolR1	3.54E+04	2.06E-04	5.82E-09
21A5 TCB	huFolR1	1.79E+04	1.1E-03	6.16E-08
	cyFolR1	1.48E+04	2.06E-03	1.4E-07
Mov19 IgG	huFolR1	2.89E+05	1.59E-04	5.5E-10
	cyFolR1	2.97E+05	1.93E-04	6.5E-10
Farletuzumab	huFolR1	4.17E+05	2.30E-02	5.53E-08
	cyFolR1	5.53E+05	3.73E-02	6.73E-08

10

2. Affinity to CD3

The affinity of the interaction between the anti-FolR1 T cell bispecifics and the recombinant human CD3 $\epsilon\delta$ -Fc was determined as described below (Table 11).

For affinity measurement, direct coupling of around 9000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 T cell bispecifics were captured at 20 nM with a flow rate of 10 μ l/min for 40 sec, the reference flow cell was left without capture. Dilution series (6.17 to 500 nM) of human CD3 $\epsilon\delta$ -Fc fusion were passed on all flow cells at 30 μ l/min for 240 sec to record the association phase. The dissociation phase was monitored for 240 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 2.1. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

25

-116-

Table 11: Monovalent binding (affinity) of selected FolR1 T-cell bispecifics (TCB) on human CD3-Fc.

Ligand	Analyte	ka (1/Ms)	kd (1/s)	KD (M)
16D5 TCB	huCD3	4.25E+04	3.46E-03	8.14E-08
21A5 TCB	huCD3	3.72E+04	3.29E-03	8.8E-08

The CD3 binding part is identical for all constructs and the affinity is similar for the measured T cell bispecifics (KD range between 60 and 90 nM).

5

Example 11

Simultaneous binding T cell bispecifics on Folate Receptor 1 and CD3

Simultaneous binding of the anti-FolR1 T cell bispecifics on recombinant Folate Receptor 1 and recombinant human CD3 $\epsilon\delta$ -Fc was determined by surface plasmon resonance as described below. Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 300-400 RU. The anti-FolR1 T cell bispecifics were injected for 60 s at 500 nM with a flow of 30 μ L/minutes through the flow cells, followed by an injection of hu CD $\epsilon\delta$ -Fc for 60 s at 500 nM. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated IL2 receptor Fc fusion. The four T cell bispecifics tested (16D5 TCB, 21A5 TCB, 51C7 TCB and 45D2 TCB) were able to bind simultaneously to Folate Receptor 1 and human CD3 as expected.

15

Example 12

Epitope binning

For epitope binning, the anti-FolR1 IgGs or T cell bispecifics were directly immobilized on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare), with a final response around 700 RU. 500 nM huFolR1-Fc was then captured for 60 s, followed by 500 nM of the different binders for 30 s. The surface was regenerated with two injections of 10 mM glycine pH 2 for 30 s each. It is assessed if the different binders can bind to huFolR1 captured on immobilized binders (Table 12).

20

25

Table 12: Epitope characterization of selected FolR1 binders as IgGs or as T-cell bispecifics (TCB) on human FolR1. + means binding, - means no binding, +/- means weak binding

-117-

		Analytes in solution					
	On huFolR1	16D5 TCB	21A5 TCB	9D11 TCB	36F2 IgG	Mov19 IgG	Farletuzumab
Immobilized	16D5 TCB	-	-	-	+	+	+
	21A5 TCB	-	-	-	+	+	+
	9D11 TCB	No additional binding on FolR1 possible once captured on 9D11					
	36F2 IgG	Measure not possible, huFolR1 dissociates too rapidly					
	Mov19 IgG	+	+	+/-	-	-	-

Based on these results and additional data with simultaneous binding on immobilized huFolR1, the binders were separated in three groups. It is not clear if 9D11 has a separate epitope because it displaces all the other binders. 16D5 and 21A5 seem to be in the same group and Mov19, Farletuzumab (Coney et al., Cancer Res. 1991 Nov 15;51(22):6125-32; Kalli et al., Curr Opin Investig Drugs. 2007 Dec;8(12):1067-73) and 36F2 in another (Table 13). However, 36F2 binds to a different epitope than Mov 19 and Farletuzumab as it binds to human, cynomous and murine FolR1.

Table 13: Epitope grouping of selected FolR1 binders as IgGs or as T-cell bispecifics (TCB) on human FolR1

Epitope 1	Epitope 2	Epitope 3
16D5	9D11	Mov19
21A5		Farletuzumab
		36F2

-118-

Example 13

Selection of binders

FolR1 binders in the IgG formats were screened by surface plasmon resonance (SPR) and by in vitro assay on cells to select the best candidates.

- 5 The anti-FolR1 IgGs were analyzed by SPR to characterize their crossreactivity (to human, murine and cynomolgus FolR1) and specificity (to human FolR1, human FolR2, human FolR3). Unspecific binding to human FolR2 and 3 was considered an exclusion factor. Binding and specificity to human FolR1 was confirmed on cells. Some binders did not bind on cells expressing FolR1 even though they recognized the recombinant human FolR1 in SPR.
- 10 Aggregation temperature was determined but was not an exclusion factor because the selected binders were all stable. Selected binders were tested in a polyreactivity ELISA to check for unspecific binding, which led to the exclusion of four binders. This process resulted in an initial selection of three binders: 36F2 (Fab library), 9D11 (Fab library) and 16D5 (common light chain). 36F2 dissociated rapidly from huFolR1 and was, therefore, initially not favored.
- 15

Example 14

Specific binding of newly generated FolR1 binders to human FolR1 positive tumor cells

New FolR1 binders were generated via Phage Display using either a Fab library or a common light chain library using the CD3 light chain. The identified binders were converted into a human

- 20 IgG1 format and binding to FolR1 high expressing HeLa cells was addressed. As reference molecule the human FolR1 binder Mov19 was included. Most of the binders tested in this assay showed intermediate to good binding to FolR1 with some clones binding equally well as Mov19 (see Figure 2). The clones 16A3, 18D3, 15H7, 15B6, 21D1, 14E4 and 16F12 were excluded because binding to FolR1 on cells could not be confirmed by flow cytometry. In a next step the
- 25 selected clones were tested for specificity to human FolR1 by excluding binding to the closely related human FolR2. HEK cells were transiently transfected with either human FolR1 or human FolR2 to address specificity. The clones 36F2 and 9D11 derived from the Fab library and the clones 16D5 and 21A5 derived from the CLC library bind specifically to human FolR1 and not to human FolR2 (see Figures 3A-B). All the other tested clones showed at least some binding to
- 30 human FolR2 (see Figures 3A-B). Therefore these clones were excluded from further characterization. In parallel cross-reactivity of the FolR1 clones to cyno FolR1 was addressed by performing binding studies to HEK cells transiently transfected with cyno FolR1. All tested clones were able to bind cyno FolR1 and the four selected human FolR1 specific clones 36F2,

-119-

9D11, 16D5 and 21A5 bind comparably well human and cyno FoLR1 (Figure 4). Subsequently three human FoLR1 specific cyno cross-reactive binders were converted into TCB format and tested for induction of T cell killing and T cell activation. These clones were 9D11 from the Fab library and 16D5 and 21A5 from the CLC library. As reference molecule Mov19 FoLR1 TCB was included in all studies. These FoLR1 TCBs were then used to compare induction of internalization after binding to FoLR1 on HeLa cells. All three tested clones are internalized upon binding to FoLR1 comparable to internalization upon binding of Mov19 FoLR1 TCB (Figure 5). 21A5 FoLR1 TCB was discontinued due to signs of polyreactivity.

10

Example 15**T cell-mediated killing of FoLR1-expressing tumor target cells induced by FoLR1 TCB antibodies**

The FoLR1 TCBs were used to determine T cell mediated killing of tumor cells expressing FoLR1. A panel of potential target cell lines was used to determine FoLR1 binding sites by Qifikit analysis.

15

The used panel of tumor cells contains FoLR1 high, intermediate and low expressing tumor cells and a FoLR1 negative cell line.

20 Table 14: FoLR1 binding sites on tumor cells

Cell line	Origin	FoLR1 binding sites
Hela	Cervix adenocarcinoma	2'240'716
Skov3	Ovarian adenocarcinoma	91'510
OVCAR5	Ovarian adenocarcinoma	22'077
HT29	Colorectal adenocarcinoma	10'135
MKN45	Gastric adenocarcinoma	54

Binding of the three different FoLR1 TCBs (containing 9D11, 16D5 and Mov19 binders) to this panel of tumor cell lines was determined showing that the FoLR1 TCBs bind specifically to FoLR1 expressing tumor cells and not to a FoLR1 negative tumor cell line. The amount of bound

-120-

construct is proportional to the FolR1 expression level and there is still good binding of the constructs to the FolR1 low cell line HT-29 detectable. In addition there is no binding of the negative control DP47 TCB to any of the used cell lines (Figures 6A-E).

- The intermediate expressing cell line SKOV3 and the low expressing cell line HT-29 were
- 5 further on used to test T cell mediated killing and T cell activation using 16D5 TCB and 9D11 TCB; DP47 TCB was included as negative control. Both cell lines were killed in the presence of already very low levels of 16D5 TCB and 9D11 TCB and there was no difference in activity between both TCBs even though 9D11 TCB binds stronger to FolR1 than 16D5 TCB. Overall killing of SKOV3 cells was higher compared to HT-29 which reflects the higher expression
- 10 levels of FolR1 on SKOV3 cells (Figures 7A-D). In line with this, a strong upregulation of the activation marker CD25 and CD69 on CD4⁺ T cells and CD8⁺ T cells was detected. Activation of T cells was very similar in the presence of SKOV3 cells and HT-29 cells. The negative control DP47 TCB does not induce any killing at the used concentrations and there was no significant upregulation of CD25 and CD69 on T cells.

15

Table 15: EC50 values of tumor cell killing and T cell activation with SKOV3 cells

Construct	Killing 24 h (pM)	Killing 48 h (pM)	CD4+ CD69+ (%)	CD4+ CD25+ (%)	CD8+ CD69+ (%)	CD8+ CD25+ (%)
9D11 FolR1 TCB	1.1	0.03	0.51	0.46	0.019	0.03
16D5 FolR1 TCB	0.7	0.04	0.34	0.33	0.025	0.031

Table 16: EC50 values of tumor cell killing and T cell activation with HT-29 cells

Construct	Killing 24 h (pM)	Killing 48 h (pM)	CD4+ CD69+ (%)	CD4+ CD25+ (%)	CD8+ CD69+ (%)	CD8+ CD25+ (%)
-----------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

-121-

9D11 FoLR1 TCB	2.3	0.1	1.22	1.11	0.071	0.084
16D5 FoLR1 TCB	2.8	0.1	0.69	0.62	0.021	0.028

Example 16**Binding to erythrocytes and T cell activation in whole blood**

To prove that there is no spontaneous activation in the absence of FoLR1 expressing tumor cells we tested if there is binding of the FoLR1 clones to erythrocytes which might potentially express FoLR1. We could not observe any specific binding of 9D11 IgG, 16D5 IgG and Mov19 IgG to erythrocytes, as negative control DP47 IgG was included (Figure 8).

To exclude any further unspecific binding to blood cells or unspecific activation via FoLR1 TCB, 9D11 TCB, 16D5 TCB and Mov19 TCB were added into whole blood and upregulation of CD25 and CD69 on CD4⁺ T cells and CD8⁺ T cells was analyzed by flow cytometry. DP47 TCB was included as negative control. No activation of T cells with any of the tested constructs could be observed by analyzing upregulation of CD25 and CD69 on CD4⁺ T cells and CD8⁺ T cells (Figure 9).

Example 17**Removal of the N-glycosylation site in 9D11 light chain**

During analysis of the different FoLR1 binders to identify potential sequence hot spots, at the end of CDR L3 of the clone 9D11 a putative N-glycosylation site was identified. Usually the consensus motif for N-glycosylation is defined as N-X-S/T-X (where X is not P). The sequence of CDR L3 (MQASIMNRT) (SEQ ID NO: 61) perfectly matches this consensus motif having the sequence N-R-T. Since glycosylation might not be completely reproducible among different production batches this could have an impact on FoLR1 binding, if the glycosylation in CDR L3 contributes to antigen binding. To evaluate if this N-glycosylation site is important for FoLR1 binding, or could be replaced without impairing binding, different variants of the 9D11 light chain were generated in which the N-glycosylation site was exchanged by site specific mutagenesis.

-122-

1. Transient transfection and production

The four T cell bispecifics were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293 EBNA cells were cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells were seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells were centrifuged for 5 min by 210 x g, supernatant was replaced by pre-warmed 20 ml CD CHO medium. Expression vectors were mixed in 20 ml CD CHO medium to a final amount of 200 µg DNA. After addition of 540 µl PEI solution was vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells were mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium was added and cell were cultivated for 24 hours. One day after transfection 1 mM valporic acid and 7 % Feed 1 was added. After 7 days cultivation supernatant was collected for purification by centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v was added, and kept at 4°C. After production the supernatants were harvested and the antibody containing supernatants were filtered through 0.22 µm sterile filters and stored at 4 °C until purification.

2. Antibody purification

All molecules were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to HiTrap PA HP (GE Healthcare, column volume (cv) = 5 ml) equilibrated with 8 column volumes (cv) *buffer A* (20 mM sodium phosphate, 20 mM sodium citrate, 0.5 M NaCl, 0.01% Tween-20, pH 7.5). After washing with 10 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (20 mM sodium citrate pH 2.5, 0.5 M NaCl, 0.01% Tween-20) over 20 cv. Fractions containing the protein of interest were pooled and the pH of the solution was gently adjusted to pH 6.0 (using 2 M Tris pH 8.0). Samples were concentrated to 1 ml using ultra-concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius) and subsequently applied to a SuperdexTM 200 10/300 GL (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl, 0.01% Tween-20. The aggregate content of eluted fractions was analyzed by analytical size exclusion chromatography. Therefore, 30 µl of each fraction was applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200

-123-

mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. Fractions containing less than 2 % oligomers were pooled and concentrated to final concentration of 1 - 1.5 mg/ml using ultra concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius). The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were frozen in liquid N₂ and stored at -80 °C.

3. Aggregation temperature

Stability of the four constructs was tested on an Optim1000 (Avacta, PALL Corporation) by a gradient heating from 25° to 80° at 0.1°C/min. The temperature at onset of aggregation is recorded.

Table 34: Yield, monomer content and aggregation temperature of four N-glycosylation site knock-out mutant of the 9D11 binder in the 2+1 inverted T-cell bispecific format. All four mutants behaved similarly to the wild-type 9D11 binder

Clone	Mutation	Yield [mg/L}	Monomer [%]	Aggregation temperature
9D11	T102N	1.34	97	56°
9D11	T102A	1.29	100	56°
9D11	N100Q	2.5	100	56°
9D11	N100S	2.05	100	56°
9D11	-	2.6	100	57°

The following variants were generated: N100S (N95S); N100Q (N95Q), T102A (T97A) and T102N (T97N) (Kabat numbering indicated in parenthesis) and converted into the T-cell bispecific format. After transient production in HEK293 EBNA cells and purification the different variants were analyzed for target binding and cell killing activity in comparison to the original 9D11 clone.

-124-

Table 17: Primers used for removal of N-glycosylation site in CDR L3 of 9D11 (sequences see below)

#	Amino acid exchange	Mutagenesis primer
1	N95S	GAB-7735
2	N95Q	GAB-7734
3	T97A	GAB7736
4	T97N	GAB-7737

Example 18

5 Binding and T cell mediated killing with 9D11 a-glyco variants

Due to a glycosylation site in the CDRs four different 9D11 variants were produced with a mutation removing the glycosylation site (Example 17). These four variants were tested in comparison to the original 9D11 for binding to FolR1 on HeLa cells (Figure 10) and induction of tumor cell killing on SKOV3 and HT-29 (Figure 11A-B, E-F). None of the variants showed
 10 differences in binding or induction of tumor cell killing. In parallel unspecific killing of the FolR1 negative cell lines MKN-45 was addressed (Figures 11C-D). Also, no differences between the variants and the original binder could be observed. None of the constructs induced unspecific killing on FolR1 negative tumor cells.

15 Example 19

FolR1 expression on primary epithelial cells

FolR1 is expressed at low levels on primary epithelial cells. Here we wanted to test if these levels are sufficient to induce T cell mediated killing in the presence of the FolR1 TCBs. To test this we used primary human bronchial epithelial cells, primary human choroid plexus epithelial
 20 cell, primary human renal cortical epithelial cells and primary human retinal pigment epithelial cells. As positive control either FolR1 positive SKOV3 cells or HT-29 cells were included. First we verified FolR1 expression on the used primary cells and determined the amount of FolR1 binding sites on these cells. Bronchial epithelial cells, renal cortical epithelial cells and retinal pigment epithelial cells express very low but significant levels of FolR1 compared to the levels
 25 expressed on tumor cells. The choroid plexus epithelial cells do not express significant levels of FolR1.

Table 18: FolR1 binding sites on primary epithelial cells

Cell line	Binding sites
Bronchial epithelium	492
Choroid plexus epithelium	104
Renal cortical epithelium	312
Retinal pigment epithelium	822
Skov3	69'890

The primary epithelial cells that demonstrated FolR1 expression on the surface were used to
 5 address the question if these cells can be killed by T cells in the presence of FolR1 TCBs. No
 significant levels of killing could be measured but induction of T cell activation in the presence
 of retinal pigment epithelial cells, bronchial epithelial cells and renal cortical cells resulting in
 upregulation of CD25 and CD69 was detected. The strongest activation is seen with retinal
 pigment epithelial cells resulting in upregulation of CD25 and CD69 both on CD4⁺ T cells and
 10 CD8⁺ T cells. In the presence of bronchial epithelial cells lower activation of T cells is induced
 with upregulation of CD69 on CD4⁺ T cells and CD8⁺ T cells but very low upregulation of
 CD25 only on CD4⁺ T cells but not on CD8⁺ T cells. The lowest activation of T cells is obtained
 in the presence of renal epithelial cells with no upregulation of CD25 on CD4⁺ T cells and CD8⁺
 T cells and CD69 been only upregulated on CD8⁺ T cells (Figures 12A-X).

15

Example 20

Comparison of different TCB formats containing either 16D5 or 9D11 binder

To determine if the TCB 2+1 inverted format is the most active format with the selected FolR1
 20 binder, different formats containing either 16D5 or 9D11 were produced and compared in target
 cell binding, T cell mediated killing and T cell activation. The 16D5 binder was tested in the
 TCB 2+1 inverted (Fig. 1A), TCB 2+1 classical (Fig. 1D), TCB 1+1 classical (Fig. 1C) and TCB

-126-

1+1 head-to-tail (Fig. 1B) format; the 9D11 binder was tested in the TCB 2+1 inverted (Fig. 1A), TCB 1+1 classical (Fig. 1C) and TCB 1+1 head-to-tail (Fig. 1B) format.

All constructs were tested for binding to FoLR1 on HeLa cells. The molecules bivalent for binding to FoLR1 bind stronger compared to the monovalent constructs due to avidity. The

- 5 difference between the bivalent vs. monovalent constructs is more pronounced for 16D5. The reason might be that due to the lower affinity of 16D5 the avidity effect for this binder is stronger. Between the two 1+1 TCBs there is no significant difference in binding but there is a difference between the two 2+1 constructs. The inverted 2+1 construct binds stronger to FoLR1 than the classical 2+1 construct. This indicates that in the classical 2+1 construct the binding to
- 10 FoLR1 is influenced by the presence of the CD3 Fab whereas in the inverted construct binding is less influenced.

By testing T cell mediated killing with these constructs we could show that stronger binding of the 2+1 inverted TCB is converted into stronger tumor cell killing and T cell activation compared to the 2+1 classical TCB. The 16D5 FoLR1 TCB 2+1 classical is only a little bit more

- 15 active than the respective 1+1 head-to-tail construct. The 1+1 head-to-tail construct is significantly more active than the 1+1 classical construct. This does not reflect the situation seen in binding and might be due to better crosslinking with the head-to-tail construct. Overall tumor cell killing and T cell activation is comparable with all tested constructs, the differences in potency seen with the differences are only in terms of EC50 values. In general it can be
- 20 concluded that the FoLR1 TCB 2+1 inverted independent of the used binder is the preferred format to induce T cell mediated tumor cell killing and T cell activation (see Fig. 13A-C and Fig. 14A-C).

Table 19 EC50 values of target cell binding and T cell mediated killing with different TCB formats

Construct	Binding EC50 (nM)	Killing 24 h (pM)	Killing 48 h (pM)
16D5 FoLR1 TCB 2+1 inverted	11.03	1.43	0.18
16D5 FoLR1 TCB 2+1 classical	17.07	5.60	2.18
16D5 FoLR1 TCB 1+1 classical	107.3	n.d.	n.d.

-127-

16D5 FoLR1 TCB 1+1 head-to-tail	102.6	26.24	6.06
9D11 FoLR1 TCB 2+1 inverted	17.52	0.74	0.14
9D11 FoLR1 TCB 1+1 classical	38.57	20.92	n.d.
9D11 FoLR1 TCB 1+1 head-to-tail	44.20	4.73	n.d.

Table 20 EC50 values of T cell activation in the presence of SKOV3 cells with different TCB formats

Construct	CD4+CD25+ (%)	CD4+CD69+ (%)	CD8+CD25+ (%)	CD8+CD69+ (%)
16D5 FoLR1 TCB 2+1 inverted	1.96	0.33	2.10	n.d.
16D5 FoLR1 TCB 2+1 classical	13.83	3.67	12.88	4.47
16D5 FoLR1 TCB 1+1 classical	38.54	n.d.	n.d.	n.d.
16D5 FoLR1 TCB 1+1 head-to-tail	17.14	7.47	25.15	n.d.
9D11 FoLR1 TCB 2+1 inverted	1.41	0.27	1.24	0.35
9D11 FoLR1 TCB 1+1 classical	34.01	n.d.	34.39	7.40
9D11 FoLR1 TCB 1+1 head-to-tail	3.73	2.47	4.98	2.89

-128-

Example 21**Tumor cell lines and primary cells**

HeLa cells (CCL-2) were obtained from ATCC and cultured in DMEM with 10% FCS and 2 mM Glutamine, SKOV3 (HTB-77) were obtained from ATCC and cultured in RPMI with 10% FCS and 2 mM Glutamine, OVCAR5 were obtained from NCI and cultured in RPMI with 10% FCS and 2 mM Glutamine, HT-29 (ACC-299) were obtained from DSMZ and cultured in McCoy's 5A medium with 10% FCS and 2mM Glutamine, MKN-45 (ACC-409) were obtained from DSMZ and cultured in RPMI with 10% FCS and 2 mM Glutamine.

All tested primary epithelial cells were obtained from ScienCell Research Laboratories. Human

- 10 Bronchial Epithelium Cells (HBepiC, Catalog Number 3210 were cultured in Bronchial Epithelial Cell Medium (BEpiCM, Cat. No. 3211, ScienCell). Human Colonic Epithelial Cells (HCoEpiC), Catalog Number 2950 were cultured in Colonic Epithelial Cell Medium (CoEpiCM, Cat. No. 2951, ScienCell). Human Retinal Pigment Epithelial Cells (HRPEpiC), Catalog Number 6540 were cultured in Epithelial Cell Medium (EpiCM, Cat. No. 4101, ScienCell).
- 15 Human Renal Cortical Epithelial Cells (HRCEpiC), Catalog Number 4110, were cultured in Epithelial Cell Medium (EpiCM, Cat. No. 4101, ScienCell). Human Choroid Plexus Epithelial Cells (HCPEpiC), Catalog Number 1310 were cultured in Epithelial Cell Medium (EpiCM, Cat. No. 4101, ScienCell).

20

Example 22**Target binding by flow cytometry**

Target cells as indicated were harvested with Cell Dissociation Buffer, washed with PBS and resuspended in FACS buffer. The antibody staining was performed in a 96well round bottom plate. Therefore 200'000 cells were seeded per well. The plate was centrifuged for 4 min at 400g and the supernatant was removed. The test antibodies were diluted in FACS buffer and 20 µl of the antibody solution were added to the cells for 30 min at 4°C. To remove unbound antibody the cells were washed twice with FACS buffer before addition of the diluted secondary antibody (FITC conjugated AffiniPure F(ab')₂ fragment goat anti-human IgG, Fcg Fragment, Jackson ImmunoResearch #109-096-098 or PE-conjugated AffiniPure F(ab')₂ Fragment goat anti-human IgG Fcg Fragment Specific, Jackson ImmunoResearch #109-116-170. After 30 min incubation on 4°C unbound secondary antibody was washed away. Before measurement the cells were resuspended in 200 µl FACS buffer and analyzed by flow cytometry using BD Canto II or BD Fortessa.

-129-

Example 23**Internalization**

The cells were harvested and the viability was determined. The cells were re-suspended in fresh cold medium at 2 Mio cells per ml and the cell suspension was transferred in a 15 ml falcon tube for each antibody. The antibodies that should be tested for internalization were added with a final concentration of 20 µg per ml to the cells. The tubes were incubated for 45 min in the cold room on a shaker. After incubation the cells were washed three times with cold PBS to remove unbound antibodies. 0.2 Mio cells per well were transfer to the FACS plate as time point zero. The labeled cells were re-suspended in warm medium and incubated at 37°C. At the indicated time-points 0.2 Mio cells per well were transferred in cold PBS, washed in plated on the FACS plate. To detect the constructs that remain on the surface the cells were stained with PE-labeled anti-human Fc secondary antibody. Therefore 20 µl of the diluted antibody were added per well and the plate was incubated for 30 min at 4°C. Then the cells were washed twice to remove unbound antibodies and then fixed with 1% PFA to prevent any further internalization. The fluorescence was measured using BD FACS CantoII.

Example 24**QIFIKIT® Analysis**

QIFIKIT® contains a series of beads, 10 µm in diameter and coated with different, but well-defined quantities of mouse Mab molecules (high-affinity anti-human CD5, Clone CRIS-1, isotype IgG2a). The beads mimic cells with different antigen densities which have been labeled with a primary mouse Mab, isotype IgG. Briefly, cells were labeled with primary mouse monoclonal antibody directed against the antigen of interest. In a separate test well, cells were labeled with irrelevant mouse monoclonal antibody (isotype control). Then, cells, Set-Up Beads and Calibration Beads were labeled with a fluorescein-conjugated anti-mouse secondary antibody included in the kit. The primary antibody used for labeling of the cells has to be used at saturating concentration. The primary antibody may be of any mouse IgG isotype. Under these conditions, the number of bound primary antibody molecules corresponds to the number of antigenic sites present on the cell surface. The secondary antibody is also used at saturating concentration. Consequently, the fluorescence is correlated with the number of bound primary antibody molecules on the cells and on the beads.

-130-

Example 25**T cell mediated tumor cell killing and T cell activation**

Target cells were harvested with Trypsin/EDTA, counted and viability was checked. The cells were resuspended in their respective medium with a final concentration of 300'000 cells per ml. Then 100 µl of the target cell suspension was transferred into each well of a 96-flat bottom plate. The plate was incubated overnight at 37°C in the incubator to allow adherence of the cells to the plate. On the next day PBMCs were isolated from whole blood from healthy donors. The blood was diluted 2:1 with PBS and overlaid on 15 ml Histopaque-1077 (# 10771, Sigma-Aldrich) in Leucosep tubes and centrifuged for 30 min at 450g without break.

After centrifugation the band containing the cells was collected with a 10 ml pipette and transferred into 50 ml tubes. The tubes were filled up with PBS until 50 ml and centrifuged (400g, 10 min, room temperature). The supernatant was removed and the pellet resuspended in PBS. After centrifugation (300g, 10 min, room temperature), supernatants were discarded, 2 tubes were pooled and the washing step was repeated (this time centrifugation 350xg, 10 min, room temperature). Afterwards the cells were resuspended and the pellets pooled in 50 ml PBS for cell counting. After counting cells were centrifuged (350g, 10 min, room temperature) and resuspended at 6 Mio cells per ml in RPMI with 2 % FCS and 2 nM Glutamine. Medium was removed from plated target cells and the test antibodies diluted in RPMI with 2% FCS and 2 nM Glutamine were added as well as. 300'000 cells of the effector cell solution were transferred to each well resulting in a E:T ratio of 10:1. To determine the maximal release target cells were lysed with Triton X-100. LDH release was determined after 24 h and 48 h using Cytotoxicity Detection Kit (#1644793, Roche Applied Science). Activation marker upregulation on T cells after tumor cell killing was measured by flow cytometry. Briefly PBMCs were harvested, transferred into a 96 well round bottom plate and stained with CD4 PE-Cy7 (#3557852, BD Bioscience), CD8 FITC (#555634, BD Bioscience), CD25 APC (#555434, BD Bioscience), CD69 PE (#310906, BioLegend) antibodies diluted in FACS buffer. After 30 min incubation at 4°C the cells were washed twice with FACS buffer. Before measuring the fluorescence using BD Canto II the cells were resuspended in 200 µl FACS buffer.

30

-131-

Example 26**T cell activation in whole blood**

280 µl of fresh blood were added into a 96 well conical deep well plate. Then 20 µl of the diluted TCBs were added to the blood and mixed well by shaking the plate. After 24 h incubation at 37°C in an incubator the blood was mixed and 35 µl were transferred to a 96well round bottom plate. Then 20 µl of the antibody staining mix were added consisting of CD4 PE-Cy7 (#3557852, BD Bioscience), CD8 FITC (#555634, BD Bioscience), CD25 APC (#555434, BD Bioscience), CD69 PE (#310906, BioLegend) and CD45 V500 (#560777, BD Horizon) and incubated for 15 min in the dark at room temperature. Before measuring 200 µl of the freshly prepared BD FACS lysing solution (#349202, BD FCAS) was added to the blood. After 15 min incubation at room temperature the cells were measured with BD Fortessa.

Example 27**SDPK (single dose pharmacokinetics) study of humanized FOLR1 TCB (clone 16D5) in immunodeficient NOD/Shi-scid/IL-2R γ null (NOG) mice**

Female NOD/Shi-scid/IL-2R γ null (NOG) mice, age 6-7 weeks at start of the experiment (bred at Taconic, Denmark) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 2011/128). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis. Mice were injected i.v. with 10 / 1 / 0.1 µg/mouse of the FOLR1 TCB whereas 3 mice were bled per group and time point. All mice were injected with a total volume of 200 µl of the appropriate solution. To obtain the proper amount of the FOLR1 TCB per 200 µl, the stock solutions were diluted with PBS when necessary. Serum samples were collected 5 min, 1h, 3h, 8h, 24h, 48h, 72h, 96h and 168h after therapy injection. Figure 15 shows that the 16D5 FOLR1 TCB shows typical and dose proportional IgG-like PK properties in NOG mice with slow clearance.

Table 21: Experimental conditions.

Compound	Dose	Formulation buffer	Concentration (mg/mL)
FOLR1 TCB (16D5)	10 µg (corresponding to ca. 0.5 mg/kg)	20mM Histidine, 140mM NaCl, pH6.0	5.43 (= stock solution)
FOLR1 TCB (16D5)	1 µg (corresponding to ca. 0.05 mg/kg)	20mM Histidine, 140mM NaCl, pH6.0	5.43 (= stock solution)
FOLR1 TCB (16D5)	0.1 µg (corresponding to ca. 0.005 mg/kg)	20mM Histidine, 140mM NaCl, pH6.0	5.43 (= stock solution)

Example 28**In vivo efficacy of FOLR1 TCB (clone 16D5) after human PBMC transfer in Skov3-bearing NOG mice**

5

The FOLR1 TCB was tested in the human ovarian carcinoma cell line Skov3, injected s.c. into PBMC engrafted NOG mice.

The Skov3 ovarian carcinoma cells were obtained from ATCC (HTB-77). The tumor cell line was cultured in RPMI containing 10 % FCS (Gibco) at 37 °C in a water-saturated atmosphere at 10 5% CO₂. Passage 35 was used for transplantation, at a viability > 95 %. 5x10⁶ cells per animal were injected s.c. into the right flank of the animals in a total of 100 µl of RPMI cell culture medium (Gibco).

Female NOD/Shi-scid/IL-2R^γnull (NOG) mice, age 6-7 weeks at start of the experiment (bred at Taconic, Denmark) were maintained under specific-pathogen-free condition with daily cycles of 15 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 2011/128). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis.

-133-

According to the protocol (Figure 16), mice were injected s.c. on study day 0 with 5×10^6 of the Skov3. At study day 21, human PBMC of a healthy donor were isolated via the Ficoll method and 10×10^6 cells were injected i.p. into the tumor-bearing mice. Two days after, mice were randomized and equally distributed in five treatment groups (n=12) followed by i.v. injection with either 10 / 1 / 0.1 $\mu\text{g}/\text{mouse}$ of the FOLR1 TCB or 10 $\mu\text{g}/\text{mouse}$ of the DP47 control TCB once weekly for three weeks. All mice were injected i.v. with 200 μl of the appropriate solution. The mice in the vehicle group were injected with PBS. To obtain the proper amount of TCB per 200 μl , the stock solutions were diluted with PBS when necessary. Tumor growth was measured once weekly using a caliper (Figure 17) and tumor volume was calculated as followed:

$$T_v: (W^2/2) \times L \quad (W: \text{Width}, L: \text{Length})$$

The once weekly injection of the FOLR1 TCB resulted in a dose-dependent anti-tumoral effect. Whereas a dose of 10 $\mu\text{g}/\text{mouse}$ and 1 $\mu\text{g}/\text{mouse}$ induced tumor shrinkage and 0.1 $\mu\text{g}/\text{mouse}$ a tumor stasis (Figure 17, Table 22). Maximal tumor shrinkage was achieved at a dose of 10 $\mu\text{g}/\text{mouse}$ as compared to a non-targeted control DP47 TCB.

Table 22: In vivo efficacy.

Compound	Dose	Tumor growth inhibition
DP47 TCB control TCB	10 μg (corresponding to ca. 0.5 mg/kg)	7%
FOLR1 TCB (16D5)	10 μg (corresponding to ca. 0.5 mg/kg)	90%
FOLR1 TCB (16D5)	1 μg (corresponding to ca. 0.05 mg/kg)	74%
FOLR1 TCB (16D5)	0.1 μg (corresponding	56%

-134-

	to ca. 0.005 mg/kg)	
--	------------------------	--

For PD read-outs, three mice per treatment group were sacrificed at study day 32, tumors were removed and single cell suspensions were prepared through an enzymatic digestion with Collagenase V, Dispase II and DNase for subsequent FACS-analysis (Figure 19 and 20). Single cells were either used directly for staining of extracellular antigens and activation markers or were re-stimulated using 5 ng/ml PMA and 500 ng/ml Ionomycin in the presence of a protein transport inhibitor Monensin for 5h in normal culture medium. After re-stimulation, cells were stained for surface antigens, followed by a fixation and permeabilization step. Fix samples were then stained intracellularly for TNF- α , IFN- γ , IL-10 and IL-2 and analyzed by flow cytometry.

Same procedure was used for the degranulation of cells, but an anti-CD107a antibody was added during the restimulation period and fixed samples were staining for intracellular perforin and granzyme-B contents. The FACS analysis revealed statistically higher number of infiltrating CD4⁺ and CD8⁺ T-cells in the tumor tissue upon treatment with FOLR1 TCB compared to vehicle and untargated control TCB. Furthermore, higher numbers of TNF- α , IFN- γ and IL-2 producing as well as perforin⁺/granzyme-B⁺ CD4⁺ and CD8⁺ T-cells were detected in FOLR1 TCB treated tumors. Tumor infiltrating T-cells treated with FOLR1 TCB also showed higher degranulation rates compared to control groups.

At study termination day 38, all animals were sacrificed; tumors were removed and weight (Figure 18). The weight of the tumors treated with 10 and 1 μ g/mouse of the FOLR1 TCB showed a statistically significant difference compared to the control groups.

Table 23: Experimental conditions.

Compound	Dose	Formulation buffer	Concentration (mg/mL)
PBS			
FOLR1 TCB (16D5)	10 μ g	20mM Histidine, 140mM NaCl, pH6.0	3.88 (= stock solution)
FOLR1 TCB (16D5)	1 μ g	20mM Histidine, 140mM NaCl, pH6.0	3.88 (= stock solution)
FOLR1 TCB (16D5)	0.1 μ g	20mM Histidine, 140mM NaCl, pH6.0	3.88 (= stock solution)
DP47 TCB	10 μ g	20mM Histidine, 140mM NaCl,	4.35 (= stock solution)

-135-

		pH6.0	
--	--	-------	--

Example 29

Generation of a bispecific FolR1 / CD3– kappa - lambda antibody

To generate a bispecific antibody (monovalent for each antigen) that simultaneously can bind to human CD3 and human folate receptor alpha (FolR1) without using any hetero-dimerization approach (e.g. knob-into-hole technology), a combination of a common light chain library with the so-called CrossMab technology was applied: The variable region of the humanized CD3 binder (CH2527_VL7_46/13) was fused to the CH1 domain of a standard human IgG1 antibody to form the VLVH crossed molecule (fused to Fc) which is common for both specificities. To generate the crossed counterparts (VHCL), a CD3 specific variable heavy chain domain (CH2527_VH_23/12) was fused to a constant human λ light chain whereas a variable heavy chain domain specific for human FolR1 (clone 16D5, isolated from common light chain library) was fused to a constant human κ light chain. This enables the purification of the desired bispecific antibody by applying subsequent purification steps with KappaSelect and LambdaFabSelect columns (GE Healthcare) to remove undesired homodimeric antibodies.

All antibody expression vectors were generated using standard recombinant DNA technology as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biological reagents were used according the manufacturer's recommendations. Genes or gene fragments were either amplified by polymerase chain reaction (PCR) or generated from synthetic oligonucleotides at Geneart AG (Regensburg, Germany) by automated gene synthesis. PCR-amplified or subcloned DNA fragments were confirmed by DNA sequencing (Synergene GmbH, Switzerland). Plasmid DNA was transformed into and amplified in suitable *E. coli* host strains for preparation of transfection-grade plasmid DNA using standard Maxiprep kits (Qiagen). For production of the bispecific molecules HEK293 EBNA cells were transfected with plasmids encoding the respective genes using a standard polyethylenimine (PEI) based method. The used plasmid ratio of the three expression vectors was 1:1:1. Transfected cells were cultivated for 7 days before supernatants were harvested for purification. The bispecific FolR1 / CD3– kappa - lambda antibodies were produced and purified as follows.

1. Transient transfection and production

The kappa-lambda bispecific antibody was transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293

-136-

EBNA cells were cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells were seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells were centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors were mixed in 20 ml CD CHO medium to a final amount of 200 µg DNA. After addition of 540 µl PEI solution is vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells were mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium was added and cell were cultivated for 24 hours. One day after transfection 1 mM valporic acid and 7 % Feed 1 was added. After 7 days cultivation supernatant was collected for purification by centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v was added, and kept at 4°C.

2. Purification

The kappa-lambda bispecific antibody was purified in three steps, using an affinity step specific for kappa light chains, followed by an affinity step specific for lambda light chains and finally by a size exclusion chromatography step for removal of aggregates. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to Capture Select kappa affinity matrix, or HiTrap KappaSelect, GE Healthcare, column volume (cv) = 1 ml, equilibrated with 5 column volumes (cv) *buffer A* (50 mM Tris, 100 mM glycine, 150 mM NaCl, pH 8.0). After washing with 15 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (50 mM Tris, 100 mM glycine, 150 mM NaCl, pH 2.0) over 25 cv. Fractions containing the protein of interest were pooled and the pH of the solution was adjusted to pH 8.0 (using 2 M Tris pH 8.0). The neutralized pooled fractions were applied to Capture Select lambda affinity matrix (now: HiTrap LambdaFabSelect, GE Healthcare, column volume (cv) = 1 ml) equilibrated with 5 column volumes (cv) *buffer A* (50 mM Tris, 100 mM glycine, 150 mM NaCl, pH 8.0). After washing with 15 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (50 mM Tris, 100 mM glycine, 150 mM NaCl, pH 2.0) over 25 cv. Fractions containing the protein of interest were pooled and the pH of the solution was adjusted to pH 8.0 (using 2 M Tris pH 8.0). This solution was concentrated using ultra-concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius) and subsequently applied to a SuperdexTM 200 10/300 GL (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl, 0.01% Tween-20. The

-137-

pooled fractions after size exclusion were again concentrated using ultra-concentrators (Vivaspin 15R 30.000 MWCO HY, Sartorius).

The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Only small amounts of protein could be purified with a final yield of 0.17 mg/L.

Example 30

10 T cell mediated killing with bispecific FoLR1 / CD3– kappa - lambda antibody

Activity of kappa lambda FoLR1 TCB was tested on SKOV3 cells in the presence of freshly isolated PBMCs. As negative control DP47 TCB was included. T cell mediated killing of SKOV3 cells was determined after 24 h and 48 h by LDH release. After 48 h the T cells were harvested and CD69 and CD25 upregulation on CD4 T cells and CD8 T cells was measured by flow cytometry.

The kappa lambda FoLR1 construct induces killing of SKOV3 cells in a concentration dependent manner which is accompanied by CD69 and CD25 upregulation both on CD4 T cells and on CD8 T cells.

SKOV3 cells were incubated with PBMCs in the presence of either kappa lambda FoLR1 TCB or DP47 TCB. After 24 h and 48 h killing of tumor cells was determined by measuring LDH release (Fig. 21). SKOV3 cells were incubated with PBMCs in the presence of either kappa lambda FoLR1 TCB or DP47 TCB. After 48 h CD25 and CD69 upregulation on CD4 T cells and CD8 T cells was measured by flow cytometry (Fig. 22).

25 Example 31

Biochemical characterization of 16D5 and 36F2 FoLR1 binders by surface plasmon resonance

Binding of anti-FoLR1 16D5 in different monovalent or bivalent T-cell bispecific formats and of anti-FoLR1 36F2 as IgG or as T-cell bispecific to recombinant human, cynomolgus and murine folate receptor 1 (all as Fc fusions) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, GE Healthcare).

-138-

1. Molecules tested

The molecules used for affinity and avidity determination are described in Table 24.

Table 24: Name and description of the 6 constructs used in SPR analysis

Name	Description
16D5 TCB	2+1 T-cell bispecific, inverted format (common light chain)
16D5 TCB classical	2+1 T-cell bispecific, classical format (common light chain)
16D5 TCB 1+1	1+1 T-cell bispecific (common light chain)
16D5 TCB 1+ 1 HT	1+1 T-cell bispecific head-to-tail (common light chain)
36F2 IgG	Human IgG1 with P329G LALA
36F2 TCB	2+1 T-cell bispecific, inverted format, crossfab

5 **2. Avidity to Folate Receptor 1**

The avidity of the interaction between the anti-FolR1 IgG or T cell bispecifics and the recombinant folate receptors was determined as described below (Table 25).

Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, GE Healthcare). The immobilization level was about 300-400 RU. The anti-FolR1 IgGs or T cell bispecifics were passed at a concentration range from 3.7 to 900 nM with a flow of 30 µL/minutes through the flow cells over 180 seconds. The dissociation was monitored for 240 or 600 seconds. The chip surface was regenerated after every cycle using a double injection of 30 sec 10 mM Glycine-HCl pH 2. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated murine CD134 Fc fusion. The binding curves resulting from the bivalent binding of the IgG or T cell bispecifics were approximated to a 1:1 Langmuir binding (even though it is a

-139-

1:2 binding) and fitted with that model to get an apparent KD representing the avidity of the bivalent binding. The apparent avidity constants for the interactions were derived from the rate constants of the fitting using the Bia Evaluation software (GE Healthcare). For the 1+1 T cell bispecifics format the interaction is a real 1:1 and the KD represents affinity since there is only one FolR1 binder in this construct.

Table 25: Bivalent binding (avidity with apparent KD) of anti-FolR1 16D5 and 36F2 as IgG or as T-cell bispecifics (TCB) on human, cyno and murine FolR1.

Analyte	Ligand	ka (1/Ms)	kd (1/s)	Apparent KD
36F2 IgG	huFolR1	2.07E+06	1.3E-02	6 nM
	cyFolR1	2.78E+06	1.75E-02	6 nM
	muFolR1	4.28E+05	8.23E-04	2 nM
36F2 TCB	huFolR1	2.45E+06	9.120E-03	4 nM
	cyFolR1	4.31E+06	1.45E-02	3 nM
	muFolR1	6.97E+05	9.51E-04	1 nM
16D5 TCB	huFolR1	1.57E+05	3.92E-04	3 nM
	cyFolR1	2.01E+05	3.81E-04	2 nM
16D5 TCB classical	huFolR1	2.04E+05	1.84E-04	0.9 nM
	cyFolR1	2.50E+05	3.05E-04	1 nM
16D5 TCB 1+ 1 HT	huFolR1	5.00E+04	2.25E-03	45 nM
	cyFolR1	5.75E+04	4.10E-03	70 nM
16D5 TCB 1+1	huFolR1	3.65E+04	2.04E-03	56 nM
	cyFolR1	4.09E+04	3.60E-03	90 nM

3. Affinity to Folate Receptor 1

10 The affinity of the interaction between the anti-FolR1 IgG or T cell bispecifics and the recombinant folate receptors was determined as described below (Table 26).

For affinity measurement, direct coupling of around 12000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at

-140-

pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 IgG or T cell bispecifics were captured at 20 nM with a flow rate of 10 μ l/min for 40 sec, the reference flow cell was left without capture. Dilution series (12.3 to 3000 nM) of human, cyno or murine Folate Receptor 1 Fc fusion were passed on all flow cells at 30 μ l/min for 240 sec to record the association phase. The dissociation phase was monitored for 300 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 1.5. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

Table 26: Monovalent binding (affinity) of anti-FolR1 16D5 and 36F2 as IgG or as T-cell bispecifics (TCB) on human, cyno and murine FolR1.

Analyte	Ligand	ka (1/Ms)	kd (1/s)	KD
36F2 IgG	huFolR1	9.10E+04	6.65E-02	730 nM
	cyFolR1	1.02E+05	5.78E-02	570 nM
	muFolR1	8.32E+04	1.78E-02	210 nM
36F2 TCB	huFolR1	5.94E+04	6.13E-02	1000 nM
	cyFolR1	6.29E+04	5.42E-02	860 nM
	muFolR1	5.68E+04	1.75E-02	300 nM
16D5 TCB	huFolR1	2.23E+04	7.33E-04	33 nM
	cyFolR1	1.57E+04	1.60E-03	100 nM
16D5 TCB classical	huFolR1	1.03E+04	7.59E-04	74 nM
	cyFolR1	9.18E+03	1.61E-03	175 nM
16D5 TCB 1+ 1 HT	huFolR1	2.05E+04	7.08E-04	35 nM
	cyFolR1	1.67E+04	1.53E-03	92 nM
16D5 TCB 1+1	huFolR1	1.43E+04	9.91E-04	69 nM
	cyFolR1	1.20E+04	1.80E-03	150 nM

The affinity (monovalent binding) to human and cyno FolR1-Fc of 36F2 TCB is similar and around 1000 nM for both, whereas the affinity to murine FolR1-Fc is slightly better and around 300 nM. The 36F2 can be used in murine and primate models, there is no need for a surrogate.

The avidity (apparent KD) of 36F2 TCB to human FolR1 is around 30 times lower than the affinity of the 16D5 TCB to human FolR1. In the bivalent format, 36F2 TCB is in the low nanomolar range, whereas 16D5 TCB is in the low picomolar range (1000 fold difference).

FolR1 is expressed on tumor cells overexpressed, at intermittent and high levels, on the surface of cancer cells in a spectrum of epithelial malignancies, including ovarian, breast, renal, colorectal, lung and other solid cancers and is also expressed on the apical surface of a limited subset of polarized epithelial cells in normal tissue. These non-tumorous, normal cells express

-141-

FolR1 only at low levels, and include, e.g., bronchiolal epithelial cells on alveolar surface, renal cortical luminal border of tubular cells, retinal pigment epithelium (basolateral membrane) and choroid plexus.

16D5 TCB binds to normal tissues cells expressing low amounts of FolR1 which results in their T cell mediated killing. This might, at least in part, account for limited tolerance observed at 10 µg/kg in cynomolgus monkeys. The inventors wanted to determine if lowering the affinity of the T cell bispecific molecule could increase the differentiation between high and low target density tissues and, thereby, lower toxicity by making use of bivalent binding and avidity. Low affinity binders are ordinarily not selected as suitable candidates for further analysis because low affinity is often associated with low potency and efficacy. Nevertheless, the low affinity FolR1 binder 36F2 was developed in several formats and characterized for its biological properties. For the 36F2 used in the bivalent T cell bispecific format the avidity effect (difference between monovalent and bivalent binding) is around 250 fold (1000 nM versus 4 nM). At low target density the affinity defined the interaction and with 1000 nM led to a low potency of the TCB. However, at high target density the molecule's avidity comes into play and with 4 nM led to a high activity of the TCB (see Example 32).

In an alternatively approach, the inventors generated monovalent formats of 16D5 and low affinity variant of 16D5 (affinity about 10-40 nM) in a bivalent format. The 16D5 binder used in a monovalent format (1+1) has an affinity of about 50 nM. The differentiation between high and low target density tissues can be better achieved by taking advantage of the avidity effect.

Example 32

T-cell killing of SKov-3 cells induced by 36F2 TCB, Mov19 TCB and 21A5 TCB

T-cell killing mediated by 36F2 TCB, Mov19 TCB and 21A5 TCB was assessed on SKov-3 cells (medium FolR1). Human PBMCs were used as effectors and the killing was detected at 24 h and 48 h of incubation with the bispecific antibodies. Briefly, target cells were harvested with Trypsin/EDTA, washed, and plated at density of 25 000 cells/well using flat-bottom 96-well plates. Cells were left to adhere overnight. Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation of enriched lymphocyte preparations (buffy coats) obtained from healthy human donors. Fresh blood was diluted with sterile PBS and layered over Histopaque gradient (Sigma, #H8889). After centrifugation (450 x g, 30 minutes, room temperature), the plasma above the PBMC-containing interphase was discarded and PBMCs transferred in a new falcon tube subsequently filled with 50 ml of PBS. The mixture was

-142-

centrifuged (400 x g, 10 minutes, room temperature), the supernatant discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps 350 x g, 10 minutes). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37°C, 5% CO₂ in cell incubator until further use (no longer than 24 h). For the killing assay, the antibody was added at the indicated concentrations (range of 0.005 pM – 5 nM in triplicates). PBMCs were added to target cells at final E:T ratio of 10:1. Target cell killing was assessed after 24 h and 48 h of incubation at 37°C, 5% CO₂ by quantification of LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit, Roche Applied Science, #11 644 793 001). Maximal lysis of the target cells (= 100%) was achieved by incubation of target cells with 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells without bispecific construct.

The results show that the killing induced by 36F2 is strongly reduced in comparison to Mov19 TCB and 21A5 TCB (Figures 23A-B). The EC₅₀ values related to killing assays, calculated using GraphPadPrism6 are summarized in Table 27.

Table 27: EC₅₀ values (pM) for T-cell mediated killing of FolR1-expressing SKov-3 cells induced by 36F2 TCB, Mov19 TCB and 21A5 TCB.

Antibody	EC ₅₀ [pM]	
	24 h	48 h
36F2 TCB	1406.07*	134.5
Mov19 TCB	0.75	0.05
21A5 TCB	2.83	0.10

* curve did not reach saturation, value is hypothetical

20

Example 33

T-cell killing induced by 36F2 TCB and 16D5 TCB

in different monovalent and bivalent T-cell bispecific formats

T-cell killing mediated by 36F2 TCB, 16D5 TCB, 16D5 TCB classical, 16D5 TCB 1+1 and 16D5 TCB HT antibodies of Hela (high FolR1, about 2 million copies, Table 14, Fig. 27), Skov-3 (medium FolR1, about 70000-90000 copies, Table 14, Fig. 27) and HT-29 (low FolR1, about 10000, Table 14, Fig. 27) human tumor cells was assessed. DP47 TCB antibody was included as negative control. Human PBMCs were used as effectors and the killing was detected at 24 h of incubation with the bispecific antibody. Briefly, target cells were harvested with Trypsin/EDTA, washed, and plated at density of 25 000 cells/well using flat-bottom 96-well plates. Cells were

25

-143-

left to adhere overnight. Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation of enriched lymphocyte preparations (buffy coats) obtained from healthy human donors. Fresh blood was diluted with sterile PBS and layered over Histopaque gradient (Sigma, #H8889). After centrifugation (450 x g, 30 minutes, room temperature), the plasma above the PBMC-containing interphase was discarded and PBMCs transferred in a new falcon tube subsequently filled with 50 ml of PBS. The mixture was centrifuged (400 x g, 10 minutes, room temperature), the supernatant discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps 350 x g, 10 minutes). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37°C, 5% CO₂ in cell incubator until further use (no longer than 24 h). For the killing assay, the antibody was added at the indicated concentrations (range of 0.01 pM – 100 nM in triplicates). PBMCs were added to target cells at final E:T ratio of 10:1. Target cell killing was assessed after 24 h of incubation at 37°C, 5% CO₂ by quantification of LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit, Roche Applied Science, #11 644 793 001). Maximal lysis of the target cells (= 100%) was achieved by incubation of target cells with 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells without bispecific construct.

The results show that target-specific killing of all three FolR1+ target cell lines induced by 36F2 TCB is much weaker compared to the killing induced by 16D5 TCB (Figures 24A-C, Table 29). Target-specific killing induced by the monovalent 16D5 TCBs (16D5 HT and 16D5 1+1) is worse compared to the bivalent 16D5 TCBs (16D5 TCB and 16D5 TCB classical). The EC₅₀ values related to killing assays, calculated using GraphPadPrism6, are summarized in Table 28. Importantly, this data shows that using the 36F2 FolR1 binder in the bivalent 2+1 TCB format widens the therapeutic window compared to the 16D5 FOLR1 TCB (Fig. 24A-C). Whereas the potency reduction between 16D5 and 36F2 FOLR1 TCB is approximately 45-fold for Hela cells (high FOLR1 expression, see Table 28: 16D5 TCB = 0.8 versus 36F2 TCB 36.0) and approximately 297-fold for Skov3 cells (medium FOLR1 expression, see Table 28: 16D5 TCB = 0.6 versus 36F2 TCB 178.4), this reduction is almost 7000-fold for HT29 with low FOLR1 expression (see Table 28: 16D5 TCB = 5.7 versus 36F2 TCB 39573). Thus, the 36F2 FOLR1 TCB differentiates between high and low expressing cells which is of special importance to reduce toxicity as the cells of some normal, non-tumorous tissues express very low levels of FolR1 (approximately less than 1000 copies per cell). Consistent with this observation, the results discussed in Example 35 below show that 36F2 TCB does not induce T-cell killing of

-144-

primary cells (Figures 26A-D) whereas for 16D5 TCB some killing can be observed on HRCEpiC and HRPEpiC cells after 48 h of incubation (Figures 26B and C). This important characteristic of 36F2 TCB allows for dosing for the treatment of FolR1-positive tumors so that it mediates potent killing of tumor tissues with high or medium FOLR1 expression, but not of
5 normal tissues with low (partially polarized) expression. Notably, this characteristic appears to be mediated by the avidity of 36F2 TCB in the bivalent 2+1 inverted format, as it was not observed when using the 1+1 monovalent formats carrying the same low affinity 36F2 binder. Stated another way, 36F2 TCB in the bivalent 2+1 format comprises FolR1 binding moieties of relatively low affinity but it possesses an avidity effect which allows for differentiation between
10 high and low FolR1 expressing cells. Because tumor cells express FolR1 at high or intermediate levels, this TCB selectively binds to tumor cells and not normal, non-cancerous cells that express FolR1 at low levels or not at all.

In addition to the above advantageous characteristics, the 36F2 TCB in the bivalent 2+1 inverted format also has the advantage that it does not require chemical cross linking or other hybrid
15 approach. This makes it suitable for manufacture of a medicament to treat patients, for example patients having FolR1-positive cancerous tumors. The 36F2 TCB in the bivalent 2+1 inverted format can be produced using standard CHO processes with low aggregates. Further, the 36F2 TCB in the bivalent 2+1 comprises human and humanized sequences making it superior to molecules that employ rat and murine polypeptides that are highly immunogenic when
20 administered to humans. Furthermore, the 36F2 TCB in the bivalent 2+1 format was engineered to abolish FcγR binding and, as such, does not cause FcγR crosslinking and infusion reactions, further enhancing its safety when administered to patients.

As demonstrated by the results described above, its head-to-tail geometry make the 36F2 TCB in the bivalent 2+1 inverted format a highly potent molecule that induces absolute target cell killing.
25 Its bivalency enhance avidity and potency, but also allow for differentiation between high and low expressing cells. Its preference for high or medium target expressing cells due to its avidity affect reduce toxicity resulting from T cell mediated killing of normal cells that express FolR1 at low levels.

A further advantage of the 36F2 TCB in the bivalent 2+1 format and other embodiments
30 disclosed herein is that their clinical development does not require the use of surrogate molecules as they bind to human, cynomous and murine FolR1. As such, the molecules disclosed herein recognize a different epitope than antibodies to FolR1 previously described that do not recognize FolR1 from all three species.

Table 28: EC50 values (pM) for T-cell mediated killing of FolR1-expressing tumor cells induced by 36F2 TCB and 16D5 TCB in different monovalent and bivalent T-cell bispecific formats after 24 h of incubation.

Antibody	Hela (FolR1 high)	Skov-3 (FolR1 medium)	HT-29 (FolR1 low)
16D5 TCB	0.8	0.6	5.7
16D5 TCB classical	4.6	2.0	13.0
16D5 TCB HT	11.6	12.3	15.1
16D5 TCB 1+1	23.8	48.9	883.8*
36F2 TCB	36.0	178.4	39573.0*

* curve did not reach saturation, only hypothetical value

- 5 Table 29 shows a comparison of EC50 values of 16D5 TCB and 36F2 TCB on the different cell lines tested. Out of the obtained EC50 values the delta (EC50 of 16D5 TCB minus EC50 of 36F2 TCB) and the x-fold difference (EC50 of 16D5 TCB divided by the EC50 of 36F2 TCB) was calculated.

Table 29: Comparison of EC50 values of 16D5 TCB and 36F2 TCB.

Antibody	Hela (FolR1 high)	Skov-3 (FolR1 medium)	HT-29 (FolR1 low)
16D5 TCB	0.82	0.63	5.73
36F2 TCB	35.99	178.40	39573.00*
Δ	35.17	177.77	39567.27
x-fold	43.83	284.61	6906.58

- 10 * curve did not reach saturation, only hypothetical value

The calculated EC50 values clearly show that the difference between 36F2 TCB and 16D5 TCB gets larger the lower the FolR1 expression on the target cells is.

- The same calculations as done for the comparison of the EC50 values of 16D5 TCB and 36F2 TCB were done for 16D5 TCB and the two monovalent 16D5 TCBs (16D5 TCB HT and 16D5 TCB 1+1). Tables 30 and 31 show the comparisons of the EC50 values of 16D5 TCB vs 16D5 TCB HT (Table 30) and 16D5 TCB vs 16D5 TCB 1+1 (Table 31) as well as the corresponding deltas (EC50 of 16D5 TCB minus EC50 of 16D5 TCB HT/1+1) and the x-fold differences (EC50 of 16D5 TCB divided by the EC50 of 16D5 TCB HT/1+1).

Table 30: Comparison of EC50 values of 16D5 TCB (2+1 inverted) and 16D5 TCB HT.

Antibody	Hela (FolR1 high)	Skov-3 (FolR1 medium)	HT-29 (FolR1 low)
----------	----------------------	--------------------------	----------------------

-146-

16D5 TCB	0.82	0.63	5.73
16D5 TCB HT	11.61	12.27	15.11
Δ	10.79	11.65	9.38
x-fold	14.14	19.58	2.64

Table 31: Comparison of EC50 values of 16D5 TCB and 16D5 TCB 1+1.

Antibody	Hela (FolR1 high)	Skov-3 (FolR1 medium)	HT-29 (FolR1 low)
16D5 TCB	0.82	0.63	5.73
16D5 TCB 1+1	23.84	48.86	883.78*
Δ	23.02	48.24	878.05
x-fold	29.03	77.95	154.24

* curve did not reach saturation, only hypothetical value

- 5 The comparison of the EC50 values of 16D5 TCB and 36F2 TCB (Table 29) shows that the difference in the EC50 values gets larger the lower the FolR1 expression on the target cells is. This effect cannot be seen in the comparison of 16D5 TCB and the monovalent 16D5 TCBs (Table 29 and Table 30). For 16D5 TCB 1+1 (Table 31) there is also a slight increase in the difference between the EC50 of 16D5 TCB and 16D5 TCB 1+1 with decreasing FolR1
- 10 expression but by far not as pronounced as can be seen in the comparison of 16D5 TCB vs 36F2 TCB.

Example 34

CD25 and CD69 upregulation on CD8⁺ and CD4⁺ effector cells after T cell-killing of FolR1-expressing tumor cells induced by 36F2 TCB and 16D5 TCB antibody

- 15 Activation of CD8⁺ and CD4⁺ T cells after T-cell killing of FolR1-expressing Hela, SKov-3 and HT-29 tumor cells mediated by 36F2 TCB and 16D5 TCB was assessed by FACS analysis using antibodies recognizing the T cell activation markers CD25 (late activation marker) and CD69 (early activation marker). DP47 TCB was included as non-binding control. The antibody and the killing assay conditions were essentially as described above (Example 32) using the same
- 20 antibody concentration range (0.01 pM – 100 nM in triplicates), E:T ratio 10:1 and an incubation time of 48h.

After the incubation, PBMCs were transferred to a round-bottom 96-well plate, centrifuged at 400 x g for 4 min and washed twice with PBS containing 0.1% BSA. Surface staining for CD8 (PE anti-human CD8, BD #555635), CD4 (Brilliant Violet 421™ anti-human CD4, Biolegend

25 #300532), CD69 (FITC anti-human CD69, BD #555530) and CD25 (APC anti-human CD25 BD #555434) was performed according to the manufacturer's instructions. Cells were washed twice

-147-

with 150 μ l/well PBS containing 0.1% BSA. After centrifugation, the samples were resuspended in 200 μ l/well PBS 0.1% for the FACS measurement. Samples were analyzed at BD FACS Canto II.

36F2 TCB induced a target-specific up-regulation of activation markers (CD25, CD69) on CD8+ and CD4+ T cells after killing of Hela (Figure 25A) and SKov-3 (Figure 25B) cells. In comparison to 16D5 TCB the up-regulation of CD25 and CD69 on CD8+ and CD4+ T cells induced by 36F2 is much weaker.

On HT-29 (low FolR1) an up-regulation of activation markers can only be seen at the highest concentration of 36F2 TCB. In contrast, with 16D5 TCB up-regulation of CD25 and CD69 can be seen already at much lower antibody concentrations (Figure 25C).

As seen as well in the tumor lysis experiment, the analysis of activation markers (CD25 and CD69) on T cells (CD4+ and CD8+) after killing clearly shows that the difference between 16D5 TCB and 36F2 TCB becomes larger the lower the FolR1 expression level on the target cells is.

Example 35

15 T-cell killing of primary cells induced by 36F2 TCB and 16D5 TCB

T-cell killing mediated by 36F2 TCB and 16D5 TCB was assessed on primary cells (Human Renal Cortical Epithelial Cells (HRCEpiC) (ScienCell Research Laboratories; Cat No 4110) and Human Retinal Pigment Epithelial Cells (HRPEpiC) (ScienCell Research Laboratories; Cat No 6540)). HT-29 cells (low FolR1) were included as control cell line. DP47 TCB served as non-binding control. Human PBMCs were used as effectors and the killing was detected at 24 h and 48 h of incubation with the bispecific antibodies. Briefly, target cells were harvested with Trypsin/EDTA, washed, and plated at density of 25 000 cells/well using flat-bottom 96-well plates. Cells were left to adhere overnight. Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation of enriched lymphocyte preparations (buffy coats) obtained from healthy human donors. Fresh blood was diluted with sterile PBS and layered over Histopaque gradient (Sigma, #H8889). After centrifugation (450 x g, 30 minutes, room temperature), the plasma above the PBMC-containing interphase was discarded and PBMCs transferred in a new falcon tube subsequently filled with 50 ml of PBS. The mixture was centrifuged (400 x g, 10 minutes, room temperature), the supernatant discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps 350 x g, 10 minutes). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37°C, 5% CO₂ in cell incubator until further use (no longer than 24 h). For the killing assay, the antibody was added at

-148-

the indicated concentrations (range of 0.01 pM – 10 nM in triplicates). PBMCs were added to target cells at final E:T ratio of 10:1. Target cell killing was assessed after 24 h and 48 h of incubation at 37°C, 5% CO₂ by quantification of LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit, Roche Applied Science, #11 644 793 001). Maximal

5 lysis of the target cells (= 100%) was achieved by incubation of target cells with 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells without bispecific construct.

The results show that 36F2 TCB does not induce T-cell killing of primary cells (Figure 26A - D) whereas for 16D5 TCB some killing can be observed on HRCEpiC and HRPEpiC cells after 48
10 h of incubation (Figure 26B and D). As described above, a strong difference in T-cell killing between of HT-29 cells was observed between 16D5 TCB and 36F2 TCB (Fig. 26E, F).

Example 36

Preparation of DP47 GS TCB

(2+1 Crossfab-IgG P329G LALA inverted = “untargeted TCB”)

15 The “untargeted TCB” was used as a control in the above experiments. The bispecific antibody engages CD3e but does not bind to any other antigen and therefore cannot crosslink T cells to any target cells (and subsequently cannot induce any killing). It was therefore used as negative control in the assays to monitor any unspecific T cell activation. This untargeted TCB was prepared as described in WO2014/131712. In brief, the variable region of heavy and light chain
20 DNA sequences have been subcloned in frame with either the constant heavy chain or the constant light chain pre-inserted into the respective recipient mammalian expression vector. The antibody expression was driven by an MPSV promoter and carries a synthetic polyA signal sequence at the 3' end of the CDS. In addition each vector contains an EBV OriP sequence.

The molecule was produced by co-transfecting HEK293-EBNA cells with the mammalian
25 expression vectors using polyethylenimine. The cells were transfected with the corresponding expression vectors in a 1:2:1:1 ratio (“vector heavy chain Fc(hole)” : “vector light chain” : “vector light chain Crossfab” : “vector heavy chain Fc(knob)-FabCrossfab”).

For transfection HEK293 EBNA cells were cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells
30 were seeded 24 hours before transfection. For transfection cells were centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors were mixed in 20 ml CD CHO medium to a final amount of 200 g DNA. After addition of 540 µl

-149-

PEI solution was vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells were mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium was added and cell were cultivated for 24 hours. One day after

5 transfection 1 mM valporic acid and 7 % Feed 1 was added. After 7 days cultivation supernatant was collected for purification by centrifugation for 15 min at 210 x g, the solution was sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v was added, and kept at 4°C.

The secreted protein was purified from cell culture supernatants by affinity chromatography

10 using ProteinA. Supernatant was loaded on a HiTrap ProteinA HP column (CV=5 mL, GE Healthcare) equilibrated with 40 ml 20 mM sodium phosphate, 20 mM sodium citrate, 0.5 M sodium chloride, pH 7.5. Unbound protein was removed by washing with at least 10 column volume 20 mM sodium phosphate, 20 mM sodium citrate, 0.5 M sodium chloride, pH 7.5. Target protein was eluted during a gradient over 20 column volume from 20 mM sodium citrate, 0.5 M

15 sodium chloride, pH 7.5 to 20 mM sodium citrate, 0.5 M sodium chloride, pH 2.5. Protein solution was neutralized by adding 1/10 of 0.5 M sodium phosphate, pH 8. Target protein was concentrated and filtrated prior loading on a HiLoad Superdex 200 column (GE Healthcare) equilibrated with 20 mM Histidine, 140 mM sodium chloride solution of pH 6.0.

The protein concentration of purified protein samples was determined by measuring the optical

20 density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence.

Purity and molecular weight of molecules were analyzed by CE-SDS analyses in the presence and absence of a reducing agent. The Caliper LabChip GXII system (Caliper lifescience) was used according to the manufacturer's instruction. 2µg sample is used for analyses.

25 The aggregate content of antibody samples was analyzed using a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-Arginine Monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C.

-150-

Table 32: Summary production and purification of DP47 GS TCB.

Construct	Titer [mg/l]	Yield [mg/l]	Aggregate after 1 st purification step [%]	HMW [%]	LMW [%]	Monomer [%]
DP47 GS TCB	103.7	8.04	8	2.3	6.9	91.8

Table 33: CE-SDS analyses of DP47 GS TCB.

	Peak	kDa	Corresponding Chain
DP47 GS TCB non reduced (A)	1	165.22	Molecule with 2 missing light chains
	2	181.35	Molecule with 1 missing light chain
	3	190.58	Correct molecule without N-linked glycosylation
	4	198.98	Correct molecule
DP47 GS TCB reduced (B)	1	27.86	Light chain DP47 GS
	2	35.74	Light chain huCH2527
	3	63.57	Fc(hole)
	4	93.02	Fc(knob)

5

Example 37

Binding of 16D5 TCB and 9D11 TCB and their corresponding CD3 deamidation variants N100A and S100aA to CD3-expressing Jurkat cells

The binding of 16D5 TCB and the corresponding CD3 deamidation variants 16D5 TCB N100A and 16D5 TCB S100aA and 9D11 TCB and the deamidation variants 9D11 TCB N100A and 9D11 TCB S100aA to human CD3 was assessed on a CD3-expressing immortalized T lymphocyte line (Jurkat). Briefly, cells were harvested, counted, checked for viability and resuspended at 2×10^6 cells/ml in FACS buffer (100 μ l PBS 0.1% BSA). 100 μ l of cell suspension (containing 0.2×10^6 cells) was incubated in round-bottom 96-well plates for 30 min at 4°C with different concentrations of the bispecific antibodies (686 pM - 500 nM). After two washing steps with cold PBS 0.1% BSA, samples were re-incubated for further 30 min at 4°C with a PE-conjugated AffiniPure F(ab')₂ Fragment goat anti-human IgG Fcγ Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-116-170). After washing the samples twice with cold PBS 0.1% BSA they were immediately analyzed by FACS using a FACS CantoII (Software FACS Diva). Binding curves were obtained using GraphPadPrism6 (Fig. 28A-B).

-151-

The results show reduced binding of the deamidation variants N100A and S100aA to CD3 compared to the parental antibodies 16D5 TCB (Fig. 28A) and 9D11 TCB (Fig. 28B).

Example 38

5 T-cell killing of SKov-3 and HT-29 cells induced by 16D5 TCB and 9D11 TCB and their CD3 deamidation variants N100A and S100aA

T-cell killing mediated by 16D5 TCB and the corresponding CD3 deamidation variants 16D5 TCB N100A and 16D5 TCB S100aA and 9D11 TCB and the deamidation variants 9D11 TCB N100A and 9D11 TCB S100aA was assessed on SKov-3 (medium FolR1) and HT-29 (low
10 FolR1) cells. Human PBMCs were used as effectors and the killing was detected at 24 h of incubation with the bispecific antibodies. Briefly, target cells were harvested with Trypsin/EDTA, washed, and plated at a density of 25 000 cells/well using flat-bottom 96-well plates. Cells were left to adhere overnight. Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation of enriched lymphocyte preparations (buffy coats)
15 obtained from healthy human donors. Fresh blood was diluted with sterile PBS and layered over Histopaque gradient (Sigma, #H8889). After centrifugation (450 x g, 30 minutes, room temperature), the plasma above the PBMC-containing interphase was discarded and PBMCs transferred in a new falcon tube subsequently filled with 50 ml of PBS. The mixture was centrifuged (400 x g, 10 minutes, room temperature), the supernatant discarded and the PBMC
20 pellet washed twice with sterile PBS (centrifugation steps 350 x g, 10 minutes). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 37°C, 5% CO₂ in cell incubator until further use (no longer than 24 h). For the killing assay, the antibody was added at the indicated concentrations (range of 0.01 pM – 10 nM in triplicates). PBMCs were added to
25 target cells at final E:T ratio of 10:1. Target cell killing was assessed after 24 h of incubation at 37°C, 5% CO₂ by quantification of LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit, Roche Applied Science, #11 644 793 001). Maximal lysis of the target cells (= 100%) was achieved by incubation of target cells with 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells without bispecific construct.
30 The results show that on SKov-3 cells the killing induced by the CD3 deamidation variants 16D5 TCB N100A and 16D5 S100aA is comparable to the one induced by 16D5 TCB (Fig. 29A). The same is true for 9D11 TCB and its variants 9D11 TCB N100A and 9D11 TCB S100aA (Fig. 29B). On FolR1 low expressing HT-29 cells the S100aA variant shows an impaired killing

-152-

efficiency which is the case for 16D5 TCB (Fig. 30A) as well as for 9D11 TCB (Fig. 30B). The EC50 values related to killing assays, calculated using GraphPadPrism6 are given in Table 35.

Table 35: EC50 values (pM) for T-cell mediated killing of FolR1-expressing SKov-3 and HT-29 cells induced by 16D5 TCB and 9D11 TCB and their deamidation variants N100A and A100aA.

Antibody	EC50 [pM]	
	SKov-3	HT-29
16D5 TCB	1.283	56.67
16D5 TCB N100A	1.886	91.95
16D5 TCB S100aA	1.939	165.6
9D11 TCB	1.283	2.827
9D11 TCB N100A	1.886	37.72
9D11 TCB S100aA	1.939	n.d.*

5

* not determined

Example 39

Biochemical characterization by surface plasmon resonance as TCBs of two CD3 binder variants (N100A and S100aA) to remove a deamidation site

Binding of two 16D5 TCBs with CD3 binder variants (N100A or S100aA) to human recombinant CD3 (CD3epsilon-CD3delta heterodimer as Fc fusion) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

Affinity to CD3ed-Fc

The affinity of the interaction between the anti-FolR1 T cell bispecifics and the recombinant CD3 epsilon-delta heterodimer was determined as described below (Table 36).

For affinity measurement, direct coupling of around 6000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 T cell bispecifics

20

-153-

were captured at 200 nM with a flow rate of 20 μ l/min for 60 sec, the reference flow cell was left without capture. Dilution series (4.1 to 3000 nM) of human and cyno Folate Receptor 1 Fc fusion were passed on all flow cells at 30 μ l/min for 240 sec to record the association phase. The dissociation phase was monitored for 240 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 1.5. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

Table 36: Monovalent binding (affinity) of two 16D5 CD3 deamidation variants as TCBs on human CD3ed-Fc.

Ligand	Analyte	k_a (1/Ms)	k_d (1/s)	KD
16D5 TCB N100A	huCD3	1.23E+04	4.67E-03	380 nM
16D5 TCB S100aA	huCD3	1.21E+04	5.49E-03	460 nM
16D5 TCB	huCD3	2.03E+04	4.41E-03	220 nM

The two CD3 deamidation variants have a slightly reduced affinity compared to the wild-type CD3 binder (CH2527), but the difference is not grave.

15

Example 40

Production and purification of two variants of the 16D5 T-cell bispecific with mutations to remove the deamidation site in the CD3 binder: 16D5 TCB N100A, 16D5 TCB S100aA

Transient transfection and production

The two deamidation variants 16D5 TCBs were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293 EBNA cells are cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells are seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells are centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 200 μ g DNA. After addition of 540 μ l PEI solution is vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an

25

-154-

incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium is added and cell are cultivated for 24 hours. One day after transfection 1 mM valporic acid and 7 % Feed 1 is added. After 7 days cultivation supernatant is collected for purification by centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C. After production the supernatant was harvested, filtered through 0.22 µm sterile filters and stored at 4 °C until purification.

Purification

The two deamidation variants 16D5 TCBs were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to MabSelect SuRe (GE Healthcare, column volume (cv) = 2 ml) equilibrated with 8 column volumes (cv) *buffer A* (20 mM sodium phosphate pH 7.5, 20 mM sodium citrate). After washing with 10 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (20 mM sodium citrate pH 3.0, 100 mM NaCl, 100 mM glycine) over 20 cv. Fractions containing the protein of interest were pooled and the pH of the solution was gently adjusted to pH 6.0 (using 0.5 M Na₂HPO₄ pH 8.0). Samples were concentrated to 1 ml using ultra-concentrators (Amicon Ultra-15, 30.000 MWCO, Millipore) and subsequently applied to a HiLoad™ 16/60 Superdex™ 200 preparative grade (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl. The aggregate content of eluted fractions was analyzed by analytical size exclusion chromatography. Therefore, 30 µl of each fraction was applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. Fractions containing less than 2 % oligomers were pooled. The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis (CE-SDS) in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were frozen in liquid N₂ and stored at -80 °C.

Table 36: Yield, monomer content and purity by CE-SDS of the two 16D5 deamidation variants in the T cell bispecific format.

Name	Mutation in the CD3 binder	Yield [mg/L]	Monomer [%]	Purity by CE-SDS [%]
------	----------------------------	--------------	-------------	----------------------

-155-

16D5 TCB	N100A	9	100	89
16D5 TCB	S100aA	23	100	83
16D5 TCB	Wild-type	9	100	93

Both TCBs were produced in good quality, similar to the construct with the wild-type CD3 binder.

5

Example 41

Production and purification of two 16D5 binder variants (D52dE and D52dQ) as IgGs to remove a hotspot in the CDR

Transient transfection and production

The two IgGs were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293 EBNA cells are cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells are seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells are centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 200 µg DNA. After addition of 540 µl PEI solution is vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium is added and cell are cultivated for 24 hours. One day after transfection 1 mM valporic acid and 7 % Feed 1 is added. After 7 days cultivation supernatant is collected for purification by centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C. After production the supernatants were harvested and the antibody containing supernatants were filtered through 0.22 µm sterile filters and stored at 4 °C until purification.

Antibody purification

The two IgGs were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to POROS MabCapture A (Applied Biosystems, column volume (cv) = 1 ml) equilibrated with 8 column volumes (cv) *buffer A* (20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5). After washing

-156-

with 10 cv of *buffer A*, the protein was eluted using a pH step to *buffer B* (20 mM sodium citrate pH 3.0, 100 mM NaCl, 100 mM glycine) over 5 cv. The 5 ml containing the protein of interest are stored in a loop on the Äkta Explorer and subsequently applied to a HiLoad 16/60 Superdex™ 200 (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl (no TWEEN was used). Fractions containing the IgGs were pooled and concentrated using ultra concentrators (Amicon Ultra-15, 30.000 MWCO, Millipore). The aggregate content of the final pool was analyzed by analytical size exclusion chromatography. Therefore, 30 µl were applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis (CE-SDS) in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were stored at 4 °C.

Table 37: Yield, monomer content and purity by CE-SDS of two 16D5 IgG hotspot variants.

Clone	Mutation HC/LC	Yield [mg/L]	Monomer [%]	Purity by CE-SDS [%]
16D5	D52dE	24	100	96
16D5	D52dQ	20	100	96

Both IgGs produced well and in good quality.

20

Example 42

Biochemical characterization by surface plasmon resonance of two 16D5 binder variants (D52dE and D52dQ) as IgGs to remove a hotspot in the CDR

Binding of two 16D5 binder variants (D52dE and D52dQ) as IgGs to human and cyno recombinant folate receptor 1 (both as Fc fusions) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

1. Avidity to Folate Receptor 1

The avidity of the interaction between the anti-FolR1 IgGs or T cell bispecifics and the recombinant folate receptors was determined as described below (Table 38).

30

-157-

Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 160. The anti-FolR1 IgGs or T cell bispecifics were passed at a concentration range from 3.7 to 900 nM with a flow of 30 µL/minutes through the flow cells over 180 seconds. The dissociation was monitored for 600 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated murine IL2 receptor Fc fusion. The binding curves resulting from the bivalent binding of the IgG or T cell bispecifics were approximated to a 1:1 Langmuir binding (even though it is a 1:2 binding) and fitted with that model to get an apparent KD representing the avidity of the bivalent binding. The apparent avidity constants for the interactions were derived from the rate constants of the fitting using the Bia Evaluation software (GE Healthcare).

Table 38: Bivalent binding (avidity with apparent KD) of two 16D5 hot spot variants as IgGs on human, murine and cyno FolR1 (no binding on muFolR1 as expected).

Analyte	Ligand	ka (1/Ms)	kd (1/s)	Apparent KD
16D5 D52dE IgG	huFolR1	1.62E+05	5.45E-04	3.4 nM
	cyFolR1	2.98E+06	7.47E-03	2.5 nM
16D5 D52dQ IgG	huFolR1	8.40E+04	7.75E-04	9.2 nM
	cyFolR1	4.12E+05	2.04E-03	5 nM
16D5 TCB	huFolR1	2.25E+05	5.00E-04	2.2 nM
	cyFolR1	2.71E+05	6.63E-04	2.5 nM

2. Affinity to Folate Receptor 1

The affinity of the interaction between the anti-FolR1 IgGs or the T cell bispecifics and the recombinant folate receptors was determined as described below (Table 39).

For affinity measurement, direct coupling of around 10000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 IgGs or T cell bispecifics were captured at 20 nM with a flow rate of 10 µl/min for 40 sec, the reference flow cell was left without capture. Dilution series (12.35 to 3000 nM) of human and cyno Folate Receptor 1 Fc fusion were passed on all flow cells at 30 µl/min for 240 sec to record the

-158-

association phase. The dissociation phase was monitored for 300 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 1.5. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

Table 39: Monovalent binding (affinity) of two 16D5 hot spot variants as IgGs on human and cyno FolR1.

Ligand	Analyte	k_a (1/Ms)	k_d (1/s)	KD
16D5 D52dE IgG	huFolR1	2.40E+04	2.27E-03	95 nM
	cyFolR1	2.25E+04	1.20E-02	530 nM
16D5 D52dQ IgG	huFolR1	6.97E+03	1.62E-03	230 nM
	cyFolR1	8.20E+03	3.32E-03	410 nM
16D5 TCB	huFolR1	2.05E+04	7.05E-04	35 nM
	cyFolR1	1.72E+04	1.62E-03	90 nM

The two 16D5 hot spot variants have similar avidity (bivalent binding) than the wild-type 16D5 binder. The avidity is slightly decreased for the D52dQ variant and this difference is even more visible in affinity (monovalent binding).

Example 43

Production and purification as IgGs of twelve variants of the 16D5 binder with mutations in the heavy and light chain to reduce affinity to FolR1

Transient transfection and production

The twelve IgGs were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. HEK293 EBNA cells are cultivated in suspension serum free in CD CHO culture medium. For the production in 500 ml shake flask 400 million HEK293 EBNA cells are seeded 24 hours before transfection (for alternative scales all amounts were adjusted accordingly). For transfection cells are centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 200 µg DNA. After addition of 540 µl PEI solution is vortexed for 15 s and subsequently incubated for 10 min

-159-

at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 500 ml shake flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 160 ml F17 medium is added and cell are cultivated for 24 hours. One day after transfection 1 mM valproic acid and 7 % Feed 1 is added. After 7 days

5 cultivation supernatant is collected for purification by centrifugation for 15 min at 210 x g, the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C. After production the supernatants were harvested and the antibody containing supernatants were filtered through 0.22 µm sterile filters and stored at 4 °C until purification.

10 Antibody purification

All molecules were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to POROS MabCapture A (Applied Biosystems, column volume (cv) = 1 ml) equilibrated with 8 column

15 volumes (cv) *buffer A* (20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5). After washing with 10 cv of *buffer A*, the protein was eluted using a pH step to *buffer B* (20 mM sodium citrate pH 3.0, 100 mM NaCl, 100 mM glycine) over 5 cv. The 5 ml containing the protein of interest are stored in a loop on the Äkta Explorer and subsequently applied to a HiLoad 16/60 Superdex™ 200 (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl,

20 0.01% Tween-20. Fractions containing the IgGs were pooled and concentrated using ultra concentrators (Amicon Ultra-15, 30.000 MWCO, Millipore). The aggregate content of the final pool was analyzed by analytical size exclusion chromatography. Therefore, 30 µl were applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7

25 running buffer at 25°C. The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis (CE-SDS) in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins

30 were stored at 4 °C.

Table 40: Yield, monomer content and purity by CE-SDS of twelve 16D5 IgG variants

Clone	Mutation HC/LC	Yield [mg/L]	Monomer [%]	Purity by CE- SDS [%]
-------	-------------------	--------------	----------------	--------------------------

-160-

16D5	W98Y/wt	32	100	100
16D5	W98Y/K53A	24	100	100
16D5	S35H/wt	21	100	100
16D5	S35H/K53A	18	100	100
16D5	S35H/S93A	18	100	100
16D5	W96Y/wt	40	100	100
16D5	W96Y/K53A	21	100	100
16D5	W96Y/S93A	25	98	100
16D5	R50S/K53A	10	98	100
16D5	R50S/S93A	7	100	100
16D5	G49S/K53A	42	100	100
16D5	G49S/S93A	45	100	100

All twelve IgGs produced well and in good quality.

Example 44

5 Biochemical characterization of 16D5 heavy and light chain combination variants as IgG by surface plasmon resonance

Binding of FolR1 16D5 heavy and light chain combination variants binders as IgG to different recombinant folate receptors (human, murine and cynomolgus FolR1; all as Fc fusions) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a
10 Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, Freiburg/Germany).

Avidity to Folate Receptor 1

The avidity of the interaction between the anti-FolR1 IgGs or T cell bispecifics and the recombinant folate receptors was determined as described below (Table 41).

15 Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 300. The anti-FolR1 IgGs or T cell bispecifics were passed at a concentration range from 11.1 to 900 nM with a flow of 30 µL/minutes through the flow cells over 180 seconds. The dissociation was
20 monitored for 240 or 600 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated murine IL2 receptor Fc fusion. The binding curves resulting from the bivalent binding of the IgG or T cell bispecifics were approximated to a 1:1 Langmuir binding (even

-161-

though it is a 1:2 binding) and fitted with that model to get an apparent K_D representing the avidity of the bivalent binding. The apparent avidity constants for the interactions were derived from the rate constants of the fitting using the Bia Evaluation software (GE Healthcare). For low affinity kinetics with association and dissociation phases too fast to be fitted by the 1:1 Langmuir

5 binding model, the steady state analysis model was applied using the Bia Evaluation software (GE Healthcare). The steady state analysis gives the K_D of the binding reaction at equilibrium.

Table 41: Bivalent binding (avidity with apparent K_D) of twelve 16D5 variants binders as IgGs on human, murine and cyno FolR1.

Analyte HC variant/LC variant	Ligand	k_a (1/Ms)	k_d (1/s)	Apparent K_D
W98Y/K53A	huFolR1			Weak binding
	cyFolR1			Weak binding
S35H/K53A	huFolR1	2.10E+04	2.91E-02	1400 nM
	cyFolR1	3.47E+04	4.04E-02	1100 nM
W96Y/K53A	huFolR1			580 nM (steady state)
	cyFolR1			660 nM (steady state)
W98Y/wt	huFolR1	1.36E+05	3.28E-02	240 nM
	cyFolR1	1.71E+05	3.61E-02	200 nM
S35H/S93A	huFolR1	2.43E+05	2.20E-02	90 nM
	cyFolR1	6.12E+05	6.77E-02	110 nM
G49S/K53A	huFolR1	1.90E+05	1.15E-02	60 nM
	cyFolR1	3.93E+05	3.28E-02	80 nM
R50S/K53A	huFolR1	3.28E+05	1.97E-02	60 nM
	cyFolR1	5.50E+05	4.55E-02	80 nM
S35H/wt	huFolR1	1.32E+05	5.68E-03	40 nM
	cyFolR1	2.23E+05	1.24E-02	55 nM
R50S/S93A	huFolR1	1.25E+05	3.23E-03	30 nM

-162-

	cyFolR1	4.39E+05	7.80E-03	20 nM
W96Y/S93A	huFolR1	6.55E+05	1.89E-02	30 nM
	cyFolR1	6.25E+05	1.74E-02	30 nM
G49S/S93A	huFolR1	1.52E+05	3.06E-03	20 nM
	cyFolR1	3.58E+05	6.22E-03	20 nM
W96Y/wt	huFolR1	1.29E+05	2.13E-03	20 nM
	cyFolR1	1.73E+05	2.11E-03	10 nM
36F2 TCB	huFolR1	2.44E+06	1.37E-02	6 nM
	cyFolR1	4.12E+06	2.15E-02	5 nM
	muFolR1	4.86E+05	1.20E-03	2.5 nM
16D5 TCB	huFolR1	1.41E+05	4.25E-04	3 nM
	cyFolR1	1.78E+05	6.39E-04	3.5 nM

Affinity to Folate Receptor 1

The affinity of the interaction between the anti-FolR1 IgGs or the T cell bispecifics and the recombinant folate receptors was determined as described below (Table 42).

- 5 For affinity measurement, direct coupling of around 10000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 IgGs or T cell bispecifics were captured at 200 nM with a flow rate of 10 μ l/min for 40 sec, the reference flow cell was left without capture. Dilution series (12.35 to 3000 nM) of human Folate Receptor 1 Fc
- 10 fusion were passed on all flow cells at 30 μ l/min for 240 sec to record the association phase. The dissociation phase was monitored for 300 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection of 60 sec 10 mM Glycine-HCl pH 1.5. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the interactions
- 15 were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare).

Table 42: Monovalent binding (affinity) of twelve 16D5 variants FolR1 binders as IgGs on human, cyno and murine FolR1.

-163-

Ligand HC variant/LC variant	Analyte	ka (1/Ms)	kd (1/s)	KD
W98Y/K53A	huFolR1			No binding
S35H/K53A	huFolR1			Weak binding
W96Y/K53A	huFolR1			Weak binding
W98Y/wt	huFolR1			5400 nM (steady state)
G49S/K53A	huFolR1	9.19E+03	1.74E-02	1900 nM
R50S/K53A	huFolR1	1.35E+04	2.45E-02	1800 nM
36F2 TCB	huFolR1	5.00E+04	8.57E-02	1700 nM
S35H/S93A	huFolR1	8.43E+03	1.12E-02	1300 nM
S35H/wt	huFolR1	8.96E+03	1.13E-02	1200 nM
R50S/S93A	huFolR1	1.57E+04	1.23E-02	780 nM
G49S/S93A	huFolR1	1.05E+04	7.99E-03	760 nM
W96Y/wt	huFolR1	9.95E+03	5.44E-03	550 nM
W96Y/S93A	huFolR1	4.05E+04	1.72E-02	420 nM
16D5 TCB	huFolR1	1.18E+04	7.22E-04	60 nM

Twelve “affinity reduced” variants of the 16D5 FolR1 binder were analyzed by surface plasmon resonance in comparison to the 16D5 wild-type binder and the 36F2 binder. The goal was to find a 16D5 variant with an affinity and an avidity comparable to 36F2. When measuring monovalent binding (affinity) there were variants with a higher and variants with a lower affinity than 36F2. However in the bivalent binding (avidity) all the variants have a higher apparent KD value than 36F2. This is mainly due to the fast association rate (ka) of 36F2 that results in a small apparent KD for 36F2. The big avidity effect when 36F2 binds bivalently seems to be unique to this binder. As noted above, 36F2 was the only human, murine and cyno crossreactive binder that could be identified.

-164-

Example 45**Binding of 16D5 HC/LC variants to human FolR1 expressed on Hela cells**

The binding of 36F2 TCB, 16D5 TCB and various HC/LC variants of 16D5 to human FolR1 was assessed on Hela cells. Briefly, cells were harvested, counted, checked for viability and
5 resuspended at 2×10^6 cells/ml in FACS buffer (100 μ l PBS 0.1% BSA). 100 μ l of cell suspension (containing 0.2×10^6 cells) was incubated in round-bottom 96-well plates for 30 min at 4°C with different concentrations of the bispecific antibodies (229 pM - 500 nM). After two washing steps with cold PBS 0.1% BSA, samples were re-incubated for further 30 min at 4°C with a PE-conjugated AffiniPure F(ab')₂ Fragment goat anti-human IgG Fcγ Fragment Specific
10 secondary antibody (Jackson Immuno Research Lab PE #109-116-170). After washing the samples twice with cold PBS 0.1% BSA they were fixed with 1% PFA overnight. Afterwards samples were centrifuged, resuspended in PBS 0.1% BSA and analyzed by FACS using a FACS CantoII (Software FACS Diva). Binding curves were obtained using GraphPadPrism6 (Fig. 32A-E). The 36F2 TCB bound FolR2, was not well tolerated in mice, and did not demonstrate the
15 desired efficacy.

Example 46**Production and purification of four variants of the 16D5 T-cell bispecific with mutations to reduce the affinity to human and cynomolgus FolR1:**

20 **16D5 TCB G49S/S93A, G49S/K53A, W96Y, W96Y/D52E**

Transient transfection and production

Four additional variants of 16D5 TCBs having reduced affinity to FolR1 were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. For transfection HEK293 EBNA cells are cultivated in suspension
25 serum free in Excell culture medium containing 6 mM L-Glutamine and 250 mg/l G418 culture medium. For the production in 600 ml tubespin flask (max. working volume 400mL) 600 million HEK293 EBNA cells are seeded 24 hours before transfection. For transfection cells are centrifuged for 5 min by $210 \times g$, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 400 μ g
30 DNA. After addition of 1080 μ l PEI solution (2.7 μ g/ml) is vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 600 ml tubespin flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation time 360 ml Excell + 6mM L-Glutamine

-165-

+ 5g/L Pepsoy + 1.0mM VPA medium is added and cells are cultivated for 24 hours. One day after transfection 7% Feed 7 is added. After 7 days cultivation supernatant is collected for purification by centrifugation for 20 - 30 min at 3600 x g (Sigma 8K centrifuge), the solution is sterile filtered (0.22 mm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C.

Purification

The reduced affinity variants 16D5 TCBs were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to HiTrap Protein A (GE Healthcare, column volume (cv) = 5 ml) equilibrated with 8 column volumes (cv) *buffer A* (20 mM sodium phosphate pH 7.5, 20 mM sodium citrate). After washing with 10 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (20 mM sodium citrate pH 3.0, 100 mM NaCl, 100 mM glycine) over 20 cv. Fractions containing the protein of interest were pooled and the pH of the solution was gently adjusted to pH 6.0 (using 0.5 M Na₂HPO₄ pH 8.0). Samples were concentrated to 1 ml using ultra-concentrators (Amicon Ultra-15, 30.000 MWCO, Millipore) and subsequently applied to a HiLoad™ 16/60 Superdex™ 200 preparative grade (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl, 0.01% Tween 20. The aggregate content of eluted fractions was analyzed by analytical size exclusion chromatography. Therefore, 30 µl of each fraction was applied to a TSKgel G3000 SW XL analytical size-exclusion column (Tosoh) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. Fractions containing less than 2 % oligomers were pooled. The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis (CE-SDS) in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were frozen in liquid N₂ and stored at -80 °C.

Table 43: Yield, monomer content and purity by CE-SDS of the reduced affinity 16D5 variants in the T cell bispecific format.

Name	Mutations to reduce affinity	Yield [mg/L]	Monomer [%]	Purity by CE-SDS [%]
------	------------------------------	--------------	-------------	----------------------

-166-

16D5 TCB	G49S S93A	10.3	100	88
16D5 TCB	G49S K53A	22.3	98.5	96
16D5 TCB	W96Y	15.2	98.7	92.5
16D5 TCB	W96Y D52E	9.9	99.3	92.9
16D5 TCB	Wild-type	5.4	96	91.6

All variants with reduced affinity could be produced in good quality.

Example 47

Binding of 36F2 TCB, 16D5 TCB and the two 16D5 affinity reduced variants 16D5

5 W96Y/D52E TCB and 16D5 G49S/S93A TCB to human FolR1 expressed on Hela cells

The binding of 36F2 TCB, 16D5 TCB and the two 16D5 affinity reduced variants 16D5 W96Y/D52E TCB and 16D5 G49S/S93A TCB to human FolR1 was assessed on Hela cells. Briefly, cells were harvested, counted, checked for viability and resuspended at 2×10^6 cells/ml in FACS buffer (100 μ l PBS 0.1% BSA). 100 μ l of cell suspension (containing 0.2×10^6 cells) was incubated in round-bottom 96-well plates for 30 min at 4°C with different concentrations of the bispecific antibodies (30 pM - 500 nM). After two washing steps with cold PBS 0.1% BSA, samples were re-incubated for further 30 min at 4°C with a FITC-conjugated AffiniPure F(ab')₂ Fragment goat anti-human IgG Fcγ Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-096-098). After washing the samples twice with cold PBS 0.1% BSA samples were centrifuged, resuspended in PBS 0.1% BSA and analyzed by FACS using a FACS CantoII (Software FACS Diva). Binding curves were obtained using GraphPadPrism6 (Fig. 33).

Example 48

Production and purification of three T-cell bispecifics with intermediate affinity to human and cynomolgus FolR1: 14B1, 6E10, 2C7

20 Transient transfection and production

The intermediate affinity TCBs were transiently produced in HEK293 EBNA cells using a PEI mediated transfection procedure for the required vectors as described below. For transfection HEK293 EBNA cells are cultivated in suspension serum free in Excell culture medium containing 6 mM L-Glutamine and 250 mg/l G418 culture medium. For the production in 600 ml tubespin flask (max. working volume 400mL) 600 million HEK293 EBNA cells are seeded 24 hours before transfection. For transfection cells are centrifuged for 5 min by 210 x g, supernatant is replaced by pre-warmed 20 ml CD CHO medium. Expression vectors are mixed in 20 ml CD CHO medium to a final amount of 400 μ g DNA. After addition of 1080 μ l PEI solution (2.7 μ g/ml) is vortexed for 15 s and subsequently incubated for 10 min at room temperature. Afterwards cells are mixed with the DNA/PEI solution, transferred to a 600 ml tubespin flask and incubated for 3 hours by 37 °C in an incubator with a 5 % CO₂ atmosphere. After incubation

-167-

time 360 ml Excell + 6mM L-Glutamine + 5g/L Pepsoy + 1.0mM VPA medium is added and cells are cultivated for 24 hours. One day after transfection 7% Feed 7 is added. After 7 days cultivation supernatant is collected for purification by centrifugation for 20 - 30 min at 3600 x g (Sigma 8K centrifuge), the solution is sterile filtered (0.22 µm filter) and sodium azide in a final concentration of 0.01 % w/v is added, and kept at 4°C.

Purification

The intermediate affinity TCBs were purified in two steps using standard procedures, such as protein A affinity purification (Äkta Explorer) and size exclusion chromatography. The supernatant obtained from transient production was adjusted to pH 8.0 (using 2 M TRIS pH 8.0) and applied to HiTrap Protein A (GE Healthcare, column volume (cv) = 5 ml) equilibrated with 8 column volumes (cv) *buffer A* (20 mM sodium phosphate pH 7.5, 20 mM sodium citrate). After washing with 10 cv of *buffer A*, the protein was eluted using a pH gradient to *buffer B* (20 mM sodium citrate pH 3.0, 100 mM NaCl, 100 mM glycine) over 20 cv. Fractions containing the protein of interest were pooled and the pH of the solution was gently adjusted to pH 6.0 (using 0.5 M Na₂HPO₄ pH 8.0). Samples were concentrated to 1 ml using ultra-concentrators (Amicon Ultra-15, 30.000 MWCO, Millipore) and subsequently applied to a HiLoad™ 16/60 Superdex™ 200 preparative grade (GE Healthcare) equilibrated with 20 mM Histidine, pH 6.0, 140 mM NaCl, 0.01% Tween 20. The aggregate content of eluted fractions was analyzed by analytical size exclusion chromatography. Therefore, 30 µl of each fraction was applied to a TSKgel G3000 SW XL analytical size-exclusion column (Toso h) equilibrated in 25 mM K₂HPO₄, 125 mM NaCl, 200 mM L-arginine monohydrochloride, 0.02 % (w/v) NaN₃, pH 6.7 running buffer at 25°C. Fractions containing less than 2 % oligomers were pooled. The protein concentration was determined by measuring the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence. Purity and molecular weight of the constructs were analyzed by SDS capillary electrophoresis (CE-SDS) in the presence and absence of a reducing agent following the manufacturer instructions (instrument Caliper LabChipGX, Perkin Elmer). Purified proteins were frozen in liquid N₂ and stored at -80 °C.

Table 44: Yield, monomer content and purity by CE-SDS of the intermediate affinity TCBs.

Name	Yield [mg/L]	Monomer [%]	Purity by CE-SDS [%]
6E10 TCB	2.3	93	95
14B1 TCB	1.8	94	70
9C7 TCB	3.4	98	99

-168-

All intermediate affinity T cell bispecifics could be produced. The yields are not high. The quality is good for 9C7 and acceptable for 14B1 and 6E10.

Example 49

Binding of 16D5 HC/LC variants to human FolR1 expressed on HT-29 cells

- 5 The binding of 36F2 TCB, 16D5 TCB and various HC/LC variants (Figure 34A-E) of 16D5 to human FolR1 was assessed on HT-29 cells. Briefly, cells were harvested, counted, checked for viability and resuspended at 2×10^6 cells/ml in FACS buffer (100 μ l PBS 0.1% BSA). 100 μ l of cell suspension (containing 0.2×10^6 cells) was incubated in round-bottom 96-well plates for 30 min at 4°C with different concentrations of the bispecific antibodies (229 pM - 500 nM). After
10 two washing steps with cold PBS 0.1% BSA, samples were re-incubated for further 30 min at 4°C with a PE-conjugated AffiniPure F(ab')₂ Fragment goat anti-human IgG Fc γ Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-116-170). After washing the samples twice with cold PBS 0.1% BSA they were fixed with 1% PFA overnight. Afterwards samples were centrifuged, resuspended in PBS 0.1% BSA and analyzed by FACS using a FACS
15 CantoII (Software FACS Diva). Binding curves were obtained using GraphPadPrism6 (Figure 34A-E).

Example 50

Binding of intermediate FolR1 binders to human and mouse FolR1 and FolR2

- Cross-reactivity of the intermediate FolR1 binders (6E10 TCB, 14B1 TCB and 9C7 TCB), as
20 well as 16D5 TCB and 36F2 TCB to human and mouse FolR1 and FolR2 was assessed in a FACS binding assay on transfected HEK293T cells.

- Briefly, cells were harvested, counted, checked for viability and resuspended at 2×10^6 cells/ml in FACS buffer (100 μ l PBS 0.1% BSA). 100 μ l of cell suspension (containing 0.2×10^6 cells) was incubated in round-bottom 96-well plates for 30 min at 4°C with 100 nM of the bispecific
25 antibodies. After two washing steps with cold PBS 0.1% BSA, samples were re-incubated for further 30 min at 4°C with a Fluorescein (FITC) AffiniPure F(ab')₂ Fragment Goat Anti-Human IgG, Fc γ Fragment Specific secondary antibody (Jackson Immuno Research Lab PE #109-096-098). After washing the samples twice with cold PBS 0.1% BSA they were fixed with 1% PFA overnight. Afterwards samples were centrifuged, resuspended in PBS 0.1% BSA and analyzed
30 by FACS using a FACS CantoII (Software FACS Diva). Graphs were obtained using GraphPadPrism6 (Fig. 35A-D).

The results show that 36F2 TCB and 14B1 TCB are cross-reactive to mouse FolR1 and human and mouse FolR2. For 6E10 TCB a weak binding to human FolR2 can be observed. 16D5 TCB

-169-

and 9C7 TCB are specific for human FolR1 and show no cross-reactivity to mouse FolR1 or human and mouse FolR2.

Example 51

Biochemical characterization by surface plasmon resonance of 16D5 reduced affinity

5 variants and additional intermediate affinity binders in the T-cell bispecific format

Binding of anti-FolR1 16D5 reduced affinity variants and additional intermediate affinity binders in the bivalent T-cell bispecific format to recombinant human, cynomolgus and murine folate receptor 1 (all as Fc fusions) was assessed by surface plasmon resonance (SPR). All SPR experiments were performed on a Biacore T200 at 25 °C with HBS-EP as running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, Biacore, GE Healthcare).

10 The molecules used for affinity and avidity determination are described in Table 45.

Table 45: Name, description and figure reference of the nine constructs used in SPR analysis.

Name	Description	Figure reference
<i>16D5 reduced affinity variants</i> 16D5 TCB 16D5 G49S/S93A TCB 16D5 G49S/K53A TCB 16D5 W96Y TCB 16D5 W96Y/D52E TCB	2+1 T-cell bispecific, inverted format (common light chain)	Fig. 1A
<i>Intermediate affinity binders</i> 36F2 TCB 6E10 TCB 14B1 TCB 9C7 TCB	2+1 T-cell bispecific, inverted format, crossfab	Fig. 1F

15 Single injections

First the anti-FolR1 TCBs were analyzed by single injections (Table 46) to characterize their crossreactivity (to human, murine and cyno FolR1) and specificity (to human FolR1, human FolR2, human FolR3). Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) or human Folate Receptor 2 and 3 (FolR2-Fc, FolR3-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, Freiburg/Germany). The immobilization level was about 300-400 RU. The TCBs were injected for 60 seconds at a concentration of 500 nM.

20

-170-

Table 46: Crossreactivity and specificity of 7 folate receptor 1 T cell bispecifics. + means binding, - means no binding, +/- means weak binding.

Clone name	Binding to huFolR1	Binding to cyFolR1	Binding to muFolR1	Binding to huFolR2	Binding to huFolR3
16D5 TCB	+	+	-	-	-
16D5 G49S/S93A TCB	+	+	-	-	-
16D5 W96Y/D52E TCB	+	+	-	-	-
36F2 TCB	+	+	+	+/-	-
6E10 TCB	+	+	-	-	-
14B1 TCB	+	+	+	+/-	-
9C7 TCB	+	+	-	-	-

Avidity to Folate Receptor 1

- 5 The avidity of the interaction between the anti-FolR1 T cell bispecifics and the recombinant folate receptors was determined as described below (Table 47).
- Recombinant biotinylated monomeric Fc fusions of human, cynomolgus and murine Folate Receptor 1 (FolR1-Fc) were directly coupled on a SA chip using the standard coupling instruction (Biacore, GE Healthcare). The immobilization level was about 200-300 RU. The anti-
- 10 FolR1 T cell bispecifics were passed at a concentration range from 11.1 to 900 nM (for the 16D5 reduced affinity variants) or 0.2 to 500 nM (for the additional intermediate affinity binders and 36F2) with a flow of 30 μ L/minutes through the flow cells over 180 seconds. The dissociation was monitored for 240 or 600 seconds. The chip surface was regenerated after every cycle using a double injection of 30 sec 10 mM Glycine-HCl pH 1.5. Bulk refractive index differences were
- 15 corrected for by subtracting the response obtained on reference flow cell immobilized with recombinant biotinylated murine IL2R Fc fusion (unrelated Fc fused receptor). The binding curves resulting from the bivalent binding of the T cell bispecifics were approximated to a 1:1 Langmuir binding (even though it is a 1:2 binding) and fitted with that model to get an apparent KD representing the avidity of the bivalent binding. The apparent avidity constants for the
- 20 interactions were derived from the rate constants of the fitting using the Bia Evaluation software (GE Healthcare).

Table 47: Bivalent binding (avidity with apparent KD) of anti-FolR1 T-cell bispecifics (TCB) on human, cyno and murine FolR1.

Analyte	Ligand	ka (1/Ms)	kd (1/s)	Apparent KD
16D5 TCB	huFolR1	1.68E+05	4.33E-04	3 nM
	cyFolR1	2.08E+05	6.95E-04	3 nM
16D5 G49S/S93A TCB	huFolR1	1.49E+05	2.09E-03	10 nM
	cyFolR1	4.54E+05	7.84E-03	20 nM
16D5 G49S/K53A TCB	huFolR1	1.32E+05	5.86E-03	40 nM
	cyFolR1	3.73E+05	2.56E-02	70 nM
16D5 W96Y TCB	huFolR1	1.15E+05	1.44E-03	10 nM
	cyFolR1	1.37E+05	1.68E-03	10 nM
16D5 W96Y/D52E TCB	huFolR1	1.24E+05	1.40E-03	10 nM
	cyFolR1	5.17E+05	1.41E-02	30 nM
36F2 TCB	huFolR1	1.12E+06	7.90E-03	7 nM
	cyFolR1	1.97E+06	1.10E-02	6 nM
	muFolR1	5.54E+05	1.47E-03	3 nM
6E10 TCB	huFolR1	7.93E+06	8.74E-03	1 nM
	cyFolR1	5.56E+06	5.72E-03	1 nM
14B1 TCB	huFolR1	1.12E+06	1.40E-03	1 nM
	cyFolR1	1.02E+06	1.66E-03	2 nM
	muFolR1	8.03E+06	8.20E-04	0.1 nM
9C7 TCB	huFolR1	1.18E+06	1.42E-03	1 nM
	cyFolR1	4.98E+06	4.82E-03	1 nM

3. Affinity to Folate Receptor 1

- 5 The affinity of the interaction between the anti-FolR1 T cell bispecifics and the recombinant folate receptors was determined as described below (Table 48).
- For affinity measurement, direct coupling of around 12000 resonance units (RU) of the anti-human Fab specific antibody (Fab capture kit, GE Healthcare) was performed on a CM5 chip at pH 5.0 using the standard amine coupling kit (GE Healthcare). Anti-FolR1 T cell bispecifics
- 10 were captured at 20 nM with a flow rate of 10 µl/min for 40 sec, the reference flow cell was left without capture. Dilution series (12.3 to 3000 nM) of human, cyno or murine Folate Receptor 1 Fc fusion were passed on all flow cells at 30 µl/min for 240 sec to record the association phase. The dissociation phase was monitored for 300 s and triggered by switching from the sample solution to HBS-EP. The chip surface was regenerated after every cycle using a double injection
- 15 of 60 sec 10 mM Glycine-HCl pH 2.1. Bulk refractive index differences were corrected for by subtracting the response obtained on the reference flow cell 1. The affinity constants for the

-172-

interactions were derived from the rate constants by fitting to a 1:1 Langmuir binding using the Bia Evaluation software (GE Healthcare). For low affinity kinetics with association and dissociation phases too fast to be fitted by the 1:1 Langmuir binding model, the steady state analysis model was applied using the Bia Evaluation software (GE Healthcare). The steady state analysis gives the KD of the binding reaction at equilibrium.

Table 48: Monovalent binding (affinity) of anti-FolR1 T-cell bispecifics (TCB) on human, cyno and murine FolR1.

Analyte	Ligand	ka (1/Ms)	kd (1/s)	KD
16D5 TCB	huFolR1	1.22E+04	7.02E-04	57 nM
	cyFolR1	1.29E+04	1.71E-03	130 nM
16D5 G49S/S93A TCB	huFolR1	1.01E+04	8.37E-03	830 nM
	cyFolR1	2.05E+04	8.60E-03	420 nM
16D5 G49S/K53A TCB	huFolR1	9.17E+03	1.59E-02	1700 nM
	cyFolR1			1900 nM (steady state analysis)
16D5 W96Y TCB	huFolR1	1.11E+04	4.05E-03	370 nM
	cyFolR1	1.17E+04	5.16E-03	440 nM
16D5 W96Y/D52E TCB	huFolR1			1400 nM (steady state analysis)
	cyFolR1			5600 nM (steady state analysis)
36F2 TCB	huFolR1			1400 nM (steady state analysis)
	cyFolR1			1500 nM (steady state analysis)
	muFolR1	3.50E+04	1.73E-02	490 nM
6E10 TCB	huFolR1			1200 nM (steady state analysis)
	cyFolR1			1500 nM (steady state analysis)
14B1 TCB	huFolR1	6.16E+04	3.03E-02	490 nM
	cyFolR1			1200 nM (steady state analysis)
	muFolR1	7.03E+04	2.28E-03	30 nM
9C7 TCB	huFolR1			840 nM (steady state analysis)
	cyFolR1			1400 nM (steady state analysis)

The mutations introduced into the 16D5 binders reduce its affinity to human and cynomolgus FolR1 as determined by surface plasmon resonance. The ranking with decreasing affinity is 16D5 WT (57 nM) > W96Y (6.5 fold lower) > G49S/S93A (14.5 fold lower) > W96Y/D52E (24.5 fold lower) > G49S/K53A (30 fold lower). The same ranking is visible in the avidity values,

-173-

however the fold differences are smaller 16D5 WT (3 nM)> W96Y, G49S/S93A, W96Y/D52E (3 fold lower)> G49S/K53A (13 fold lower).

The intermediate affinity binders have following ranking in affinity 16D5 (57 nM)>14B1 (8.5 fold lower)> 9C7 (15 fold lower) > 6E10 (21 fold lower)>36F2 (24.5 fold lower). These differences however disappear in the avidity measurement 14B1, 9C7, 6E10 (1nM)> 16D5 (3 nM) > 36F2 (7 nM).

16D5 W96Y/D52E TCB addresses the problems observed with previous candidates. 16D5 W96Y/D52E TCB is based on the common light chain 16D5 binder and has two point mutations on the heavy chain with respect to the parental 16D5 binder. The W96Y mutation reduces the affinity of the binder to FolR1 compared to the parental binder and the D52E mutation removes a deamidation site and also contributes to the reduction in affinity. 16D5 W96Y/D52E TCB binds to human and cynomolgus FolR1, but not to murine FolR1. It is specific for FolR1 and does not bind to recombinant human FolR2 or human FolR3. The affinity (monovalent binding) of 16D5 W96Y/D52E is around 1.4 μ M for human FolR1 (24.5 fold lower than the parental 16D5 binder) and the avidity (bivalent binding) is around 10 nM (3 fold lower than the parental 16D5 binder).

Example 52

T-cell killing of Hela, SKov-3 and HT-29 cells induced by intermediate FolR1 TCBs

T-cell killing mediated by intermediate FolR1 binders (6E10 TCB, 14B1 TCB and 9C7 TCB), was assessed on Hela (high FolR1), SKov-3 (medium FolR1) and HT-29 (low FolR1) cells. 16D5 TCB and 36F2 TCB were included as benchmarks. Human PBMCs were used as effectors and the killing was detected at 24 h and 48 h of incubation with the bispecific antibodies. Briefly, target cells were harvested with Trypsin/EDTA, washed, and plated at a density of 25 000 cells/well using flat-bottom 96-well plates. Cells were left to adhere overnight. Peripheral blood mononuclear cells (PBMCs) were prepared by Histopaque density centrifugation of enriched lymphocyte preparations (buffy coats) obtained from healthy human donors. Fresh blood was diluted with sterile PBS and layered over Histopaque gradient (Sigma, #H8889). After centrifugation (450 x g, 30 minutes, room temperature), the plasma above the PBMC-containing interphase was discarded and PBMCs transferred in a new falcon tube subsequently filled with 50 ml of PBS. The mixture was centrifuged (400 x g, 10 minutes, room temperature), the supernatant discarded and the PBMC pellet washed twice with sterile PBS (centrifugation steps 350 x g, 10 minutes). The resulting PBMC population was counted automatically (ViCell) and stored in RPMI1640 medium containing 10% FCS and 1% L-alanyl-L-glutamine (Biochrom,

-174-

K0302) at 37°C, 5% CO₂ in cell incubator until further use (no longer than 24 h). For the killing assay, the antibody was added at the indicated concentrations (range of 0.01 pM – 10 nM in triplicates). PBMCs were added to target cells at final E:T ratio of 10:1. Target cell killing was assessed after 24 h and 48 h of incubation at 37°C, 5% CO₂ by quantification of LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit, Roche Applied Science, #11 644 793 001). Maximal lysis of the target cells (= 100%) was achieved by incubation of target cells with 1% Triton X-100. Minimal lysis (= 0%) refers to target cells co-incubated with effector cells without bispecific construct.

The results show that tumor lysis induced by the intermediate FolR1 binders (6E10 TCB, 14B1 TCB and 9C7 TCB) ranges between the one obtained for the high affinity 16D5 TCB and the low affinity 36F2 TCB (Fig. 36A-F).. Among the intermediate FolR1 binders, 14B1 TCB shows the strongest killing as can be seen after 48h of incubation (Fig. 36D-F). The EC₅₀ values related to killing assays after 24 h and 48 h of incubation, calculated using GraphPadPrism6, are given in Table 49 and Table 50.

Table 49: EC₅₀ values (pM) for T-cell mediated killing of HeLa, SKov-3 and HT-29 cells induced by intermediate FolR1 TCBs after 24 h of incubation.

Antibody	EC ₅₀ [pM]		
	HeLa	SKov-3	HT-29
6E10 TCB	6.5	n.d.	*n.d.
14B1 TCB	8.5	30.1	*n.d.
9C7 TCB	2.8	741.4	*n.d.
16D5 TCB	2.2	1.5	*n.d.
36F2 TCB	31.1	*n.d.	*n.d.

* not determined

Table 50: EC₅₀ values (pM) for T-cell mediated killing of HeLa, SKov-3 and HT-29 cells induced by intermediate FolR1 TCBs after 48 h of incubation.

Antibody	EC ₅₀ [pM]		
	HeLa	SKov-3	HT-29
6E10 TCB	2.1	2164.0	*n.d.
14B1 TCB	5.5	4.7	397.7
9C7 TCB	4.3	519.6	*n.d.
16D5 TCB	2.3	*n.d.	4.9
36F2 TCB	10.5	*n.d.	n.d.

* not determined

-175-

Example 53**T-cell killing of Hela, SKov-3 and HT-29 cells induced by affinity reduced 16D5 variants**

T-cell killing mediated by affinity reduced 16D5 variants (16D5-G49S/S93A TCB, 16D5-G49S/K53A TCB, 16D5 W96Y TCB, 16D5 W96Y/D52E TCB) was assessed on Hela (high FolR1), SKov-3 (medium FolR1) and HT-29 (low FolR1) cells. 16D5 TCB and 36F2 TCB were included as benchmarks. The assay was performed as described above (Example 52).

The results show that tumor lysis induced by affinity reduced 16D5 variants (16D5-G49S/S93A TCB, 16D5-G49S/K53A TCB, 16D5 W96Y TCB, 16D5 W96Y/D52E TCB), ranges between the one obtained for the high affinity 16D5 TCB and the low affinity 36F2 TCB. The EC50 values related to killing assays after 24 h and 48 h of incubation, calculated using GraphPadPrism6, are given in Table 51 and Table 52 (Fig. 37A-F).

Table 51: EC50 values (pM) for T-cell mediated killing of FolR1-expressing Hela, SKov-3 and HT-29 cells induced by 16D5 TCB and its affinity reduced variants after 24 h of incubation.

Antibody	EC50 [pM]		
	Hela	SKov-3	HT-29
16D5 TCB	2.2	1.5	*n.d.
16D5-G49S/S93A TCB	2.3	430.4	*n.d.
16D5-G49S/K53A TCB	4.4	1701.9	*n.d.
16D5 W96Y TCB	3.0	164.5	*n.d.
16D5 W96Y/D52E TCB	1.3	235.4	*n.d.
36F2 TCB	31.1	*n.d.	*n.d.

* not determined

Table 52: EC50 values (pM) for T-cell mediated killing of FolR1-expressing Hela, SKov-3 and HT-29 cells induced by 16D5 TCB and its affinity reduced variants after 48 h of incubation.

Antibody	EC50 [pM]		
	Hela	SKov-3	HT-29
16D5 TCB	2.3	0.1	4.9

-176-

16D5- G49S/S93A TCB	0.9	95.9	99.3
16D5- G49S/K53A TCB	0.5	950.4	1790.7
16D5 W96Y TCB	1.8	24.7	99.3
16D5 W96Y/D52E TCB	0.9	93.0	399.4
36F2 TCB	10.5	968.5	*n.d.

* not determined

Thus, as with 36F2 FOLR1 TCB described above, the 16D5 W96Y/D52E TCB differentiates between high and low expressing cells which is of special importance to reduce toxicity as the cells of some normal, non-tumorous tissues express very low levels of FolR1 (approximately less than 1000 copies per cell). Consistent with this observation, the results discussed in Example 54 below show that 16D5 W96Y/D52E TCB induces much lower levels of T-cell-mediated killing of primary cells (Fig. 38A-F) compared to the parental 16D5 TCB. As such, 16D5 W96Y/D52E TCB mediates potent killing of tumor tissues with high or medium FOLR1 expression, but not of normal tissues with low expression. 16D5 W96Y/D52E TCB in the bivalent 2+1 format comprises FolR1 binding moieties of relatively low affinity but it possesses an avidity effect which allows for differentiation between high and low FolR1 expressing cells. Because tumor cells express FolR1 at high or intermediate levels, this TCB selectively binds to tumor cells and not normal, non-cancerous cells that express FolR1 at low levels or not at all. As an additional advantage over the 36F2 FOLR1 TCB described above, the 16D5 W96Y/D52E TCB binds specifically to FolR1 and not to FolR2 or FolR3, further enhancing its safety for in vivo treatment.

In addition to the above advantageous characteristics, the 16D5 W96Y/D52E TCB in the bivalent 2+1 inverted format also has the advantage that it does not require chemical cross linking or other hybrid approach. This makes it suitable for manufacture of a medicament to treat patients, for example patients having FolR1-positive cancerous tumors. The 16D5 W96Y/D52E TCB in the bivalent 2+1 inverted format can be produced using standard CHO processes with low aggregates. Further, the 16D5 W96Y/D52E TCB in the bivalent 2+1 comprises human and humanized sequences making it superior to molecules that employ rat and murine polypeptides that are highly immunogenic when administered to humans. Furthermore, the 16D5 W96Y/D52E TCB in the bivalent 2+1 format was engineered to abolish FcγR binding

-177-

and, as such, does not cause FcγR crosslinking and infusion reactions, further enhancing its safety when administered to patients.

As demonstrated by the results described above, its head-to-tail geometry make the 16D5 W96Y/D52E TCB in the bivalent 2+1 inverted format a highly potent molecule that induces absolute target cell killing. Its bivalency enhance avidity and potency, but also allow for differentiation between high and low expressing cells. Its preference for high or medium target expressing cells due to its avidity affect reduce toxicity resulting from T cell mediated killing of normal cells that express FolR1 at low levels.

A further advantage of the 16D5 W96Y/D52E TCB in the bivalent 2+1 format and other embodiments disclosed herein is that their clinical development does not require the use of surrogate molecules as they bind to human and cynomous FolR1. As such, the molecules disclosed herein recognize a different epitope than antibodies to FolR1 previously described that do not recognize FolR1 from both species (see also Fig. 41).

Example 54

T-cell killing of primary cells induced by affinity reduced 16D5 variants and intermediate FolR1 TCBs

T-cell killing mediated by affinity reduced 16D5 variants (16D5-G49S/S93A TCB, 16D5 W96Y/D52E TCB) and the intermediate FolR1 binder 14B1 TCB was assessed on primary cells (Human Renal Cortical Epithelial Cells (HRCEpiC) (ScienCell Research Laboratories; Cat No 4110) and Human Retinal Pigment Epithelial Cells (HRPEpiC) (ScienCell Research Laboratories; Cat No 6540)). HT-29 cells (low FolR1) were included as control cell line. 16D5 TCB and 36F2 TCB were included as benchmarks and DP47 TCB served as non-binding control.

The assay was performed as described in Example 52, with a concentration range of the antibodies of 0.1 pM – 100 nM (in triplicates).

When human primary cells are used as targets, the overall lysis is much lower due to a lower expression rate of FolR1 on these cells (Fig. 38A-F). For the high affinity FolR1 binder 16D5 TCB a T-cell mediated lysis can be observed on both primary cell types used. As observed previously when tumor cell lines were used as targets, lysis induced by the intermediate FolR1 binder 14B1 TCB and the affinity reduced 16D5 variants (16D5-G49S/S93A TCB, 16D5 W96Y/D52E TCB), ranges between the one obtained for the high affinity 16D5 TCB and the low affinity 36F2 TCB. The significantly reduced lysis of cells that express FolR1 at low levels

-178-

is consistent with low off target activity and the affinity reduced 16D5 variants 16D5-G49S/S93A TCB and 16D5 W96Y/D52E TCB are, thus, expected to be well tolerated in vivo.

Example 55

5 Single dose PK of FOLR1 TCB constructs in female NOG mice

Female NOD/Shi-scid/IL-2R γ null (NOG) mice at an average age of 8-10 weeks at start of experiment (purchased from Taconic, SOPF facility) were maintained under specific-pathogen-free condition with daily cycles of 12 h light /12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local
10 government (ZH193/2014). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis.

A single dose pharmacokinetic study (SDPK) was performed to evaluate exposure of FOLR1 TCB constructs (36F2, 16D5, 16D5 G49S/S93A and 16D5 W96Y/D52E). An i.v. bolus
15 administration of 0.5 mg/kg was administered to NOG mice and blood samples were taken at selected time points for pharmacokinetic evaluation. Mouse serum samples were analyzed by ELISA. Biotinylated a-huCD3-CDR (mAb<ID-mAb<CD3>>M-4.25.93-IgG-Bi), test samples, Digoxigenin labelled a-huFc antibody (mAb<H-FC pan>M-R10Z8E9-IgG-Dig) and anti-Digoxigenin detection antibody (POD) were added stepwise to a 96-well streptavidin-coated
20 microtiter plate and incubated after every step for 1h at roomtemperature. The plate is washed three times after each step to remove unbound substances. Finally, the peroxidase-bound complex is visualized by adding ABTS substrate solution to form a colored reaction product. The reaction product intensity, which is photometrically determined at 405nm (with reference wavelength at 490nm), is proportional to the analyte concentration in the serum sample. The
25 calibration range of the standard curve for the constructs is was 0.078 to 5 ng/ml, where 1.5 ng/ml is the lower limit of quantification (LLOQ).

The SDPK study revealed an IgG-like PK-profile for the 16D5, 16D5 W96Y/D52E and 16D5 G49S/S93A constructs (Fig. 39A-B). Because of that, a once per weeks scheduling was chosen for the efficacy study (Fig. 40B). The half-life for 36F2 is lower as compared to the other clones.
30 36F2 is the only out of the four molecules tested that is cross-reactive to mouse FOLR1, which might explain the lower half-life for this molecule and indicates a TMDD (Target Mediated Drug Disposition).

-179-

Example 56**In vivo efficacy of FOLR1 TCB constructs (16D5, 16D5 G49S/S93A and 16D5 W96Y/D52E) after human PBMC transfer in Hela-bearing NOG mice**

The FOLR1 TCB constructs were tested in the FOLR1-expressing human cervical cancer cell line Hela, injected s.c. into PBMC engrafted NOG mice.

Hela cells were originally obtained from ATCC (CCL2) and after expansion deposited in the Roche-Glycart internal cell bank. The tumor cell line was routinely cultured in RPMI containing 10 % FCS (Gibco) at 37 °C in a water-saturated atmosphere at 5% CO₂. Passage 13 was used for transplantation, at a viability > 95 %. 1x10⁶ cells per animal were injected s.c. into the right flank of the animals in a total of 100 µl of RPMI cell culture medium (Gibco).

60 female NOG mice, age 8-10 weeks at start of the experiment (bred at Taconic, Denmark) were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (ZH193/2014). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis.

According to the study protocol (Fig. 40B), mice were injected s.c. on study day 0 with 1x10⁶ Hela cells. At study day 30, when tumor reached a size of app. 150 mm³, human PBMC of a healthy donor were isolated via the Ficoll method and 10x10⁶ cells were injected i.v. into the tumor-bearing mice. Two days after (day 32), mice were randomized and equally distributed in six treatment groups (n=10) followed by i.v. injection with either 16D5 (0.5mg/kg), 16D5 G49S/S93A (2.5 or 0.5 mg/kg) and 16D5 W96Y/D52E (2.5 or 0.5 mg/kg). All treatments group were injected once weekly for three weeks in total. Mice were injected i.v. with 200 µl of the appropriate solution. The mice in the vehicle group were injected with PBS. To obtain the proper amount of TCB per 200 µl, the stock solutions were diluted with PBS when necessary. Tumor growth was measured once weekly using a caliper (Figure 40C-E) and tumor volume was calculated as followed:

$$Tv: (W^2/2) \times L \quad (W: \text{Width}, L: \text{Length})$$

The once weekly injection of the FOLR1 TCB constructs resulted in significant tumor regression (Fig. 40C-E). The efficacy of 16D5 (0.5 mg/kg) and 16D5 W96Y/D52E (0.5 mg/kg) was comparable, whereas 16D5 G49S/S93A (0.5 mg/kg) showed slight less potency. The higher doses of 2.5 mg/kg of 16D5 W96Y/D52E and 16D5 G49S/S93A didn't show increased efficacy compared to 0.5 mg/kg doses. For PD read-outs, mice were sacrificed at study day 52,

-180-

tumors were removed, weighted and single cell suspensions were prepared through an enzymatic digestion with Collagenase V, Dispase II and DNase for subsequent FACS-analysis. Explanted tumors of all treatment groups showed significant lower tumor weight at study termination as compared to vehicle control tumors (Fig. 40F). Single cell suspensions from tumors where

5 stained for huCD45 and huCD3 and DAPI for dead cell exclusion and were analyzed at the BD Fortessa. The FACS analysis revealed statistically higher numbers of infiltrated CD3-positive human T-cells in the tumor tissue upon treatment with 16D5 as well as 16D5 W96Y/D52E16D5 compared to vehicle control tumors (Fig. 40C).

10

Example 57**Toxicity study in cynomolgus monkey**

A pharmacokinetic (PK), pharmacodynamic (PD) and tolerability study is performed to investigate the tolerability, PK and PD effects of a single intravenous dose of affinity reduced 16D5 variant TCBs (e.g., 16D5-G49S/S93A TCB, 16D5 W96Y/D52E TCB) in cynomolgus

15 monkeys. In this study, naïve cynomolgus monkeys, (1 male and 1 female monkey / group), receive a single intravenous dose of affinity reduced 16D5 variant TCBs, including 16D5 W96Y/D52E TCB, following a dose escalating protocol. Exemplary dose levels include 0.003, 0.03, and 0.09 mg/kg. Standard toxicity parameters (clinical signs, body weights, hematology & clinical chemistry) and the kinetics of T cell numbers and activation status in blood and the

20 kinetics of cytokine release are assessed. Blood samples are also taken for PK for a period of 28 days for the measurement of affinity reduced 16D5 variant TCBs, including 16D5 W96Y/D52E TCB, and of anti-drug antibodies.

25

Amino acid sequences of exemplary embodiments

1) FolR binders useful in common light chain format, variable heavy chain

Description	Sequence	Seq ID No
16A3	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TA VYYCARNYYAGVTPFDYWGQGLTLVTSS	1
18D3	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TA VYYCARNYYTGGSSAFDYWGQGLTLVTSS	2
15H7	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TA VYYCARNYYLFSTSFQDYWGQGLTLVTSS	3
15B6	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TA	4

-181-

	VYYCARNYYIGIVPFDYWGQGLVTVSS	
21D1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGGGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED VYYCARNYYVGVSPFDYWGQGLVTVSS	5
16F12	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGGGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED VYYCARNFTVLRVPFDYWGQGLVTVSS	6
15A1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGGGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED VYYCARNYYIGVVTFDYWGQGLVTVSS	7
15A1_CDR 1	SYMH	8
15A1_CDR 2	IINPSGGSTSYAQKFQ	9
15A1_CDR 3	NYIGVVTFDY	10
19E5	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGGGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED VYYCARGEWRRYTSFDYWGQGLVTVSS	11
19E5_CDR 1	SYMH	8
19E5_CDR 2	IINPSGGSTSYAQKFQ	9
19E5_CDR 3	GEWRRYTSFDY	12
19A4	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGGGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED VYYCARGGWIRWEHFDYWGQGLVTVSS	13
19A4_CDR 1	SYMH	8
19A4_CDR 2	IINPSGGSTSYAQKFQ	9
19A4_CDR 3	GGWIRWEHFDY	14
16D5	EVQLVESGGGLVKPGGSLRLSAAAGFTFSNAWMSWVRQAPGKGLE WVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTED TAVYYCTTPWEWSWYDYWGQGLVTVSS	15
16D5_CDR 1	NAWMS	16
16D5_CDR 2	RIKSKTDGGTTDYAAPVK	17
16D5_CDR 3	PWEWSWYDY	18
15E12	EVQLVESGGGLVKPGGSLRLSAAAGFTFSNAWMSWVRQAPGKGLE WVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTED TAVYYCTTPWEWSYFDYWGQGLVTVSS	19
15E12_CD	NAWMS	16

-182-

R1		
15E12_CD R2	RIKSKTDGGTTDYAAPVKG	17
15E12_CD R3	PWEWSYFDY	20
21A5	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLE WVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTED TAVYYCTTPWEWAWFDYWGQGTLLTVSS	21
21A5_CDR 1	NAWMS	16
21A5_CDR 2	RIKSKTDGGTTDYAAPVKG	17
21A5_CDR 3	PWEWAWFDY	22
21G8	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLE WVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTED TAVYYCTTPWEWAYFDYWGQGTLLTVSS	23
21G8_CDR 1	NAWMS	16
21G8_CDR 2	RIKSKTDGGTTDYAAPVKG	17
21G8_CDR 3	PWEWAYFDY	24
19H3	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARTGWSRWGYMDYWGQGTLLTVSS	25
19H3_CDR 1	SYMH	8
19H3_CDR 2	IINPSGGSTSYAQKFQG	9
19H3_CDR 3	TGWSRWGYMDY	26
20G6	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARGEWIRYYHFDYWGQGTLLTVSS	27
20G6_CDR 1	SYMH	8
20G6_CDR 2	IINPSGGSTSYAQKFQG	9
20G6_CDR 3	GEWIRYYHFDY	28
20H7	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARVGWYRWGYMDYWGQGTLLTVSS	29
20H7_CDR	SYMH	8

-183-

1		
20H7_CDR 2	IINPSGGSTSYAQKFQG	9
20H7_CDR 3	VGWYRWGYMDY	30

2) CD3 binder common light chain (CLC)

Description	Sequence	Seq ID No
common CD3 light chain (VL)	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQKEP GQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPED EAEYYCALWYSNLWVFGGGTKLTVL	31
common CD3 light chain_CDR 1	GSSTGAVTTSNYAN	32
common CD3 light chain_CDR 2	GTNKRAP	33
common CD3 light chain_CDR 3	ALWYSNLWV	34
common CD3 light chain (VLCL)	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQKEP GQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPED EAEYYCALWYSNLWVFGGGTKLTVLGQPKAAPSVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	35

3) CD3 binder, heavy chain

Description	Sequence	Seq ID No
CD3 variable heavy chain (VH)	EVQLLESQGGGLVQPGGSLRLSCAASGFTTFSTYAMNWVRQAPGKG LEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSL RAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLLTVSS	36
CD3 heavy chain (VH)_CDR 1	TYAMN	37

-184-

CD3 heavy chain (VH)_CDR 2	RIRSKYNNYATYYADSVKG	38
CD3 heavy chain (VH)_CDR 3	HGNFGNSYVSWFAY	39
CD3 full heavy chain (VHCH1)_	EVQLLES GG LVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKG LEWVSRI R SKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSL RAEDTAVYYCVRHGNFGNSYVSWFAYWGQGT L VTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFP A VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSC	40
CD3 constant heavy chain CH1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFP A VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSC	84

4) FolR binders useful for crossfab Format

Description	Sequence	Seq ID No
11F8_VH	QVQLVQSGAEVKKPGSSVKVSC K ASGGTFSSYAISWVRQAPGQGLE WMGGIIP I FGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTA VYYCARAVFYRAWYSFDYWGQGT T TVTVSS	41
11F8_VH_CD R1	SYAIS	42
11F8_VH_CD R2	GIIP I FGTANYAQKFQG	43
11F8_VH_CD R3	AVFYRAWYSFDY	44
11F8_VL	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLA W YQQKPGKAPKL LIYDASSLES G VPSRFSGSGSGTEFTLT I SSSLQPD D FATYYCQQYT SPEPTFGQGT K VEIK	45
11F8_VL_CD R1	RASQSISSWLA	46
11F8_VL_CD R2	DASSLES	47
11F8_VL_CD R3	QQYTSPPT	48
36F2_VH	QVQLVQSGAEVKKPGASVKVSC K ASGYTFTSYMH W VRQAPGQGLE WMGIINP S GGSTSYAQKFQGRVTMT H DTSTSTVY M ELSSLRSEDTA VYYCAR S FFTGFHLDYWGQGT L VTVSS	49
36F2_VH_CD	SYMH	8

-185-

R1		
36F2_VH_CD R2	IINPSGGSTSYAQKFQG	9
36F2_VH_CD R3	SFFTGFHLDY	50
36F2_VL	EIVLTQSPGTL ^S SLSPGERATL ^S CRASQSVSSSYLAWYQQKPGQAPR LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQY TNEHYTTFGQGTKVEIK	51
36F2_VL_CD R1	RASQSVSSSYLA	52
36F2_VL_CD R2	GASSRAT	53
36F2_VL_CD R3	QYTNHYYT	54
9D11_VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGGLE WMGIINPSGGPTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARGDFAWLDYWGQGT ^L LVTVSS	55
9D11_VH_CD R1	SYMH	8
9D11_VH_CD R2	IINPSGGPTSYAQKFQG	56
9D11_VH_CD R3	GDFAWLDY	57
9D11_VL	DIVMTQSP ^L SLPVT ^P GPASISCRSSQ ^L LLHSNGYNYLDWYLQKPG QSPQLLIYLG ^S NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQASIMNRTFGQGTKVEIK	58
9D11_VL_CD R1	RSSQ ^L LLHSNGYNYLD	59
9D11_VL_CD R2	LGSNRAS	60
9D11_VL_CD R3	MQASIMNRT	61
9D11_VL N95S	DIVMTQSP ^L SLPVT ^P GPASISCRSSQ ^L LLHSNGYNYLDWYLQKPG QSPQLLIYLG ^S NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQASIMSR ^T FGQGTKVEIK	62
9D11_VL N95S_CDR3	MQASIMSR ^T	63
9D11_VL N95Q	DIVMTQSP ^L SLPVT ^P GPASISCRSSQ ^L LLHSNGYNYLDWYLQKPG QSPQLLIYLG ^S NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQASIMQRTFGQGTKVEIK	64
9D11_VL N95Q_CDR3	MQASIMQRT	65
9D11_VL T97A	DIVMTQSP ^L SLPVT ^P GPASISCRSSQ ^L LLHSNGYNYLDWYLQKPG QSPQLLIYLG ^S NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQASIMNRAFGQGTKVEIK	66
9D11_VL	MQASIMNRA	67

-186-

T97A		
9D11_VL T97N	DIVMTQSP ^{LS} LPVTPGEPASISCRSSQSL ^{LHS} NGYNYLDWYLQKPG QSPQLLIYLGSNRASGV ^{PDR} FSGSGSGTDFTLKISRVEAEDVG ^{VYY} CMQASIMNRNFGQGTKVEIK	68
9D11_VL T97N_CDR3	MQASIMNRN	69
5D9_VH	QVQLVQSGAEVKKPGASVKV ^{SCK} ASGYTFTSY ^{YMH} WVRQAPGQGLE WMGIINP ^{SGG} STSYAQKFQGRVTMTRDTSTSTVY ^{MEL} SSLRSEDTA VYYCARSYIDMDYWGQGT ^{LVT} VSS	70
5D9_VH_CDR 1	SY ^{YMH}	8
5D9_VH_CDR 2	IINP ^{SGG} STSYAQKFQ ^G	9
5D9_VH_CDR 3	SYIDMDY	71
5D9_VL	EIVLTQSPGT ^{LS} LPGERATLSCRASQSV ^{SSY} LAWYQQKPGQAPR LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC ^{QQD} NWSPTFGQGTKVEIK	72
5D9_VL_CDR 1	RASQSV ^{SSY} LA	52
5D9_VL_CDR 2	GASSRAT	53
5D9_VL_CDR 3	QQDNWSPT	73
6B6_VH	QVQLVQSGAEVKKPGASVKV ^{SCK} ASGYTFTSY ^{YMH} WVRQAPGQGLE WMGIINP ^{SGG} STSYAQKFQGRVTMTRDTSTSTVY ^{MEL} SSLRSEDTA VYYCARSYVDMDYWGQGT ^{LVT} VSS	74
6B6_VH_CDR 1	SY ^{YMH}	8
6B6_VH_CDR 2	IINP ^{SGG} STSYAQKFQ ^G	9
6B6_VH_CDR 3	SYVDMDY	75
6B6_VL	EIVLTQSPGT ^{LS} LPGERATLSCRASQSV ^{SSY} LAWYQQKPGQAPR LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC ^{QQD} IWSPTFGQGTKVEIK	76
6B6_VL_CDR 1	RASQSV ^{SSY} LA	52
6B6_VL_CDR 2	GASSRAT	53
6B6_VL_CDR 3	QQDIWSPT	77
14E4_VH	EVQLLES ^{GGGL} VQPGGSLRLSCAASGFTFSS ^{YAMS} WVRQAPGKGLE WVSAISGSGGSTYYADSVKGRFTISRDN ^{SKNT} LYLQMNSLRAEDTA VYYCAK ^{DSS} YVEWYAFDYWGQGT ^{LVT} VSS	78
14E4_VH_CD	SYAMS	79

-187-

R1		
14E4_VH_CD R2	AISGSGGSTYYADSVKG	80
14E4_VH_CD R3	DSSYVEWYAFDY	81
14E4_VL	EIVLTQSPGTL ^S SLSPGERATL ^S CRASQSVSSSYLAWYQQKPGQAPR LLIYGASSRATGIPDRFSGSGSGTDSTLTISRLEPEDFAVYYCQQP TSSPITFG QGTKVEIK	82
14E4_VL_CD R1	RASQSVSSSYLA	52
14E4_VL_CD R2	GASSRAT	53
14E4_VL_CD R3	QQPTSSPIT	83

5) CD3 binder useful in crossfab Format

Description	Sequence	Seq ID No
CD3 heavy chain (VH)	EVQLLES ^G GGGLVQPGGSLRLS ^C CAASGFTTFSTYAMNWVRQAPG KGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQ MNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGT ^L LVTVSS	36
CD3 heavy chain (VH)_CDR 1	TYAMN	37
CD3 heavy chain (VH)_CDR 2	RIRSKYNNYATYYADSVKG	38
CD3 heavy chain (VH)_CDR 3	HGNFGNSYVSWFAY	39
CD3 light chain (VL)	QAVVTQEP ^S SLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEK ^P GQAFRGLIGGTNKRAPGTPARFSGSLLGGKAAL ^T LSGAQPED EAEYYCALWYSNLWVFGGGTKLTVL	31
CD3 light chain_CDR 1	GSSTGAVTTSNYAN	32
CD3 light chain_CDR 2	GTNKRAP	33
CD3 light	ALWYSNLWV	34

-188-

chain_CDR 3		
pETR12940: crossed common CD3 light chain (VLCH1)	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPED EAEYYCALWYSNLWVFGGGTKLTVLSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE PKSC	86
Crossed CD3 heavy chain (VHCκ); e.g. in pCON1057	EVQLLESGGGLVQPGGSLRLSCAASGFTTFSTYAMNWVRQAPG KGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQ MNSLRAEDTAVYYCVRHGNFNGNSYVSWFAYWGQGTLLTVSSA SVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC	87
CD3- CH1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKKVEPKSC	85
CD3- ckappa	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC	88

6) – Exemplary amino acid sequences of CD3-FolR bispecific antibodies 2+1 inverted crossmab format

Description	Sequence	Seq ID No
VHCH1[9D 11]_VHCL[CD3]_Fckn ob_PGLAL A pCON1057	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGPTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARGDFAWLDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGGSGGGG SEVQLLESGGGLVQPGGSLRLSCAASGFTTFSTYAMNWVRQAPGKGL EWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAE DTAVYYCVRHGNFNGNSYVSWFAYWGQGTLLTVSSASVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC DKHTHTCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCR DELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSD GSFFLYSLKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK	94
9D11_Fchol e_PGLALA _HYRF	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGPTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTA VYYCARGDFAWLDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKHTHTCPCP APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALGAPIEKTISKAKGQPREPQVCTLPSPRDELTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDK	95

-189-

	SRWQQGNVFSQSVMEALHNHYTQKSLSLSPGK	
9D11_LC pCON1063	DIVMTQSPLSLPVTGPGEPAISCRSSQSLHNSNGYNLDWYLQKPG QSPQLLIYLGSNRASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQASIMNRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSTLSSTL TLISKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC	96
VLCH1[CD 3] pETR12940	QAVVTQEPSTLVSPGGTTLTCSSTGAVTTSNYANWVQEKPGQAF RGLIGGTNKRAPGTPARFSGSLGGKAALTLGAQPEDEAEYYCAL WYSLNLWVFGGKTLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSLGTQTYICNVNHKPSNTKVDKKVEPKSC	86
CH1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD	307
VHCH1[36 F2]_VHCL[CD3]_Fc knob_PGL ALA pCON1056	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTHTDSTSTVYMELESLRSED TAVYYCARSFDTGFHLDYWGQGLTVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGSGG GGSEVQLLESGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGK GLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLR AEDTAVYYCVRHGNFGNSYVSWFAYWGQGLTVTVSSASVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSYSTLSSTLTLISKADYEEKHKVYACEVTHQGLSSPVTKSF NRGECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALGAPIEKTIKAKGQPREPQVYTLTPP CRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQKSLSLSP GK	308
36F2-Fc hole PGLALA pCON1050	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTHTDSTSTVYMELESLRSED TAVYYCARSFDTGFHLDYWGQGLTVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALGAPIEKTIKAKGQPREPQVCTLPPSRDELTKNQVSL CAVKGFPYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSQSVMEALHNHYTQKSLSLSPGK	309
36F2 LC pCON1062	EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPR LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQY TNEHYTFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSTLSSTLTL ISKADYEEKHKVYACEVTHXGLSSPVTKSFNRGEC	310
CD3 VLCH1 pETR12940	QAVVTQEPSTLVSPGGTTLTCSSTGAVTTSNYANWVQEKPGQAF RGLIGGTNKRAPGTPARFSGSLGGKAALTLGAQPEDEAEYYCAL WYSLNLWVFGGKTLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP SSLGTQTYICNVNHKPSNTKVDKKVEPKSC	86

7) Exemplary amino acid sequences of CD3-FcR bispecific antibodies with common light chain

VHCH1[16]	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEW	89
-----------	---	----

-190-

D5]_VHCH1[CD3]_Fcknob pCON999	VGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA VYYCTTPWEWSWYDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGGSGGGGSE VQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWV SRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAV YYCVRHGNFGNSYVSWFAYWGQGLTVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	
VHCH1[16D5]_Fchole pCON983	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEW VGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA VYYCTTPWEWSWYDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP EAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALGAPIEKTISKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNRYTQKSLSLSPGK	90
CD3_comm on light chain pETR13197	QAVVTQEPSTLTVSPGGTVTLTCSGSTGAVTTSNYANWVQEKPGQAFR GLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWY SNLWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISD FYPGAVTVAWKADSSPVKAGVETTPPSKQSNKYAASSYLSLTPEQW KSHRSYSCQVTHEGSTVEKTVAPTECS	35
VHCH1[CD3]_VHCH1[16D5]_Fc knob_PGLALA pETR13932	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEW VSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTA VYYCVRHGNFGNSYVSWFAYWGQGLTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGK GLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKT EDTAVYYCTTPWEWSWYDYWGQGLTVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	91
CD3_Fcknob_PGLALA pETR13917	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEW VSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTA VYYCVRHGNFGNSYVSWFAYWGQGLTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	92

-191-

Fc_hole_PG LALA_HYR F pETR10755	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPSSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLVSKLTVDKSRWQQGNVFCSCVMHEALHNRFTQKSLSLSPGK	93
VHCL[CD3]_Fcknob_P GLALA pETR13378	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIISKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNGFNSYVSWFAYWGQGTLLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSLKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKSLSLSPGK	98
16D5 inverted 2+1 with N100A in CDR H3 pETR14096	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEWSWYDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIISKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNGFNGASYVSWFAYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSLKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKSLSLSPGK	99
16D5 inverted 2+1 with S100aA in CDR H3 pETR14097	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEWSWYDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIISKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNGFNGAYVSWFAYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSLKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKSLSLSPGK	100
CD3 light chain fused to CH1; Fc_PGLAL A; pETR13862	QAVVTQEPSTLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGKAAALTLGSAQPEDEAEYYCALWYSNLWVFGGGTKLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFLYSLKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKSLSLSPGK	101

-192-

16D5 VH fused to constant kappa chain; pETR13859	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEW VGRIRSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA VYYCTPWEWSWYDYWGQGTLLTVTVSSASVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	102
CD3 VH fused to constant lambda chain; pETR13860	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEW VSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTA VYYCVRHGNFGNSYVSWFAYWGQGTLLTVTVSSASPKAAPSVTLFPPSS EELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVET'TPSKQSN NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	103
IGHV1- 46*01 (X92343), plus JH4 element	QVQLVQSGAEVKKPGASVKVSKASGYTFTSYMHVVRQAPGQGLEW MGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TAVY YCARGGSGGSFDYWGQGTLLTVTVSS	104
IGHV1- 69*06 (L22583), plus JH6 element	QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQGLEW MGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSED TAVY YCARGGSGGSMDAWGQGTITVTVSS	105
IGHV3- 15*01 (X92216), plus JH4 element	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEW VGRIRSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA VYYCTTGGSGGSFDYWGQGTLLTVTVSS	106
IGHV3- 23*01 (M99660), plus JH4 element	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW VSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVY YCAKGSGGSFDYWGQGTLLTVTVSS	107
IGHV4- 59*01 (AB019438) , plus JH4 element	QVQLQESGPGLVKPSSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEW IGYIYYSGSTNYNPSLKSRTVISVDTSKNQFSLKLSSVTAADTAVYY CARGGSGGSFDYWGQGTLLTVTVSS	108
IGHV5- 51*01 (M99686), plus JH4 element	EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEW MGI IYPGDS DTRYSPSFQGGVTISADKSISTAYLQWSSLKASDTAMY YCARGGSGGSFDYWGQGTLLTVTVSS	109

-193-

CD3 specific antibody based on humanized CH2527 light chain	QTVVTQEPSLTVSPGGTVTLTCSSTGAVTTSNYANWVQEKPGQAFR GLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPEDEAEYYCALWY SNLWVFGGGTKLTVL	110
hVK1-39 (JK4 J-element)	DIQMTQSPSSLSASVGRVTITCRASQSISSYLNWYQQKPGKAPKLL IYAASSLQSGVPSRFSGSGSDFTLTISLQPEDFATYYCQQSYST PLTFGGGTKEIK	111
VL7_46-13 (humanized anti-CD3 antibody light chain)	QAVVTQEPSLTVSPGGTVTLTCSSTGAVTTSNYANWVQEKPGQAFR GLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPEDEAEYYCALWY SNLWVFGGGTKLTVL	112

8) Exemplary 16D5 variants with reduced affinity

a. Exemplary light chain variants with reduced affinity

Name	Sequence	Seq ID No
K53A aa	QTVVTQEPSLTVSPGGTVTLTCSSTGAVTTSNYANWVQKPGQAPRGLIGG <u>TNARAP</u> GT PARFSGSLLGGKAALTLSGVQPEDEAEYYC <u>ALWYSNLWV</u> FGGGT KLTVL	113
K53A_VL_CDR1	GSSTGAVTTSNYAN	32
K53A_VL_CDR2	GTNARAP	311
K53A_VL_CDR3	ALWYSNLWV	34
S93A aa	QTVVTQEPSLTVSPGGTVTLTCSSTGAVTTSNYANWVQKPGQAPRGLIGG <u>TNKRAP</u> GT PARFSGSLLGGKAALTLSGVQPEDEAEYYC <u>ALWYANLWV</u> FGGGT KLTVL	114
S93A_VL_CDR1	GSSTGAVTTSNYAN	32
S93A_VL_CDR2	GTNKRAP	33
S93A_VL_CDR3	ALWYANLWV	312

b. Exemplary heavy chain variants with reduced affinity

Name	Sequence	Seq ID No
S35H aa	EVQLVESGGGLVKPGGSLRLSCAASGFTFS <u>NAWMH</u> WVRQAPGKGLEWVGRIK <u>SKTDGGTTDYAAPVKGR</u> FTISRDDSKNTLYLQMNSLKTEDTAVYYCTT <u>PWEW</u> <u>SWYDYGQGT</u> LT VSSAS	115
S35H_VH_CDR1	NAWMH	313

-194-

S35H_VH _CDR2	RIKSKTDGGTTDYAAPVKG	17
S35H_VH _CDR3	PWEWSWYDY	18
G49S aa	EVQLVESGGGLV KPGGSLRLSCAASGFTFS <u>NAWMSWVRQAPGKGLEWV</u> SRIK <u>SKTDGGTTDYAAPVKG</u> RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT <u>PWEW</u> <u>SWYDYWGQGT</u> LVTVSSAS	116
G49S_VH _CDR1	NAWMS	16
G49S_VH _CDR2	RIKSKTDGGTTDYAAPVKG	17
G49S_VH _CDR3	PWEWSWYDY	18
R50S aa	EVQLVESGGGLV KPGGSLRLSCAASGFTFS <u>NAWMSWVRQAPGKGLEWV</u> SRIK <u>SKTDGGTTDYAAPVKG</u> RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT <u>PWEW</u> <u>SWYDYWGQGT</u> LVTVSSAS	117
R50S_VH _CDR1	NAWMS	16
R50S_VH _CDR2	SIKSKTDGGTTDYAAPVKG	314
R50S_VH _CDR3	PWEWSWYDY	18
W96Y aa	EVQLVESGGGLV KPGGSLRLSCAASGFTFS <u>NAWMSWVRQAPGKGLEWV</u> GRIK <u>SKTDGGTTDYAAPVKG</u> RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT <u>PYEW</u> <u>SWYDYWGQGT</u> LVTVSSAS	118
W96Y_V H_CDR1	NAWMS	16
W96Y_V H_CDR2	RIKSKTDGGTTDYAAPVKG	17
W96Y_V H_CDR3	PYEWWSWYDY	315
W98Y aa	EVQLVESGGGLV KPGGSLRLSCAASGFTFS <u>NAWMSWVRQAPGKGLEWV</u> GRIK <u>SKTDGGTTDYAAPVKG</u> RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT <u>PWEY</u> <u>SWYDYWGQGT</u> LVTVSSAS	119
W98Y_V H_CDR1	NAWMS	16
W98Y_V H_CDR2	RIKSKTDGGTTDYAAPVKG	17
W98Y_V H_CDR3	PWEYSWYDY	232

9) Additional exemplary embodiments generated from a phage display library (CDRs underlined)

Name	Sequence	Seq ID No
90D7	QVQLVQSGAEVKKPGASVKVSCKASGYTFT <u>SYMH</u> WVRQAPGQGLEWMG <u>IIN</u> <u>PSGGSTSYAQKFQG</u> RVMTMTRDTSTSTVYMEISSLRSED TAVYYCARNY <u>TIVV</u>	120

-195-

aa	<u>SPFDY</u> WGQGTLLTVSSAS	
90D7_VH _CDR1	SYMH	8
90D7_VH _CDR2	IINPSGGSTSYAQKFQG	9
90D7_VH _CDR3	NYTIVSPFDY	233
90C1 aa	QVQLVQSGAEVKKPGASVKVSCKASGYTFT <u>SYMH</u> WVRQAPGQGLEWMG <u>IIN</u> <u>PSGGSTSYAQKFQG</u> RVMTMTRDTSTSTVYMESSLRSEDYAVYYCARN <u>NYFIGS</u> <u>VAMDY</u> WGQGTLLTVSSAS	121
90C1_VH _CDR1	SYMH	8
90C1_VH _CDR2	IINPSGGSTSYAQKFQG	9
90C1_VH _CDR3	NYFIGSVAMDY	234
5E8 VH aa	QVQLVQSGAEVKKPGASVKVSCKASGYTFT <u>SYMH</u> WVRQAPGQGLEWMG <u>IIN</u> <u>PSGGSTSYAQKFQG</u> RVMTMTRDTSTSTVYMESSLRSEDYAVYYCARG <u>GLTYSM</u> <u>DY</u> WGQGTLLTVSSAS	122
5E8_VH_ CDR1	SYMH	8
5E8_VH_ CDR2	IINPSGGSTSYAQKFQG	9
5E8_VH_ CDR3	GLTYSMDY	235
5E8 VL aa	DIVMTQSPSLSPVTPGEPASISCR <u>SSQSL</u> LHSNGYNYLDWYLQKPGQSPQLL IY <u>LGSNRAS</u> GVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYC <u>MQALQIPNT</u> FG QGTKVEIKRT	123
5E8_VL_ CDR1	RSSQSLHSNGYNYLD	59
5E8_VL_ CDR2	LGSNRAS	60
5E8_VL_ CDR3	MQALQIPNT	236
12A4 VH aa	EVQLLESGGGLVQPGGSLRLSCAASGFTFS <u>SYAMS</u> WVRQAPGKLEWVS <u>AIS</u> <u>GSGGSTYYADSVKGR</u> FTISRDN SKNTLYLQMNSLR AEDYAVYYCAK <u>YAYALD</u> <u>Y</u> WGQGTLLTVSSAS	124
12A4_VH _CDR1	SYAMS	79
12A4_VH _CDR2	AISGSGGSTYYADSVKGR	80
12A4_VH _CDR3	YAYALDY	237
12A4 VL aa	EIVLTQSPGTLSPGERATLSC <u>RASQSVSSSYLA</u> WYQQKPGQAPRLLTYGA <u>SSRAT</u> GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC <u>QQHGSST</u> FGQGTKV EIKRT	125

-196-

12A4_VL_ CDR1	RASQSVSSSYLA	52
12A4_VL_ CDR2	GASSRAT	53
12A4_VL_ CDR3	QQHGSSST	238
7A3 VH aa	QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMH WVRQAPGQGLEWMG IIN PSGGSTSYAQKFQG RVMTMTRDTSTSTVYMESSLRSED TAVYYCARG GDFSAG RLMDY WGQGTLLTVSSAS	126
7A3_VH_ CDR1	SYMH	8
7A3_VH_ CDR2	IINPSGGSTSYAQKFQG	9
7A3_VH_ CDR3	GDFSAGRLMDY	239
7A3 VL aa	DIVMTQSPLSLPVTPGEPASIS CRSSQSLHLSNGYNYLD WYLQKPGQSPQLL IY LGSNRAS GVDPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQALQTPPIT F GQGTKVEIKRT	127
7A3_VL_ CDR1	RSSQSLHLSNGYNYLD	59
7A3_VL_ CDR2	LGSNRAS	60
7A3_VL_ CDR3	MQALQTPPIT	240
6E10 VH aa	QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMH WVRQAPGQGLEWMG IIN PSGGSTSYAQKFQG RVMTMTRDTSTSTVYMESSLRSED TAVYYCARG GDYNAF DY WGHGTLTVSSAS	128
6E10_VH _CDR1	SYMH	8
6E10_VH _CDR2	IINPSGGSTSYAQKFQG	9
6E10_VH _CDR3	GDYNAFDY	241
6E10 VL aa	DIVMTQSPLSLPVTPGEPASIS CRSSQSLHLSNGYNYLD WYLQKPGQSPQLL IY LGSNRAS GVDPDRFSGSGSGTDFTLKISRVEAEDVGVYY CMQAWHSPT FGQ GTKVEIKRT	129
6E10_VL_ CDR1	RSSQSLHLSNGYNYLD	59
6E10_VL_ CDR2	LGSNRAS	60
6E10_VL_ CDR3	MQAWHSPT	242
12F9 VH aa	QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYMH WVRQAPGQGLEWMG IIN PSGGSTSYAQKFQG RVMTMTRDTSTSTVYMESSLRSED TAVYYCARG GATYTM DY WGQGTLLTVSSAS	130
12F9_VH	SYMH	8

-197-

_CDR1		
12F9_VH _CDR2	IINPSGGSTSYAQKFQG	9
12F9_VH _CDR3	GATYTM DY	243
12F9_VL aa	DIVMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPITFG QGTKVEIKRT	131
12F9_VL_ CDR1	RSSQSLLSNGYNYLD	59
12F9_VL_ CDR2	LGSNRAS	60
12F9_VL_ CDR3	MQALQTPIT	244

10) 9D11 Glycosite variants: variable light chain of exemplary embodiments (CDRs underlined)

Variant	Sequence	Seq ID No
N95S	DIVMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQASIMSRFTFG QGTKVEIK	132
12F9_VL_ CDR1	RSSQSLLSNGYNYLD	59
12F9_VL_ CDR2	LGSNRAS	60
12F9_VL_ CDR3	MQASIMSR	63
N95Q	DIVMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQASIMQRTFG QGTKVEIK	133
N95Q_VL_ _CDR1	RSSQSLLSNGYNYLD	59
N95Q_VL_ _CDR2	LGSNRAS	60
N95Q_VL_ _CDR3	MQASIMQRT	65
T97A	DIVMTQSPLSLPVTGPGEPAISCRSSQSLLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQASIMNRAFG QGTKVEIK	134
T97A_VL_ _CDR1	RSSQSLLSNGYNYLD	59
T97A_VL_ _CDR2	LGSNRAS	60
T97A_VL_ _CDR3	MQASIMNRA	67

-198-

T97N	DIVMTQSPLSLPVTGPGEPAISCRSSQSLHNSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQASIMNRFNG QGTKVEIK	135
T97N_VL _CDR1	RSSQSLHNSNGYNYLD	59
T97N_VL _CDR2	LGSNRRAS	60
T97N_VL _CDR3	MQASIMNRRN	69

11) Deamination Variants

Variant	Sequence	Seq ID No
16D5 VH_D52d E	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIK SKT E GGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEW SWYDYWGQGTLLTVSS	248
16D5 VH_D52d Q	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIK SKT Q GGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEW SWYDYWGQGTLLTVSS	249
CD3_VH N100A	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIR SKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNF G ASYVSWFAYWGQGTLLTVSS	250
CD3_VH S100aA	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIR SKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNF G NAYVSWFAYWGQGTLLTVSS	251
16D5 [VHCH1] - CD3[VHC H1- N100A]- Fcknob_P GLALA	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIK SKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEW SWYDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASG FTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSK NTLYLQMNSLRAEDTAVYYCVRHGNFASYVSWFAYWGQGTLLTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDNLNGKEYCKKVSNAKALGA PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLVCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHN HYTQKSLSLSPGK	252
16D5- Fchole- PGLALA	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIK SKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEW SWYDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDNLNGKEYCKKVSNAKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKN QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVD KSRWQQGNVSCSVMHEALHNRTQKSLSLSPGK	253
CD3-CLC	QAVVTQEPSTLVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGG TNKRAPGTPARFSGSLGGAALTLGSAQPEDEAEYYCALWYSLWVFGGGT KLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSS PVKAGVETTTTPSKQSNKYAASSYLSLTPEQWKSRSYSCQVTHEGSTVEKT	254

-199-

	VAPTECS	
16D5 [VHCH1] - CD3[VHC H1- S100aA]- Fcknob_P GLALA	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKLEWVGRIK SKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPWEW SWYDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDGGGSGG GGSEVQLLESGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKLEWVS RIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRH GNFGNAYVSWFAYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQT YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSFLTTLHQLDNLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPP CRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF LYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK	255
9D11 [VHCH1] - CD3[VHC L- N100A]- Fcknob_P GLALA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGIIN PSGGPTSYAQKFQGRVTMTRDTSTSTVYMESSLRSEDVAVYYCARGDFAWL DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDGGGSGGGGSEVQLLESGLVQPGGSLRLSCAASGFTF STYAMNWVRQAPGKLEWVSRIIRSKYNNYATYYADSVKGRFTISRDDSKNTL YLQMNSLRAEDTAVYYCVRHGNFGNAYVSWFAYWGQGTLLTVSSASVAAPSV FIFFPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTTLHQLDNLNGKEYKCKVSNKALG APIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALH NHYTQKSLSLSPGK	256
9D11- Fchole	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGIIN PSGGPTSYAQKFQGRVTMTRDTSTSTVYMESSLRSEDVAVYYCARGDFAWL DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTTLHQL DNLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPSPRDELTKNQV SLCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFCSCVMHEALHNHYTQKSLSLSPGK	257
9D11_LC [N95Q]	DIVMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLL IYLGSRASGVDRFSGSGSGTDFTLKIISRVAEADVGVYYCMQASIMQRTFG QGKTKVEIKRTVAAPSVFIFFPSDEQLKSGTASVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEEKHKVYACEVTHQGLSS PVTKSFNRGEC	258
CD3_VLC H1	QAVVTQEPSTLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGG TNKRAPGTPARFSGSLLGGKAALTLGAQPEDEAEYCALWYSNLWVFGGGT KLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKK VEPKSC	259
9D11 [VHCH1] - CD3[VHC H1- S100aA]- Fcknob_P GLALA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGIIN PSGGPTSYAQKFQGRVTMTRDTSTSTVYMESSLRSEDVAVYYCARGDFAWL DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDGGGSGGGGSEVQLLESGLVQPGGSLRLSCAASGFTF STYAMNWVRQAPGKLEWVSRIIRSKYNNYATYYADSVKGRFTISRDDSKNTL YLQMNSLRAEDTAVYYCVRHGNFGNAYVSWFAYWGQGTLLTVSSASVAAPSV FIFFPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTTLHQLDNLNGKEYKCKVSNKALG APIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEW	260

-200-

	ESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALH NHYTQKSLSLSPGK	
--	---	--

12) Mov19 based TCBs of exemplary embodiments (CDRs underlined)

Name	Sequence	Seq ID No
pETR1164 6 Mov19 VH-CH1- Fchole PG/LALA	QVQLQQSGAELVKPGASVKISCKASGYSFTGYFMNWVKQSHGKSLEWIGRIH PYDGDTFYNQNFKD KATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRA MDYWGQGT TTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV TCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPSSRDELTKNQV SLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKS RWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK	136
pETR1164 7 Mov19 VH-CH1- CD3 VH- CL- Fcknob PG/LALA	QVQLQQSGAELVKPGASVKISCKASGYSFTGYFMNWVKQSHGKSLEWIGRIH PYDGDTFYNQNFKD KATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRA MDYWGQGT TTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKGGGSGGGSEVQLVESGGGLVQPKGSLKLSCAASGFT FNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYADSVKDRFTISRDDSQSI LYLQMNNLKTEDTAMYVCVRHGNFGNSYVSWFAYWGQGLTVTVSAASVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DKTH TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL GAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVE WESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEAL HNHYTQKSLSLSPGK	137
pETR1164 4 Mov19 LC	DIETQSPASLAVSLGQRATISCKASQSVSFAGTSLMHWHYHQKPGQKPKLLI YRASNLEAGVPTRFSGSGSKTDFTLNHPVEEEDAATYYCQQSREYPYTFGG GTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDYSLSSLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC	138

Name	Sequence	Seq ID No
Hu IgG1 Fc	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVM HEALHNHYTQKSLSLSPGK	245

5 13) Additional FolR1 TCBs with intermediate affinity binders (CDRs according to Kabat, underlined):

Name	Sequence	Seq ID No
16D5 variant W96Y/D52E VH	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIK SKTEGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPYEW SWYDYWGQGLTVTVSS	274
W96Y/D52E _VH CDR1	NAWMS	16
W96Y/D52E _VH CDR2	RIKSKTEGGTTDYAAPVKG	275
W96Y/D52E _VH CDR3	PYEWSWYDY	315

-201-

16D5 variant W96Y/D52E VL	QAVVTQEPSTLVSPGGTVTLTCSSTGAVTTSNYANWVQEKPG QAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPEDEA EYYCALWYSNLWVFGGGTKLTVL	31
W96Y/D52 E_CD3- VHCH1_Fc - knob_PGL ALA pETR14945	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKLEWVGRIK SKTEGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPYEW SWDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDGGGSGGGGSEVQLLESGLGQPGGSLRLSCAASG FTFSTYAMNWVRQAPGKLEWVSRIISKYNNYATYYADSVKGRFTISRDDSK NTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTTLTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGA PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWE SNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVCSVMHEALHN HYTQKSLSLSPGK	276
W96Y/D52 E_Fc- hole_PGLA LA_HYRF pETR14946	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKLEWVGRIK SKTEGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTPYEW SWDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE VTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPSPRDELTKN QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLVSKLTVD KSRWQQGNVFSVCSVMHEALHNRFTQKSLSLSPGK	277
14B1 VH	EVQLLESGLGQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAIS <u>SGGGSTYYADSVKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCARGDYR <u>YFDYWGQGTTLTVSS</u>	278
14B1 VL	SSELTQDPAVSVALGQTVRITCQGDLSRYYASWYQQKPGQAPVLIYIGKNN <u>RPSGI</u> PDRFSGSSSGNTASLTITGAQAEDADYYCNSRESPTGLVVF GGGT KLTVL	279
14B1[EE]_ CD3[VLC H1]_Fc- knob_PGL ALA pETR14976	EVQLLESGLGQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAIS GSGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARGDYR YFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHK PSNTKVDKVEPKSCDGGGSGGGGSAVVTQEPSTLVSPGGTVTLTCSSTG AVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLG AQPEDEAEYYCALWYSNLWVFGGGTKLTVLSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSV FLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPRE PQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVCSVMHEALHNYTQKSLSLSPGK	280
14B1[EE]_ Fc- hole_PGLA LA pETR14977	EVQLLESGLGQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAIS GSGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARGDYR YFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHK PSNTKVDKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE VTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPSPRDELTKN QVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLVSKLTVDK SRWQQGNVFSVCSVMHEALHNYTQKSLSLSPGK	281
14B1 LC [KK] Constant lambda	SSELTQDPAVSVALGQTVRITCQGDLSRYYASWYQQKPGQAPVLIYIGKNN RPSGI PDRFSGSSSGNTASLTITGAQAEDADYYCNSRESPTGLVVF GGGT KLTVLGQPKAAPSVTLFPPSSKKLQANKATLVCLISDFYPGAVTVAWKADSS PVKAGVETTTPSKQSNKYAASSYLSLTPEQWKSRRSYSCQVTHEGSTVEKT VAPTECS	282

-202-

pETR14979		
9C7 VH	QVQLVQSGAEVKKPGASVKVSCKASGYFTFTSYMHVWRQAPGQGLEWMGIIN PSGGSTSYAQKFQGRVTMTTRDTSTSTVYMELSSLRSEDAVYYCARGDWSYY MDYWGQGTLVTVSS	283
9C7 VL	DIVMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPTFGQ GTKVEIK	284
9C7[EE]_C D3[VLCHI]_Fc- knob_PGL ALA pETR14974	QVQLVQSGAEVKKPGASVKVSCKASGYFTFTSYMHVWRQAPGQGLEWMGIIN PSGGSTSYAQKFQGRVTMTTRDTSTSTVYMELSSLRSEDAVYYCARGDWSYY MDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS NTKVDEKVEPKSCDGGGSGGGGSAVVTQEPSTLVSPGGTVTLTCGSSTGA VTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGA QPEDEAEYYCALWYSLWVFGGKTKLTVLSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFL FPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVHLQDNLNGKEYKCKVSNKALGAPIEKTISKAKGQPREP QVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD SDGSFFLYSLKLTVDKSRWQQGNVSCFVMSHEALHNHYTQKSLSLSPGK	285
9C7[EE]_F c- hole_PGLA LA pETR14975	QVQLVQSGAEVKKPGASVKVSCKASGYFTFTSYMHVWRQAPGQGLEWMGIIN PSGGSTSYAQKFQGRVTMTTRDTSTSTVYMELSSLRSEDAVYYCARGDWSYY MDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS NTKVDEKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEV TCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVHLQ DNLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQV SLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSR WQQGNVSCFVMSHEALHNHYTQKSLSLSPGK	286
9C7 LC [RK] pETR14980	DIVMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLL IYLGSNRASGVDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPTFGQ GTKVEIKRTVAAPSVFIFPPSDRKLKSGTASVVCLLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC	316

14) Antigen Sequences

Antigen	Sequence	Seq ID No
hu FolR1	MAQRMTTQLLLLLLVWVAVVGEAQT RIAWARTELLNVC MAKHHEKPGPEDKL HEQCRPWRKNACCSTNTSQEAHKDVS YLYRFNWNHCGEMAPACKRHFIQDTCL YECSPNLGPW IQQVDQSWRKERVNLNVLCKEDCEQWWEDCRTSYTCKSNWHKG WNWTSGFNKA CAVGAACQPFHFYFPTPTVLCNEIWTSHSYKVSNSYRSGSGRCIQM WFDPAQGNPN EEVARFYAAAMSGAGPWAAPFLLSLALMLLWLLS	139
huFolR1 ECD- AcTev- Fcknob- Avi tag	RIAWARTELLNVC MAKHHEKPGPEDKL HEQCRPWRKNACCSTNTSQEAHKD VS YLYRFNWNHCGEMAPACKRHFIQDTCL YECSPNLGPW IQQVDQSWRKERV N VLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKA CAVGAACQPFHFYF PTPTVLCNEIWTSHSYKVSNSYRSGSGRCIQMWFDPAQGNPN EEVARFYAAAM VE QLYFQGG SPKSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVHLQDNL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRWQQG NVFSCSVMSHEALHNHYTQKSLSLSPGSG GLNDIFEAQKIEWHE	140
Fchole	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVHLQDNLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVCTLPSPSRDELTKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQQGNVSCSVMSHEAL HNRFTQKSLSLSPGK	141
mu	MAHLMTVQLLLLLVMWMAECAQSRAT RRARTELLNVC MAKHHEKPGPEDNLHD	142

FolR1	QCSPWKTNSCCSTNTSQEAHKDISYLYRFNWNHCGTMTSECKRHFIQDTCLYE CSPNLGPWIIQQVDQSWRKERILDVPLCKEDCQQWEDCQSSFTCKSNWHKGWN WSSGHNECPVGASCHPFTFYFPTSAAALCEEIWSHSYKLSNYSRSGSGRCIQMWF DPAQGNPNNEEVARFYAEAMSGAGLHGTWPLLCSLSLVLLWVIS	
mu FolR1 ECD- AcTev- Fcknob- Avitag	TRARTELLNVCMADAKHHKEKPGPEDNLHDQCSPWKTNSCCSTNTSQEAHKDIS YLYRFNWNHCGTMTSECKRHFIQDTCLYECSPNLGPWIIQQVDQSWRKERILDV PLCKEDCQQWEDCQSSFTCKSNWHKGWNWSSGHNECPVGASCHPFTFYFPTS AALCEEIWSHSYKLSNYSRSGSGRCIQMWFDPAQGNPNNEEVARFYAEAMVDEQL YFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMEALHNHYTQKSLSLSPGKSGGLNDIFEAQKIEWHE	143
cy FolR1	MAQRMTTQLLLLLLVWVAVVGEAQTRTARARTELLNVCMNAKHHKEKPGPEDKL HEQCRPWKKNACCSTNTSQEAHKDVSYLYRFNWNHCGEMAPACKRHFIQDTC LYECSPNLGPWIIQQVDQSWRKERVNLVPLCKEDCERWWEDCRTSYTCKSNWHKG WNWTSGFNKCVPVGAACQPFHFYFPTPTVLCNEIWTYSYKVSNSYRSGSGRCIQM WFDPAQGNPNNEEVARFYAAAMSGAGPWAAPLLLSLALTLWLWS	144
cy FolR1 ECD- AcTev- Fcknob- Avi tag	RTARARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWKKNACCSTNTSQEAHKD VSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIIQQVDQSWRKERV NLVPLCKEDCQWEDCRTSYTCKSNWHKGWNWTSGFNKCVPVGAACQPFHFYF TPTVLCNEIWTYSYKVSNSYRSGSGRCIQMWFDPAQGNPNNEEVARFYAAAMVDE QLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMEALHNHYTQKSLSLSPGKSGGLNDIFEAQKIEWHE	145
hu FolR2	MVWKWMLLLLLLVCAVMCSAQDRDLDLNVCMADAKHHKTKPGPEDKLHDQCSP WKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPACKRHFIQDTCLYECSPN LGPWIIQQVNSWRKERFLDVPLCKEDCQRWEDCHTSHTCCKSNWHRGWDWTS GNKCPAGALCRTFESYFPTPAALCEGLWSHSYKVSNSYRSGSGRCIQMWFDSAQ GNPNNEEVARFYAAAMHVNAGEMLHGTGGLLLSLALMLQLWLLG	146
hu FolR2 ECD- AcTev- Fcknob- Avi tag	TMCSAQDRDLDLNVCMADAKHHKTKPGPEDKLHDQCSPWKKNACCTASTSQELH KDT SRLYNFNWDHCGKMEPACKRHFIQDTCLYECSPNLGPWIIQQVNSWRKER FLDVPLCKEDCQRWEDCHTSHTCCKSNWHRGWDWTSGNKCPAGALCRTFESY FPTPAALCEGLWSHSYKVSNSYRSGSGRCIQMWFDSAQGNPNNEEVARFYAAAMH VDEQLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRT EVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQV SLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNV FSCSVMEALHNHYTQKSLSLSPGKSGGLNDIFEAQKIEWHE	147
hu FolR3	MAWQMMQLLLLLLVTAAGSAQPR SARARTDLDLNVCMNAKHHKTPSPEDELYG QCSPWKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPTCKRHFIQDSCLYE CSPNLGPWIRQVNSWRKERILNVPLCKEDCERWWEDCRTSYTCKSNWHKGWN WTSGINECPAGALCSTFESYFPTPAALCEGLWSHSFKVSNYSRSGSGRCIQMWF DSAQGNPNNEEVAKFYAAAMNAGAPSRGIIDS	148
hu FolR3 ECD- AcTev- Fcknob- Avi tag	SARARTDLDLNVCMNAKHHKTPSPEDELYGQCSPWKKNACCTASTSQELHKDT SRLYNFNWDHCGKMEPTCKRHFIQDSCLYECSPNLGPWIRQVNSWRKERILN VPLCKEDCERWWEDCRTSYTCKSNWHKGWNWTSGINECPAGALCSTFESYFPT PAALCEGLWSHSFKVSNYSRSGSGRCIQMWFDSAQGNPNNEEVAKFYAAAMNAGA PSRGIIDS VDEQLYFQGGSPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRD ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK LTVDKSRWQQGNV FSCSVMEALHNHYTQKSLSLSPGKSGGLNDIFEAQKIEW HE	149
hu CD3ε	MQSGTHWRVLGLCLLSVGWVGQDGNNEEMGGITQTPYKVSISGTTVILTCPOYP GSEILWQHNDKNIGGEDDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPE DANFYLYLRARVCENCMEMDVMSVATIVVDICITGGLLLLVYWSKNRKAKA KPVTRGAGAGGRQGRQONKERPPVPNPDIYPIRKQQRDLYSGLNQRI	150

15) Nucleotide sequences of exemplary embodiments

Description	Sequence	Seq ID No
16A3	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACGCTGGTGTACTCCGTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	151
15A1	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACATCGGTGTTGTACTTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	152
18D3	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACACTGGTGGTTCTTCTGCTT TCGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	153
19E5	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG NTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGAATGGCGTCGTTACACTTCTTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	154
19A4	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGGTTGGATCCGTTGGGAACATTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	155
15H7	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACCTGTTCTCTACTTCTTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	156

-205-

15B6	CAGGTGCAATTGGTTCAATCTGGTGCTGAGGTAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACATCGGTATCGTTCCGTTTCG ACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCT	157
16D5	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAAACCGGGCG GTTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTTCGCCAGGCCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTCGTTTTACCATTTCCCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCC	158
15E12	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAAACCGGGCG GTTCCNGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTTCGCCAGGCCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTCGTTTTACCATTTCCCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTACTTTCG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCC	159
21D1	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTACTACGTTGGTGTCTTCCGTTTCG ACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCT	160
16F12	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCG NTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCNTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCAACTTCACTGTTCTGCGTGTCTCCGTTTCG ACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCT	161
21A5	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAAACCGGGCG GTTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTTCGCCAGGCCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTCGTTTTACCATTTCCCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGGCTTGGTTTCG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCC	162
21G8	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAAACCGGGCG GTTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTTCGCCAGGCCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTCGTTTTACCATTTCCCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCTTGGGAATGGGCTTACTTTCG	163

-206-

	ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCC	
19H3	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCACTGGTTGGTCTCGTTGGGGTTACATGG ACTATTGGGGCCAAGGCACCCTCGTAACGGTTTCTTCT	164
20G6	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGAATGGATCCGTTACTACCATTTTCG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	165
20H7	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGTTGGTTGGTACCGTTGGGGTTACATGG ACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	166
11F8_VH	CAGGTGCAATTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGT CCTCGGTGAAGGTCTCCTGCAAGGCCTCCGGAGGCACATTCAGCAG CTACGCTATAAGCTGGGTGCGACAGGCCCTGGACAAGGGCTCGAG TGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACCTACGCAC AGAAGTTCAGGGCAGGGTAACCATTACTGCAGACAAATCCACGAG CACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACCGCC GTGTATTACTGTGCGAGAGCTGTTTTCTACCGTGCTTGGTACTCTT TCGACTACTGGGGCCAAGGGACCACCGTGACCGTCTCCTCA	167
11F8_VL	GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAG GAGACCGTGTCAACCATCACTTGCCGTGCCAGTCAGAGTATTAGTAG CTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC CTGATCTATGATGCCTCCAGTTTGAAAGTGGGGTCCCATCACGTT TCAGCGGCAGTGGATCCGGGACAGAATTCACTCTCACCATCAGCAG CTTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGTATACC AGCCCACCACCAACGTTTGGCCAGGGCACCAAAGTCGAGATCAAG	168
36F2_VH	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCAGGGTCGCGTCACGATGACCCATGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCTCTTTCTTCACTGGTTTCCATCTGGACT ATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT	169
36F2_VL	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAG GGGAAAGAGCCACCCTCTCTTGCAAGGGCCAGTCAGAGTGTTAGCAG CAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGG CTCCTCATCTATGGAGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGATCCGGGACAGACTTCACTCTCACCATCAG CAGACTGGAGCCTGAAGATTTTGCACTGTATTACTGTGCAGCAGTAT ACCAACGAACATTATTATACGTTTCGGCCAGGGGACCAAAGTGGA	170

-207-

	TCAAA	
9D11_VH	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTCTGCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCCCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTGGACTATTGGG GTCAAGGCACCCTCGTAACGGTTTCTTCT	171
9D11_VL	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACC CGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAACCGGACTTTTGGTCAAGGCACCA AGGTCGAAATTAAA	172
9D11_VL N95S	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACC CGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAGCCGGACTTTTGGTCAAGGCACCA AGGTCGAAATTAAA	173
9D11_VL N95Q	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACC CGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAGCCGGACTTTTGGTCAAGGCACCA AGGTCGAAATTAAA	174
9D11_VL T97A	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACC CGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAACCGGGCTTTTGGTCAAGGCACCA AGGTCGAAATTAAA	175
9D11_VL T97N	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACC CGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAACCGGAATTTTGGTCAAGGCACCA AGGTCGAAATTAAA	176
5D9_VH	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTCTGCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAAACCAAGCGGTGGCTCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA	177

-208-

	GTGTACTACTGTGCACGCTCTTACATCGACATGGACTATTGGGGTC AAGGCACCCCTCGTAACGGTTTCTTCT	
5D9_VL	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAG GGGAAAGAGCCACCCTCTCTTGCAGGGCCAGTCAGAGTGTTAGCAG CAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGG CTCCTCATCTATGGAGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGATCCGGGACAGACTTCACTCTCACCATCAG CAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTGACAGGAT AACTGGAGCCCAACGTTTCGGCCAGGGGACCAAAGTGGAAATCAAA	178
6B6_VH	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCG CTTCCGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAACCAAGCGGTGGCTCTACCTCTACGCGC AGAAATTCAGGGTTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCTCTTACGTTGACATGGACTATTGGGGTC AAGGCACCCCTCGTAACGGTTTCTTCT	179
6B6_VL	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAG GGGAAAGAGCCACCCTCTCTTGCAGGGCCAGTCAGAGTGTTAGCAG CAGCTACCTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGG CTCCTCATCTATGGAGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGATCCGGGACAGACTTCACTCTCACCATCAG CAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTGACAGGAT ATTTGGAGCCCAACGTTTCGGCCAGGGGACCAAAGTGGAAATCAAA	180
14E4_VH	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGG GGTCCCTGAGACTCTCCTGTGCAGCCTCCGGATTACCTTTAGCAG TTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAG TGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAG ACTCCGTGAAGGGCCGGTTTACCATCTCCAGAGACAATTCCAAGAA CACGCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGACACGGCC GTATATTACTGTGCGAAAGACTCTTCTTACGTTGAATGGTACGCTT TCGACTACTGGGGCCAAGGAACCTGGTCAACCGTCTCGAGT	181
14E4_VL	GAAATCGTGTTAACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAG GGGAAAGAGCCACCCTCTCTTGCAGGGCCAGTCAGAGTGTTAGCAG CAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGG CTCCTCATCTATGGAGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGATCCGGGACAGACTCCACTCTCACCATCAG CAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTGACAGCCA ACCAGCAGCCCAATTACGTTTCGGCCAGGGGACCAAAGTGGAAATCA AA	182
CD3 heavy chain (VHCH1)	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCT GGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACC TTCAGCACCTACGCCATGAACTGGGTGCGCCAGGCCCTTGGC AAAGGCCTGGAATGGGTGTCCCGGATCAGAAGCAAGTACAAC AACTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTC ACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTGCAG ATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTATTGT GTGCGGCACGGCAACTTCGGCAACAGCTATGTGTCTTGGTTT GCCACTGGGGCCAGGGCACCTCTGTGACCGTGTCAAGCGCT AGTACCAAGGGCCCCAGCGTGTTCCCCCTGGCACCCAGCAGC AAGAGCACATCTGGCGGAACAGCCGCTCTGGGCTGTCTGGTG AAAGACTACTTCCCCGAGCCCGTGACCGTGTCTTGGAACTCT GGCGCCCTGACCAGCGGCGTGACACCTTTCCAGCCGTGCTG CAGAGCAGCGGCTGTACTCCCTGTCTCCGTGGTCACCGTG	183

	CCCTCTAGCTCCCTGGGAACACAGACATATATCTGTAATGTC AATCACAAGCCTTCCAACACCAAAGTCGATAAGAAAGTCGAG CCCAAGAGCTGC	
Crossed CD3 heavy chain (VHCκ)	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCG GATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAC CTACGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAGGCCTGGAA TGGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTACT ACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAG CAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGAC ACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACAGCT ATGTGTCTTGGTTTGCTTACTGGGGCCAGGGCACCCCTCGTGACCGT GTCAAGCGCTAGTGTGGCCGCTCCCTCCGTGTTTATCTTTCCCCCA TCCGATGAACAGCTGAAAAGCGGCACCGCCTCCGTCTGTGTCTGC TGAACAATTTTACCCTAGGGAAGCTAAAGTGCAAGTGGAAAGTGGA TAACGCACTGCACTCCGGCAACTCCCAGGAATCTGTGACAGAACAG GACTCCAAGGACAGCACCTACTCCCTGTCTCCACCCTGACACTGT CTAAGGCTGATTATGAGAAACACAAAGTCTACGCTCGGAAGTCAC CCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGT	184
Mutagenesi s primer GAB7734 N95Q	GCAGGCAAGCATTATGCAGCGGACTTTTGGTCAAGG	185
Mutagenesi s primer GAB7735 N95S	CAGGCAAGCATTATGAGCCGGACTTTTGGTCAAGG	186
Mutagenesi s primer GAB7736 T97A	CATTATGAACCGGGCTTTTGGTCAAGGCACCAAGGTC	187
Mutagenesi s primer GAB7737 T97N	CATTATGAACCGGAATTTTGGTCAAGGCACCAAGGTC	188
VHCH1[16 D5]_VHCH 1[CD3]_Fck nob_PGLA LA pCON999 (Inverted TCB with 16D5 2+1: pCON999 + pCON983 + pETR13197)	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGGCG GTTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTGCCAGGCCCGGGCAAAGGCCTCGAG TGGGTTGGTCTGATCAAGTCTAAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTCGTTTACCATTTCCTCGGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCCGCTAGCAC AAAGGGCCCTAGCGTGTTCCCTCTGGCCCCCAGCAGCAAGAGCACA AGCGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCC CCGAGCCCGTGACAGTGTCTTGGAAACAGCGGAGCCCTGACAAGCGG CGTGACACTTTCCCTGCCGTGCTGCAGAGCAGCGGCCTGTACTCC CTGAGCAGCGTGGTCACCGTGCCTAGCAGCAGCCTGGGCACCCAGA CCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGA CAAGAAGGTGGAGCCCCAAGAGCTGTGATGGCGGAGGAGGTCGGGA	189

-210-

	GGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGG TGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTT CACCTTCAGCACCTACGCCATGAACTGGGTGCGCCAGGCCCTGGC AAAGGCCTGGAATGGGTGTCCCGGATCAGAAGCAAGTACAACA ACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAG CCGGGACGACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTG CGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACT TCGGCAACAGCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCAC CCTCGTGACCGTGTCAAGCGCTAGTACCAAGGGCCCCAGCGTGTT CCCCTGGCACCCAGCAGCAAGAGCACATCTGGCGAACAGCCGCTC TGGGCTGTCTGGTGAAAGACTACTTCCCCGAGCCCGTGACCGTGT TTGGAACTCTGGCGCCCTGACCAGCGGCGTGACACCTTTCCAGCC GTGCTGCAGAGCAGCGGCCGTGACTCCCTGTCTCCGTGGTCAACG TGCCCTCTAGCTCCCTGGGAACACAGACATATCTGTAATGTCAA TACAAGCCTTCCAACACCAGTTCGATAAGAAAGTCGAGCCCAAG AGCTGCGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAG CTGCAGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGA CACCTCATGATCTCCCGACCCCTGAGGTACATGCGTGGTGGTG GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCGGCGCCCCATCGAGAAAACCATCTCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGTGTACACCTGCCCCCATCGCGGAT GAGCTGACCAAGAACCAGGTGAGCCTGTGGTGCCTGGTCAAAGGCT TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAACCTACAAGACCAGCCTCCCGTGTGGACTCCGACGGC TCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
VHCH1[16 D5]_Fchole _PGLALA_ HYRF pCON983	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGGCG GTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTCCGCCAGGCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAACTGACGGTGGCACACGGATT ACGCGGCTCCAGTTAAAGGTGTTTTACCATTTCCCGGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCCGCTAGCAC CAAGGGCCCCCTCCGTGTTCCCCCTGGCCCCAGCAGCAAGAGCACC AGCGGCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCC CCGAGCCCGTGACCGTGTCTGGAACAGCGGAGCCCTGACCTCCGG CGTGACACCTTCCCCGCGGTGCTGCAGAGTTCTGGCCTGTATAGC CTGAGCAGCGTGGTCAACGTGCCTTCTAGCAGCCTGGGCACCCAGA CCTACATCTGCAACGTGAACCACAAGCCAGCAACACCAAGGTGGA CAAGAAGGTGGAGCCCAAGAGCTGCGACAAAACCTCACACATGCCCA CCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCTCT TCCCCCAAAACCAAGGACACCCTCATGATCTCCCGACCCCTGA GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTC AAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGA CAAAGCCGCGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAG CGTCTCACCGTCTGCACACGAGTGGTGAATGGCAAGGAGTAC AAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCATCGAGAAAA CCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTGCAC CCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTGAGCCTC	190

-211-

	TCGTGCGCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC CGTGCTGGACTCCGACGGCTCCTTCTTCTCGTGAGCAAGCTCACC GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCGCTTCACGCAGAAGAGCCTCTC CCTGTCTCCGGTAA	
CD3_comm on light chain pETR13197	CAGGCCGTCTGACCCAGGAACCCAGCCTGACAGTGTCTCTGGCG GCACCGTGACCTGACATGTGGCAGTTCTACAGGCGCCGTGACCAC CAGCAACTACGCCAACTGGGTGCAGGAAAAGCCCGCCAGGCCTTC AGAGGACTGATCGGCGGCACCAACAAGAGAGCCCCCTGGCACCCTG CCAGATTGACGGATCTCTGCTGGGAGGAAAGGCCGCCCTGACACT GTCTGGCGCCAGCCAGAAGATGAGGCCGAGTACTACTGCGCCCTG TGGTACAGCAACCTGTGGGTGTTTCGGCGGAGGCACCAAGCTGACAG TCCTAGGTCAACCAAGGCTGCCCCAGCGTGACCTGTTCCTCC CAGCAGCGAGGAACTGCAGGCCAACAAAGGCCACCTGGTCTGCCTG ATCAGCGACTTCTACCCAGGCGCGTGACCGTGGCCTGGAAGGCCG ACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCCCCAGCAA GCAGAGCAACAACAAGTACGCGCCAGCAGCTACCTGAGCCTGACC CCCCGAGCAGTGGAAGAGCCACAGGTCTTACAGCTGCCAGGTGACCC ACGAGGGCAGCACCGTGGAGAAAACCGTGGCCCCACCGAGTGCAG C	191
VHCH1[C D3]_VHCH 1[16D5]_Fc knob_PGL ALA pETR13932 (Classical TCB with 16D5; 2+1: pETR13932+ pCON983 + pETR13197)	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCG GATCTCTGAGACTGAGCTGTGCCGCGAGCGGCTTCACCTTCAGCAC CTACGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAGGCTGGAA TGGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTACT ACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAG CAAGAACACCTGTACTTGTGCTGCGGCACGGCAACTTCGGCAACAGCT ACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACAGCT ATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCTCTGACCGT GTATCTGCTAGCACAAAGGGCCCTAGCGTGTTCCTCTGGCCCC AGCAGCAAGAGCACAAAGCGCGGAACAGCCGCCCTGGGTGCTCTCG TGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCTTGGAAACAGCGG AGCCCTGACAAGCGGCGTGCACACCTTCCCTGCCGTGCTGCAGAGC AGCGGCCTGTACTCCCTGAGCAGCGTGGTACCGTGCCCTAGCAGCA GCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCAG CAACACCAAAGTGGACAAGAAGGTGGAGCCAAGAGCTGTGATGGC GGAGGAGGGTCCGGAGGCGGAGGATCCGAGGTGCAATTGGTTGAAT CTGGTGGTGGTCTGGTAAAACCGGGCGGTTCCCTGCGTCTGAGCTG CGCGGCTTCCGGATTACCTTCTCCAACGCGTGGATGAGCTGGGT CGCCAGGCCCCGGGCAAAGGCCTCGAGTGGGTGGTCTGATCAAGT CTAAACTGACGGTGGCACCACGGATTACGCGGCTCCAGTTAAAGG TCGTTTTACCATTTCCCGCAGCAGATAGCAAAAACACTCTGTATCTG CAGATGAACTCTCTGAAAACCTGAAGACACCGCAGTCTACTACTGTA CTACCCCGTGGGAATGGTCTTGGTACGATTATTGGGGCCAGGGCAC GCTGGTTACGGTGTCTAGCGCTAGTACCAAGGGCCCCAGCGTGTTC CCCCTGGCACCCAGCAGCAAGAGCACATCTGGCGGAACAGCCGCTC TGGGCTGTCTGGTGAAGACTACTTCCCCGAGCCCGTGACCGTGTCT TTGGAACCTTGCGGCCCTGACCAGCGGCGTGCACACCTTCCAGCC GTGCTGCAGAGCAGCGGCTGTACTCCCTGTCTCCGTGGTCAACG TGCCCTCTAGCTCCCTGGGAACACAGACATATCTGTAATGTCAA TCACAAGCCTTCCAACACCAAAGTCGATAAGAAAGTCGAGCCCAAG AGCTGCGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAG CTGCAGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCCAAGGA CACCTCATGATCTCCCGACCCCTGAGGTACATGCGTGGTGGTGG GACGTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGG	192

-212-

	ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCCTCCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGTGTACACCTGCCCCCATGCCGGGAT GAGCTGACCAAGAACCAGGTGAGCCTGTGGTGCTGGTCAAAGGCT TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAACACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCTCTACAGCAAGCTCACCCTGGACAAGAGCAGGTGGC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
VHCH1[C D3]_Fckno b_PGLALA pETR13719 (16D5 IgG format, 1+1: pETR13719 + pCON983 + pETR13197)	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCG GATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAC CTACGCCATGAACTGGGTGCGCCAGGCCCCCTGGCAAAGGCTGGAA TGGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTACT ACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAG CAAGAACACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGAC ACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACAGCT ATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCTCGTGACCGT GTCATCTGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG TCAAGGACTACTTCCCCGAACCGGTGACGGTGTGCTGGAACCTCAGG CGCCCTGACCAGCGGCGTGACACCTTCCCGGCTGTCTTACAGTCC TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCA GCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCAG CAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA ACTCACACATGCCACCGTGCCAGCACCTGAAGCTGCAGGGGGAC CGTCAGTCTTCTCTTCCCCCAAAACCCAAAGGACACCCCTCATGAT CTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCAC GAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGG TGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCTCACCCTCCTGCACCAGGACTGGCTG AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCG CCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA ACCACAGGTGTACACCTGCCCCCATGCCGGGATGAGCTGACCAAG AACCAGGTGAGCCTGTGGTGCTGGTCAAAGGCTTCTATCCCAGCG ACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACTA CAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTC TACAGCAAGCTCACCCTGGACAAGAGCAGGTGGCAGCAGGGGAACG TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC GCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	193
Fc_hole_PG LALA_HYR F pETR10755 (16D5 Head- to-tail, 1+1: pCON999 + pETR10755 + pETR13197)	GACAAAACCTCACACATGCCACCGTGCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCTCTTCCCCCAAAACCCAAAGGACACCCCT CATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTG AGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA CAGCACGTACCGTGTGGTCAGCGTCCTCACCCTCCTGCACCAGGAC TGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCC TCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC CCGAGAACCACAGGTGTGCACCCTGCCCCCATCCCGGGATGAGCTG ACCAAGAACCAGGTGAGCCTCTCGTGCGCAGTCAAAGGCTTCTATC CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC TTCCTCGTGAGCAAGCTCACCCTGGACAAGAGCAGGTGGCAGCAGG GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCG	194

-213-

	CTTCACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
VHCH1[9D 11]_VHCL[CD3]_Fckn ob_PGLAL A pCON1057 (9D11 inverted format, 2+1: pCON1057 + pCON1051 + pCON1063 + pETR12940)	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACC GGCG CTTCGGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTCTGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAACCCAAGCGGTGGCCCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTGGACTATTGGG GTCAAGGCACCCTCGTAACGGTTTCTTCTGTCTAGCACAAAGGGCCC CAGCGTGTTCCCTCTGGCCCCTAGCAGCAAGAGCACATCTGGCGGA ACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCTG TGACCGTGTCTGGAACTCTGGCGCCCTGACAAGCGGCTGCACAC CTTTCCAGCCGTGCTGCAGAGCAGCGGCCCTGTA CTCTCTGAGCAGC GTGGTCACCGTGCTTAGCAGCAGCCTGGGCACCCAGACCTACATCT GCAACGTGAACCACAAGCCAGCAACACCAAAGTGGACAAGAAGGT GGAGCCCCAAGAGCTGTGATGGCGGAGGAGGGTCCGGAGGCGGAGGA TCCGAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTG GCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAG CACCTACGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAGGCCTG GAATGGGTGTCCCGGATCAGAAGCAAGTACAACA ACTACGCCACCT ACTACGCCGACAGCGTGAAGGGCCGGTTCA CCATCAGCCGGGACGA CAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAG GACACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACA GGTATGTGTCTTGGTTTGCTACTGGGGCCAGGGCACCTCGTGAC CGTGTCAAGCGCTAGTGTGGCCGCTCCCTCCGTGTTTATCTTTCCC CCATCCGATGAACAGCTGAAAAGCGGCACCGCCTCCGTCTGTGTCT TGCTGAACAATTTTACCCTAGGGAAGCTAAAGTGCAGTGGAAAGT GGATAACGCACTGCAGTCCGGCAACTCCCAGGAATCTGTGACAGAA CAGGACTCCAAGGACAGCACCTACTCCCTGTCTCCACCCTGACAC TGTCTAAGGCTGATTATGAGAAACACAAAGTCTACGCCCTGCGAAGT CACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGG GGAGAGTGTGACAAGACCCACACCTGTCCCCCTTGTCTCTGCCCTG AAGCTGTGCGGCCCTTCTGTGTTCTCTGTTCCCCC CAAAGCCAA GGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTG GTGGATGTGTCCACGAGGACCCTGAAGTGAAGTTCAATTGGTACG TGGACGGCGTGAAGTGCACAACGCCAAGACAAAGCCGCGGGAGGA GCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCCTG CACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCA ACAAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCAAGCCAA AGGGCAGCCCCGAGAACACAGGTGTACACCCTGCCCCCATGCCGG GATGAGCTGACCAAGAACCAGGTGAGCCTGTGGTGCCTGGTCAAAG GCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA GCCGGAGAACA ACTACAAGACCACGCCTCCCGTGTGGACTCCGAC GGCTCCTTCTTCTCTACAGCAAGCTCACCCTGGACAAGAGCAGGT GGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	195
9D11_Fchol e_PGLALA _HYRF pCON1051	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACC GGCG CTTCGGTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTC CTATTACATGCACTGGGTTCTGTCAAGCCCCGGGCCAGGGTCTGGAA TGGATGGGCATCATTAACCCAAGCGGTGGCCCTACCTCCTACGCGC AGAAATTCCAGGGTCGCGTCACGATGACCCGTGACACTAGCACCTC TACCGTTTATATGGAGCTGTCCAGCCTGCGTTCTGAAGATACTGCA GTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTGGACTATTGGG GTCAAGGCACCCTCGTAACGGTTTCTTCTGTCTAGCACCAAGGGCCC CTCCGTGTTCCCTCTGGCCCCAGCAGCAAGAGCACCAGCGGCGGC	196

	ACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCG TGACCGTGTCTTGGAAACAGCGGAGCCCTGACCTCCGGCGTGACAC CTTCCCCGCGGTGCTGCAGAGTTCTGGCTGTATAGCCTGAGCAGC GTGGTCACCGTGCCTTCTAGCAGCCTGGGCACCCAGACCTACATCT GCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGT GGAGCCCCAAGAGCTGCGACAAAACCTCACACATGCCACCGTGCCCA GCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCTCTTCCCCCAA AACCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATG CGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAGCCGC GGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCAC CGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAG GTCTCCAACAAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCA AAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTGCACCCTGCCCC ATCCCGGGATGAGCTGACCAAGAACCAGGTACGCTCTCGTGCGCA GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA ATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGA CTCCGACGGCTCTTCTTCTCGTGAGCAAGCTCACCGTGGACAAG AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC GGTAAA	
9D11_LC pCON1063	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAG GCGAACCGGCGAGCATTCTTCTGCCGTTCCAGCCAGTCTCTGCTGCA CTCCAACGGCTACAACCTATCTCGATTGGTACCTGCAAAAACCGGGT CAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACCGCGCTTCCG GTGTACCGGACCGTTTTCAGCGGCTCTGGATCCGGCACCGATTTCAC GTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTAC TGTATGCAGGCAAGCATTATGAACCGGACTTTTGGTCAAGGCACCA AGGTGCAAAATTAACGTACGGTGGCTGCACCATCTGTCTTCATCTT CCC GCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTG TGCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGA AGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTAC AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTG ACGCTGAGCAAAGCAGACTACGAGAAACAAAAGTCTACGCCTGCG AAGTACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAA CAGGGGAGAGTGT	197
VLCH1[CD 3] pETR12940	CAGGCCGTCTGACCCAGGAACCCAGCCTGACAGTGTCTCTGGCG GCACCGTGACCTGACATGTGGCAGTTCTACAGGCGCCGTGACCAC CAGCAACTACGCCAACTGGGTGCAGGAAAAGCCCGCCAGGCCTTC AGAGGACTGATCGGCGGCACCAACAAGAGAGCCCCCTGGCACCCCTG CCAGATTACGCGATCTCTGCTGGGAGGAAAGGCCGCCCTGACACT GTCTGGCGCCAGCCAGAAGATGAGGCCGAGTACTACTGCGCCCTG TGGTACAGCAACCTGTGGGTGTTTCGGCGGAGGCACCAAGCTGACAG TGCTGAGCAGCGCTTCCACCAAAGGCCCTTCCGTGTTTCTCTGGC TCCTAGCTCCAAGTCCACCTCTGGAGGCACCGCTGCTCTCGGATGC CTCGTGAAGGATTATTTTCTGAGCCTGTGACAGTGTCTTGGGAATA GCGGAGCACTGACCTCTGGAGTGCATACTTTCCCCGCTGTGCTGCA GTCTCTGGACTGTACAGCCTGAGCAGCGTGGTGACAGTGCCAGC AGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGC CCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGTCTTGT	198
VHCL[CD3]_Fcknob_P GLALA pETR13378	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGACAGCTGGCG GATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCTTCAGCAC CTACGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAGGCCTGGAA TGGGTGTCCCGATCAGAAGCAAGTACAACAACCTACGCCACCTACT ACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAG	199

-215-

(9D11 CrossMab format, 1+1: pETR13378 + pCON1051 + pCON1063 + pETR12940)	CAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGAC ACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACAGCT ATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCCCTCGTGACCGT GTCATCTGCTAGCGTGGCCGCTCCCTCCGTGTTTATCTTTCCCCCA TCCGATGAACAGCTGAAAAGCGGCACCGCTCCGTGCTGTGTCTGC TGAACAATTTTACCCTAGGGAAGCTAAAGTGCAAGTGGAAAGTGGGA TAACGCACTGCACTCCGGCAACTCCCAGGAATCTGTGACAGAACAG GACTCCAAGGACAGCACCTACTCCCTGTCTCCACCCTGACACTGT CTAAGGCTGATTATGAGAAAACAAAAGTCTACGCCTGCCAAGTCAC CCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA GAGTGTGACAAGACCCACACCTGTCCCCCTGTCTGCCCCCTGAAG CTGCTGGCGGCCCTTCTGTGTCTCTGTTCCCCCAAGCCCAAGGA CACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTG GATGTGTCCCACGAGGACCCCTGAAGTGAAGTTCAATTGGTACGTGG ACGGCGTGGAAGTGCACAACGCCAAGACAAAGCCGCGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTGCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCGGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGAT GAGCTGACCAAGAACCAGGTGACGCTGTGGTGCCCTGGTCAAAGGCT TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAACACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGC TCCTTCTTCTCTACAGCAAGCTCACCCTGGACAAGAGCAGGTGGC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
16D5 inverted 2+1 with N100A in CDR H3 pETR14096 (pETR14096 + pCON983 + pETR13197)	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGGCG GTCCCTGCGTCTGAGCTGCGCGGCTTCCGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTCCGCCAGGCCCCGGGCAAAGGCCTCGAG TGGGTTGGTTCGTATCAAGTCTAAACTGACGGTGGCACCCACGGATT ACGCGGCTCCAGTTAAAGGTGTTTTACCATTTCCCGCAGCAGATAG CAAAAACACTCTGTATCTGCAGATGAACCTCTGTGAAAATGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCACGCTGAGTTACGGTGTCTTCCGCTAGCAC AAAGGGCCCTAGCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCACA AGCGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCC CCGAGCCCGTGACAGTGTCTTGGAAACAGCGGAGCCCTGACAAGCGG CGTGACACTTTCCCTGCCGTGCTGCAGAGCAGCGGCCCTGTACTCC CTGAGCAGCGTGGTCACCGTGCCTAGCAGCAGCCTGGGCACCCAGA CCTACATCTGCAACGTGAACCACAAGCCAGCAACACCAAAGTGGA CAAGAAGGTGGAGCCCAAGAGCTGTGATGGCGGAGGAGGGTCCGGA GGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGG TGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTT CACCTTCAGCACCTACGCCATGAACTGGGTGCGCCAGGCCCCCTGGC AAAGGCCTGGAATGGGTGTCCCGGATCAGAAGCAAGTACAACAAC ACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAG CCGGGACGACAGCAAGAACACCCCTGTACCTGCAGATGAACAGCCTG CGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACT TCGGCGCCAGCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCAC CCTCGTGACCGTGTCAAGCGCTAGTACCAAGGGCCCCAGCGTGTTC CCCCTGGCACCCAGCAGCAAGAGCACATCTGGCGGAACAGCCGCTC TGGGCTGTCTGGTGAAAGACTACTTCCCCGAGCCCGTGACCGTGT TTGGAACTCTGGCGCCCTGACCAGCGGCGTGACACCTTTCCAGCC GTGCTGCAGAGCAGCGGCCCTGTACTCCCTGTCTCCGTGGTCAACG TGCCCTCTAGTCCCTGGGAACACAGACATATATCTGTAATGTCAA TCACAAGCCTTCCAACACCAAAGTCGATAAGAAAGTCGAGCCCAAG	200

-216-

	AGCTGCGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAG CTGCAGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGA CACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGTTGGTG GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCAAGCCAAAGG GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGAT GAGCTGACCAAGAACCAGGTACAGCCTGTGGTGCTGGTCAAAGGCT TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAACCTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGACAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
16D5 inverted 2+1 with S100aA in CDR H3 pETR14097 (pETR14097 + pCON983 + pETR13197)	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAAACGGGCG GTTCCCTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCAA CGCGTGGATGAGCTGGGTTCCGCCAGGCCCGGGCAAAGGCTCGAG TGGGTTGGTCTGATCAAGTCTAAACTGACGGTGGCACCACGGATT ACGCGGCTCCAGTTAAAGGTGCTTTTACCATTTCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACCTCTGAAAACTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCACGCTGGTTACGGTGTCTTCCGCTAGCAC AAAGGGCCCTAGCGTGTTCCCTCTGGCCCCAGCAGCAAGAGCACA AGCGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCC CCGAGCCCGTGACAGTGTCTTGGAAACAGCGGAGCCCTGACAAGCGG CGTGACACACTTCCCTGCCGTGCTGCAGAGCAGCGGCCCTGTACTCC CTGAGCAGCGTGGTCAACGTGCCTAGCAGCAGCCTGGGCACCCAGA CCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGGA CAAGAAGGTGGAGCCCAAGAGCTGTGATGGCGGAGGAGGTCCGGA GGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGG TGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTT CACCTTCAGCACCTACGCCATGAACCTGGGTGCGCCAGGCCCTGGC AAAGGCCTGGAATGGGTGTCCCGGATCAGAAGCAAGTACAACAAC ACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAG CCGGGACGACAGCAAGAACACCCCTGTACCTGCAGATGAACAGCCTG CGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACT TCGGCAACGCCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCAC CCTCGTGACCGTGTCAAGCGCTAGTACCAAGGGCCCCAGCGTGTTT CCCCTGGCACCCAGCAGCAAGAGCACATCTGGCGGAACAGCCGCTC TGGGCTGTCTGGTGAAAGACTACTTCCCCGAGCCCGTGACCGTGTCT TTGGAACCTTGCGGCCCTGACCAGCGGCGTGACACCTTTCAGGCC GTGCTGCAGAGCAGCGGCCCTGTACTCCCTGTCTCCGTGGTCAACG TGCCCTCTAGCTCCCTGGGAACACAGACATATATCTGTAATGTCAA TCACAAGCCTTCCAACACCAAAGTCGATAAGAAAGTCGAGCCCAAG AGCTGCGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAG CTGCAGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGA CACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGTTGGTG GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCAAGCCAAAGG GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGAT GAGCTGACCAAGAACCAGGTACAGCCTGTGGTGCTGGTCAAAGGCT	201

-217-

	TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC GGAGAACAAC TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
CD3 light chain fused to CH1; Fc_PGLAL A; pETR13862 (Kappa- lambda antibody with CD3 common light chain fused to CH1 + Fc_PGLALA. VHs fused to kappa or lambda constant chain pETR13859 + pETR13860 + pETR13862)	CAGGCCGTGCTGACCCAGGAACCCAGCCTGACAGTGTCTCTGGCG GCACCGTGACCTGACATGTGGCAGTTCTACAGGCGCCGTGACCAC CAGCAACTACGCCAACTGGGTGCAGGAAAAGCCCGGCCAGGCCTTC AGAGGACTGATCGGCGGCACCAACAAGAGAGCCCCCTGGCACCCCTG CCAGATTGAGCGGATCTCTGCTGGGAGGAAAGGCCGCCCTGACACT GTCTGGCGCCAGCCAGAAGATGAGGCCGAGTACTACTGCGCCCTG TGGTACAGCAACCTGTGGGTGTTCTGGCGGAGGCACCAAGCTGACAG TGCTGAGCAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGC ACCCTCTCCAAGAGCACCTCTGGGGGACAGCGGCCCTGGGCTGC CTGGTCAAGGACTACTTCCCGAACCAGGTGACGGTGTCTGGAACT CAGGCGCCCTGACCAGCGCGGTGCACACCTTCCCGGCTGTCTTACA GTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC AGCAGCTTGGGCACCCAGACTACATCTGCAACGTGAATCACAAGC CCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGA CAAACTCACACATGCCACCGTGCCAGCACCTGAAGCTGCAGGG GGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGACACCTCA TGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAG CCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG GAGGTGCATAATGCCAAGACAAGCCGCGGAGGAGCAGTACAACA GCACGTACCGTGTGGTCAAGTCTCCTCACCGTCTGCACCAAGGACTG GCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAAGCCCTC GGCGCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCC GAGAACCA CAGGTGTACACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACC AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACAT CGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG ACCACGCCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTACA GCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGACGTCTT CTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG AAGAGCCTCTCCCTGTCTCCGGGTAAA	202
16D5 VH fused to constant kappa chain; pETR13859	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGGCG GTTCCTTGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAA CGCGTGGATGAGCTGGGTTCCGCCAGGCCCCGGGCAAAGGCTCGAG TGGGTTGGTCTGATCAAGTCTAAACTGACGGTGGCACACCGGATT AGCGGCTCCAGTTAAAGGTCGTTTTACCATTTCCGCGACGATAG CAAAAACACTCTGTATCTGCAGATGAACTCTCTGAAAACCTGAAGAC ACCGCAGTCTACTACTGTACTACCCCGTGGGAATGGTCTTGGTACG ATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCCGCTAGCGT GGCCGCTCCCTCCGTGTTTCATCTTCCACCTTCCGACGAGCAGCTG AAGTCCGGCACCGCTTCTGTGCTGTGCCTGTGAACAACCTTCTACC CCGCGAGGCCAAGGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGTC CGGCAACAGCCAGGAATCCGTGACCGAGCAGGACTCCAAGGACAGC ACCTACTCCCTGTCTTCCACCCTGACCTGTCCAAGGCCGACTACG AGAAGCACAAGGTGTACGCTGCGAAGTGACCCACCAGGGCCTGTCT TAGCCCCGTGACCAAGTCTTTCAACCGGGGCGAGTGC	203
CD3 VH fused to constant lambda	GAAGTGCAGCTGCTGGAATCCGGCGGAGGACTGGTGCAGCCTGGCG GATCTCTGAGACTGTCTTGTGCCGCTCCGGCTTACCTTCTCCAC CTACGCCATGAACTGGGTGCGACAGGCTCCTGGCAAGGGCCTGGAA TGGGTGTCCCGGATCAGATCCAAGTACAACAACCTACGCCACCTACT ACGCCGACTCCGTGAAGGGCCGGTTACCATCTCTCGGGACGACTC	204

-218-

chain; pETR13860	CAAGAACACCCTGTACCTGCAGATGAACTCCCTGCGGGCCGAGGAC ACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAACTCCT ATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCCCTCGTGACCGT GTCATCTGCTAGCCCCAAGGCTGCCCCAGCGTGACCCTGTTTCCC CCCAGCAGCGAGGAACTGCAGGCCAACAAGGCCACCCTGGTCTGCC TGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGCCCTGGAAGGC CGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGC AAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGA CCCCGAGCAGTGGAAAGAGCCACAGGTCTACAGCTGCCAGGTGAC CCACGAGGGCAGCAC GTGGAGAAAACCGTGGCCCCCACCAGTGCAGC	
VHCH1[36 F2]_VHCL[CD3]_Fc knob_PGL ALA pCON1056	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGCGCTTCC GTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTATTACATG CACTGGGTTCTGCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCCAGCGGTGGCTCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTC ACGATGACCCATGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTACTACTGTGCACGCTCTTTCTTCACT GGTTTCCATCTGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT GCTAGCACAAGGGCCCCAGCGTGTTCCTCTGGCCCCTAGCAGCAAGAGC ACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCC GAGCCTGTGACCGTGTCTGGAACCTCTGGCGCCCTGACAAGCGGCGTGAC ACCTTTCCAGCCGTGCTGCAGAGCAGCGCCCTGTACTCTCTGAGCAGCGTG GTCACCGTGCCCTAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG AACCACAAGCCAGCAACACCAAAGTGGACAAGAAGGTGGAGCCCAAG AGCTGTGATGGCGGAGGAGGTTCCGGAGGCGGAGGATCCGAGGTGCAGCTG CTGGAATCTGGCGCGGACTGGTGACGCTGGCGGATCTCTGAGACTGAGC TGTGCCGCCAGCGCTTCACTTTCAGCACCTACGCCATGAACCTGGGTGCGC CAGGCCCTGGCAAAGGCCTGGAATGGGTGTCCCGATCAGAAGCAAGTAC AACAATACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCAACCATC AGCCGGGACGACAGCAAGAACCCCTGTACCTGCAGATGAACAGCCTGCGG GCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTCGGCAAC AGCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCCCTCGTGACCGTG TCAAGCGCTAGTGTGGCCGCTCCCTCCGTGTTTATCTTTCCCCCATCCGAT GAACAGCTGAAAAGCGGCACCGCCTCCGTCTGTGTCTGCTGAACAATTTT TACCTAGGGAAGCTAAAGTGCAAGTGGAAAGTGGATAACGCACTGCACTG GGCAACTCCAGGAATCTGTGACAGAACAGGACTCCAAGGACAGCACCTAC TCCCTGTCTCCACCCTGACACTGTCTAAGGCTGATTATGAGAAACAC AAAGTCTACGCTGCGAAGTCAACCATCAGGGCCTGAGCTCGCCCGTCACA AAGAGCTTCAACAGGGGAGAGTGTGACAAGACCCACACCTGTCCCCCTTGT CCTGCCCTGAAGCTGTGGCGGCCCTTCTGTGTTCTGTTCCTTCCCCCAAAG CCCAAGGACACCTGATGATCAGCCGACCCCCGAAGTGACCTGCGTGGTG GTGGATGTGTCCACGAGGACCTGAAGTGAAGTTCAATTGGTACGTGGAC GGCGTGAAGTGCAACGCAAGACAAAGCCGCGGAGGAGCAGTACAAC AGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCACCAGGACTGGCTG AATGGCAAGGAGTACAAGTGCAAGGTCTCAACAAAGCCCTCGGCGCCCC ATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTG TACACCTGCCCCATGCGGGATGAGCTGACCAAGAACCAGGTCAGCCTG TGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCTCCCGTGCTGGAC TCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGC AGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAAGAGCCTCTCCCTGTCTCCGGGTAAA	246
36F2-Fc hole PGLALA pCON1050	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGCGCTTCC GTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTATTACATG CACTGGGTTCTGCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCCAGCGGTGGCTCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTC ACGATGACCCATGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTACTACTGTGCACGCTCTTTCTTCACT GGTTTCCATCTGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCT GCTAGCACCAAGGGCCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGC	247

-219-

	ACCAGCGGCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCC GAGCCCGTGACCGTGTCTTGGAACAGCGGAGCCCTGACCTCCGGCGTGAC ACCTTCCCCGCGGTGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTG GTCACCGTGCCCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTG AACCACAAGCCCGAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAG AGCTGCGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAGCTGCA GGGGGACCGTCAGTCTTCCTCTTCCCCCAAAACCAAGGACACCCCTCATG ATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGAGCTGAGCCACGAA GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAAT GCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC AGCGTCTCACCGTCTGCAACAGGACTGGCTGAATGGCAAGGAGTACAAG TGCAAGGTCTCAACAAAGCCCTCGGCGCCCCATCGAGAAAACCATCTCC AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTGCACCCCTGCCCCATCC CGGGATGAGCTGACCAAGAACAGGTGAGCCTCTCGTGCGCAGTCAAAGGC TTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG AACAATAACAAGACCAGCCTCCCGTGTGGACTCCGACGGCTCCTTCTTC CTCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAG AAGAGCCTCTCCCTGTCTCCGGGTAAA	
36F2 LC pCON1062	GAAATCGTGTAAACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAA AGAGCCACCCTCTCTTGACAGGGCCAGTCAAGTGTAGCAGCAGCTACTTA GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCAGGCTCCTCATCTATGGA GCATCCAGCAGGGCCACTGGCATCCCAAGACAGGTTCAAGTGGCAGTGGATC CGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGC AGTGTATTACTGTCAAGTATACCAACGAACATTATTATACGTTCCGGCCA GGGGACCAAAGTGGAATCAAACGTACGGTGGCTGCACCATCTGTCTTCAT CTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTG CCTGTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGAAGGTGGA TAACGCCCTCCAATCGGGTAACCTCCAGGAGAGTGTACAGAGCAGGACAG CAAGGACAGCCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGA CTACGAGAAACACAAAGTCTACGCTGCGAAGTCACCCATCANGCCCTGAG CTCGCCCGTCAAAAGAGCTTCAACAGGGGAGAGTGT	97
CD3 VLCH1 pETR12940	CAGGCCGTCGTGACCCAGGAACCCAGCCTGACAGTGTCTCCTGGCGGCACC GTGACCCTGACATGTGGCAGTTCTACAGGCGCCGTGACCACCAGCAACTAC GCCAACTGGGTGCAGGAAAAGCCCGCCAGGCTTCCAGAGGACTGATCGGC GGCACCACCAAGAGAGCCCTGGCACCCCTGCCAGATTACGCGGATCTCTG CTGGGAGGAAAGGCCGCCCTGACACTGTCTGGCGCCAGCCAGAAGATGAG GCCGAGTACTACTGCGCCCTGTGGTACAGCAACCTGTGGGTGTTCGGCGGA GGCACCAAGCTGACAGTGTGAGCAGCGCTTCCACCAAGGCCCTTCCGTG TTTCTCTGGCTCCTAGCTCAAGTCCACCTCTGGAGGCACCGCTGCTCTC GGATGCCTCGTGAAGGATTATTTTCTGAGCCTGTGACAGTGTCTTGGAA AGCGGAGCACTGACCTCTGGAGTGACATACTTTCCCGCTGTGTGTCAGTCC TCTGGACTGTACAGCCTGAGCAGCGTGGTACAGTGTCCAGCAGCAGCCTG GGCACCCAGACCTACATCTGCAACGTGAACCAAGCCAGCAACACCAAG GTGGACAAGAAGGTGGAACCAAGTCTTGT	198

Name	Sequence	Seq ID No
K53A nt	CAGACCGTCGTGACCCAGGAACCCAGCCTGACAGTGTCTCCTGGCGGCACC GTGACCCTGACATGTGGCAGTTCTACAGGCGCCGTGACCACCAGCAACTAC GCCAACTGGGTGCAGCAGAAGCCAGGCCAGGCTCCAGAGGACTGATCGGC GGCACCAACGCCAGAGCCCTGGCACCCCTGCCAGATTACGCGGATCTCTG CTGGGAGGAAAGGCCGCCCTGACACTGTCTGGCGTGCAGCCTGAAGATGAG GCCGAGTACTACTGCGCCCTGTGGTACAGCAACCTGTGGGTGTTCGGCGGA GGCACCAAGCTGACAGTCCTA	205
S93A nt	CAGACCGTCGTGACCCAGGAACCCAGCCTGACAGTGTCTCCTGGCGGCACC GTGACCCTGACATGTGGCAGTTCTACAGGCGCCGTGACCACCAGCAACTAC GCCAACTGGGTGCAGCAGAAGCCAGGCCAGGCTCCAGAGGACTGATCGGC GGCACCAACGCCAGAGCCCTGGCACCCCTGCCAGATTACGCGGATCTCTG CTGGGAGGAAAGGCCGCCCTGACACTGTCTGGCGTGCAGCCTGAAGATGAG GCCGAGTACTACTGCGCCCTGTGGTACAGCAACCTGTGGGTGTTCGGCGGA	206

-220-

	CTGGGAGGAAAGGCCGCCCTGACACTGTCTGGCGTGCAGCCTGAAGATGAG GCCGAGTACTACTGCGCCCTGTGGTACGCCAACCTGTGGGTGTTTCGGCGGA GGCACCAAGCTGACAGTCCTA	
--	--	--

Name	Sequence	Seq ID No
S35H nt	GAGGTGCAATTGGTGGAAAGCGAGGCGGCCTCGTGAAGCCTGGCGGATCT CTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAACGCCTGGATG CACTGGGTGCGCCAGGCCCTTGAAAAGGACTCGAGTGGGTGGGACGGATC AAGAGCAAGACCGATGGCGGCACCAACCGACTATGCCGCCCTGTGAAGGGC CGGTTTACCATCAGCAGGGAACGACAGCAAGAACACCCTGTACCTGCAGATG AACAGCCTGAAAACCGAGGACACCGCGGTGTACTACTGCACCAACCCCTGG GAGTGGTCTTGGTACGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCC TCTGCTAGC	207
G49S nt	GAGGTGCAATTGGTGGAAAGCGAGGCGGCCTCGTGAAGCCTGGCGGATCT CTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAACGCCTGGATG AGCTGGGTGCGCCAGGCCCTTGAAAAGGACTCGAGTGGGTGTCCCGGATC AAGAGCAAGACCGATGGCGGCACCAACCGACTATGCCGCCCTGTGAAGGGC CGGTTTACCATCAGCAGGGAACGACAGCAAGAACACCCTGTACCTGCAGATG AACAGCCTGAAAACCGAGGACACCGCGGTGTACTACTGCACCAACCCCTGG GAGTGGTCTTGGTACGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCC TCTGCTAGC	208
R50S nt	GAGGTGCAATTGGTGGAAAGCGAGGCGGCCTCGTGAAGCCTGGCGGATCT CTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAACGCCTGGATG AGCTGGGTGCGCCAGGCCCTTGAAAAGGACTCGAGTGGGTGGGATCTATC AAGAGCAAGACCGACGGCGGCACCAACCGACTATGCCGCCCTGTGAAGGGC CGGTTTACCATCAGCAGGGAACGACAGCAAGAACACCCTGTACCTGCAGATG AACAGCCTGAAAACCGAGGACACCGCGGTGTACTACTGCACCAACCCCTGG GAGTGGTCTTGGTACGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCC TCT GCTAGC	209
W96Y nt	GAGGTGCAATTGGTGGAAAGCGAGGCGGCCTCGTGAAGCCTGGCGGATCT CTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAACGCCTGGATG AGCTGGGTGCGCCAGGCCCTTGAAAAGGACTCGAGTGGGTGGGACGGATC AAGAGCAAGACCGATGGCGGCACCAACCGACTATGCCGCCCTGTGAAGGGC CGGTTTACCATCAGCAGGGAACGACAGCAAGAACACCCTGTACCTGCAGATG AACAGCCTGAAAACCGAGGACACCGCGGTGTACTACTGCACCAACCCCTAC GAGTGGTCTTGGTACGACTACTGGGGCCAGGGCACCCCTCGTGACCGTGTCA TCT GCTAGC	210
W98Y nt	GAGGTGCAATTGGTGGAAAGCGAGGCGGCCTCGTGAAGCCTGGCGGATCT CTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAACGCCTGGATG AGCTGGGTGCGCCAGGCCCTTGAAAAGGACTCGAGTGGGTGGGACGGATC AAGAGCAAGACCGATGGCGGCACCAACCGACTATGCCGCCCTGTGAAGGGC CGGTTTACCATCAGCAGGGAACGACAGCAAGAACACCCTGTACCTGCAGATG AACAGCCTGAAAACCGAGGACACCGCGGTGTACTACTGCACCAACCCCTGG GAGTACTCTTGGTACGACTACTGGGGCCAGGGCACCCCTCGTGACCGTGTCA TCT GCTAGC	211

Name	Sequence	Seq ID No
90D7 nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCC GTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTATTACATG CACTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCCAAGCGGTGGCTCTACCTCCTACGCGCAGAAATCCAGGGTCGCGTC ACGATGACCCGTGACACTAGACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTACTACTGTGCACGCAACTACACTATC GTTGTTTCTCCGTTCTGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCT TCTGCTAGC	212

-221-

90C1 nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCC GTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTTATTACATG CACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCAAGCGGTGGCTCTACCTCTACGCGCAGAAATCCAGGGTCGCGTC ACGATGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTAATACTGTGCACGCAACTACTTCATC GGTTCTGTTGCTATGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCT TCTGCTAGC	213
5E8 VH nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCC GTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTTATTACATG CACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCAAGCGGTGGCTCTACCTCTACGCGCAGAAATCCAGGGTCGCGTC ACGATGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTAATACTGTGCACGCGGTCTGACTTAC TCTATGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCTGCTAGC	214
5E8 VL nt	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAA CCGGCGAGCATTTCTTGCCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGC TACAATATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTG CTGATCTACCTGGGCTCTAACC GCGCTTCCGGTGTAACGGACCGTTTCAGC GGCTCTGGATCCGGCACCGATTTACGTTGAAAATCAGCCGTGTTGAAGCA GAAGACGTGGGCGTTTATTACTGTATGCAGGCACTGCAGATTCCAAACACT TTTGGTCAAGGCACCAAGGTGCAAAATTAACGTACG	215
12A4 VH nt	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGTCC CTGAGACTCTCCTGTGCAAGCTCCCGATTACCTTTAGCAGTTATGCCATG AGCTGGGTCCGCGAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATT AGTGGTAGTGGTGGTAGCACATACTACGCACTCCGTGAAGGGCCGGTTC ACCATCTCCAGAGACAAATTC AAGAACAGCTGTATCTGCAGATGAACAGC CTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAATACGCTTACGCT CTGGACTACTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGTGCTAGC	216
12A4 VL nt	GAAATCGTGTTAACGCACTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAA AGAGCCACCCTCTCTTGCAAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTA GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCAGGCTCCTCATCTATGGA GCATCCAGCAGGGCCACTGGCATCCAGACAGGTTCACTGGCAGTGGATCC GGGACAGACTTCACTCTACCATCAGCAGACTGGAGCCTGAAGATTTTGA GTGTATTACTGTGAGCAGCATGGCAGCAGCAGCAGCTTCGGCCAGGGGACC AAAGTGGAATCAAACGTACG	217
7A3 VH nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCC GTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTTATTACATG CACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCAAGCGGTGGCTCTACCTCTACGCGCAGAAATCCAGGGTCGCGTC ACGATGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTAATACTGTGCACGCGGTGACTTCTCT GCTGGTCGTCTGATGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCT TCTGCTAGC	218
7A3 VL nt	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAA CCGGCGAGCATTTCTTGCCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGC TACAATATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTG CTGATCTACCTGGGCTCTAACC GCGCTTCCGGTGTAACGGACCGTTTCAGC GGCTCTGGATCCGGCACCGATTTACGTTGAAAATCAGCCGTGTTGAAGCA GAAGACGTGGGCGTTTATTACTGTATGCAGGCACTGCAGACCCACCAATT ACCTTTGGTCAAGGCACCAAGGTGCAAAATTAACGTACG	219
6E10 VH nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCC GTTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTTATTACATG CACTGGGTTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATT AACCAAGCGGTGGCTCTACCTCTACGCGCAGAAATCCAGGGTCGCGTC ACGATGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGC CTGCGTTCTGAAGATACTGCAGTGTAATACTGTGCACGCGGTGACTACAA GCTTTCGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCTGCTAGC	220
6E10 VL nt	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAA CCGGCGAGCATTTCTTGCCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGC	221

-222-

	TACAACTATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACCGCGCTTCGGGTGTACCGGACCGTTTCAGCGGCTCTGGATCCGGCACCAGATTTACAGTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTACTGTATGCAGGCATGGCATAGCCCAACTTTTGGTCAAGGCACCAAGGTCGAAATTAACGTACG	
12F9 VH nt	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCCGTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACTTCTTATTACATGCACTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAACCAAGCGGTGGCTTACCTCCTACGCGCAGAAATCCAGGGTCGCGTCAAGATGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCTGCGTTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGCTACTTACACTATGGACTATTGGGGTCAAGGCACCCCTCGTAACGGTTTCTTCTGCTAGC	222
12F9 VL nt	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAAACCGGCGAGCATTTCTTGGCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGCTACAACTATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTGCTGATCTACCTGGGCTCTAACCGCGCTTCGGGTGTACCGGACCGTTTCAGCGGCTCTGGATCCGGCACCAGATTTACAGTTGAAAATCAGCCGTGTTGAAGCAGAAGACGTGGGCGTTTATTACTGTATGCAGGCAGTGCAGACCCCAATTACTTTTGGTCAAGGCACCAAGGTCGAAATTAACGTACG	223

Name	Sequence	Seq ID No
pETR11646 Mov19 VH- CH1-Fchole PG/LALA	CAGGTGCAGCTGCAGCAGTCTGGCGCCGAGCTCGTGAACCTGGCGCCTCCGTGAAGATCAGCTGCAAGGCAGCGGTACAGCTTACCCGGCTACTTCATGAACTGGGTCAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCAGAATCCACCCCTACGACGGCGACACCTTCTACAACCAGAACTTCAAGGACAAGGCCACCCCTGACCGTGGACAAGAGCAGCAACACCGCCACATGGAAGTGTGAGCTGACACAGCGAGGACTTCGCCGTGTACTACTGCACAGATACGACGGCAGCCGGCCATGGATTATTGGGGCCAGGGCACCACCGTGACAGTGTCCAGCGCTAGCACCAAGGGCCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACAGCGGCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCCGTGACCGTGTCTCTGGAAACAGCGGAGCCCTGACCTCCGGCGTGCACACCTTCCCCCGCTGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCAACCGTGCTTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACACAAAGCCAGCAACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAGCTGCAGGGGACCCGTCACTCTTCTCTTCCCCCAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAAGCCTCTCACCGTCTGCAACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACACAGGTGTGCACCTGTCCCCCATCCCGGATGAGCTGACCAAGAACAGGTGAGCCTCTCGTGCGCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCGTGAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	224
pETR11647 Mov19 VH- CH1-CD3 VH-CL- Fcknob PG/LALA	CAGGTGCAGCTGCAGCAGTCTGGCGCCGAGCTCGTGAACCTGGCGCCTCCGTGAAGATCAGCTGCAAGGCAGCGGTACAGCTTACCCGGCTACTTCATGAACTGGGTCAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCAGAATCCACCCCTACGACGGCGACACCTTCTACAACCAGAACTTCAAGGACAAGGCCACCCCTGACCGTGGACAAGAGCAGCAACACCGCCACATGGAAGTGTGAGCTGACACAGCGAGGACTTCGCCGTGTACTACTGCACAGATACGACGGCAGCCGGCCATGGATTATTGGGGCCAGGGCACCACCGTGACAGTGTCCAGCGCTAGCACAAAGGGCCCCAGCGTGTTCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCCGAGCCTGTGACCGTGTCTCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCAGCCGTGTCTGCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTGGTCAACCGTGCTAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAAC	225

-223-

	<p>CACAAGCCCAGCAACACCAAAGTGGACAAGAAGGTGGAGCCCCAAGAGCTGT GATGGCGGAGGAGGGTCCGGAGGCGGAGGATCCGAAGTGCAGCTGGTGGAA AGCGGCGGAGGCTGGTGCAGCCTAAGGGCTCTCTGAAGCTGAGCTGTGCC GCCAGCGGCTTACCTTCAACACCTACGCCATGAAGTGGGTGCGCCAGGCC CCTGGCAAAGGCTGGAATGGGTGGCCCGGATCAGAAGCAAGTACAACAAT TACGCCACCTACTACGCCGACAGCGTGAAGGACCGGTTACCATCAGCCGG GACGACAGCCAGAGCATCCTGTACCTGCAGATGAACAACCTGAAAACCGAG GACACCGCCATGTACTACTGCTGCGGCACGGCAACTTCGGCAACAGCTAT GTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCTCGTGACAGTGTCTGCT GCTAGCGTGGCGCTCCCTCCGTGTTTATCTTTCCCCATCCGATGAACAG CTGAAAAGCGGCACCGCTCCGTGCTGTCTGCTGAACAATTTTACCT AGGGAAGCTAAAGTGCAGTGGAAAGTGGATAACGCAGTGCAGTCCGGCAAC TCCAGGAATCTGTGACAGAACAGGACTCCAAGGACAGCACCTACTCCCTG TCCTCCACCTGACACTGTCTAAGGCTGATTATGAGAAACACAAAGTCTAC GCCTGCGAAGTACCCATCAGGGCCTGAGCTCGCCCCGTACAAAGAGCTTC AACAGGGGAGAGTGTGACAAGACCCACACCTGTCCCCCTGTCTGCCCCCT GAAGCTGCTGGCGGCCCTTCTGTGTTCTGTTCCTCCCCCAAAGCCAAAGAC ACCTGATGATCAGCCGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTG TCCACGAGGACCTGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAA GTGCACAACGCCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTAC CGTGTGGTTCAGCGTCTCACCCTGCTGCACAGGACTGGCTGAATGGCAAG GAGTACAAGTGAAGGTCTCCAACAAAGCCCTCGGCGCCCCATCGAGAAA ACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCTG CCCCATGCCGGGATGAGCTGACCAAGAACCAGGTGAGCTGTGGTGCCTG GTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG CAGCCGAGAACTACAAGACCACGCTCCCGTGTGGACTCCGACGGC TCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG GGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACGCAGAAGAGCTCTCCCTGTCTCCGGGTAAA</p>	
pETR11644 Mov19 LC	<p>GACATCGAGCTGACCCAGAGCCCTGCCTCTCTGGCCGTGTCTCTGGGACAG AGAGCCATCATCAGCTGCAAGGCCAGCCAGAGCGTGTCTTTCGGCGCACCC TCTCTGATGCACTGGTATCACCAGAAGCCCGGCCAGCAGCCCCAAGCTGCTG ATCTACAGAGCCAGCAACCTGGAAGCCGGCGTGCACCAAGATTTCCGGC AGCGGCAGCAAGACCGACTTCACCTGAACATCCACCCCGTGGAGAAGAG GACGCGCCCTACTACTGCCAGCAGAGCAGAGAGTACCCCTACACCTTC GGCGGAGGCACCAAGCTGGAAATCAAGCGTACGGTGGCTGCACCATCTGTC TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTT GTGTGCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGGAAAG GTGGATAACGCCCTCCAATCGGGTAACTCCAGGAGAGTGTACAGAGCAG GACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACCGTGGAGCAAA GCAGACTACGAGAAACACAAAGTCTACGCTGCGAAGTACCCATCAGGGC CTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT</p>	226

Variant	Sequence	Seq ID No
16D5 VH_D52d E	<p>GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGCGGTTCCC TGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAACGCGTGGATGAG CTGGGTTCCGCGAGGCCCGGGCAAAGGCTCGAGTGGGTGGTGGTATCAAG TCTAAAACTGAGGGTGGCACACGGATTACGCGGCTCCAGTTAAAGGTCGTT TTACCATTTCCCGCAGCATAGCAAAAACACTCTGTATCTGCAGATGAACTC TCTGAAAACCTGAAGACACCGCAGTCTACTACTGTACTACCCCGTGGGAATGG TCTTGGTACGATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCC</p>	261
16D5 VH_D52d Q	<p>GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGCGGTTCCC TGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAACGCGTGGATGAG CTGGGTTCCGCGAGGCCCGGGCAAAGGCTCGAGTGGGTGGTGGTATCAAG TCTAAAACTCAGGGTGGCACACGGATTACGCGGCTCCAGTTAAAGGTCGTT TTACCATTTCCCGCAGCATAGCAAAAACACTCTGTATCTGCAGATGAACTC TCTGAAAACCTGAAGACACCGCAGTCTACTACTGTACTACCCCGTGGGAATGG TCTTGGTACGATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCC</p>	262
CD3_VH	<p>GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAAACCGGCGGTTCCC TGAGACTGAGCTGTGCCCGCAGCGGCTTACCTTCAGCACCTACGCCATGAA</p>	263

-224-

N100A	CTGGGTGCGCCAGGCCCTGGCAAAGGCCTGGAATGGGTGTCCCGGATCAGA AGCAAGTACAACAACCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGT TCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTGCAGATGAACAG CCTGCGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTC GGCGCCAGCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCCCTCGTGA CCGTGTCAAGC	
CD3_VH S100aA	GAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTC TGAGACTGAGCTGTGCCGCCAGCGGCTTACCTTCAGCACCTACGCCATGAA CTGGGTGCGCCAGGCCCTGGCAAAGGCCTGGAATGGGTGTCCCGGATCAGA AGCAAGTACAACAACCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGT TCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTGCAGATGAACAG CCTGCGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGCAACTTC GGCAACGCCCTATGTGTCTTGGTTTGCCTACTGGGGCCAGGGCACCCCTCGTGA CCGTGTCAAGC	264
16D5 [VHCH1] - CD3[VHC H1- N100A]- Fcknob_P GLALA	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAACCGGGCGGTTCCC TGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAACGCGTGGATGAG CTGGGTTCGCCAGGCCCGGGCAAAGGCCTCGAGTGGGTGGTGGTATCAAG TCTAAACTGACGGTGGCACCAGGATTACGCGGCTCCAGTTAAAGGTCGTT TTACCATTTCCCGCAGCATAGCAAAAACACTCTGTATCTGCAGATGAACCTC TCTGAAAACCTGAAGACACCGCAGTCTACTACTGTACTACCCCGTGGGAATGG TCTTGGTACGATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCCGCTA GCACAAGGGCCCTAGCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCACAAAG CGGCGGAACAGCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCGAGCCCC GTGACAGTGTCTTGGAACAGCGGAGCCCTGACAAGCGGCGTGACACACTTCC CTGCGCGTGTCTGCAGAGCAGCGGCTGTACTCCCTGAGCAGCGTGGTCACCGT GCCCTAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAG CCAGCAACACCAAAGTGGAACAAGAAGGTGGAGCCCAAGAGCTGTGATGGCG GAGGAGGGTCCGGAGGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGG CGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGC TTCACCTTCAGCACCTACGCCATGAACCTGGGTGCGCCAGGCCCTGGCAAAG GCCTGGAATGGGTGTCCCGATCAGAAGCAAGTACAACAACCTACGCCACTA CTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAG AACACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGT ACTATTGTGTGCGGCACGGCAACTTCCGCGCCAGCTATGTGTCTTGGTTTGC CTACTGGGGCCAGGCCACCCCTCGTGACCGTGTCAAGCGCTAGTACCAAGGGC CCCAGCGTGTTCCTTCCCTGGCACCCAGCAGCAAGAGCAATCTGGCGGAACAG CCGCTCTGGGCTGTCTGGTGAAAGACTACTTCCCGAGCCCGTGACCGTGTCT TTGGAATCTTGGCGCCCTGACAGCGGCGTGACACCTTTCAGCCCGTGTCTG CAGAGCAGCGGCTGTACTCCTGTCTCCGTGGTCACCGTGCCCTCTAGCT CCCTGGGAACACAGACATATATCTGTAATGTCAATCAAGCCCTTCCAACAC CAAAGTCGATAAGAAAGTCGAGCCCAAGAGCTGCGACAAAACCTACACATGC CCACCGTGCCCGACCTGAAGCTGCAGGGGGACCGTCAGTCTTCTCTTCC CCCCAAAACCAAGGACACCCTCATGATCTCCCGACCCCTGAGGTACATG CGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT ACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCTGCACCCAGGACTG GCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAGCCCTCGGCGCC CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGG TGTAACCCCTGCCCCATGCGGGATGAGCTGACCAAGAACCAGGTGAGCCT GTGGTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACCTACAAGACCAGCCTCCCGTGTGGACT CCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGAACAAGAGCAGGTG GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC CACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	265
16D5- Fchole- PGLALA	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAACCGGGCGGTTCCC TGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAACGCGTGGATGAG CTGGGTTCGCCAGGCCCGGGCAAAGGCCTCGAGTGGGTGGTGGTATCAAG TCTAAACTGACGGTGGCACCAGGATTACGCGGCTCCAGTTAAAGGTCGTT TTACCATTTCCCGCAGCATAGCAAAAACACTCTGTATCTGCAGATGAACCTC TCTGAAAACCTGAAGACACCGCAGTCTACTACTGTACTACCCCGTGGGAATGG TCTTGGTACGATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCCGCTA GCACAAGGGCCCTAGCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCACAAAG CGGCGGAACAGCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCGAGCCCC GTGACAGTGTCTTGGAACAGCGGAGCCCTGACAAGCGGCGTGACACACTTCC CTGCGCGTGTCTGCAGAGCAGCGGCTGTACTCCCTGAGCAGCGTGGTCACCGT GCCCTAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAG CCAGCAACACCAAAGTGGAACAAGAAGGTGGAGCCCAAGAGCTGTGATGGCG GAGGAGGGTCCGGAGGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGG CGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGC TTCACCTTCAGCACCTACGCCATGAACCTGGGTGCGCCAGGCCCTGGCAAAG GCCTGGAATGGGTGTCCCGATCAGAAGCAAGTACAACAACCTACGCCACTA CTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAG AACACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGT ACTATTGTGTGCGGCACGGCAACTTCCGCGCCAGCTATGTGTCTTGGTTTGC CTACTGGGGCCAGGCCACCCCTCGTGACCGTGTCAAGCGCTAGTACCAAGGGC CCCAGCGTGTTCCTTCCCTGGCACCCAGCAGCAAGAGCAATCTGGCGGAACAG CCGCTCTGGGCTGTCTGGTGAAAGACTACTTCCCGAGCCCGTGACCGTGTCT TTGGAATCTTGGCGCCCTGACAGCGGCGTGACACCTTTCAGCCCGTGTCTG CAGAGCAGCGGCTGTACTCCTGTCTCCGTGGTCACCGTGCCCTCTAGCT CCCTGGGAACACAGACATATATCTGTAATGTCAATCAAGCCCTTCCAACAC CAAAGTCGATAAGAAAGTCGAGCCCAAGAGCTGCGACAAAACCTACACATGC CCACCGTGCCCGACCTGAAGCTGCAGGGGGACCGTCAGTCTTCTCTTCC CCCCAAAACCAAGGACACCCTCATGATCTCCCGACCCCTGAGGTACATG CGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT ACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCTGCACCCAGGACTG GCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAGCCCTCGGCGCC CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGG TGTAACCCCTGCCCCATGCGGGATGAGCTGACCAAGAACCAGGTGAGCCT GTGGTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACCTACAAGACCAGCCTCCCGTGTGGACT CCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGAACAAGAGCAGGTG GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC CACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	266

-225-

	GCACCAAGGGCCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAG CGGCGGCACAGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCC GTGACCGTGTCTGGAAACAGCGGAGCCCTGACCTCCGGCGTGACACCTTCC CCGCCGTGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCACCGT GCCTTTAGCAGCCTGGGCAACCAGACCTACATCTGCAACGTGAACCACAAG CCCAGCAACACCAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGCGACAAAA CTCACACATGCCACCCTGCGCCAGCACCTGAAGCTGCAGGGGGACCGTCAGT CTTCCTCTTCCCCCAAACCCAAGGACACCTCATGATCTCCCGGACCCCT GAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCTTGAGGTCAAGT TCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTG CACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAG CCCTCGCGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGCGAGCCCCG AGAACCACAGGTGTGCACCTGCCCCCATCCCGGGATGAGCTGACCAAGAAC CAGGTACGCTCTCGTGCAGTCAAAAGGCTTCTATCCAGCGACATCGCCG TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCC CGTGCTGGACTCCGACGGCTCCTTCTTCTCGTGAGCAGCTCACCGTGGAC AAGAGCAGGTGGCAGCAGGGGAACGCTTCTCATGCTCCGTGATGCATGAGG CTCTGCACAACCGCTTACGCGAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
CD3-CLC	CAGGCGTGTGACCCAGGAACCCAGCCTGACAGTGTCTCCTGGCGGCACCG TGACCCGTGACATGTGGCAGTTCTACAGCGCCGTGACCACCAGCAACTACGC CAACTGGGTGCAGGAAAAGCCCGGCCAGGCCTTCAGAGGACTGATCGGCGGC ACCAACAAGAGAGCCCCCTGGCACCCCTGCCAGATTACGCGGATCTCTGCTGG GAGGAAAGGCCGCCCTGACACTGTCTGGCGCCAGCCAGAAGATGAGGCCGA GTACTACTGCGCCTGTGGTACAGCAACCTGTGGGTGTTGCGCGGAGGCACC AAGCTGACAGTCTAGGTCAACCCAAGGCTGCCCCAGCGTGACCTGTCTTCC CCCCAGCAGCGAGGAACCTGACGGCCAACAAGGCCACCTGGTCTGCCTGAT CAGCGACTTCTACCCAGGCGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGC CCCGTGAAGGCCGCGGTGGAGACCACCACCCAGCAAGCAGAGCAACAACA AGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCGAGCAGTGAAGAGCCA CAGGTCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAGAAAACC GTGGCCCCCACCAGTGCAGC	267
16D5 [VHCH1] - CD3[VHC H1- S100aA]- Fcknob_P GLALA	GAGGTGCAATTGGTTGAATCTGGTGGTGGTCTGGTAAACCGGGCGGTTCCC TGCGTCTGAGCTGCGCGGCTTCCGGATTACCTTCTCCAACCGCTGGATGAG CTGGGTTCCGACGCCCCGGGCAAAGGCCTCGAGTGGGTGGTGTATCAAG TCTAAACTGACGGTGGCACACGGATTACGCGGCTCCAGTTAAAGGTGCTT TTACCATTTCCGCGACGATAGCAAAACACTCTGTATCTGCAGATGAACTC TCTGAAACTGAAGACACCGCAGTCTACTACTGTACTACCCCGTGGGAATGG TCTTGGTACGATTATTGGGGCCAGGGCAGCTGGTTACGGTGTCTTCCGCTA GCACAAAGGGCCCTAGCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCAACAAG CGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCCGAGCCC GTGACAGTGTCTTGGAAACAGCGGAGCCCTGACAAGCGGCGTGACACTTTCC CTGCCGTGTGCAGAGCAGCGGCTGTACTCCCTGAGCAGCGTGGTCACCGT GCCTAGCAGCAGCCTGGGCAACCAGACCTACATCTGCAACGTGAACCACAAG CCCAGCAACACCAAAGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGATGGCG GAGGAGGGTCCGAGGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGG CGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGC TTCACCTTCAGCACCTACGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAG GCCTGGAATGGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTA CTACGCCGACAGCGTGAAGGGCCGCTTACCATCAGCCGGGACGACAGCAAG AACACCTGTACTGTGAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGT ACTATTGTGTGCGGCACGGCAACTTCGGCAACGCCTATGTGTCTTGGTTTGC CTACTGGGGCCAGGGCACCTCGTGACCGTGTCAAGCGTAGTACCAAGGGC CCCAGCGTGTCCCCCTGGCACCCAGCAGCAAGAGCACATCTGGCGGAACAG CCGCTCTGGGCTGTCTGGTGAAGACTACTTCCCCGAGCCCGTGACCGTGTCT TTGGAACCTTGGCGCCCTGACCAAGCGCGTGACACCTTCCAGCCGTGTCTG CAGAGCAGCGGCTGTACTCCCTGTCTCCGTGGTCACCGTGCCCTCTAGCT CCCTGGGAACACAGACATATATCTGTAATGTCAATCACAAGCCTTCCAACAC CAAAGTCGATAAGAAAGTCGAGCCCAAGAGCTGCGACAAAACCTCACACATGC CCACCGTGCCCAAGCACTGAAGCTGCAGGGGGACCGTCAGTCTTCTCTTCC CCCCAAACCCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATG	268

	<p>CGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGT ACAACAGCACGTACCGTGTGGTTCAGCGTCCTCACCCTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCC CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGG TGTACACCTTGCCCCATGCCGGATGAGCTGACCAAGAACCAGGTACGCCT GTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAG AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACT CCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCCTGGACAAGAGCAGGTG GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC CACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA</p>	
<p>9D11 [VHCH1] - CD3[VHC L- N100A]- Fcknob_P GLALA</p>	<p>CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGCTTCCG TTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCAC'TTCTATTACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCCCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTG GACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCTGCTAGCACAAAGG GCCCCAGCGTGTCCCTCTGGCCCTTAGCAGCAAGAGCACATCTGGCGGAAC AGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCTGTGACCGTG TCCTGGAACTCTGGCGCCCTGACAAGCGCGTGCACACCTTTCAGCCGTGC TGCAGAGCAGCGCCCTGTACTCTCTGAGCAGCGTGGTCAACGTGCCTAGCAG CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCAAGCCAGCAAC ACCAAAGTGGACAAGAAGGTGGAGCCCCAAGAGCTGTGATGGCGGAGGAGGT CCGGAGCGGAGGATCCGAGGTGCAGCTGCTGGAATCTGGCGCGGACTGGT GCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCTTC AGCACCTACCGCATGAACTGGGTGCGCCAGGCCCTTGGCAAAGCCTGGAAT GGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTACTACGCCGA CAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAACACCTTG TACCTGCAGATGAACAGCCTGCCGGCCGAGGACACCGCCGTGTACTATTGTG TGCGGCACGGCAACTTCGGCGCCAGCTATGTGTCTTGGTTTGCCTACTGGGG CCAGGGCACCCCTCGTGACCGTGTCAAGCGCTAGTGTGGCCGCTCCCTCCGTG TTTATCTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACCGCTCCGTG TGTGTCTGCTGAACAATTTTACCTAGGGAAGCTAAAGTGCAGTGGAAAGT GGATAACGCACCTGCAGTCCGGCACTCCAGGAATCTGTGACAGAACAGGAC TCCAAGGACAGCACCTACTCCCTGTCTCCACCTGACACTGTCTAAGGCTG ATTATGAGAAACACAAAGTCTACGCCTGCGAAGTCACCATCAGGGCCTGAG CTCGCCCGTCAAAAGAGCTTCAACAGGGGAGAGTGTGACAAGACCCACACC TGTCCCCCTTGTCTGCCCTGAAGCTGCTGGCGGCCCTTCTGTGTTCTGTG TCCCCCAAAGCCCAAGGACACCTGATGATCAGCCGGACCCCGAAGTGAC CTGCGTGGTGGTGGATGTGTCCACGAGGACCTGAAGTGAAGTTCAATTGG TACGTGGACGGCGTGAAGTGCACAACGCCAAGACAAAGCCGCGGGAGGAGC AGTACAACAGCAGTACCGTGTGGTCAAGCTCCTCACCCTCCTGCACCAGGA CTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAGCCCTCGGC GCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCAC AGGTGTACACCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTGAG CCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG GAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGTGTGG ACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCCTGGACAAGAGCAG GTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC AACCCTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA</p>	269
<p>9D11- Fchole</p>	<p>CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAAACCGGGCGCTTCCG TTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCAC'TTCTATTACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCCCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTG GACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCTGCTAGCACCAAGG GCCCCCTCCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCACAGCGGCGGCAC AGCCGCTCTGGGCTGCCTGGTCAAGGACTACTTCCCGAGCCCGTGACCGTG TCCTGGAAACAGCGGAGCCTGACCTCCGGCGTGCACACCTTCCCGCCGTGC</p>	270

-227-

	TGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTCAACCGTGCCTTCTAG CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAAC ACCAAGGTGGACAAGAAGGTGGAGCCCCAAGAGCTGCGACAAAACCTCACACAT GCCACCGTGCCAGCACCTGAAGCTGAGGGGGACCGTCAGTCTTCTCTT CCCCCAAAACCAAGGACACCCCTCATGATCTCCCGACCCCTGAGGTCA TGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGT ACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA GTACAACAGCACGTACCGTGTGGTCAAGCTCCTACCGTCTTGCACCAGGAC TGGTCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAACAAAGCCCTCGGCG CCCCATCGAGAAAACCATCTCCAAAGCCAAGGGCAGCCCCGAGAACCACA GGTGTGCACCCCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTCA CTCTCGTGGCAGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCGAGCCGAGAACAACTACAAGACCACGCTCCCGTGTGGA CTCCGACGGCTCTTCTTCTCGTGAAGCTCACCCTGGACAAGAGCAGG TGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA ACCACTACACGAGAAGAGCCTCTCCCTGTCTCCGGTAAA	
9D11_LC [N95Q]	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAAC CGGCGAGCATTTCTTGCCGTTCAGCCAGTCTCTGCTGACTCCAACGGCTA CAACTATCTCGATTGGTACCTGCAAAAACCGGTGAGAGCCCTCAGTCTGT ATCTACCTGGGCTCTAACCGCGCTTCCGGTGTACCGGACCGTTTCAGCGGCT CTGGATCCGGCACCGATTTCACGTTGAAAATCAGCCGTGTTGAAGCAGAAGA CGTGGGCGTTTATTACTGTATGCAGGCAAGCATTATGCAGCGGACTTTTGGT CAAGGCACCAAGGTGAAATTAACGTACGGTGGCTGCACCATCTGTCTTCA TCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCTGTTGTGTG CCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGAAGGTGGAT AACGCCCTCCAATCGGGTAACTCCAGGAGAGTGTACAGAGCAGGACAGCA AGGACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTA CGAGAAACACAAAGTCTACGCCTGCGAAGTCAACCATCAGGGCCTGAGCTCG CCCGTCAAAAGAGCTTCAACAGGGGAGAGTGT	271
CD3_VLC H1	CAGGCCGTGCTGACCCAGGAACCCAGCCTGACAGTGTCTCCTGGCGGCACCG TGACCTGACATGTGGCAGTTCTACAGGCGCGGTGACCACCAGCAACTAGCG CAACTGGGTGCAGGAAAAGCCCGCCAGGCCCTCAGAGGACTGATCGGCGGC ACCAACAAGAGAGCCCCCTGGCACCCCTGCCAGATTCAAGCGATCTCTGTGG GAGGAAAGGCCGCCCTGACACTGTCTGGCGCCAGCCAGAAGATGAGGCCGA GTACTACTGCGCCCTGTGGTACAGCAACCTGTGGGTGTTGCGCGGAGGCACC AAGCTGACAGTGTGAGCAGCGCTTCCACCAAGGCCCTTCCGTGTTTCTC TGGCTCCTAGCTCCAAGTCCACCTCTGGAGGCACCGCTGCTCTCGGATGCCT CGTGAAGGATTATTTTCTGAGCCTGTGACAGTGTCTTGAATAGCGGAGCA CTGACCTCTGGAGTGCATACTTTCCCCGCTGTGCTGCAGTCTCTGGACTGT ACAGCCTGAGCAGCGTGGTACAGTGGCCAGCAGCAGCCTGGGCACCCAGAC CTACATCTGCAACGTGAACCAAGCCAGCAACACCAAGGTGGACAAGAAG GTGGAACCCAAGTCTTGT	272
9D11 [VHCH1] - CD3[VHC H1- S100aA]- Fcknob_P GLALA	CAGGTGCAATTGGTTCAATCTGGTGTCTGAAGTAAAAAACCGGCGCTTCCG TTAAAGTGAGCTGCAAAAGCATCCGGATACACCTTCACTTCCCTATTACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCCCTACCTCCTACGCGCAGAAATCCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTTCGCTTGGCTG GACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCTGCTAGCACAAAGG GCCCCAGCGTGTTCCTCTGGCCCTAGCAGCAAGAGCACATCTGGCGGAAC AGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCTGTGACCGTG TCCTGGAACTCTGGCGCCCTGACAAGCGCGGTGCACACCTTTCCAGCCGTGC TGACAGCAGCGCCCTGTACTCTCTGAGCAGCGTGGTCAACGTGCCTAGCAG CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCAAGCCAGCAAC ACCAAGTGGACAAGAAGGTGGAGCCCCAAGAGCTGTGATGGCGGAGGAGGT CCGGAGGCGGAGGATCCGAGGTGCAGCTGTGGAATCTGGCGCGGACTGGT GCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCGCCAGCGGCTTACCTTC AGCACCTAGCCATGAACTGGGTGCGCCAGGCCCTGGCAAAGCCTGGAAT GGGTGTCCCGGATCAGAAGCAAGTACAACAACCTACGCCACCTACTACGCCGA CAGCGTGAAGGGCCGTTCAACATCAGCCGGGACGACAGCAAGAACACCCCTG TACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCGTGTACTATTGTG	273

-228-

	<p>TGCGGCACGGCAACTTCGGCAACGCCTATGTGTCTTGGTTTGCCTACTGGGG CCAGGGCACCCCTCGTGACCGTGTCAAGCGCTAGTGTGGCCGCTCCCTCCGTG TTTATCTTTCCCCCATCCGATGAACAGCTGAAAAGCGGCACCGCTCCGTG TGTGTCTGCTGAACAATTTTACCCTAGGGAAGCTAAAGTGACGTGGAAAGT GGATAACGCACTGCAGTCCGGCAACTCCCAGGAATCTGTGACAGAACAGGAC TCCAAGGACAGCACCTACTCCTGTCTCCACCCTGACACTGTCTAAGGCTG ATTATGAGAAAACAAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAG CTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGACAAGACCCACACC TGTCGCCCTTGTCTGCCCCCTGAAGCTGCTGGCGGCCCTTCTGTGTTCTGTG TCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGACCCCGAAGTGAC CTGCGTGGTGGTGGATGTGTCCACGAGGACCCTGAAGTGAAGTTCAATTGG TACGTGGACGGCGTGGAAAGTGACAACGCCAAGACAAAGCCGCGGGAGGAGC AGTACAACAGCAGTACCGTGTGGTCAAGCTCCTCACCCTCCTGCACCAGGA CTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGC GCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACAC AGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTCAG CCTGTGGTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGG GAGAGCAATGGGCAGCCGAGAACAACTACAAGACCACGCCCTCCCGTGTG ACTCCGACGGCTCCTTCTCTCTACAGCAAGCTCACCCTGGACAAGAGCAG GTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC AACCCTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA</p>	
--	--	--

Name	Sequence	Seq ID No
16D5 variant W96Y/D52 E VH	<p>GAGGTGCAATTGGTGGAAAGCGGAGGCGGCCCTCGTGAAGCCTGGCGGATCTC TGAGACTGAGCTGTGCCGCCAGCGGCTTCACTTCAGCAACGCCTGGATGAG CTGGGTGCGCCAGGCCCTGGAAAAGGACTCGAGTGGGTGGGACGGATCAAG AGCAAGACCGAGGGCGGCACCACCGACTATGCCGCCCTGTGAAGGGCCGGT TCACCATCAGCAGGGACGACAGCAAGAACACCCTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACCGCCGTGTACTACTGCACCACCCCTACGAGTGG TCTTGGTACGACTACTGGGGCCAGGGCACCCCTCGTGACCGTGTCTATCT</p>	287
W96Y/D52 E_CD3- VHCH1_F c- knob_PGL ALA pETR1494 5	<p>GAGGTGCAATTGGTGGAAAGCGGAGGCGGCCCTCGTGAAGCCTGGCGGATCTC TGAGACTGAGCTGTGCCGCCAGCGGCTTCACTTCAGCAACGCCTGGATGAG CTGGGTGCGCCAGGCCCTGGAAAAGGACTCGAGTGGGTGGGACGGATCAAG AGCAAGACCGAGGGCGGCACCACCGACTATGCCGCCCTGTGAAGGGCCGGT TCACCATCAGCAGGGACGACAGCAAGAACACCCTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACCGCCGTGTACTACTGCACCACCCCTACGAGTGG TCTTGGTACGACTACTGGGGCCAGGGCACCCCTCGTGACCGTGTCTATCTGCTA GCACAAAGGGCCCTAGCGTGTTCCTCTGGCCCCCAGCAGCAAGAGCACAAG CGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCCGAGCCC GTGACAGTGTCTTGGAAACAGCGAGCCCTGACAAGCGGCGTGCACACCTTCC CTGCCGTGTGCAGAGCAGC GGCCTGTACTCCTTGAGCAGCGTGGTCACCGTGCTAGCAGCAGCCTGGGCA CCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAAGTGGA CAAGAAGGTGGAGCCCAGAGCTGTGATGGCGGAGGAGGTCGGAGGCGGA GGATCCGAGGTGCAGCTGCTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCG GATCTCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACTTCAGCACCTACGC CATGAACCTGGGTGCGCCAGGCCCTGGCAAAGGCTGGAATGGGTGTCCCGG ATCAGAAGCAAGTACAACAACCTACGCCACCTACTACGCCGACAGCGTGAAGG GCCGGTTACCATCAGCCGGGACGACAGCAAGAACAACCTGTACCTGCAGAT GAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTATTGTGTGCGGCACGGC AAGTTGCGCAACAGCTATGTGTCTTGGTTTGCCCTACTGGGGCCAGGGCACCC TCGTGACCGTGTCAAGCGCT AGTACCAAGGGCCCCAGCGTGTCCCCCTGGCACCCAGCAGCAAGAGACAT CTGGCGGAACAGCCGCTCTGGGCTGTCTGGTGAAGACTACTTCCCCGAGCC CGTGACCGTGTCTTGGAACTCTGGCGCCCTGACCAGCGGCGTGACACCTTT CCAGCCGTGCTGCAGAGCAGCGCCTGTACTCCCTGTCTCCGTGGTCAACG TGCCCTCTAGTCCCTGGGAACACAGACATATCTGTGAATGTCAATCACAA GCCTTCCAACACCAAAGTCGATAAGAAAGTCGAGCCCAAGAGCTGCGACAAA ACTCACACATGCCCCACCGTGCCAGCACCTGAAGCTGAGGGGGACCGTCAG TCTTCTCTTCCCCCAAAACCAAGGACACCCTCATGATCTCCCGACCCC</p>	288

	<p>TGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAG TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGC GGGAGGAGCAGTACAACAGC ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCATCGA GAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC CTGCCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTGAGCCTGTGGTGCC TGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG GCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGTGGACTCCGACGGC TCTTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGG GGAACGTCTTCTCATGTCCGTGATGCATGAGGCTCTGCACAACCACCTACAC GCAGAAGAGCCTCTCCCTGTCTCCGGTAAA</p>	
W96Y/D5 2E_Fc- hole_PGL ALA_HY RF pETR1494 6	<p>GAGGTGCAATTGGTGGAAAGCGGAGGCGGCCTCGTGAAGCCTGGCGGATCTC TGAGACTGAGCTGTGCCGCCAGCGGCTTCACTTCAGCAACGCCTGGATGAG CTGGGTGCGCCAGGCCCTGGAAAAGGACTCGAGTGGGTGGGACGGATCAAG AGCAAGACCGAGGGCGGCACCACCGACTATGCCGCCCTGTGAAGGGCCGGT TCACCATCAGCAGGGACGACAGCAAGAACACCTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACCGCCGTGTACTACTGCACCACCCCTACGAGTGG TCTTGGTACGACTACTGGGGCCAGGGCACCCCTCGTGACCGTGTCTCTGTAC GCACCAAGGGCCCTCCGTGTTCCCTTGGCCCCAGCAGCAAGAGCACCAG CGGCGGCACAGCCGCTCTGGGTGTCCTGGTCAAGGACTACTTCCCCGAGCCC GTGACCGTGTCTGGAACAGCGGAGCCCTGACCTCCGGCGTGACACCTTCC CCGCCGTGCTGCAGAGTTCT GGCCTGTATAGCCTGAGCAGCGTGGTCACCGTGCCTTCTAGCAGCCTGGGCA CCCAGACCTACATCTGCAACGTGAACCAAGCCAGCAACACCAAGGTGGA CAAGAAGGTGGAGCCCCAAGAGCTGCGACAAAACCTCACACATGCCACCGTGC CCAGCACCTGAAGCTGCAGGGGACCGTCAGTCTTCTTCTTCCCCCAAAAC CCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGT GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCA CGTACCCTGTGGTCAAGCTCCTCACCGTCTGCACCAGGACTGGTGAATGG CAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCGGCGCCCCATCGAG AAAACCATCTCCAAGCCAAAGGCGAGCCCCGAGAACCACAGGTGTGACCC TGCCCCCATCCCGGGATGAG CTGACCAAGAACCAGGTGAGCCTCTCGTGCGCAGTCAAAGGCTTCTATCCCA GCGACATCGCCGTGGAGTGGGAGAGCAATGGGCGAGCCGGAGAACAACTACAA GACCACGCTCCCGTGTGACTCCGACGGCTCCTTCTTCTCTGTGAGCAAG CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGTCTCG TGATGCATGAGGCTCTGCACAACCGCTTACGCAGAAGAGCCTCTCCCTGTCT TCCGGGTAAA</p>	289
14B1 VH	<p>GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC TGAGACTCTCCTGTGCAGCCTCCGGATTACCTTTAGCAGTTATGCCATGAG CTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGT GGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCAACA TCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAGATGAACAGCCTGAG AGCCGAGGACACGGCCGTATATTACTGTGCGCGTGGTGAACCTTACCGT TACTTCGACTACTGGGGCCAAGGAACCTGGTCACCGTCTCGAGT</p>	290
14B1 VL	<p>TCTTCTGAAGTGAATCAAGATCCAGCTGTAGCGTGGCTCTGGGTGAGACTG TACGTATCACCTGCCAAGGCGATTCTCTGCGCTCCTACTACGCAAGCTGGTA CCAGCAGAAACCGGGTCAGGCCCGAGTTCTGGTGATTACGGCAAAAACAAC CGTCCGTCTGGGATCCCGGACCGTTTCTCCGGCAGCTCTTCCGGTAACACGG CGAGCCTCACCATCACTGGCGCTCAAGCAGAAGACGAGGCCGACTATTACTG TAACTCTCGGGAAGGCCACCAACCGGCTGGTGTCTTCTGGTGGCGGTACC AAGCTGACCGTCTTA</p>	291
14B1[EE]_ CD3[VLC H1]_Fc- knob_PGL	<p>GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC TGAGACTCTCCTGTGCAGCCTCCGGATTACCTTTAGCAGTTATGCCATGAG CTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGT GGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCAACA TCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAGATGAACAGCCTGAG AGCCGAGGACACGGCCGTATATTACTGTGCGCGTGGTGAACCTTACCGT TACTTCGACTACTGGGGCCAAGGAACCTGGTCACCGTCTCGAGTGTCTAGCA</p>	292

ALA pETR1497 6	CCAAGGGCCCTCCGTGTTTCTCTGGCCCCCTTCCAGCAAGTCCACCTCTGG CGGAACCTGCCGCTCTGGGCTGCCTGGTGAAGATTACTTCCCCGAGCCCGTG ACCGTGTCTCTGGAATTCTGGCGCTCTGACCTCCGGCGTGACACCTTTCCAG CTGTGCTGCAGTCTCTCCGGCCTGTACTCCCTGTCTCTCCGTCGTGACAGTGCC TCCAGTCTCTCTGGGCAACCCAGACCTACATCTGCAACGTGAACCACAAGCCC TCCAACACCAAGGTGGACGAGAAGGTGAACCCCAAGTCTCGACGCGTGGCG GAGGTTCCGGAGGCGGAGGATCCCAGGCTGTCTGACCCAGGAACCCCTCCCT GACAGTGTCTCTGGCGGCACCGTGACCTGACCTGTGGATCTTCTACCGGC GCTGTGACCACTCCAACCTACGCCAATTTGGGTGCAGGAAAAGCCCGGCCAGG CCTTCAGAGGACTGATCGCGGCACCAACAAGAGAGCCCTGGCACCCCTGC CAGATTCTCCGTTCTCTGCTGGCGGCAAGGCTGCCCTGACTCTGTCTGGT GCTCAGCCTGAGGACGAGGCCGAGTACTACTGCGCCCTGTGGTACTCCAACC TGTGGGTGTTCCGGCGGAGGCACCAAGCTGACCGTGTCTCCAGCGCTTCCAC CAAGGGACCCAGTGTGTTCCCCCTGGCCCCCAGCTCCAAGTCTACATCCGGT GGCAAGCTGCCCTGGGATGTCTCGTGAAGGACTACTTCTCTGAGCCTGTGA CAGTGTCTTGGAACAGCGGAGCCCTGACCAGCGAGTGCACACATTCCCTGC AGTGCTGCAGAGCAGCGCCTGTATAGCCTGAGCAGCGTCTGTGACCGTGCCT TCCTCTAGCCTGGGAACACAGACATATATCTGTAATGTGAATCATAAGCCCCA GTAATACCAAGTGGATAAAGAAAGTGAACCTAAGAGCTGCGATAAAGACCCA CACCTGTCCCCCTGCCCTGCTCCTGAAGCTGCTGGTGGCCCTAGCGTGTTC CTGTTCCCCCAAGGCCAAGGACACCCCTGATGATCTCCCGGACCCCGAAG TGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCCTGAAGTGAAGTTCAA TTGGTACGTGGACGGCGTGGAAAGTGACAACGCCAAGACCAAGCCTAGAGAG GAACAGTACAACCTCCACCTACCGGGTGGTGTCCGTGCTGACAGTGTGCACC AGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGCCCT GGGCGCTCCCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCCCGGGAA CCCCAGGTGTACACCTGCCCCCATGCCGGATGAGCTGACCAAGAACCAGG TCAGCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGA GTGGGAGAGCAATGGGCGAGCCGAGAAACAACATAAGACACCGCTCCCGTG CTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGA GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
14B1[EE]_ Fc- hole_PGL ALA pETR1497 7	GAGGTGCAATTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGTCCC TGAGACTCTCCTGTGCAGCCTCCGGATTACCTTTAGCAGTTATGCCATGAG CTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGT GGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTACCA TCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAGATGAACAGCCTGAG AGCCGAGGACACGGCCGTATATTAAGTGTGCGCGTGGTGAACCTTACCGT TACTTCGACTACTGGGGCCAAGGAACCTGGTACCCTCTCGAGTGTAGCA CCAAGGCCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACAGCGG CGGCACAGCCGCTCTGGGCTGCCTGGTGCAGGACTACTTCCCCGAGCCCGTG ACCGTGTCTTGAACAGCGGAGCCCTGACCTCCGGCGTGCAACCTTCCCCG CCGTGTGTCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTACCCTGCCC TTCTAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCC AGCAACACCAAGGTGGACGAGAAGGTGGAGCCCAAGAGCTGCGACAAAACCTC ACACATGCCACCGTGCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTT CCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAG GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCGTGAGGTCAAGTTCA ACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA GGAGCAGTACAACAGCACGTACCGTGTGGTCAAGCTCTCACCGTCTCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAAGCCC TCGGCGCCCCCATCGAGAAAACCATCTCCAAGGCCAAGGGCAGCCCCGAGA ACCACAGGTGTGACCCCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAG GTCAGCCTCTCGTGCAGTCAAAGGCTTCTATCCAGCGACATCGCCGTGG AGTGGGAGAGCAATGGGCGAGCCGAGAAACAACATAAGACACCGCTCCCGT GCTGGACTCCGACGGCTCCTTCTTCTCTCGTGAGCAAGCTCACCGTGGACAAG AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTC TGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	293
14B1 LC [KK]	TCTTCTGAACCTGACTCAAGATCCAGCTGTTAGCGTGGCTCTGGGTGAGACTG TAGCTATCACTGCCAAGGCGATTCTCTCGCTCCTACTACGCAAGCTGGTA CCAGCAGAAACCGGTCAGGCCCAAGTCTGTGGTATTACGGCAAAAACAAC	294

-231-

Constant lambda pETR1497 9	CGTCCGTCTGGGATCCCGGACCGTTTCTCCGGCAGCTCTTCCGGTAACACGG CGAGCCTCACCATCACTGGCGCTCAAGCAGAAGACGAGGCCGACTATTACTG TAACTCTCGGAAAGCCCCACCAACCGGCTGGTTGTCTTCGGTGGCGGTACC AAGCTGACCGTCTAGGTCAACCAAGCTGCCCCAGCGTGACCCTGTTC CCCCCAGCAGCAAGAACTGCAGGCCAACAAGGCCACCTGGTCTGCCTGAT CAGCGACTTCTACCCAGGCGCGGTGACCGTGGCTGGAAGGCCGACAGCAGC CCCGTGAAGGCCGGCGTGGAGACCACCCCCAGCAAGCAGAGCAACAACA AGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGAAGAGCCA CAGGCTCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAGAAAACC GTGGCCCCACCGAGTGCAGC	
9C7 VH	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCCG TTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACCTCCTATTACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCTCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTGGTCTTACTAC ATGGACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCT	295
9C7 VL	GATATTGTTATGACTCAATCTCCACTGTCTCTGCCGGTGACTCCAGGCGAAC CGGCGAGCATTCTTGCCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGCTA CAACTATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTGCTG ATCTACCTGGGCTCTAACC GCGCTTCCGGTGTACCCGACCGTTTCAGCGGCT CTGGATCCGGCACCGATTTACGTTGAAAATCAGCCGTGTTGAAGCAGAAGA CGTGGCGTTTTATTACTGTATGCAGGCACGGCAGACCCCACTTTTGGTCAA GGCACCAAGGTGCAAAATTA	296
9C7[EE]_ CD3[VLC H1]_Fc- knob_PGL ALA pETR1497 4	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCCG TTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACCTCCTATTACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCTCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTGGTCTTACTAC ATGGACTATTGGGGTCAAGGCACCTCGTAACGGTTTCTTCTGCTAGCACCA AGGGCCCCCTCGTGTTTCTCTGGCCCCCTTCCAGCAAGTCCACCTCTGGCGG AACTGCCGCTCTGGGCTGCCTGGTGAAGATTACTTCCCCGAGCCCGTGACC GTGTCTTGGAATTCTGGCGCTCTGACCTCCGGCGTGACACCTTTCAGCTG TGCTGCAGTCTCCGGCCTGTACTCCCTGTCTCCGTGCTGACAGTGCCCTC CAGCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACCAAGCCCTCC AACACCAAGGTGGACGAGAAGGTGAACCCAAGTCTGCGACGGTGGCGGAG GTTCCGGAGGCGGAGGATCCAGGCTGTGCTGACCCAGGAACCTCCCTGAC AGTGTCTCCTGGCGGCACCGTGACCTGACCTGTGGATCTTCTACCGGCGCT GTGACCACTCCAACTACGCCAATTGGGTGAGGAAAAGCCCGGCCAGGCCT TCAGAGGACTGATCGGCGGCACCAACAAGAGAGCCCTGGCACCCCTGCCAG ATTCTCCGGTTCTCTGCTGGGCGGCAAGGCTGCCCTGACTCTGTCTGGTGCT CAGCCTGAGGACGAGGCCGAGTACTACTGCGCCCTGTGGTACTCCAACCTGT GGGTGTTTCGGCGGAGGCACCAAGCTGACCGTGCTGTCCAGCGCTTCCACCA GGGACCCAGTGTGTTCCCCCTGGCCCCCAGCTCCAAGTCTACATCCGGTGGC ACAGCTGCCCTGGGATGTCTCGTGAAGGACTACTTCTCTGAGCCTGTGACAG TGTCTTGGAACAGCGGAGCCCTGACAGCGGAGTGACACATTCCTGTCAGT GCTGCAGAGCAGCGGCCCTGTATAGCCTGAGCAGCGTCTGACCGTGCCCTCC TCTAGCCTGGGAACACAGACATATATCTGTAATGTGAATCATAAGCCCAGTA ATACCAAAGTGATAAGAAAGTGAACCTAAGAGCTGCGATAAGACCCACAC CTGTCCCCCTGCCCTGCTCTGAAGCTGCTGGTGGCCCTAGCGTGTTCCTG TTCCCCCAAGCCCAAGGACACCCTGATGATCTCCCGGACCCCGAAGTGA CCTGCGTGGTGGTGGATGTGTCCACGAGGACCTGAAGTGAAGTTCAATTG GTACGTGGACGCGGTGAAGTGACAACGCCAAGACCAAGCCTAGAGAGGAA CAGTACAACCTCCACCTACCGGGTGGTGTCCGTGCTGACAGTGTGACACAGG ACTGGCTGAACGGCAAAGAGTACAAGTGCAAGTGTCCAACAAGGCCCTGGG CGCTCCCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCCGGGAACCC CAGGTGTACACCTGCCCCATGCCGGGATGAGCTGACCAAGAACCAGGTCA GCCTGTGGTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTG GGAGAGCAATGGGCAGCCGAGAGAACTACAAGACCAGCCTCCCGTGTGCTG GACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA	297

-232-

	GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	
9C7[EE]_ Fc- hole_PGL ALA pETR1497 5	CAGGTGCAATTGGTTCAATCTGGTGCTGAAGTAAAAAACCGGGCGCTTCCG TTAAAGTGAGCTGCAAAGCATCCGGATACACCTTCACCTTCTTATACATGCA CTGGGTTCGTCAAGCCCCGGGCCAGGGTCTGGAATGGATGGGCATCATTAAC CCAAGCGGTGGCTCTACCTCCTACGCGCAGAAATTCAGGGTCGCGTCACGA TGACCCGTGACACTAGCACCTCTACCGTTTATATGGAGCTGTCCAGCCTGCG TTCTGAAGATACTGCAGTGTACTACTGTGCACGCGGTGACTGGTCTTACTAC ATGGACTATTGGGGTCAAGGCACCCTCGTAACGGTTTCTTCTGCTAGCACCA AGGGCCCCCTCCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCG CACAGCCGCTCTGGGCTGCCTGGTTCGAGGACTACTTCCCCGAGCCCGTGACC GTGTCTGGAACAGCGGAGCCCTGACCTCCGGCGTGACACCTTCCCCGCCG TGCTGCAGAGTTCTGGCCTGTATAGCCTGAGCAGCGTGGTACCGTGCCCTTC TAGCAGCCTGGGCAACCAGACCTACATCTGCAACGTGAACCACAAGCCCAGC AACACCAAGGTGGACGAGAAGGTGGAGCCCAAGAGCTGCGACAAAACCTCACA CATGCCCCACCGTGCCCAGCACCTGAAGCTGCAGGGGGACCGTCAGTCTTCTCT CTTCCCCCAAAACCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCT ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACT GGTACGTGGACGCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGA GCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGCACCAG GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCG GCGCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACC ACAGGTGTGCACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTCT AGCCTCTCGTGCGCAGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT GGGAGAGCAATGGGCAGCCGGAGAACAACTACAGACCACGCCCTCCCGTGCT GGACTCCGACGGCTCCTTCTTCTCGTGAGCAAGCTCACCGTGGAACAAGAGC AGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA	298
9C7 LC [RK] pETR1498 0	GATATTGTTATGACTCAATCTCCTACTGTCTCTGCCGGTGACTCCAGGCGAAC CGGCGAGCATTTCTTGCCGTTCCAGCCAGTCTCTGCTGCACTCCAACGGCTA CAACTATCTCGATTGGTACCTGCAAAAACCGGGTCAGAGCCCTCAGCTGCTG ATCTACCTGGGCTCTAACC CGCTTCCGGTGTACCGGACCGTTTCAGCGGCT CTGGATCCGGCACCGATTTCAGTTGAAAATCAGCCGTGTTGAAGCAGAAGA CGTGGGCGTTTATTACTGTATGACGGCAGGCAGACCCCAACTTTTGGTCAA GGCACCAAGGTCGAAATTAAACGTACGGTGGCTGCACCATCTGTCTTCATCT TCCCGCCATCTGATCGGAAGTTGAAATCTGGAACCTGCCTCTGTTGTGTGCCT GCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAAC GCCCTCCAATCGGGTAACTCCAGGAGAGTGTACAGAGCAGGACAGCAAGG ACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGA GAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGCGCTGAGCTCGCCC GTCACAAAGAGCTTCAACAGGGGAGAGTGT	299

* * *

Although the foregoing invention has been described in some detail by way of illustration and
5 example for purposes of clarity of understanding, the descriptions and examples should not be
construed as limiting the scope of the invention. The disclosures of all patent and scientific
literature cited herein are expressly incorporated in their entirety by reference.

-233-

Claims

1. A T cell activating bispecific antigen binding molecule comprising
 - (iii) a first antigen binding moiety which is a Fab molecule capable of specific binding
5 to CD3, and which comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34;
 - 10 (iv) a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1).
2. The T cell activating bispecific antigen binding molecule of claim 1, wherein the first antigen binding moiety comprises a variable heavy chain comprising an amino acid
15 sequence of SEQ ID NO: 36 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
3. The T cell activating bispecific antigen binding molecule of claim 1 or 2, additionally comprising
 - 20 (v) a third antigen binding moiety capable of specific binding to FolR1.
4. The T cell activating bispecific antigen binding molecule of claim 3, wherein the second and third antigen binding moiety capable of specific binding to FolR1 comprise identical heavy chain complementarity determining region (CDR) and light chain CDR sequences.
25
5. The T cell activating bispecific antigen binding molecule of claim 3 or 4, wherein the third antigen binding moiety is identical to the second antigen binding moiety.
6. The T cell activating bispecific antigen binding molecule of any of claims 1 to 5, wherein at least one of the second and third antigen binding moiety is a Fab molecule.
- 30 7. The T cell activating bispecific antigen binding molecule of any of claims 1 to 6, additionally comprising

-234-

- (vi) an Fc domain composed of a first and a second subunit capable of stable association.
8. The T cell activating bispecific antigen binding molecule of claim 7, wherein the first
5 antigen binding moiety and the second antigen binding moiety are each connected at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain.
9. The T cell activating bispecific antigen binding molecule of claims 7 or 8, wherein a third
10 antigen binding moiety is connected at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, optionally via a peptide linker.
10. The T cell activating bispecific antigen binding molecule of any of the preceding claims, wherein the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR)
15 amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.
11. The T cell activating bispecific antigen binding molecule of claim 10, wherein the
20 antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 15 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
12. The T cell activating bispecific antigen binding molecule of any of claims 1 to 9, wherein
25 the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 56 and SEQ ID NO: 57 and at least one light chain CDR selected from the group of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 65.
30
13. The T cell activating bispecific antigen binding molecule of claim 12, wherein the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1)

-235-

comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 55 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 64.

14. The T cell activating bispecific antigen binding molecule of any of the preceding claims, wherein the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 50 and at least one light chain CDR selected from the group of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54.
15. The T cell activating bispecific antigen binding molecule of claim 14, wherein the antigen binding moiety capable of specific binding to FolR1 comprises:
- (a) a complementarity determining region heavy chain 1 (CDR-H1) amino acid sequences of SEQ ID NO: 8;
 - (b) a CDR-H2 amino acid sequence of SEQ ID NO: 9;
 - (c) a CDR-H3 amino acid sequence of SEQ ID NO: 50;
 - (d) a complementarity determining region light chain 1 (CDR-L1) amino acid sequence of SEQ ID NO: 52;
 - (e) a CDR-L2 amino acid sequence of SEQ ID NO: 53, and
 - (f) a CDR-L3 amino acid sequence of SEQ ID NO: 54.
16. The T cell activating bispecific antigen binding molecule of claim 15, wherein the antigen binding moiety capable of specific binding to FolR1 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 49 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 51.
17. The T cell activating bispecific antigen binding molecule of any of claims 1 to 9, wherein the antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1) comprises at least one heavy chain complementarity determining region (CDR) amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 275 and SEQ ID NO: 315 and at least one light chain CDR selected from the group of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34.
18. The T cell activating bispecific antigen binding molecule of claim 17, wherein the antigen binding moiety capable of specific binding to FolR1 comprises:

-236-

- (a) a complementarity determining region heavy chain 1 (CDR-H1) amino acid sequences of SEQ ID NO: 16;
- (b) a CDR-H2 amino acid sequence of SEQ ID NO: 275;
- (c) a CDR-H3 amino acid sequence of SEQ ID NO: 315;
- 5 (d) a complementarity determining region light chain 1 (CDR-L1) amino acid sequence of SEQ ID NO: 32;
- (e) a CDR-L2 amino acid sequence of SEQ ID NO: 33, and
- (f) a CDR-L3 amino acid sequence of SEQ ID NO: 34.
- 10 19. The T cell activating bispecific antigen binding molecule of claim 18, wherein the antigen binding moiety capable of specific binding to FolR1 comprises a variable heavy chain comprising an amino acid sequence of SEQ ID NO: 274 and a variable light chain comprising an amino acid sequence of SEQ ID NO: 31.
20. The T cell activating bispecific antigen binding molecule of any of the preceding claims which binds to a human FolR1.
- 15 21. The T cell activating bispecific antigen binding molecule of any of the preceding claims which binds to a human FolR1 and a cynomolgus monkey FolR1.
22. The T cell activating bispecific antigen binding molecule of any of claims 1 to 16, which binds to a human FolR1, a cynomolgus monkey FolR1 and a murine FolR1.
- 20 23. The T cell activating bispecific antigen binding molecule of any of claims 17 to 19, which binds to a human FolR1 and a cynomolgus monkey FolR1 and not a murine FolR1.
24. The T cell activating bispecific antigen binding molecule of claim 13 or 16, wherein the first antigen binding moiety is a crossover Fab molecule wherein either the variable or the constant regions of the Fab light chain and the Fab heavy chain are exchanged.
- 25 25. The T cell activating bispecific antigen binding molecule of any one of the preceding claims, comprising not more than one antigen binding moiety capable of specific binding to CD3.
26. The T cell activating bispecific antigen binding molecule of any of claims 7 to 25, wherein the first and the second antigen binding moiety and the Fc domain are part of an immunoglobulin molecule.

-237-

27. The T cell activating bispecific antigen binding molecule of claim 26, wherein the Fc domain is an IgG class immunoglobulin, specifically an IgG₁ or IgG₄, Fc domain.
28. The T cell activating bispecific antigen binding molecule of any one of claims 7 to 27, wherein the Fc domain is a human Fc domain.
- 5 29. The T cell activating bispecific antigen binding molecule of any one of claims 7 to 28, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.
- 10 30. The T cell activating bispecific antigen binding molecule of claim 29, wherein in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.
- 15 31. The T cell activating bispecific antigen binding molecule of any one of claims 7 to 30, wherein the Fc domain comprises at least one amino acid substitution that reduces binding to an Fc receptor and/or effector function, as compared to a native IgG₁ Fc domain.
- 20 32. The T cell activating bispecific antigen binding molecule of claim 31, wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce binding to an activating Fc receptor and/or effector function wherein said amino acid substitutions are L234A, L235A and P329G (Kabat numbering).
- 25 33. The T cell activating bispecific antigen binding molecule of claims 27 or 28, wherein the Fc receptor is an Fcγ receptor.
34. The T cell activating bispecific antigen binding molecule of any one of claims 31 to 33, wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).

-238-

35. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 34,
wherein the T cell activating bispecific antigen binding molecule induces proliferation of
a human CD3 positive T cell in vitro.
- 5 36. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 35,
wherein the T cell activating bispecific antigen binding molecule induces human
peripheral blood mononuclear cell mediated killing of a FolR1-expressing human tumor
cell in vitro.
- 10 37. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 36,
wherein the T cell activating bispecific antigen binding molecule induces T cell mediated
killing of a FolR1-expressing human tumor cell in vitro.
38. The T cell activating bispecific antigen binding molecule of claim 36 or 37, wherein the
FolR1-expressing human tumor cell is a Hela, Skov-3, or a cell.
- 15 39. The T cell activating bispecific antigen binding molecule of any one of claims 37 to 38,
wherein the T cell activating bispecific antigen binding molecule induces T cell mediated
killing of the FolR1-expressing human tumor cell in vitro with an EC50 of between about
36 pM and about 39573 pM after 24 hours.
- 20 40. The T cell activating bispecific antigen binding molecule of any one of claims 37 to 38,
wherein the T cell activating bispecific antigen binding molecule induces T cell mediated
killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 36 pM after 24
hours.
41. The T cell activating bispecific antigen binding molecule of any one of claims 37 to 38,
wherein the T cell activating bispecific antigen binding molecule induces T cell mediated
killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 178.4 pM after
24 hours.
- 25 42. The T cell activating bispecific antigen binding molecule of any one of claims 37 to 38,
wherein the T cell activating bispecific antigen binding molecule induces T cell mediated
killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 134.5 pM or
greater after 48 hours.

-239-

43. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 42, wherein the T cell activating bispecific antigen binding molecule induces upregulation of cell surface expression of at least one of CD25 and CD69 on the T cell as measured by flow cytometry.
- 5 44. The T cell activating bispecific antigen binding molecule of claim 43, wherein the T cell is a CD4 positive T cell or a CD8 positive T cell.
45. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 44, wherein the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 5.36 pM to about 4 nM.
- 10 46. The T cell activating bispecific antigen binding molecule of claims 1 to 44, wherein the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with an apparent K_D of about 4 nM.
47. The T cell activating bispecific antigen binding molecule of claim 46, wherein the T cell activating bispecific antigen binding molecule binds murine FolR1 with an apparent K_D of about 1.5 nM.
- 15 48. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 44, wherein the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM.
49. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 48, wherein the T cell activating bispecific antigen binding molecule binds to FolR1 expressed on a human tumor cell.
- 20 50. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 49, wherein the T cell activating bispecific antigen binding molecule binds to a conformational epitope on human FolR1.
- 25 51. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 9 and 17 to 19, wherein the T cell activating bispecific antigen binding molecule does not bind to human Folate Receptor 2 (FolR2) or to human Folate Receptor 3 (FolR3).

-240-

52. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 50, wherein the antigen binding moiety binds to a FolR1 polypeptide comprising the amino acids 25 to 234 of human FolR1 (SEQ ID NO:227).
53. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 50, wherein the FolR1 antigen binding moiety binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:227, 230 and 231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence of SEQ ID NOs:228 and 229.
54. A bispecific antibody comprising a) a first antigen-binding site that competes for binding to human FolR1 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 49 and a variable light chain domain of SEQ ID NO: 51; and b) a second antigen-binding site that competes for binding to human CD3 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31, wherein binding competition is measured using a surface plasmon resonance assay.
55. A bispecific antibody comprising a) a first antigen-binding site that competes for binding to human FolR1 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 274 and a variable light chain domain (VL) of SEQ ID NO: 31; and b) a second antigen-binding site that competes for binding to human CD3 with a reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain (VL) of SEQ ID NO: 31, wherein binding competition is measured using a surface plasmon resonance assay.
56. A T cell activating bispecific antigen binding molecule comprising a first antigen binding moiety capable of specific binding to CD3, and a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1), wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human FolR1 as a first reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 49 and a variable light chain domain of SEQ ID NO: 51; and wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human CD3 as a second reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31.

-241-

57. A T cell activating bispecific antigen binding molecule comprising a first antigen binding moiety capable of specific binding to CD3, and a second antigen binding moiety capable of specific binding to Folate Receptor 1 (FolR1), wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human FolR1 as a first reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 274 and a variable light chain domain of SEQ ID NO: 31; and wherein the T cell activating bispecific antigen binding molecule binds to the same epitope on human CD3 as a second reference antibody comprising a variable heavy chain domain (VH) of SEQ ID NO: 36 and a variable light chain domain of SEQ ID NO: 31.
58. A T cell activating bispecific antigen binding molecule comprising the amino acid sequence of SEQ ID NO:276.
59. The T cell activating bispecific antigen binding molecule of claim 58, further comprising the amino acid sequence of SEQ ID NO:277 and of SEQ ID NO:35.
60. The T cell activating bispecific antigen binding molecule of any of claims 17-19, 55, 58 and 59, wherein the T cell activating bispecific antigen binding molecule has a monovalent binding affinity to human FolR1 of about 1.4 μ M.
61. The T cell activating bispecific antigen binding molecule of any of claims 17-19, 55, 58 and 59, wherein the T cell activating bispecific antigen binding molecule has a bivalent binding avidity to human FolR1 of about 10nM.
62. The T cell activating bispecific antigen binding molecule of any of claims 17-19, 55, 58 and 59, wherein the T cell activating bispecific antigen binding molecule has a monovalent binding affinity to human FolR1 of about 1.4 μ M and a bivalent binding avidity to human FolR1 of about 10nM.
63. A T cell activating bispecific antigen binding molecule, wherein the T cell activating bispecific antigen binding molecule comprises a first, a second, a third, a fourth and a fifth polypeptide chain that form a first, a second and a third antigen binding moiety, wherein the first antigen binding moiety is capable of binding CD3 and the second and the third antigen binding moiety each are capable of binding Folate Receptor 1 (FolR1), wherein a) the first and the second polypeptide chain comprise, in amino (N)-terminal to carboxyl (C)-terminal direction, VLD1 and CLD1; b) the third polypeptide chain

-242-

comprises, in N-terminal to C-terminal direction, VLD2 and CH1D2; e) the fourth polypeptide chain comprises, in N-terminal to C-terminal direction, VHD1, CH1D1, CH2D1 and CH3D1; d) the fifth polypeptide chain comprises VHD1, CH1D1, VHD2, CLD2, CH2D2 and CH3D2; wherein

- 5 VLD1 is a first light chain variable domain
- VLD2 is a second light chain variable domain
- CLD1 is a first light chain constant domain
- CLD2 is a second light chain constant domain
- 10 VHD1 is a first heavy chain variable domain
- VHD2 is a second heavy chain variable domain
- CH1D1 is a first heavy chain constant domain 1
- CH1D2 is a second heavy chain constant domain 1
- CH2D1 is a first heavy chain constant domain 2
- CH2D2 is a second heavy chain constant domain 2
- 15 CH3D1 is a first heavy chain constant domain 3
- CH3D2 is a second heavy chain constant domain 3.

64. The T cell activating bispecific antigen binding molecule of claim 63, wherein

- 20 (i) the third polypeptide chain and VHD2 and CLD2 of the fifth polypeptide chain form the first antigen binding moiety capable of binding CD3;
- (ii) the first polypeptide chain and VHD1 and CH1D1 of the fourth polypeptide chain form the second binding moiety capable of binding to FoIR1; and
- (iii) the second polypeptide chain and VHD1 and CH1D1 of the fifth polypeptide chain form the third binding moiety capable of binding to FoIR1.

25

65. The T cell activating bispecific antigen binding molecule of claim 63 or 64, wherein CH2D1, CH3D1, CH2D2 and CH3D2 form an Fc domain of an IgG class immunoglobulin.

66. The T cell activating bispecific antigen binding molecule of claim 65, wherein the Fc domain is a human Fc domain.

30

67. The T cell activating bispecific antigen binding molecule of any one of claim 65 or 66, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.

-243-

68. The T cell activating bispecific antigen binding molecule of claim 67, wherein CH3D2 comprises an amino acid residue having a larger side chain volume, which is positionable in a cavity within CH3D1.
- 5 69. The T cell activating bispecific antigen binding molecule of any one of claims 65 to 68, wherein the Fc domain comprises at least one amino acid substitution that reduces binding to an Fc receptor and/or effector function, as compared to a native IgG₁ Fc domain.
- 10 70. The T cell activating bispecific antigen binding molecule of claim 69, wherein each subunit of the Fc domain comprises three amino acid substitutions that reduce at least one of binding to an activating Fc receptor and effector function wherein said amino acid substitutions are L234A, L235A and P329G according to Kabat numbering.
71. The T cell activating bispecific antigen binding molecule of claim 69 or 70, wherein the Fc receptor is an Fc γ receptor.
- 15 72. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 71, wherein the T cell activating bispecific antigen binding molecule induces proliferation of a human CD3 positive T cell in vitro.
- 20 73. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 72, wherein the T cell activating bispecific antigen binding molecule induces human peripheral blood mononuclear cell mediated killing of a FolR1-expressing human tumor cell in vitro.
74. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 73, wherein the T cell activating bispecific antigen binding molecule induces T cell mediated killing of a FolR1-expressing human tumor cell in vitro.
- 25 75. The T cell activating bispecific antigen binding molecule of any one of claim 73 or 74, wherein the FolR1-expressing human tumor cell is a HeLa, Skov-3, HT-29, or HRCEpiC cell.
76. The T cell activating bispecific antigen binding molecule of any one of claims 73 to 75, wherein the T cell activating bispecific antigen binding molecule induces T cell mediated

-244-

killing of the FolR1-expressing tumor cell in vitro with an EC50 of between about 36 pM and about 39573 pM after 24 hours.

- 5 77. The T cell activating bispecific antigen binding molecule of claim 76, wherein the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 36 pM after 24 hours.
78. The T cell activating bispecific antigen binding molecule of any one of claims 73 to 75, wherein the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 178.4 pM after 24 hours.
- 10 79. The T cell activating bispecific antigen binding molecule of any one of claims 73 to 75, wherein the T cell activating bispecific antigen binding molecule induces T cell mediated killing of the FolR1-expressing tumor cell in vitro with an EC50 of about 134.5 pM or greater after 48 hours.
- 15 80. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 79, wherein the T cell activating bispecific antigen binding molecule induces upregulation of cell surface expression of at least one of CD25 and CD69 on the T cell as measured by flow cytometry.
81. The T cell activating bispecific antigen binding molecule of claim 80, wherein the T cell is a CD4 positive T cell or a CD8 positive T cell.
- 20 82. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 81, wherein the T cell activating bispecific antigen binding molecule binds human FolR1 with an apparent K_D of about 5.36 pM to about 4 nM.
83. The T cell activating bispecific antigen binding molecule of claim 82, wherein the T cell activating bispecific antigen binding molecule binds human and cynomolgus FolR1 with
25 an apparent K_D of about 4 nM.
84. The T cell activating bispecific antigen binding molecule of claim 82, wherein the T cell activating bispecific antigen binding molecule binds murine FolR1 with an apparent K_D of about 1.5 nM.

-245-

85. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 84, wherein the T cell activating bispecific antigen binding molecule binds human FolR1 with a monovalent binding K_D of at least about 1000 nM.
- 5 86. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 84, wherein the T cell activating bispecific antigen binding molecule binds to FolR1 expressed on a human tumor cell.
87. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 86, wherein the T cell activating bispecific antigen binding molecule binds to a conformational epitope on human FolR1.
- 10 88. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 87, wherein the T cell activating bispecific antigen binding molecule does not bind to human Folate Receptor 2 (FolR2) or to human Folate Receptor 3 (FolR3).
89. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 87, wherein the antigen binding moiety binds to a FolR1 polypeptide comprising the amino
15 acids 25 to 234 of human FolR1 (SEQ ID NO:227).
90. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 87, wherein the FolR1 antigen binding moiety binds to a FolR1 polypeptide comprising the amino acid sequence of SEQ ID NOs:227, 230 and 231, and wherein the FolR1 antigen binding moiety does not bind to a FolR polypeptide comprising the amino acid sequence
20 of SEQ ID NOs:228 and 229.
91. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 90, wherein the T cell activating bispecific antigen binding molecule is a humanized or a chimeric molecule.
92. The T cell activating bispecific antigen binding molecule of claim any one of claims 63
25 to 91, wherein VHD2 and CH1D1 are linked through a peptide linker.
93. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 92, wherein the first and second polypeptide chain comprise the amino acid sequence of SEQ ID NO:230.

-246-

94. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 92, wherein the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:86.
- 5 95. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 92, wherein the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:309.
96. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 92, wherein the fifth polypeptide chain comprises the amino acid sequence of SEQ ID NO:228.
- 10 97. The T cell activating bispecific antigen binding molecule of any one of claims 63 to 92, wherein
- (i) the first and second polypeptide chain comprise the amino acid sequence of SEQ ID NO:230;
 - (ii) the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:86;
 - 15 (iii) the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:309; and
 - (iv) the fifth polypeptide chain comprise the amino acid sequence of SEQ ID NO:228.
98. A T cell activating bispecific antigen binding molecule comprising the amino acid sequence of SEQ ID NO:228.
- 20 99. The T cell activating bispecific antigen binding molecule of claim 98, further comprising the amino acid sequence of SEQ ID NO: and of SEQ ID NO:230.
100. An affinity variant of a T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 having a lower affinity as compared to the T cell activating bispecific antigen binding molecule of any one of claims 1 to 88 and wherein the affinity
- 25 variant is capable of inducing T cell-mediated lysis of a FolR1⁺ cancer cell.
101. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:274.

-247-

102. The isolated polypeptide of claim 101, comprising the amino acid sequence of SEQ ID NO:276.
103. The isolated polypeptide of claim 101, comprising the amino acid sequence of SEQ ID NO:277.
- 5 104. An isolated polynucleotide encoding the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 or a fragment thereof.
105. An isolated polynucleotide encoding an antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:287.
106. An isolated polynucleotide encoding an antigen binding molecule comprising the
10 nucleotide sequence of SEQ ID NO:288.
107. An isolated polynucleotide encoding an antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:289.
108. An isolated polynucleotide encoding an antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:97.
- 15 109. An isolated polynucleotide encoding an antigen binding molecule comprising the nucleotide sequence of SEQ ID NO:198
110. A polypeptide encoded by the polynucleotide of any one of claims 104-109.
111. A vector, particularly an expression vector, comprising the polynucleotide of claim 107.
- 20 112. A host cell comprising the polynucleotide of any one of claims 104-109 or the vector of claim 111.
113. A method of producing the T cell activating bispecific antigen binding molecule capable of specific binding to CD3 and a target cell antigen, comprising the steps of a) culturing the host cell of claim 112 under conditions suitable for the expression of the T
25 cell activating bispecific antigen binding molecule and b) recovering the T cell activating bispecific antigen binding molecule.

-248-

114. A T cell activating bispecific antigen binding molecule produced by the method of claim 113.
115. A pharmaceutical composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 and a pharmaceutically acceptable carrier.
- 5 116. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 or the pharmaceutical composition of claim 115 for use as a medicament.
117. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 or the pharmaceutical composition of claim 115 for use in the treatment of a disease in an individual in need thereof.
- 10 118. The T cell activating bispecific antigen binding molecule or pharmaceutical composition of claim 117, wherein the disease is cancer.
119. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.
- 15 120. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 in a pharmaceutically acceptable form.
121. The use of claim 119 or the method of claim 120, wherein said disease is cancer.
- 20 122. A method for inducing lysis of a FolR1⁺ target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 in the presence of a CD3⁺ T cell.
123. The invention as described hereinbefore.